

Curriculum Vitae Sintetico

Alfonso Iorio

Formazione professionale

- Laurea in Medicina e Chirurgia, Perugia, 1991, 110/110 e lode
- Master in Medicina Vascolare, Perugia, 1994
- Specialita' in Biochimica e Chimica Clinica, Perugia, 1995
- Master in Tecniche Analitiche Avanzate, Bologna, 1998
- Specialita' in Medicina Interna, Perugia, 2006
- Dottorato di Ricerca, Perugia, 2011

Posizioni lavorative

- Dirigente Medico I livello, Analisi Chimico Cliniche, Az Osp Reggio Emilia, 1996-2001
- Ricercatore Universitario, Medicina Interna, Università di Perugia, 2001-2010
- Professore Associato, Epidemiologia Clinica e Medicina Interna, McMaster University, Canada, 2010-2017
- Professore Ordinario, Epidemiologia Clinica e Medicina Interna, McMaster University, Canada, 2017 – presente
- Direttore di Dipartimento di Health Research Methods, Evidence, and Impact, McMaster University, Canada, 2020 – presente (in aspettativa)
- Professore Ordinario, Medicina Interna, Università di Bologna, dal 1 luglio 2025.

Idoneita'

Professore I fascia, ASN 06/B1 - MEDICINA INTERNA, [III Sessione 2017](#)

Onoreficienze

Canadian Academy of Health Sciences

Ulteriore formazione rilevante per lo specifico ambito direzionale nella metodologia della ricerca clinica.

2001	Fifth and sixth European Community Framework Granting Program, University of Perugia, Perugia, Italy
2002	Analysis Methods, Training Course, Cochrane Collaboration, London, England
2005	Evidence-Based Medicine, Workshop, GIMBE, Bologna, Italy
2007	Identifying and publishing uncertainties about the effects of treatments in Duets - the database of uncertainties about the effects of treatments, Cochrane Workshop, Milan, Italy
2006	Systematic reviews of diagnostic accuracy, advanced course., III Workshop, Institute Neurologico C. Besta, Milan, Italy
2005	Systematic reviews of diagnostic accuracy, II Workshop, Institute Mario Negri, Milan, Italy
2007	Transparency in the production of guidelines and recommendations: "The WHO Experience", Cochrane Workshop, Milan, Italy
2009	Workshop: The role of ethical committees in the evaluation of design and meaningfulness of clinical trials, Italian Cochrane Centre, Perugia, Italy
2009	Bayesian Statistics, Cambridge (UK)
2014	Summer School on Prognostic Research - Keele University & Medical Research Council, United Kingdom
2014	Faculty of Health Sciences, Faculty Leadership Course, McMaster University, Hamilton, Ontario, Canada
2021	Managing People Program (leadership development training and coaching). 2WA Consulting Inc., Hamilton, Ontario.
2021	Equitable Recruitment and Search/Selection Committee Training, McMaster University, Hamilton, Ontario
2022	Continuing Health Sciences Education Program, Certificate in Equity, Diversity, Inclusion and Indigenous Health Equity Speaker Series: Colonialism & Accessibility to Healthcare, McMaster University, Hamilton, Ontario.
2023	International Guideline Development Credentialing & Certification (INGUIDE) Program Hosted by the Guidelines International Network and McMaster University
2023	National Health Fellow, National Health Fellows Program, Michael G. DeGroote Health Leadership Academy, McMaster University, Hamilton, Ontario

Esperienze professionali e di leadership

Dall'ottobre 2020 direzione del Dipartimento di Health Research Methodology, Evidence, and Impact. Il Dipartimento, in passato denominato epidemiologia clinica e biostatistica e' stato fondato da David Sackett, ed ha visto la nascita e crescita della medicina basata sull'evidenza. Al Dipartimento afferiscono 37 professori a tempo pieno, 90 professori associate e oltre 200 unita di personale amministrativo di supporto alla ricerca. Il budget annuale del Dipartimento e' di circa 18 M di dollari, mentre i fondi di ricerca annualmente gestiti variano tra il 30 e i 60 milioni di dollari.

Durante il mio mandato ho completamente ridisegnato l'organigramma della struttura e rinnovato il team amministrativo centrale.

Al Dipartimento fanno capo 4 corsi di Master e PhD e 2 Diplomi online. Master e Dottorato di metodologia della ricerca clinica (75 studenti per anno per il master, 12 posti di dottorato); master in sanità pubblica (50 posti); Dottorato in politica sanitaria (10 posti); master in e-Health (50 posti), in collaborazione con ingegneria ed economia e commercio; e due corsi di Diploma online: Diploma di epidemiologia clinica (25 posti) e Diploma di sanità pubblica e medicina di comunità (20 posti).

Al Dipartimento fanno capo le seguenti unita di ricerca: unita di biostatistica dell'ospedale St Joseph Healthcare (Lehana Thabane, Lawrence Mbuagaw); CHEPA (centro per l'economia sanitaria e analisi politica and Health Technology Assessment, Feng Xie, Jean Eric Tarride); Unita di Ricerca sull'informazione sanitaria (Alfonso Iorio); Health Forum (John Lavis).

Tra i successi recenti del Dipartimento si notano:

Accelerate Clinical Trial (ACT), fondi di ricerca pubblica CIHR, 32 M, investigatore principale PJ Devereaux. Piattaforma nazionale diretta a facilitare l'approvazione ed esecuzione di trial clinici.

Canadian Longitudinal Study on Aging (CLSA), fondi di ricerca pubblica, 125 M, investigatore principale Parminder Raina. CLSA e' la coorte di pazienti anziani piu consistente a livello globale.

Linee guida per la diagnosi e il trattamento della Post Covid Condition, fondi della agenzia di sanità pubblica, 9.2 M, investigatore principale Robby Nieulaat (co-PI Holger Schunemann)

REVISE (re-evaluating the inhibition of stress erosions: gastrointestinal bleeding prophylaxis in ICU), fondi di ricerca pubblica, 4 M, investigatore principale Deborah Cook.

Tra i professori di spicco nel dipartimento si notano:

Gordon Guyatt, inventore del termine 'Medicina Basata sull'Evidenza' e fondatore del Gruppo di lavoro GRADE; tra i 25 scienziati piu citati

Salim Yusuf, Direttore del Population Health Research Institute, tra i 25 scienziati piu citati

Lehana Thabane, president della Società Internazionale per i Clinical Trial, co-chair della vicepresidenza scientifica dell'associazione ospedali dell'ontario (OHA) e chair della commissione metodologica dell'Istituto PCORI (Patient Centered Outcome Research Institute) del National Institute of Health degli USA.

Attività di ricerca in ambito di epidemiologia clinica

Studi Clinici

Ho disegnato ed eseguito due studi randomizzati e controllati in pazienti in terapia con anticoagulanti orali; sono stato co-investigatore di uno studio di profilassi della trombosi venosa profonda in pazienti neurochirurgici; ho analizzato gli obiettivi secondari di uno studio di trombolisi nell'embolia polmonare.

Review sistematiche e meta-analisi

Ho condotto >20 meta-analisi, sia su dati aggregate che dati di pazienti individuali, nel campo della diagnosi, prognosi e trattamento della trombosi venosa profonda, dello sviluppo di inibitori in emofilia, dell'efficacia e sicurezza di vari regimi terapeutici nell'emofilia. Quattro metanalisi in particolare sono diventate milestones nei campi rispettivi e tuttora citate in linee guida (rischio di recidiva di trombosi venosa dopo primo episodio "provocato"; incidenza di inibitori in pazienti emofilici precedentemente trattati; uso dei fattori della coagulazione per prevenire il sanguinamento in emofilia; prevalenza e prevalenza alla nascita di emofilia)

Linee guida

Ho sviluppato il programma di linee guida della SISET (società italiana per lo studio dell'emorragia e trombosi), pubblicando la metodologia e 6 linee guida. Ho condotto linee guida GRADE in ambito di malattie rare (emofilia, porpora trombotica trombocitopenica, sindrome catastrofica da anticorpi anti-fosfolipidi) e per l'uso corretto degli oppiacei.

Metodologia della ricerca.

GRADE prognosis working group

Ho fondato il sottogruppo sugli studi prognostici del GRADE, pubblicando 2 guidance e 2 concept papers. Ho sviluppato metodi di analisi e meta-analisi per eventi rari e per studi con gruppo con eventi a frequenza zero. Ho sviluppato e pubblicato metodologia per lo sviluppo di linee guida in ambito di malattie rare. Ho collaborato allo sviluppo di varie pubblicazioni di GRADE guidance. Più recentemente ho sviluppato algoritmi per ricercare bibliografica basati sull'intelligenza artificiale.

Outcome research

La mia attività di systematic reviewer e avvocato dell'evidenza nel campo delle malattie emorragiche mi ha portato a realizzare che uno dei problemi più seri nell'ambito specifico era la mancanza di outcome che fossero condivisi nella comunità scientifica, importanti per i pazienti, misurabili e rilevanti. Per questo motivo ho co-creato e co-condotto in collaborazione con i pazienti progetti come CoreHeme (adottato dalla maggior parte degli studi di terapia genica in emofilia) e PROBE (misura di disease specific QoL standard nel settore, con dati di benchmark disponibili per molte giurisdizioni anche in soggetti normali). Ho poi partecipato alla creazione di altri outcome sets in ambito di trombosi.

Health Information Research Unit (HIRU)

Dal 2014 a tutt'oggi sono direttore dell'HIRU, una unità di ricerca costituita da circa 15 persone. L'attività fondamentale dell'unità è effettuare la sorveglianza sistematica della letteratura (circa 120 core clinical journals), selezionando circa 4000 lavori all'anno da un pool di >60,000 sulla base di criteri di rigore metodologico e di rilevanza clinica. I suddetti lavori sono inclusi in un database (McMaster PLUS/MORE) che può essere interrogato online, o consegnati per e-mail tramite il servizio gratuito "Evidence Alerts". Il database è inoltre la base per "research service agreements" che generano circa il 50% del budget operativo annuale dell'HIRU (circa 2.7 M \$/anno). I principali servizi di ricerca sono:

- 1) American College of Physician Journal Club – ogni mese i 10 articoli di maggiore impatto vengono riassunti in un abstract strutturato e ripubblicati, insieme ad un commento, su Annals of Internal Medicine.
- 2) American College of Physician Journal Wise – la parte del database PLUS/MORE di pertinenza internistica è disponibile sotto forma di e-mail periodica per i 170,000 membri del College
- 3) A partire da quest'anno ho lanciato un nuovo programma collaborativo tra le 8 scuole di specializzazione in ambito internistico alla McMaster e l'editorial board di Annals of Internal Medicine per la produzione di 8 articoli intitolati "what you may have missed" che commenta gli 8-10 lavori di pertinenza specialistica ma di competenza internistica. Gli otto articoli sono in pubblicazione online in Aprile.

Poco dopo l'inizio della mia direzione dell'HIRU ho iniziato una collaborazione con un contratto decennale con il team editoriale responsabile dello sviluppo di DynaMedEx, il secondo più diffuso manuale di medicina interna "point-of-care" dopo UpToDate. HiRU, sotto la mia guida, fornisce supporto al team editorial di DynaMedEx provvedendo: 1) ricerche bibliografiche quotidiane con priorità assegnata mediante AI; 2) supporto software al management dell'aggiornamento continuo dei capitoli; 3) dashboard interattiva per il controllo di processo e qualità; 4) consulenza individuale alla leadership editoriale; 5) formazione permanente del personale in ambito di medicina basata sull'evidenza

Attività di ricerca in ambito clinico (ematologia benigna)

Canadian Bleeding Disorders Registry

Nel 2012 sono stato incaricato dall'AHDCDC (Association of Hemophilia Center Directors of Canada) di sviluppare un nuovo registro nazionale dell'emofilia. Dopo aver assemblato un progetto e realizzato un pilota con fondi assegnati dall'ufficio di presidenza della McMaster ho ottenuto un finanziamento federale per lo sviluppo del registro CBDR (Canadian Bleeding Disorders Registry). Il registro è presto diventato uno degli standard internazionali del settore, e' utilizzato dal Ministero della Sanità Canadese e dall'Agenza di Health Technology Assessment Canadese (CADTH) per le valutazioni comparative in occasione di gare per i prodotti della coagulazione. Il modulo CBDR-Research è usato per implementare studi clinici nazionali ed internazionali (permette di identificare pazienti eligibili a livello nazionale, e permette di assemblare una cartella raccolta dati che integra dati già esistenti con dati specifici raccolti per lo studio). CBDR ha originato più di 10 pubblicazioni ed è stato accreditato da CADTH per il monitoraggio della terapia genica. Nell'ambito dei registri internazionali delle coagulopatie congenite sono stato chair per due mandati della Data and Demographics Committee della Federazione Mondiale dell'Emofilia (WFH), co-chair della steering committee del Registro Mondiale dell'Emofilia (WBDR) e chair della commissione qualità del registro internazionale sulla terapia genica nell'emofilia (GTR).

Web Accessible Population Pharmacokinetic Service (WAPPS-Hemo)

Personalmente ritengo questo progetto il fiore all'occhiello della mia ricerca clinica. Basato su un'idea concepita e sviluppata nel 2008 ma rigettata dall'AICE (Associazione Italiana Centri Emofilia) e' stato finanziato per 3 cicli consecutivi da grant competitivi dell'AHDCDC e successivamente da CIHR (Canadian Institute of Health Research). WAPPS-Hemo è un'applicazione web che utilizza un sofisticato approccio predittivo bayesiano e una regressione non lineare (farmacocinetica di popolazione) per stimare profili farmacologici individuali basati su dosaggi di campioni "sparsi"; il profilo individuale è poi usato da un calcolatore clinico che assiste la formulazione di un piano terapeutico ottimizzato che può essere utilizzato su una mobile app dai pazienti per visualizzare il loro livello di fattore in tempo reale, raccogliendo dati di utilizzo ed aderenza. Utilizzato da oltre 800 centri in >70 nazioni WAPPS-Hemo ha generato un database di oltre 13,000 pazienti e 27,000 profili individuali, il più grande database esistente nel settore. WAPPS-Hemo ha permesso la pubblicazione di oltre 25 lavori su riviste top nel settore, e ottenuto nel 2022 il premio per l'innovazione tecnologica della Società Americana di Farmacologia Clinica.

Attività clinica

- 1996-2001 Reggio Emilia. Direttore Medico di I livello, Laboratorio di Chimica Clinica. Inizialmente responsabile del settore di coagulazione ho allestito un laboratorio di terzo livello, complete di aggregometria piastrinica e PCR per la ricerca delle trombofilie. Successivamente, come responsabile del centro dipartimentale di informatica ho pianificato e supportato l'informatizzazione di tutti i laboratori del Dipartimento (chimica clinica, endocrinologia, microbiologia) e successivamente interfacciato tutti i reparti dell'ospedale Santa Maria Nuova. Nei 7 anni successive, come consulente esterno, ho supportato l'informatizzazione e messa in rete di tutti i laboratori analisi della provincia di Reggio Emilia
- 2001-2010 Università di Perugia. Dipartimento di Medicina, Istituto di Medicina Interna e Vascolare (prof Nenci) e successivamente Istituto di Medicina Interna e Medicina D'Urgenza (prof Agnelli). Ricercatore Universitario convenzionato. Ho effettuato attività clinica in regime di ricovero e ambulatoriale, medicina interna generale, e successivamente, in aggiunta, ottenuto l'incarico di alta professionalità per la gestione del paziente con coagulopatie emorragiche congenite ed acquisite. In collaborazione con l'Azienda ASL di Perugia e con finanziamento regionale ho sviluppato una rete decentrata per il monitoraggio della terapia anticoagulante orale con utilizzo di coagulometri point-of-care.
- 2010-presente Professore Associato e successivamente Ordinario, McMaster University. Convenzione con gli Ospedali Riuniti "Hamilton Health Sciences" e Saint Joseph Hospital. Ho ottenuto la registrazione presso il College of Physicians and Surgeons of Ontario (CPSO) e l'iscrizione in qualità di fellow al "Royal College of Physician And Surgeons of Canada (FRCPS-C). Ho prestato servizio per due anni in General Internal Medicine (pazienti in regime di ricovero e ambulatoriali) e successivamente e sino ad ora presso il Servizio di Trombosi (Dipartimento di Medicina, Divisione di Ematologia), con pazienti in regime di ricovero e ambulatoriali. Dal 2004 sono anche Direttore del Programma loco-regionale per la cura delle coagulopatie congenite (servizio ambulatoriale).

Finanziamenti (selezione – lista completa nel CV esteso)

- 2022-2024 Title: PIVOT (Patient-Inspired Validation of Outcome Tools) initiative's post-doctoral research fellowship
Iorio A (PI)
Funding Agency: COPD Foundation
Total Funding: \$141,600 (Sept 1, 2022 – Aug 31, 2024)
- 2022-2026 Title: Project title: Chronic Pain Network: Moving towards knowledge mobilization and implementation science.

Buckley DN, [...] Iorio A, [...].

Funding Agency: CIHR: SPOR Networks - Knowledge Mobilization and Implementation Science

Total Funding: \$3,749,500 (April 1, 2022 – March 31, 2026)

2021 – 2023 Title: Coronavirus Variants Rapid Response Network: CoVaRR-Net - Leveraging research to support Canadians' decisions about COVID-19 variants of concern.

Iorio A (PI)

Funding Agency: University of Ottawa

Total Funding: \$104,000 (March 1, 2021 – March 31, 2023)

2021/2022 Title: Improving the Quality of Academic Publishing: Identifying Recommendations for the Development of Journal Creation Guidelines and Publisher Preferences for a Journal Authenticator Tool.

Moher D (PI), Iorio A, Cobey K.

Funding Agency: Mitacs-Accelerate

Total Funding: \$59,999.00 (September 2021- November 2022)

2021-2022 Title: SAME PAGE: Bridging the gaps between high-quality clinical research evidence for COVID-19 and clinicians, guideline developers, and policy makers.

Linkins L-A [...], Iorio A, [...]

Funding Agency: CIHR – Emerging COVID-19 Research Gaps & Priorities – Confidence in science

Total funding: \$181,125 (June 2021 – May 2022)

2020 – 2021 Title: COVID-19 Evidence Network to support Decision-making (COVID-END)

Lavis JN [...] Iorio A [...]

Funding Agency: Canadian Institutes of Health Research

Total Funding: \$1,000,000 (December 2020 – November 2021))

2020 – 2021 Title: A systematic and living evidence and guideline recommendation map on COVID-19.

Schunemann, Holger [...] Alfonso Iorio, [...]

Funding Agency: CIHR

Total Funding: \$1.456.275 (Jun 1, 2020 – May 31, 2021)

2019 Jun - 2024 Software License, Development and Service Agreement between SOBI and McMaster University for the McMaster Platform, a software platform powering a web-based application for pharmacokinetic estimation in patients. Term: 5 years from Effective date (June 2019).

PI: Alfonso Iorio. Amount: \$2,175,000.

- 2019 Jul Title: Establishing an International Core Outcome Set for Clinical Trials of Interventions for Venous Thromboembolism in Adults (VTE-COS)
Funding source: Canadian Institutes of Health Research (CIHR)/Circulatory and Respiratory Health Principal Applicant: Dr. Grégoire Le Gal
Co-Applicants: [...]A. Iorio [...]
Total Funding: \$263,926; Term: 3 years.
- 2017 Sep Application: Title: Personalized Medicine for Canadians with Hemophilia: a pragmatic evaluation of Web-Accessible Population Pharmacokinetics Service-Hemophilia (WAPPS-Hemo) tailored dosing
Applicant:– **Alfonso Iorio**
Funding Source: Canadian Institutes of Health Research (CIHR), Total Funding: \$335,000
- 2016 Oct – 2026 Sep EBSCO-Dynamed Partnership.
Alfonso Iorio, Brian Haynes.
Total Funding: \$7,463,634.
- 2016 Apr – 2021 Mar Chronic Pain Network Principal Investigators:
Buckley, David N, [...] Iorio A
Canadian Institutes of Health Research (SPOR) –12,500,000.00.
- 2015 Sep - 2020 Aug CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network,
Kahn, Susan Rebecca, [...] Alfonso Iorio,
Grant, Canadian Institutes of Health Research (ICRH Community Development Program Grants), Research - New Project,
\$1,500,000.00.
- 2015 Dec - 2017 Nov The Canadian Hemophilia Carriers Study
Paula James, Alfonso Iorio, [...],
Baxalta-Canadian Hemophilia Epidemiological Research Program (B-CHERP), Research - New Project, \$225,000.00.
- 2015 Apr - 2016 Mar MASCOT - II:Linkage at McMaster Health Sciences of Accesss, Clinical Clustering Information, Oscar and the ad hoc Developed Trust Xt Database. Proof of Concept of a Knowledge Translation Need and Impact Assessment Strategy, Grant, Iorio A [...]
HAHSO/OMOHLTC, \$197,162.00.
- 2014 May – 2015 Dec Development of Evidence-Based Practice Guidelines for the Management of Hemophilia. Holger Schunemann, Nancy Santesso, Alfonso Iorio,
National Hemophilia Foundation \$275,000.00.

- 2013 Jul - 2016 Jun WAPPS-Hemo (Web Accessible Population Pharmacokinetics Service- Hemophilia),
Iorio, Alfonso, McKibbin K. Ann, Thabane Lehana,
Grant, B-CHERP grant competition, AHCDC - New Project,
\$221,839.00
- 2012 Jun - 2015 May CHESS- Canadian Haemophilia Surveillance Scheme,
Iorio, Alfonso,
Grant, Association of Hemophilia Clinic Directors of Canada
(AHCDC), Research - New Project, \$135,000.00
- 2013 Dec - 2015 Dec WAPPS-Hemo project (Web Accessible Population Pharmacokinetics Service - Hemophilia),
Iorio, Alfonso,
Grant, Novo Nordisk Health Care AG (NNHC), Research – First Time,
\$53,500.00
- 2012 Mar Intervention to enhance patient adherence with prescribed
medications: A systematic review and
analysis of components of interventions,
Haynes, Brian, Hill Sophie, Iorio Alfonso, Jack Susan, Nieuwlaat
Robby,
Grant, Canadian Institutes of Health Research (CIHR), Research -
Team, \$93,750.00.

**Pubblicazioni selezionate, raggruppate per area tematica,
e allegate in PDF alla presente domanda.**

A. Trial clinici

1. Cuker A, Kavakli K, Frenzel L, Wang JD, Astermark J, Cerqueira MH, Iorio A, Katsarou-Fasouli O, Klamroth R, Shapiro AD, Hermans C, Ishiguro A, Leavitt AD, Oldenburg JB, Ozelo MC, Teitel J, Biondo F, Fang A, Fuiman J, McKay J, Sun P, Rasko JEJ, Rupon J; BENEENE-2 Trial Investigators. Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B. *N Engl J Med*. 2024 Sep 26;391(12):1108-1118. doi: 10.1056/NEJMoa2302982. PMID: 39321362.

Prima pubblicazione con un innovativo costrutto per la terapia genica dell'emofilia B. Il mio centro e' stato l'unico in Canada, ed ha arruolato pazienti provenienti da tutti i centri dell'Ontario.

2. Schulman S, Bhagirath V, Chan N, Germini F, Ikesaka R, Iorio A, Mithoowani S, Weitz JI, Gross PL. Prothrombin complex concentrate for emergency surgery in patients on oral Xa-inhibitors. *J Thromb Haemost.* 2024 Oct;22(10):2761-2766. doi: 10.1016/j.jtha.2024.07.002. Epub 2024 Jul 11. PMID: 39002730.

Studio osservazionale sulle opzioni di reversal degli anticoagulanti diretti in caso di sanguinamento. Ho arruolato il maggior numero di pazienti alla McMaster.

3. Iorio A, Basileo M, Marcucci M, Guercini F, Camilloni B, Paccamiccio E, Vecchioli M, Iorio AM. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. *Arch Intern Med.* 2010 Apr 12;170(7):609-16. PubMed PMID: 20386004.

Studio randomizzato e controllato disegnato ed eseguito dal sottoscritto, a dimostrare la sicurezza di effettuare la vaccinazione antinfluenzale su pazienti anticoagulati ed in range, escludendo un effetto sull'INR.

4. Iorio A, Federici MO, Mourvaki E, Ferolla P, Piroddi M, Stabile A, Timi A, Celleno R, Benedetti MM. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. *Thromb Haemost.* 2007 Sep;98(3):635-41. PubMed PMID: 17849053.

Studio randomizzato e controllato a dimostrare gli effetti sulla funzione endoteliale dell'interruzione dell'infusione insulinica continua. Ho disegnato il sottostudio ed eseguito l'analisi.

5. Baldi G, Altomonte F, Altomonte M, Ghirarduzzi A, Brusasco C, Parodi RC, Ricciardi A, Remollino V, Spisni V, Saporito A, Caiazza A, Musso G, Cervellin G, Lamberti S, Buzzalino M, De Giorgi F, Del Prato C, Golinelli MP, Gai V, Monsù R, Gioffre' M, Giovanardi D, Cattaneo S, Frumento F, Caporrella A, Re G, De Iaco F, Bologna G, Nocenti F, Lorenzi C, Zoratti R, Sciolla A, Tiscione V, Pastorello M, Vandelli A, Villa A, Zanna M, De Palma A, Iorio A. Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. *Cerebrovasc Dis.* 2006;22(4):286-93. Epub 2006 Jul 17. PubMed PMID: 16847397.

Studio osservazionale in una rete di pronti soccorso in Italia.

6. Iorio AM, Camilloni B, Basileo M, Guercini F, Conti S, Ferrante F, Paccamiccio E, Iaboni S, Vecchioli M, Iorio A. Influenza vaccination in patients on long-term anticoagulant therapy. *Vaccine.* 2006 Nov 10;24(44-46):6624-8. Epub 2006 Jun 8. PubMed PMID:

16828939.

Dimostrazione della sicurezza della vaccinazione influenzale nel paziente anticoagulato. Risultati clinici.

B. Linee guida e review sistematiche

7. Saskia Middeldorp, Robby Nieuwlaat, Lisa Baumann Kreuziger, Michiel Coppens, Damon Houghton, Andra H. James, Eddy Lang, Stephan Moll, Tarra Myers, Meha Bhatt, Chatree Chai-Adisaksopha, Luis E. Colunga-Lozano, Samer G. Karam, Yuan Zhang, Wojtek Wiercioch, Holger J. Schünemann, Alfonso Iorio. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing Blood Adv (2023) 7 (22): 7101–7138.

Linea guida in ambito di screening che adotta un modello decisionale per combinare la prevalenza di malattia, il rischio associato al fattore prognostico e l'effetto dell'intervento terapeutico. Practice changing e molto discussa.

8. Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A. McMaster RARE-Best practices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. Journal of Thrombosis and Haemostasis 2018; 16(8): 1656-64.

Esempio di linea guida in ambito di malattia ultrarara, con impiego di un adattamento di GRADE.

9. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with haemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost. 2017 Dec;15(12):2461-2465. Doi: 10.1111/jth.13867. Epub 2017 Nov 9. No abstract available. PMID: 29119666.

Questa linea guida ha cambiato il modo di trattare l'emofilia. Il tailoring basato sulla population PK e' adesso raccomandato dalle maggiori linee guida internazionali.

10. Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt G. Guideline for opioid therapy and chronic noncancer pain. CMAJ. 2017 May 8;189(18): E659-E666. Doi: 10.1503/cmaj.170363. PMID: 28483845.

Linea guida che ha determinato la riduzione delle dosi prescritte e la fine dell'opiates crisis in Canada.

11. Brignell A, Harwood RC, May T, Woolfenden S, Montgomery A, Iorio A, Williams K. Overall prognosis of preschool autism spectrum disorder diagnoses. Cochrane Database Syst Rev. 2022 Sep 28;9(9):CD012749. doi: 10.1002/14651858.CD012749.pub2. PMID: 36169177; PMCID: PMC9516883.

Review Cochrane esemplare in ambito prognostico.

C. Metodologia delle ricerca e delle linee guida

12. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, McGinn T, Guyatt G. Discrimination and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. JAMA. 2017 Oct 10;318(14):1377-1384.

Il mio apporto a questo lavoro e' stato nella scelta di uno degli esempi, e nella discussione dell'interpretazione della calibrazione. Lavoro divulgativo, di grande impatto

13. Lokker C, McKibbin KA, Afzal M, Navarro T, Linkins LA, Haynes RB, Iorio A. The McMaster Health Information Research Unit: Over a Quarter-Century of Health Informatics Supporting Evidence-Based Medicine. J Med Internet Res. 2024 Jul 31;26:e58764. doi: 10.2196/58764. PMID: 39083765; PMCID: PMC11325105.

Review narrativa del contributo della Health Information Research Unit incluso sotto la mia leadership

14. Shaver N, Katz M, Darko Asamoah G, Linkins LA, Abdelkader W, Beck A, Bennett A, Hughes SE, Smith M, Begin M, Coyle D, Piggott T, Kagina BM, Welch V, Colijn C, Earn DJD, El Emam K, Heffernan J, O'Brien SF, Wilson K, Collins E, Navarro T, Beyene J, Boutron I, Bowdish D, Cooper C, Costa A, Curran J, Griffith L, Hsu A, Grimshaw J, Langlois MA, Li X, Pham-Huy A, Raina P, Rubini M, Thabane L, Wang H, Xu L, Brouwers M, Horsley T, Lavis J, Iorio A, Little J. Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness. Vaccine. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.09.012. Epub ahead of print. PMID: 37718186.

Protocollo di studio per la review che e' alla base delle raccomandazioni della Agenzia di Sanità Pubblica Canadese per tutta la durata della pandemia. Abbiamo effettuato 54 aggiornamenti della SR.

15. Pai M, Yeung CHT, Akl EA, Darzi A, Hillis C, Legault K, Meerpohl JJ, Santesso N, Taruscio D, Verhovsek M, Schünemann HJ, Iorio A. Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. BMC Med Res Methodol. 2019

Mar 28;19(1):67. doi: 10.1186/s12874-019-0713-0. PubMed PMID: 30922227; PubMed Central PMCID: PMC6437842.

Approccio all'elicitazione dell'evidenza in ambito di malattie rare. Applicata in parecchie linee guida del settore.

16. Pai M, Santesso N, Yeung CH, Lane SJ, Schunemann HJ, Iorio A. Methodology for the development of the NHF-McMaster Guideline on Care Models for Haemophilia Management. *Haemophilia*. 2016 Jul;22 Suppl 3:17-22. doi: 10.1111/hae.13007

Approccio allo sviluppo di linee guida in ambito di malattie rare. Applicata in parecchie linee guida del settore.

17. Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, Vernooij R, Arevalo-Rodriguez I, Munn Z, Roshanov P, Riley R, Schandelmaier S, Kuijpers T, Siemieniuk R, Canelo-Aybar C, Schunemann H, Iorio A. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks. *J Clin Epidemiol*. 2020 Jan 23;121:62-70. Doi: 10.1016/j.jclinepi.2019.12.023.

Lavoro seminale alla base dell'impiego di fattori prognostici per definire sottogruppi per i panel impegnati a produrre linee guida. Secondo prodotto del sottogruppo sulla prognosi (di cui sono co-convenuto) del GRADE working group.

18. Alper BS, Oettgen P, Kunnamo I, Iorio A, Ansari MT, Murad MH, Meerpohl JJ, Qaseem A, Hultcrantz M, Schünemann HJ, Guyatt G; GRADE Working Group. Defining certainty of net benefit: a GRADE concept paper. *BMJ Open*. 2019 Jun 4;9(6):e027445. Doi: 10.1136/bmjopen-2018-027445. PMID: 31167868 [PubMed – in process] Free PMC Article.

Modello logico per la valutazione semiquantitativa (e pertanto automatizzabile) del bilancio di benefici e rischi di un trattamento sotto studio

19. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, Alper BS, Meerpohl JJ, Murad MH, Ansari MT, Katikireddi SV, Ostlund P, Tranaeus S, Christensen R, Gartlehner G, Brozek J, Izcovich A, Schunemann H, Guyatt G. The GRADE Working Group clarifies the construct of certainty of evidence. *J Clin Epidemiol*. 2017 May 18. pii: S0895-4356(16)30703-X. Doi: 10.1016/j.jclinepi.2017.05.006. [Epub ahead of print]. PMID: 28529184.

Lavoro che ha trasformato l'approccio GRADE, introducendo l'assessment della rilevanza clinica come migliorativo rispetto al semplice uso del p-value.

D. Registri: lavori metodologici e analisi di dati

20. Barco S, Valerio L, Ageno W, Cohen AT, Goldhaber SZ, Hunt BJ, Iorio A, Jimenez D, Klok FA, Kucher N, Mahmoudpour SH, Middeldorp S, Münzel T, Tagalakakis V, Wendelboe AM, Konstantinides SV. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. *Lancet Respir Med*. 2021(1):33-42. doi: 10.1016/S2213-2600(20)30417-3.

Il mio contributo e' stato relativo all'accesso e interpretazione dei dati canadesi. L'originalità di questo contributo è il ridimensionamento della mortalità attribuibile all'embolia polmonare.

21. Schünemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, Noble S, Macbeth F, Griffiths G, Garcia D, Lyman GH, Di Nisio M, Iorio A, Mbuagbaw L, Neumann I, van Es N, Brouwers M, Guyatt G, Streiff MB, Marcucci M, Baldeh T, Florez ID, Alma OG, Solh Z, Bossuyt PM, Kahale LA, Ageno W, Bozas G, Büller HR, Lebeau B, Lecumberri R, Loprinzi C, McBane R, Sideras K, Maraveyas A, Pelzer U, Perry J, Klerk C, Agnelli G, Akl EA. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. *Lancet Haematol*. 2020 Oct;7(10):e746-e755. doi: 10.1016/S2352-3026(20)30293-3. PMID: 32976752.

Per questo lavoro ho contribuito alla selezione del metodo analitico impiegato per l'IPDMA, sulla base di precedenti simili studi. Questa meta-analisi e' stata di supporto alla linea guida ASH sulla profilassi antitrombotica.

22. Alfonso Iorio, Jeffrey S. Stonebraker, Herve Chambost, Michael Makris, Donna Coffin, Christine Herr, Federico Germini for the Data and Demographics Committee of the World Federation of Hemophilia. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. *Ann Intern Med*. 2019;171(8):540-547.

Questo lavoro ha cambiato la stima della prevalenza dell'emofilia, utilizzando una tecnica innovativa, da me proposta, di analisi dei dati dei registry di patologia. La referenza viene ormai citata in una vasta proporzione delle pubblicazioni sull'emofilia.

23. Coffin D, Gouider E, Konkle B, Hermans C, Lambert C, Diop S, Ayoub E, Tootoonchian E, Youttanankorn T, Dakik P, Pereira T, Iorio A, Pierce GF; World Bleeding Disorders Registry Participating Investigators. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients. *Res Pract Thromb Haemost*. 2023 Nov 20;7(8):102264. doi: 10.1016/j.rpth.2023.102264. PMID: 38193052; PMCID: PMC10772874.

Risultati preliminari del registro mondiale dell'emofilia. Ho personalmente contribuito al disegno, lancio e formazione relativa al registro, nonché all'analisi dei dati.

24. Fischer K, Lassila R, Peyvandi F, Gatt A, Hollingsworth R, Lambert T, Kaczmarek R, Bettel A, Samji N, Rivard GÉ, Carcao M, Iorio A, Makris M; EUHASS and CHES participants. Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada. *Res Pract Thromb Haemost*. 2023 Nov 20;7(8):102265. doi: 10.1016/j.rpth.2023.102265. PMID: 38193044; PMCID: PMC10772871

Registro di farmacovigilanza sui fattori della coagulazione. Io sono coordinatore del braccio Canadese.

E. Analisi (farmaco)economiche e outcome research

25. Tarride JE, Okoh A, Aryal K, Prada C, Milinkovic D, Keepanasseril A, Iorio A. Scoping review of the recommendations and guidance for improving the quality of rare disease registries. *Orphanet J Rare Dis*. 2024 May 6;19(1):187. doi: 10.1186/s13023-024-03193-y. PMID: 38711103; PMCID: PMC11075280.

Lavoro commissionato dalla Canadian Drug Agency come base della ristrutturazione e futura certificazione dei registri di malattie rare in Canada.

26. Hirniak S, Edginton AN, Iorio A, Alsabbagh MW, Hajducek DM, Wong WW. Health utilities in adults with hemophilia A: A retrospective cohort study. *Haemophilia*. 2024 May;30(3):733-742. doi: 10.1111/hae.14979. Epub 2024 Mar 20. PMID: 38506967.

Il primo set di utilities per l'Health Technology Assessment dell'Emofilia in Canada

27. Yu JK, Wong WWL, Keepanasseril A, Iorio A, Edginton AN. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. *Haemophilia*. 2022 Dec 18 *Haemophilia*. 2023;29(2):488-497. doi: 10.1111/hae.14723.

Studio effettuato per creare una base di valutazione per la terapia genica in Canada.

28. Germini F, Noronha N, Borg Debono V, Abraham Philip B, Pete D, Navarro T, Keepanasseril A, Parpia S, de Wit K, Iorio A. Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature. *J Med Internet Res* 2022;24(1):e30791.

Studio preliminare all'utilizzo di device per la rilevazione del livello di attività fisica in pazienti domiciliari.

29. Olasupo OO, Haddix C, Nakar C, Maahs J, Greist A, Ghafoor A, Donfield SM, Iorio a, Shapiro AD. Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders. *Eur J Haematol*. 2021;00:1-12. doi:10.1111/ejh.13731

Il primo studio del piu vasto registro chirurgico nell'ambito. Studio propedeutico alla stesura di linee guida.

30. van Balen EC, O'Mahony B, Cnossen MH, Dolan G, Blanchette VS, Fischer K, Gue D, O'Hara J, Iorio A, Jackson S, Konkle BA, Nugent DJ, Coffin D, Skinner MW, Smit C, Srivastava A, van Eenennaam F, van der Bom JG, Gouw SC. Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set. *Res Pract Thromb Haemost.* 2021;5(4):e12488. doi: 10.1002/rth2.12488.

Il secondo Core Outcome Set nell'ambito di ricerca

31. Spinella PC, El Kassir N, Cap AP, Kindzelski AL, Almond CS, Barkun A, Gernsheimer TB, Goldstein JN, Holcomb JB, Iorio A, Jensen DM, Key NS, Levy JH, Mayer SA, Moore EE, Stanworth SJ, Lewis RJ, Steiner ME; Hemostasis Trials Outcomes Working Group. Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Blood Products and Agents in Patients with Bleeding: Proceedings of a National Heart Lung and Blood Institute and United States Department of Defense Consensus Conference. *J Trauma Acute Care Surg.* 2021 Aug 1;91(2S Suppl 2):S19-S25. doi: 10.1097/TA.0000000000003300.

Lavoro commissionato dall'NIH (NHLBI) per individuare marker di sicurezza da includere negli studi clinici di settore.

32. Konkle B, Pierce G, Coffin D, Naccache M, Clark RC, George L, Iorio A, O'Mahony B, Pipe S, Skinner M, Watson C, Peyvandi F, Mahlangu J; ISTH subcommittee on Factor VIII, Factor IX, rare bleeding disorders. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. *J Thromb Haemost.* 2020;18(11):3074-3077.

Core Outcome Set per il registro mondiale della terapia genica e studi associati

33. Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, et al. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. *Haemophilia* [Internet]. 2018 Jul 20;24(4):e167-72.

Il primo Core Outcome Set in emofilia

34. Iorio A, Stonebraker JS, Brooker M, Soucie JM; Data and Demographics Committee of the World Federation of Hemophilia. Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. *Haemophilia.* 2016 Dec 8. Doi: 10.111/hae.13127. [Epub ahead of print] PMID: 27928881.

Il lavoro propone e valida un metodo per misurare l'efficienza e il progresso della cura dell'emofilia attraverso differenti nazioni

F. Core GRADE

35. Guyatt G, Hultcrantz M, Agoritsas T, Iorio A, Vandvik PO, Montori VM. Why Core GRADE is needed: introduction to a new series in The BMJ. BMJ. 2025 Apr 15;389:e081902. doi: 10.1136/bmj-2024-081902. PMID: 40233981.

Gli otto lavori di questa sezione sono il risultato di una estesa ristrutturazione dell'approccio GRADE alla valutazione dell'evidenza e sua trasposizione in raccomandazioni nell'ambito delle linee guida. Io sono uno dei 5 leader del processo.

36. Guyatt G, Agoritsas T, Brignardello-Petersen R, Mustafa RA, Rylance J, Foroutan F, Prasad M, Agarwal A, De Beer H, Murad MH, Schandelmaier S, Iorio A, Yao L, Jaeschke R, Vandvik PO, Zeng L, Parpia S, D'Souza R, Rind D, Chu DK, Eachempati P, Prasad K, Hultcrantz M, Montori VM. Core GRADE 1: overview of the Core GRADE approach. BMJ. 2025 Apr 22;389:e081903. doi: 10.1136/bmj-2024-081903. PMID: 40262844

Gli otto lavori di questa sezione sono il risultato di una estesa ristrutturazione dell'approccio GRADE alla valutazione dell'evidenza e sua trasposizione in raccomandazioni nell'ambito delle linee guida. Io sono uno dei 5 leader del processo.

37. Guyatt G, Zeng L, Brignardello-Petersen R, Prasad M, De Beer H, Murad MH, Iorio A, Agarwal A, Yao L, Agoritsas T, Rylance J, Mustafa RA, Vandvik PO, Eachempati P, Zhai C, Zhang L, Montori VM, Hultcrantz M. Core GRADE 2: choosing the target of certainty rating and assessing imprecision. BMJ. 2025 Apr 29;389:e081904. doi: 10.1136/bmj-2024-081904. PMID: 40300802.

Gli otto lavori di questa sezione sono il risultato di una estesa ristrutturazione dell'approccio GRADE alla valutazione dell'evidenza e sua trasposizione in raccomandazioni nell'ambito delle linee guida. Io sono uno dei 5 leader del processo.

38. Guyatt G, Schandelmaier S, Brignardello-Petersen R, De Beer H, Prasad M, Murad MH, Eachempati P, Chu DK, D'Souza R, Iorio A, Agoritsas T, Yao L, Mustafa RA, Parpia S, Santaguida P, Vandvik PO, Hultcrantz M, Montori VM. Core GRADE 3: rating certainty of evidence-assessing inconsistency. BMJ. 2025 May 6;389:e081905. doi: 10.1136/bmj-2024-081905. PMID: 40328467.

Gli otto lavori di questa sezione sono il risultato di una estesa ristrutturazione dell'approccio GRADE alla valutazione dell'evidenza e sua trasposizione in raccomandazioni nell'ambito delle linee guida. Io sono uno dei 5 leader del processo.

39. Guyatt G, Wang Y, Eachempati P, Iorio A, Murad MH, Hultcrantz M, Chu DK, Florez ID, Hemkens LG, Agoritsas T, Yao L, Vandvik PO, Montori VM, Brignardello-Petersen R. Core GRADE 4: rating certainty of evidence-risk of bias, publication bias, and reasons for rating up certainty. BMJ. 2025 May 13;389:e083864. doi: 10.1136/bmj-2024-

083864. Erratum in: BMJ. 2025 Jul 29;390:r1468. doi: 10.1136/bmj.r1468. PMID: 40360206.

Gli otto lavori di questa sezione sono il risultato di una estesa ristrutturazione dell'approccio GRADE alla valutazione dell'evidenza e sua trasposizione in raccomandazioni nell'ambito delle linee guida. Io sono uno dei 5 leader del processo.

40. Guyatt G, Iorio A, De Beer H, Owen A, Agoritsas T, Murad MH, Karthikeyan G, Cuello C, Prasad M, Kim K, Ali DS, Agarwal A, Hemkens LG, Yao L, Hultcrantz M, Rylance J, Chu DK, Vandvik PO, Djulbegovic B, Mustafa RA, Zeng L, Eachempati P, Rochwerg B, Prasad K, Montori VM, Brignardello-Petersen R. Core GRADE 5: rating certainty of evidence-assessing indirectness. BMJ. 2025 May 20;389:e083865. doi: 10.1136/bmj-2024-083865. PMID: 40393729.

Gli otto lavori di questa sezione sono il risultato di una estesa ristrutturazione dell'approccio GRADE alla valutazione dell'evidenza e sua trasposizione in raccomandazioni nell'ambito delle linee guida. Io sono uno dei 5 leader del processo.

41. Guyatt G, Yao L, Murad MH, Hultcrantz M, Agoritsas T, De Beer H, Schandelmaier S, Iorio A, Zeng L, Prasad M, Vandvik PO, Mustafa RA, Agarwal A, Devji T, Florez ID, Djulbegovic B, Chu DK, Rochwerg B, Montori VM, Brignardello-Petersen R. Core GRADE 6: presenting the evidence in summary of findings tables. BMJ. 2025 May 27;389:e083866. doi: 10.1136/bmj-2024-083866. PMID: 40425239.

Gli otto lavori di questa sezione sono il risultato di una estesa ristrutturazione dell'approccio GRADE alla valutazione dell'evidenza e sua trasposizione in raccomandazioni nell'ambito delle linee guida. Io sono uno dei 5 leader del processo.

42. Guyatt G, Vandvik PO, Iorio A, Agarwal A, Yao L, Eachempati P, Zeng L, Chu DK, D'Souza R, Agoritsas T, Murad MH, Schandelmaier S, Rylance J, Djulbegovic B, Montori VM, Hultcrantz M, Brignardello-Petersen R. Core GRADE 7: principles for moving from evidence to recommendations and decisions. BMJ. 2025 Jun 3;389:e083867. doi: 10.1136/bmj-2024-083867. PMID: 40461180.

Gli otto lavori di questa sezione sono il risultato di una estesa ristrutturazione dell'approccio GRADE alla valutazione dell'evidenza e sua trasposizione in raccomandazioni nell'ambito delle linee guida. Io sono uno dei 5 leader del processo.

43. Foroutan, F., Guyatt, G., Trivella, M., Kreuzberger, N., Skoetz, N., Riley, R. D., Roshanov, P. S., Alba, A. C., Sekercioglu, N., Canelo-Aybar, C., Munn, Z., Brignardello-Petersen, R., Schünemann, H. J., & Iorio, A. (2022). GRADE concept paper 2: Concepts for judging certainty on the calibration of prognostic models in a body of validation studies. Journal of Clinical Epidemiology, 143(xxxx), 202–211. <https://doi.org/10.1016/j.jclinepi.2021.11.024>

Altro milestone nell'approccio alla valutazione della qualità dei modelli prognostici

G. Farmacocinetica di popolazione

44. Kim MS, Hajducek DM, Gilbert JC, Iorio A, Jilma B, Edginton AN. Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans. AAPS J. 2024 Jul 12;26(4):81. doi: 10.1208/s12248-024-00952-4. PMID: 38992298

Applicazione della modellistica di popolazione allo sviluppo di una nuova terapia per il VWD.

45. Hajducek DM, Chelle P, Iorio A, Iserman E, Edginton AN. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients. Haemophilia. 2024 Jul;30(4):925-932. doi: 10.1111/hae.15032. Epub 2024 May 13. PMID: 38738967.

Approccio teorico ed esemplificazioni pratiche basate sui dati raccolti tramite WAPPS-Hemo sull'impatto di settare target terapeutici per gli emoderivati a una soglia del 3%. Il lavoro ha impatto clinico e farmacoeconomico, incluso produrre informazione utile per le gare.

46. Hajducek DM, Chelle P, Hermans C, Iorio A, McEneny-King A, Yu J, Edginton A. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project. Haemophilia. 2020 May;26(3):384-400. doi: 10.1111/hae.13977. Epub 2020 Apr 13. PMID: 32281726.

Descrizione delle valutazioni di performance di tutti i modelli di farmacocinetica di popolazione sviluppati per l'uso con WAPPS-Hemo

47. Iorio A. Using pharmacokinetics to individualize hemophilia therapy. Hematology. Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):595-604. doi: 10.1182/asheducation-2017.1.595. Review. Pubmed PMID: 29222309.

Report della Key note educational session sull'individualizzazione della terapia dell'emofilia basata sulla farmacocinetica di popolazione.

H. Intelligenza artificiale

48. Lokker C, Bagheri E, Abdelkader W, Parrish R, Afzal M, Navarro T, Cotoi C, Germini F, Linkins L, Brian Haynes R, Chu L, Iorio A. Deep Learning to Refine the Identification of High-Quality Clinical Research Articles from the Biomedical Literature: Performance Evaluation. J Biomed Inform. 2023 Jun;142:104384. doi: 10.1016/j.jbi.2023.104384.

Lavoro seminale a dimostrare la performance di un sistema esperto nell'identificare articoli che rispondano a criteri di rigore metodologico.

49. Ng JY, Maduranayagam SG, Suthakar N, Li A, Lokker C, Iorio A, Haynes RB, Moher D. Attitudes and perceptions of medical researchers towards the use of artificial

intelligence chatbots in the scientific process: an international cross-sectional survey. Lancet Digit Health. 2025 Jan;7(1):e94-e102. doi: 10.1016/S2589-7500(24)00202-4. Epub 2024 Nov 15. PMID: 39550312.

Esplorazione delle percezioni associate all'uso dell'AI nel processo di produzione di un lavoro scientifico.

50. Lokker C, Abdelkader W, Bagheri E, Parrish R, Cotoi C, Navarro T, Germini F, Linkins LA, Haynes RB, Chu L, Afzal M, Iorio A. Boosting efficiency in a clinical literature surveillance system with LightGBM. PLOS Digit Health. 2024 Sep 23;3(9):e0000299. doi: 10.1371/journal.pdig.0000299. PMID: 39312500; PMCID: PMC11419392.

Analisi dell'impatto dell'adozione di uno step di preprocessing basato sull'AI nel processo di sorveglianza della letteratura presso l'Health Information Research Unit.

51. CHART Collaborative; Huo B, Collins GS, Chartash D, Thirunavukarasu AJ, Flanagan A, Iorio A, Cacciamani G, Chen X, Liu N, Mathur P, Chan AW, Laine C, Pacella D, Berkwitz M, Antoniou SA, Camaradou JC, Canfield C, Mittelman M, Feeney T, Loder EW, Agha R, Saha A, Mayol J, Sunjaya A, Harvey H, Ng JY, McKechnie T, Lee Y, Verma N, Stiglic G, McCradden M, Ramji K, Boudreau V, Ortenzi M, Meerpohl JJ, Vandvik PO, Agoritsas T, Samuel D, Frankish H, Anderson M, Yao X, Loeb S, Lokker C, Liu X, Guallar E, Guyatt GH. Reporting Guideline for Chatbot Health Advice Studies: The CHART Statement. JAMA Netw Open. 2025 Aug 1;8(8):e2530220. doi: 10.1001/jamanetworkopen.2025.30220. PMID: 40747871.

Report di un consenso internazionale di esperti sulla maniera ottimale di riportare studi che valutino l'uso di intelligenza artificiale in tool che supportino il clinico nelle decisioni quotidiane.

52. Zhou F, Parrish R, Afzal M, Saha A, Haynes RB, Iorio A, Lokker C. Benchmarking domain-specific pretrained language models to identify the best model for methodological rigor in clinical studies. J Biomed Inform. 2025 Jun;166:104825. doi: 10.1016/j.jbi.2025.104825. Epub 2025 Apr 15. PMID: 40246186.

Porposta di un approccio standardizzato al confronto delle caratteristiche di algoritmi di AI per valutare il rigore di un articolo

53. Bhavsar D, Duffy L, Jo H, Lokker C, Haynes RB, Iorio A, Marusic A, Ng JY. Policies on artificial intelligence chatbots among academic publishers: a cross-sectional audit. Res Integr Peer Rev. 2025 Feb 28;10(1):1. doi: 10.1186/s41073-025-00158-y. PMID: 40022253; PMCID: PMC11869395.

Audit delle policies adottate dagli editori accademici relativamente all'intelligenza artificiale.

Bologna 20 agosto 2025

Alfonso Iorio

NAME

Alfonso Iorio

WORK ADDRESS

Università di Bologna
Ospedale Policlinico Sant'Orsola

McMaster University
Department of Health Research Methods, Evidence, and Impact (HEI)

EDUCATIONAL BACKGROUND

Degrees and Diplomas

2011	PhD, University of Perugia
1998	Master's Equivalent, Advanced Analytical Techniques, Pharmacology, University of Bologna
1994	Master's Equivalent, Vascular Medicine, Internal Medicine, University of Perugia
1991	MD, University of Perugia

Qualifications, Licensures and Certifications

2021	FCAHS, Canadian Academy of Health Sciences
2011	FRCP, Royal College of Physicians & Surgeons (Canada) - Internal Medicine
2006	Internal Medicine, University of Perugia, Perugia, Italy
1995	Clinical Chemistry and Biochemistry, Department of Experimental Medicine, University of Perugia, Perugia, Italy

Research Training

2009	Bayesian Statistics, University of Cambridge and the Royal Statistical Society
------	--

2008	Training Course on antithrombotic therapy in Cardiology, Florence
2007	Identifying and publishing uncertainties about the effects of treatments in Duets - the database of uncertainties about the effects of treatments, Cochrane Workshop, Milan, Italy
2007	Transparency in the production of guidelines and recommendations: “The WHO Experience”, Cochrane Workshop, Milan, Italy
2007	Transparency of production and dissemination of scientific information, XII Annual Meeting, Italian Cochrane Network, Milan, Italy
2006	Systematic reviews of diagnostic accuracy, advanced course., III Workshop, Institute Neurologico C. Besta, Milan, Italy
2005	Systematic reviews of diagnostic accuracy, II Workshop, Institute Mario Negri, Milan, Italy
2005	Evidence-Based Medicine, Workshop, GIMBE, Bologna, Italy
2004	Diagnostic Systematic Reviews, Italian Cochrane Centre, Florence, Italy
2004	Critical appraisal of the grading system for guidelines, Italian Cochrane Centre, Florence, Italy
2002	Analysis Methods, Training Course, Cochrane Collaboration, London, England

Other Specialized Training

2023	International Guideline Development Credentialing & Certification (INGUIDE) Program Hosted by the Guidelines International Network and McMaster University
2023	National Health Fellow, National Health Fellows Program, Michael G. DeGroote Health Leadership Academy, McMaster University, Hamilton, Ontario
2023	Department of Medicine’s Equity and Diversity 2021 Survey
2022	Continuing Health Sciences Education Program, Certificate in Equity, Diversity, Inclusion and Indigenous Health Equity Speaker Series: Colonialism & Accessibility to Healthcare, McMaster University, Hamilton, Ontario.
2021	Managing People Program (leadership development training and coaching). 2WA Consulting Inc., Hamilton, Ontario.
2021	Equitable Recruitment and Search/Selection Committee Training, McMaster University, Hamilton, Ontario
2014	Faculty of Health Sciences, Faculty Leadership Course, McMaster University, Hamilton, Ontario, Canada
2014	Summer School on Prognostic Research - Keele University & Medical Research Council, United Kingdom
2012	Program for Faculty Development, Fundamentals of Clinical Teaching, McMaster University

2011 - 2012	Program for Faculty Development, Orientation to Mentorship: Building a Mentoring Relationship - Parts 1-4, McMaster University, Hamilton, Ontario, Canada
2011	Program for Faculty Development, Tutoring 101, McMaster University, Hamilton, Ontario, Canada
2011	Program for Faculty Development, Experimental PBL, McMaster University, Hamilton, Ontario, Canada
2009	Workshop: The role of ethical committees in the evaluation of design and meaningfulness of clinical trials, Italian Cochrane Centre, Perugia, Italy
2001 - 2002	Fifth and sixth European Community Framework Granting Program, University of Perugia, Perugia, Italy
1997	Microsoft Access and Database Planning, Arcispedale S.M. Nuova - Azienda Ospedaliera di Reggio Emilia
1989 - 1995	Research Fellow, Clinical Fellowship of the International Inter-University Centre for Thrombosis & Haemostasis, Perugia, Italy
1994	Vascular Medicine, Department of Internal Medicine, University of Perugia, Perugia, Italy
1992	European Intensive Course in Haematology and Haemostasis, Amsterdam University & Erasmus Program, Amsterdam, Netherlands
1988	Fondazione Internazionale Menarini, by the Centro di Ricerche Mario Negri Sud, Course: Congenital and acquired alteration in blood coagulation. Study Methods”, Centro Angelo Bianchi Bonomi, Milan, Italy - sponsored by Siset & Cismel

CURRENT STATUS AT UNIVERSITY OF BOLOGNA

2025 July 1st Professor of Medicine, DISEM, Facoltà di Medicina (part-time)

CURRENT STATUS AT MCMASTER UNIVERSITY

2020 – present	Chair, Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University (<u>on leave since July 1st 2025</u>)
2017 – present	Professor, Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University
2010 - 2017	Associate Professor, Department of Health Research Methods, Evidence, and Impact (HEI), CAWAR (2013), Health Sciences, McMaster University
2010 - present	Professor and Joint Member, Department of Medicine, Health Sciences, McMaster University

PROFESSIONAL ORGANIZATIONS

2013 - present	American College of Physicians, Fellow
2012 - present	American Society of Hematology, Member

2011 - present	Association Hemophilia Centres Director of Canada, Member
2007 - present	Prognosis Method Group, The Cochrane Collaboration, Member
2002 - present	World Federation of Hemophilia, Member
2001 - present	Associazione Italiana dei Centri Emofilia (AICE), Member
1993 - present	International Society on Thrombosis and Haemostasis
1992 - present	Italian Society for Hemostasis and Thrombosis (elected executive 2006-8)
1992 - present	Italian Society for Vascular Pathology, Member
1992 - present	The Biometric Society, Member

EMPLOYMENT HISTORY

University Appointments

2025 – Present	Professor of Medicine (Part-time), University of Bologna
2025 – Present	Director, Evidence Synthesis and Support Institute, McMaster University
2020 – present	Chair, Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University (<u>on leave since July 1st, 2025</u>)
2017 – present	Professor, Department of Health Research Methods, Evidence, and Impact (HEI), CAWAR, McMaster University
2013 - 2017	Associate Professor, Health Research Methods, Evidence, and Impact (HEI), CAWAR, Faculty of Health Sciences, McMaster University
2010 - present	Joint Member, Department of Medicine, Faculty of Health Sciences, McMaster University
2010 - 2013	Associate Professor, Clinical Epidemiology and Biostatistics, Special, Faculty of Health Sciences, McMaster University

Academic

11/2021-10/2023	Adjunct Professor, School of Pharmacy, University of Waterloo
2020 – present	Mike Gent Chair in Health Care Research, McMaster University
2018 – 2020	Bayer Endowed Chair for Clinical Epidemiology Research and Bleeding Disorders at McMaster University
2017 - present	Professor, Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University

2013 - 2017	Associate Professor, CAWAR, Jointly in the Department of Health Research Methods, Evidence, and Impact (HEI) & Medicine, McMaster University, Faculty of Health Sciences, Hamilton, Ontario, Canada
2010 - 2013	Associate Professor, Special Appointment, Jointly in the Department of Clinical Epidemiology & Biostatistics and Medicine, McMaster University, Clinical Epidemiology and Biostatistics, Faculty of Health Sciences, Hamilton, Ontario, Canada
2004 - 2010	Aggregate Professor (tenured), University of Perugia, Internal Medicine, Perugia, Italy
2001 - 2004	Assistant Professor, University of Perugia, Internal Medicine, Perugia, Italy

Administrative

2020 – present	Chair, Department of Health Research Methods, Evidence, and Impact, McMaster University (leave)
2014 – Present	Director, Health Information Research Unit (HIRU), McMaster University
2013 – 2014	Deputy Chief, Health Information Research Unit, Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University
2012 - 2017	Departmental Education Coordinator, Health Research Methods, Evidence, and Impact (HEI), McMaster University
2002 - 2010	Elected representative, Assistant Professor, Faculty Council, University of Perugia
2002 - 2010	Elected Representative as Assistant Professor to the Faculty Teaching Council, University of Perugia

Clinical

2011 - Present	Director of the Hamilton-Niagara Regional Hemophilia Treatment Centre located in the McMaster Children's Hospital, Hamilton, Health Sciences, Hamilton, Ontario (on leave)
2010 - Present	Clinical Service at Hamilton General Hospital as Clinical Teaching Unit Attending Physician, Hamilton Health Sciences Corporation, Hamilton General Hospital, Hamilton, Ontario, Canada (on leave)
2010 - Present	Thrombosis Staff for Hamilton Health Sciences Corporation, Juravinski Hospital and McMaster Children's Hospital (outpatient & inpatient), Hamilton, Ontario, Canada
2003 - 2010	Chief of the Program "Health care management network for congenital and acquired bleeding disorders, with particular attention to haemophilia and oral anticoagulant therapy", Azienda Ospedaliera di Perugia, Department of Internal Medicine, Perugia, Italy
2001 - 2010	Clinical Teaching Unit, Internal Medicine and Thrombosis and Haemostasis, Azienda Ospedaliera & University of Perugia, Perugia, Italy
1996 - 2001	Dirigente Medico (tenured), Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Clinical Chemistry and Biochemistry, Italy

1996	Dirigente Medico, temporary appointment, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Clinical Chemistry and Biochemistry, Italy
1996	Emergency Service Physician, Regione Umbria, Foligno, Health Care Unit #3, Italy
1996	Medicina dei Servizi, Clinical Chemistry Laboratory of the Ospedale Civile, Riccione., Italy
1995	Emergency Service Physician, Regione Umbria, Citta di Castello, Health Care Unit #1, Italy

Consulting

2001 - 2010	Evidence-Based Medicine, Gruppo Moccia, Rome, Italy
2002 - 2010	Program Director, Remote oral anticoagulation monitoring Network, Local Health Care Agency #2 of the Region Umbria, Perugia, Italy
2001 - 2007	Coagulation and Laboratory Information Technology, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy
1999	Azienda USL of Reggio Emilia (task force for the integration of the information systems of the Reggio Emilia District), Italy

SCHOLARLY AND PROFESSIONAL ACTIVITIES

Editorial Boards

2016- present	Associate Editor, Thrombosis Research
2018 – present	Statistical Reviewer, Journal of Thrombosis and Haemostasis
2014 - present	Advisory Board Member, Haemophilia Journal
2013 - present	Associate Editor, Rare Diseases and Orphan Drugs
2012 - present	Deputy Editor, ACP Journal Club
2012 - present	Advisory Board Member, Journal of Thrombosis and Haemostasis
2011 - present	Advisory Board Member, World Journal of Experimental Medicine
2009 - present	Advisory Board Member, Internal and Emergency Medicine
2009 - present	Associate Editor, Cystic Fibrosis and Genetic Disorders Group, Cochrane Collaborations
2010	Guest co-editor of the Abstract Book of the XXI National Congress of the SISET
2004	Advisory Board Member, Journal of Thrombosis and Haemostasis

Grant & Personnel Committees

2021-present	Member, Academic & Education Awards Review Committee, Department of Medicine, McMaster University
--------------	---

2021 – present	Member, McMaster Institute for Research on Aging (MIRA) Executive Committee, McMaster University.
2019 - present	NIH Special Emphasis Panel - “Rare Disease Cohorts in Heart, Lung, Blood and Sleep Disorders” – Reviewer of Funding Applications.
2019 -2020	CIHR Peer Review Committee Member (CID)
2017-2020	Chair, HAHSO AFP Innovation Grant Review Panel
2016-2017	Scientific Officer, HAHSO AFP Grant Review Panel
2014 - present	Chair, HERO Program Research Grants Adjudication Committee
2014 - present	Member, McMaster University, Continuing Health Sciences Education Advisory Committee (CHSE Advisory)
2014 - present	Member, McMaster University, Continuing Health Sciences Education Research & Innovation Committee (CHSE RIC)
2014 - 2017	Member, Tenure & Promotion Committee, Faculty of Health Sciences, McMaster University
2014 - present	Reviewer, Foundation and Project Grant Program, CIHR
2013 - 2016	Member, HAHSO/AFP grant review committee
2013	Reviewer, Peer Review Committee, Internal Grants, Juravinski Cancer Center
2012 - 2017	Member, Academic Tenure and Promotion (ATP) Committee, Health Research Methods, Evidence, and Impact, McMaster University
2012 - present	Member, Steering Committee, Health Research Methods, Evidence, and Impact, McMaster University
2012 - 2014	Member, Clinical Investigation D Panel Review Grant, Canadian Institutes of Health Research.
2005 - 2010	Member, Departmental Committee for staff selection, Department of Internal Medicine, University of Perugia.
2005	Member (elected) in the Evaluation Procedures (II session) for Admission to University positions, Padua

Executive Positions

2018-present	Member, McMaster Centre for Transfusion Research (MCTR) Steering Committee
2018 – present	Member, Data and Demographics Committee, World Federation of Hemophilia
2018 – present	co-Chair, World Bleeding Disorders Registry, World Federation of Hemophilia
2018 – present	member, Gene Therapy Registry committee, World Federation of Hemophilia
2016 – present	Co-Chair, Chronic Pain SPOR Network Knowledge Translation Committee
2016 – present	Member, Chronic Pain SPOR Network Executive Committee

2016 – present	Member, Chronic Pain SPOR Network Steering Committee
2016 – present	Member, Chronic Pain SPOR Network Training and Mentoring Committee
2016 – 2018	Member, Clinical Guidelines Committee, American College of Physicians
2015 - present	Member, Guideline Oversight Committee, American Society of Hematology
2014 - present	Chair, Canadian Bleeding Disorders Registries Committee (CBDR-C) of the Association of Hemophilia Clinic Directors of Canada
2014 - 2018	Chair, Data and Demographics Committee, World Federation of Hemophilia
2014 - present	Member, Medical Advisory Board, World Federation of Hemophilia
2012 - 2014	Secretary, CHARMS & CHR Subcommittee of the Association of Hemophilia Clinic Directors of Canada
2012 - present	Member, Inhibitor Committee of the Association of Hemophilia Clinic Directors of Canada
2012 – 2014	Medical Advisor, Canadian Hemophilia Association, Montreal, Quebec, Canada
2012 - 2013	Member, Data and Demographics Committee, World Federation of Hemophilia
2006 - 2010	Secretary, Italian Society for Thrombosis and Haemostasis
2004 - present	Member and Secretary of the Scientific Board, Fondazione Emo ONLUS, Macerata, Italy
2004 - 2010	Steering Committee Member, Guidelines Project of the Italian Society for Thrombosis and Haemostasis (SISST).
2004 - 2006	Executive Committee (elected member), Italian Society for Thrombosis and Haemostasis
2004 - 2006	Member of the Scientific Board, Fondazione Paracelso, Milan
2002 - 2010	Coordinator of the Congenital Bleeding Disorders National Registry of the Italian Association of Hemophilia Centres (AICE).

Journal Referee

2014 - present	Haematologica
2014	Lancet Haematology
2014	Implementation Science
2013 - present	PlosMedicine
2013 - present	PlosOne
2013 - present	BMJ Open
2012 - present	Journal of Clinical Epidemiology

2012	Annals of Hematology
2011 - present	Journal of Thrombosis and Thrombolysis
2011 - present	European Journal of Internal Medicine
2011	Transfusion Medicine
2011	Journal of the American Geriatric Society
2011	British Medical Journal (BMJ)
2010	Asian Journal of Transfusion Science
2009 - present	Blood
2009	Journal of Pediatric Hematology and Oncology
2008 - present	Haemophilia
2008 - present	Internal and Emergency Medicine
2008 - present	Blood Transfusion
2008	Journal of Medical Case Reports
2007	Journal of the American College of Cardiology
2007	Expert Opinion on Pharmacotherapy
2007	BMC Medicine
2007	Acta Hematologica
2006 - 2007	Cochrane Library
2006	American Journal of Hematology
2005 - present	Thrombosis and Haemostasis
2004 - 2006	Stroke
2004	Diabetes Research and Clinical Practice
2002 - 2004	Clinical Drug Investigation
2003	Diabetes Nutrition and Metabolism
2002 - present	Journal of Thrombosis and Haemostasis

External Grant Reviews

2015 - present	Peer Reviewer, REPRISE - Register of Expert Peer Reviewers for Italian Scientific Evaluation, Ministry of Education, University and Research, Italy
2013	Reviewer, Peer Review Committee, Internal Grants, University Roma
2011	Reviewer, The Netherlands Organization for Health Research and Development
2011	Reviewer, France National Granting Agency (Agence Nationale par la Recherche)
2008 - 2011	Reviewer, University of Padua grant review process
2004 - present	Reviewer, Italian Ministry of Health - Grant Peer review committee - (PRIN & FIRB programs), Medicine
2005	Member (elected), Evaluation Procedures (II session) for Admission to University positions, Padua

Other

2020	Chair, Data and Safety Monitoring Board (DSMB), Randomised controlled trial comparing efficacy and safety of high versus low Low- Molecular Weight Heparin dosages in hospitalised patients with severe COVID-19 pneumonia or coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD), University of Modena, Emilia Romagna, Italy
------	---

HONOURS AND AWARDS

2012	Teaching excellence award, Department of Medicine, McMaster University
2003	Awarded the Prize “Unità Malattie Tromboemboliche ed Emorragiche Cattedra di Ematologia dell’Università di Palermo” during the National Siset National Teaching Course, held in Palermo.
1999	Awarded the “Individual Performance Quality Prize” by the Azienda Ospedaliera Santa Maria Nuova di Reggio Emilia, for the fundamental contribution in the development of the information technology system of the Clinical Pathology Department.
1994	Awarded the “Scientific Research Prize 1994” by the Association Against Thrombosis (ALT)
1992	Awarded the “Italian Society for Vascular Pathology Prize” for the best research work submitted to the Annual Meeting of the Tosco-Umbra Section.

COURSES TAUGHT

Undergraduate Teaching

Bachelor of Health Sciences (Hons.)

2012 Jul - 2013 Jun	Thesis Supervisor, 4A09, student (2)
---------------------	--------------------------------------

2011 Jul - 2012 Jun Inquiry Supervisor, 3H03, course (1)

Physician Assistant Education Program

2015 Jul - 2020 Jun Supervisor, Elective, Interviewing, Examination and Reasoning, half-day (9)

Undergraduate Medical

2019 Jul - 2020 Jun Supervisor, Elective, Visiting Student, week per student (4)

2017 Jul - 2018 Jun Speaker, Large Group Session, Professional Competencies, occasion (1)

2012 Jul - 2013 Jun Supervisor, Block Elective, week (3)

2011 Jul - 2012 Jun Examiner, Observed Structured Clinical Examination, occasion (1)

Undergraduate Medical Clerkship

2010 Jul - 2013 Jun Supervisor, Medicine, 6 weeks (6)

Graduate Teaching

Graduate Programs in Health Sciences

2013 Jul - 2014 Jun Oral Presentation Judge, session (1)

2011 Jul - 2012 Jun Member, Scholarship Selection, Committee, year (1)

Health Research Methodology

2011 Jul - 2019 Jun Lecturer, Teaching Session, occasion (30)

2012 Jul - 2019 Jun Member, Admissions Committee, MSc, year (6)

2014 Jul - 2019 Jun Member, Transfer Committee, year (3)

2011 Jul - 2019 Jun Reviewer, Scholarly Paper, occasion (4)

2018 Jul - 2019 Jun Student Advisor, student per year (1)

2014 Jul - 2018 Jun Course Co-ordinator, course (4)

2017 Jul - 2018 Jun Member, Comprehensive Committee, year (1)

2011 Jul - 2017 Jun Instructor, 721, session (19)

2011 Jul - 2017 Jun Instructor, 730, session (12)
2016 Jul - 2017 Jun Thesis Examiner, PhD, candidate (1)
2016 Jul - 2017 Jun Thesis Examiner, Internal or External, MSc, student (1)
2015 Jul - 2016 Jun Instructor, 743, session (3)
2012 Jul - 2016 Jun Presenter, Comprehensive Seminar, occasion (4)
2014 Jul - 2015 Jun Supervisor, Independent Study, student (1)
2013 May - Course coordinator, lecturer, instructor, HRM 777

Postgraduate Teaching

Internal Medicine and its subspecialties

2017 Jul - 2020 Jun Presenter, Academic Half Day/Core Curriculum, presentation (4)
2013 Jul - 2014 Jun Examiner, Observed Structured Clinical Examination, half-day (1)
2012 Jul - 2013 Jun Presenter, EBM Curriculum, September 12, 2012: Introduction to MacPLUS (1)

Other

Continuing Education

2016 Jul - 2018 Jun Member, Planning Committee, year (2)
2016 Jul - 2017 Jun Speaker, occasion (1)
2015 Improving Patient Care Through Evidence-Based Clinical Practice (EBCP) – The 4th Kuwait EBCP Workshop, December 15-17, 2015 (3 days intensive course for Residents and Fellows – Member of the Faculty team).
2014 Clinical Epidemiology and Evidence Based Medicine, Intensive Course, United Arab Emirates, El Shargia, (3 days intensive course – course key faculty)
2023 Level 1: Guideline Group or Panel Member Course. International Guideline Development Credentialing & Certification (INGUIDE) Program.

FACULTY DEVELOPMENT

2015 Jul - 2016 Jun Facilitator, Short Session, Other, occasion (2)
2011 Jul - 2012 Jun Mentorship Part 1: Mentee (BEST 2.5 hrs.) - Oct. 25, 2011 (2)
2011 Jul - 2012 Jun Mentorship Part 3: Mentee (BEST 2.5 hrs.) - Jan. 24, 2012 (2)
2011 Jul - 2012 Jun Experimental PBL - October 24, 2011 (3)
2011 Jul - 2012 Jun Tutoring 101 - October 25, 2012 (3)

2011 Jul - 2012 Jun	Clinical Teaching Fundamentals - Feb 13 and March 3, 2012 (12)
2011 Jul - 2012 Jun	Mentorship Part 4: Mentee - March 6, 2012 (2)
2011 Jul - 2012 Jun	5th Annual Faculty Development Day - Direct Observation - April 25, 2012 (2)
2011 Jul - 2012 Jun	Mentorship Series, Part 2 - Nov 15/12. (3)
2010 Jul - 2011 Jun	Your McMaster CV: Tips & Advice - Feb. 09, 2011 (BEST 1.5 hours) (2)

Equity, Diversity and Inclusion

2023 Feb	Department of Medicine's Equity and Diversity 2021 Survey
----------	---

Faculty of Health Sciences

2013 Jul - 2017 Jun	Department Education Coordinator
---------------------	----------------------------------

CONTRIBUTIONS TO TEACHING PRACTICE

Course/Curriculum Development

2013 - present	Development of HRM #777 "Diagnosis and Prognosis". This course was newly introduced in the HRM MSc portfolio in response to a growing request for designing and running methodologically sound studies in the specific categories, which in turn is a consequence of the current interest in personalized medicine and evidence-based communication to patients and shared decision making. The course was developed in 2013 and 2014 in collaboration with Mark Smieja and Alice Lytwyn, and first delivered during the Academic Year 2014-15, as intensive course in the spring term. My personal contribution, beyond overall coordination and planning, was the development of the 5 units on prognosis, revision of the units on Diagnosis and Guideline Development, and co-development of all the ancillary materials. I am currently acting as co-coordinator of the course with Dr. Lytwyn. I have developed a specific self-learning module, delivered as HRM #705, centered on the Analysis of Registry Data. The course covers aspects as prospective registry data structure planning, linking registry data, data validation, longitudinal data analysis, handling of confounding, foundations of propensity score analysis. The course has been requested by fellows in hematology and transfusion medicine to date.
----------------	---

Development/Evaluation of Educational Materials

2015 - present	As a clinical teacher, I completely redesigned the 4 teaching units for Hemophilia, Von Willebrand Disease, Rare Bleeding Disorders and Laboratory Screening and Diagnosis of Bleeding Disorders for the Bleeding Disorders and Transfusion Medicine Rotation of the Fellowship Curriculum in Hematology. Specifically, I have successfully changed the format of the frontal component of teaching from criticizing a presentation proposed by the learner to the critical appraisal of a set of articles, among which some mandatory readings and some new references to be proposed by the learners. A specific goal obtained with this change is allowing teaching critical appraisal of literature in the field of rare disease.
2015 - 2016	I developed a specific self-learning module, delivered as HRM #705, centered on the Analysis of Registry Data. The course covers aspects as prospective registry data structure planning, linking registry data, data validation, longitudinal data analysis, handling of confounding, and foundations of propensity score analysis. The course has been requested by fellows in hematology and transfusion medicine to date. As lecturer and tutor of HRM #721 and #730 I have contributed new teaching and tutoring material (particularly for the units on Outcomes and Measurements)
Leadership	
2013 - 2017	I was Department Education Coordinator for the Department. In this capacity, and in addition to the usual DEC activity, I introduced the following innovations: - I designed a standard operating procedure, complete with the necessary forms, to ensure faculty in HEI smoothly get all the needed teaching peer-review requested by McMaster to fulfil assessment to the scope of renewal and promotion. - I was instrumental in creating a new "Education Council" within the Department, chaired by the DEC and composed by all the Program Directors of the 8 Programs homed in the Department. The scope for this committee is to advise the Chair on the needed interventions to harmonize teaching and best use resources to respond to educational needs. As a part of the scope of action of the Committee, we have planned an educational role Departmental Database, contributions to which will be going forward integrated into the recruitment and Career Review process for full and part-time faculties.
2020 – present	Chair, Department of Health Research Methods, Evidence, and Impact

SUPERVISORSHIPS

Supervisory Committees

Health Research Methodology

2021 Sept - current	Member, PhD Thesis Committee, Antonio Bognanni
2021 Jul – May 2022	Member, MSc Supervisory Committee, Giovanna Muti Schünemann: "Antithrombotic prophylaxis for Thromboembolism in adult patients with a Left Ventricular Assist Device (LVAD): an update of a systematic review"
2014 Jul - 2019 Jun	Member, Supervisory Committee PhD, student per year (8)
2017 Jul - 2019 Jun	Member, Thesis Committee, MSc, student per year (3)
2016 Jul - 2019 Jun	Thesis Supervisor, PhD, student per year (3)

2011 Jul - 2015 Jun Member, Supervisory Committee, MSc, student per year (4)

2011 Jul - 2018 Jun Thesis Supervisor, MSc, student per year (10)

e-Health MSc Program

2012 Jul - 2015 Jun Thesis Supervisor, MSc, student per year (4)

Health Policy PhD Program

2022 Dec Chair, Thesis Committee Final Oral Examination – Ahmednur Ali

Medical Sciences

2024- Member, Supervisory Committee, PhD, Syed Mahamad

Other

2021 Sept – present Member, Thesis Advisory Committee, MSc, Sam Himiak, University of Waterloo

Postdoctoral Fellowship

2023 April – 2025 March Sanna Alsubheen (PIVOT/COPDF)

2023 January – 2024 Jan Elham Razmpoosh (EBSCO)

LIFETIME RESEARCH FUNDING

Grants Peer Reviewed (Primary Investigator's name is the first name listed)

- | | |
|-----------|--|
| 2023-2025 | Title: Evidence-based Abstracts for the Journal of Bone and Joint Surgery
Iorio A, Lori Linkins
Funding: Journal of Bone and Joint Surgery
Total Funding: \$66,249 USD (January 1, 2023 – December 31, 2025) |
| 2024-2025 | Title: Estimation of an updated Green Gene F and Green Mono population pharmacokinetic model appropriate for use on Accessible Population Pharmacokinetics Service – Hemophilia (WAPPS-Hemo) platform
Iorio, A (PI)
Funding: Green Cross Corporation
Total Funding: \$19,830 (April 19, 2024 -April 19, 2025) |
| 2024-2026 | Title: Development and validation of a prediction model for chronic post-surgical pain after (Mac-PROSPER)
Iorio A (PI), Sadeghirad B, Busse J, Shanthanna H, Madden K, Mac-PROSPER Group.
Funding Agency: HAHSO
Total Funding: 186,683 (April 1, 2024 -September 30, 2026). |
| 2023-2025 | Title: A clinical prediction model for the diagnosis of thrombocytopenia
Arnold DM, DiRaimo J, Foroutan F, Iorio A, Li N, Parpia S, Xie F.
Funding Agency: CIHR |

	Total Funding \$120,000 (Oct 1, 2023 – Sept 30, 2025)
2022-2024	Title: PIVOT (Patient-Inspired Validation of Outcome Tools) initiative's post-doctoral research fellowship Iorio A (PI) Funding Agency: COPD Foundation Total Funding: \$141,600 (Sept 1, 2022 – Aug 31, 2024)
2022-2024	Title: ACP Journal Club and ACP Journal Wise Production Iorio A (PI) Funding Agency: American College of Physicians Total Funding: \$2,437,149 (January 1, 2022 – December 31, 2024)
2022-2026	Title: Chronic Pain Network: Moving towards knowledge mobilization and implementation science. Buckley DN, Hudspeth M, Raymond V, Beaudry H, Birnie KA, Bonin RP, Bosma RL, Choinière M, Gilron I, Iorio A, Latimer MA, Lavis JN, MacDermid JC, Noel ME, Poulin PA, Presseau J, Rash JA, Stinson JN, SylliboyJR. Funding Agency: CIHR: SPOR Networks - Knowledge Mobilization and Implementation Science Total Funding: \$3,749,500 (April 1, 2022 – March 31, 2026)
2021-2023	Title: Project for the realization of Phase 2 of the PROBE service: a pilot study for longitudinal questionnaire completion and validation against the HAL questionnaire. Iorio A (PI) Funding Agency: F. Hoffmann-La Roche Ltd. – Switzerland Total Funding: \$260,418.00 USD (Sept 30, 2021 – Dec 31, 2023)
2022-2022	Title: Empowering patient ambassadors to champion research outcomes that are a priority for people who have lived experience with venous thromboembolism. Duffett, L (PI), West, C (PI), Iorio A, Gal G, Shea B. Funding Agency: Ontario SPOR Support Unit Total Funding: \$25,000 (Jan1, 2022 – June 30, 2022)
2021 – 2023	Title: Coronavirus Variants Rapid Response Network: CoVaRR-Net - Leveraging research to support Canadians' decisions about COVID-19 variants of concern. Iorio A (PI) Funding Agency: University of Ottawa Total Funding: \$104,000 (March 1, 2021 – March 31, 2023)
2021/2022	Title: Improving the Quality of Academic Publishing: Identifying Recommendations for the Development of Journal Creation Guidelines and Publisher Preferences for a Journal Authenticator Tool. Moher D (PI), Iorio A, Cobey K. Funding Agency: Mitacs-Accelerate Total Funding: \$59,999.00 (September 2021- November 2022)
2021-2022	Title: SAME PAGE: Bridging the gaps between high-quality clinical research evidence for COVID-19 and clinicians, guideline developers, and policy makers. Linkins L-A (PI), Abdelkader W, Brignardello Peterson R, Haynes R, Iorio A, Lavis J, Lokker C, Schunemann H. Funding Agency: CIHR – Emerging COVID-19 Research Gaps & Priorities – Confidence in science Total funding: \$181,125 (June 2021 – May 2022)

- 2021 – 2023 Title: Supporting Canadian Health Service Users with Decision-Making on COVID-19 vaccination during pregnancy and lactation.
Barrett J (PI), D'Souza R (PI), Agarwal G, Alton G, Alvarez E, Apatu E, Bisnaire L, Boamah S, Bogler T, Castillo E, Cook J, Darling E, Dube E, Dunn J, El-Chaar D, Ellis S, Fadel S, Fell D, Iorio A, Katherine W, Kuret V, Lavis J, MacDonald S, Malhamé I, Poliquin V, Schwartz L, Scott H, Sprague AE, Sussman D, Thabane L, Walker M, Yudin M, DeFrance B, Downey B, Money D, Schoenfeld E, Vohra-Miller S, Wolfe S.
Funding Agency: PHAC. Immunization Partnership Fund: Increasing Confidence, Acceptance and Uptake of COVID-19 Vaccine.
Total funding: \$500,000 (July 2021 – June 2023)
- 2021 - 2022 Title: Encouraging vaccine confidence among pregnant and breastfeeding Canadians.
Barrett J (NPI), Agarwal G, Alvarez E, Boamah S, Castillo E, D'Souza R, Darling E, Dunn J, Iorio A, Alton G, Apatu E, Bisnaire L, Bogler T, Cook J, Dube E, El-Chaar D, Ellis S, Fadel S, Fell D, Katherine W, Kuret V, Lavis J, MacDonald S, Malhame I, Poliquin V, Schwartz L, Scott H, Sprague AE, Sussman D, Thabane L, Walker M, Yudin M, DeFrance B, Downey B, Money B, Schoenfeld E, Vohra-Miller S, Wolfe S.
Funding Agency: Natural Sciences and Engineering Research Council of Canada. Encouraging vaccine confidence in Canada Spring 2021 competition.
Total funding: \$50,000 (July 2021 – June 2022)
- 2020 – 2021 Title: COVID-19 Evidence Network to support Decision-making (COVID-END)
Lavis JN (Principal Applicant), Grimshaw JM, Santesso NAM, Tricco AC (Co-Principal Applicants), Abou Setta A, Adams O, Adhikari N, Bacon S, Bean T, Bhutta Z, Bignami S, Bornstein S, Brennan J, Brignardello Peterson R, Brouwers M, Bryan S, Chilibeck P, Clement F, Conly J, Corneil T, Curran J, Diamond D, Dobbins M, Dumez D, Durnford K, Florez I, Forest P-G, Fowler R, Friedenreich C, Gagnon A, Garrity C, Ghali W, Greenwood M, Grinspun D, Guyatt G, Hartling L, Hayden J, Hayes A, Hazlewood G, Hebert P, Hutton B, Iorio A, Jedwab J, Kellner J, Kelly S, Khawaja Z, Lamontagne F, Leblanc A, Leontiadis G, Levinson W, Li L, Little J, Manns B, Meddings J, Milaney K, Mittmann N, Mitton C, Moayyedi P, Moffitt P, Moher D, Montesanti S, Morris A, Murthy S, Neil-Sztramko S, Pottie K, Proulx L, Reid R, Reiger K, Roy D, Salvadori M, Sawatzky R, Saxinger L, Schuckel V, Schunemann H, Sharma N, Shaw S, Shea B, Siemieniuk R, Smith M, Southern D, Spinks N, Stelfox H, Straus S, Thombs B, Tonelli M, Tugwell P, Turgeon A, Watson-Creed G, Welch V, Wells G, Williamson T, Wilson MG, Wright J (Co-Applicants and Knowledge Users)
Funding Agency: Canadian Institutes of Health Research
Total Funding: \$1,000,000 (December 2020 – November 2021))
- 2020 – 2021 Title: A systematic and living evidence and guideline recommendation map on COVID-19.
Schunemann, Holger (PI), Co-applicants: Adrienne Stevens, Tamara Lotfi, Gunn Vist, Signe Flottorp, Elie Akl, Derek Chu, Jan Brozek, Nancy Santesso, Robby Nieuwlaat, Artur Nowak, Joerg Meerpohl, Mark Loeb, Alfonso Iorio, Dominik Mertz, Thomas Piggott, Lawrence Mbuagbaw, Waleed Alhazzani, Anisa Hajizadeh, Romina Brignardello-Petersen, Marge Reinap, Tanja Kuchenmüller, Ludovic Reveiz, Lorenzo Moja, Zac Munn, Elaine Harrow, Anne Hayes, Vivan Welch, Peter Tugwell, Lisa Hartling, Nav Persaud, Kevin Pottie, Tamara Kredo, Jim Wright, Joseph Mathew, Ignacio Neumann, Pablo Alonso, Reem Mustafa, Maicon Falavigna, Maureen Smith, Nicole Mittman, Rachel Rodin, Marc Avey, Miranda Langendam, Marina Davoli, Alexis Turgeon, FEaslav Klugar
Funding Agency: CIHR
Total Funding: \$1,456,275 (Jun 1, 2020 – May 31, 2021)
- 2019 Jun - 2024 Title: Software License, Development and Service Agreement between SOBI and McMaster University for the McMaster Platform, a software platform powering a web-based application for pharmacokinetic estimation in patients. Term: 5 years from Effective date (June 2019). PI: Alfonso Iorio. Amount: \$2,175,000.

- 2019 Jul Title: Establishing an International Core Outcome Set for Clinical Trials of Interventions for Venous Thromboembolism in Adults (VTE-COS)
Funding source: Canadian Institutes of Health Research (CIHR)/Circulatory and Respiratory Health
Principal Applicant: Dr. Grégoire Le Gal
Co-Applicants: Dr. L. Duffett Dr. B. Hutton Prof. A. Iorio Dr. B. Shea Dr. L. Skeith Dr. T. Tritschler Dr. P. Tugwell
Total Funding: \$263,926; Term: 3 years.
- 2019 Apr Project Title: Peri-surgical management of persons living with hemophilia A or B in the Indiana Hemophilia & Thrombosis Center: description of current practices and analysis of risk factors for hemorrhagic complications, including pharmacokinetics data from the web accessible pharmacokinetics service (WAPPS). Principal Investigator: Alfonso Iorio.
Funding source: Indiana Hemophilia & Thrombosis Center, Inc. Total funding: \$100,000.00 USD. Term April 2019 – June 2022 (Four years).
- 2018 Nov Project Title: Bayer support of MyWAPPS activities. Principal Investigator: Alfonso Iorio.
Funding source: Bayer Consumer Care AG, Basel Switzerland. Total Funding: 500,000 Euros. Term: November 1, 2018 – October 31, 2021.
- 2018 Jan Project Title: Probe Service (Roche-PROBE). Principal Investigator: Alfonso Iorio. Funding source: Hoffman-La Roche Limited. Total Funding: 182,640.00 USD. Term: January 2018-December 2020.
- 2017 Nov Project Title: Economic Burden of Illness in Hemophilia A in Canada: a Multi-Center, Retrospective, Non-Interventional Study. Principal Investigator: Alfonso Iorio. Funding source: Hoffman-La Roche Limited (Canada). Total Funding: \$111,500.00 (CAD). Term: Nov 2017-Nov 2019.
- 2017 Sep Application: Title: Personalized Medicine for Canadians with Hemophilia: a pragmatic evaluation of Web-Accessible Population Pharmacokinetics Service-Hemophilia (WAPPS-Hemo) tailored dosing

Applicant: & Independent Researcher – Senior Investigator – **Alfonso Iorio**

Principal Applicant: Andrea Edginton, University of Waterloo (Ontario), School of Pharmacy
Principal Applicant: David Lillicrap, Queen's University, (Kingston, Ontario), Pathology and Molecular Medicine
Principal Applicant: Man-Chiu Poon, University of Calgary, Hematology-Oncology, Cumming School of Medicine
Co-Applicant: Paula James, Queen's University (Kingston, Ontario), Department of Medicine
Collaborator: Shannan Jackson, University of British Columbia, Department of Hematology
Collaborator: Adrienne Lee, University of Calgary, Department of Oncology
Collaborator: Michel Long, Canadian Hemophilia Society (Montreal)
Collaborator: David Page, Canadian Hemophilia Society (Montreal)
Collaborator: Jayson Stoffman, Cancer Care Manitoba
Collaborator: Lehana Thabane, Health Research Methods, Evidence, and Impact (HEI)
Funding Source: Canadian Institutes of Health Research (CIHR), Total Funding: \$335,000
- 2016 Oct – 2026 Sep Principal Investigators: Alfonso Iorio, Brian Haynes. EBSCO-Dynamed Partnership.
Total Funding: \$7,463,634.

2016 Apr – 2021 Mar	Principal Investigators: Buckley, David N, Hudspith Maria, Choiniere Manon, Davis Karen D, Diatchenko Luda, Finlay G.A, Frechette Pierre, Gilron Ian, Iorio Alfonso, Latimer Margot A, Macdermid Joy C, Poulin Patricia A, Schneider Cyril, Stevens Bonnie J, Stinson Jennifer. Co-Investigators: Beaudet Nicolas, Busse Jason W, Craig Kenneth D, Devereaux Philip J, El-Gabalawy Renee, Gendron Louis, Ghasemlou Nader, Gordon Allan S, Hadjistavropoulos, Thomas, Jarvi Keith A, Katz Joel D, Mcgillion Michael H, Moulin Dwight E, Noel Malanie E, Prescott Steven, Salter Michael W, Sessle Barry J, Shamji Mohammed F, Singh Gurmit, Toupin April, Walton Karine, Ware David M, Watt-Watson Mark A, Watt-Watson Judith. Chronic Pain Network, Grant, Canadian Institutes of Health Research (SPOR) – New Project, 12,500,000.00.
2015 Sep - 2020 Aug	Kahn, Susan Rebecca, Rodger, Marc Alan, Afilalo, Marc, Anderson, David Robert, Bates, Shannon Marie et al., CanVECTOR (Canadian Venous Thromboembolism Clinical Trials and Outcomes Research) Network, Grant, Canadian Institutes of Health Research (ICRH Community Development Program Grants), Research - New Project, \$1,500,000.00.
2015 Nov – 2017 Dec	Alfonso Iorio, Determining the half-life of prophylaxis treatment using population pharmacokinetic. Mitacs-Accelerate Graduate Research Internship Program. Recipient: Chatree Chai-Adisaksopha. Partner Organization: Novo Nordisk Canada Inc. Studentships: \$90,000.00.
2014 Apr – 2018 Mar	Evaluating the impact of McMaster Optimal aging Portal on knowledge, behavioural interventions and health behaviours related to cancer risk in underserved populations. Co-Applicant: Alfonso Iorio. Canadian Institutes of Health Research (CIHR) CIHR Catalyst Grant: Health services and economics research cancer control. Total funding: \$100,000.00 (CDN). Funding Competitive: Yes.
2012 Jan – 2017 Dec	The Labarge Optimal Aging Opportunities Fund. Principal Applicant: John Lavis. Principal Investigators: Maureen Dobbins, Brian Haynes, Anthony Levinson, Parminder Raina. Susanne Labarge Foundation. Optimal Aging Initiative. Total Funding: \$5,000,000.00 (CDN).
2015 Dec - 2017 Nov	Paula James, Alfonso Iorio, Arun Keepanasseril, Shannon Jackson, Michelle Sholzberg, Rochelle Winikoff, Natalia Rydz, Sue Robinson, and Emily Rimmer, The Canadian Hemophilia Carriers Study., Grant, 2015 Baxalta-Canadian Hemophilia Epidemiological Research Program (B-CHERP), Research - New Project, \$225,000.00.
2015 Apr - 2016 Mar	Alfonso Iorio, Michelle Zeller, Nancy Heddle, Mark Crowther, Wendy Gerry, Lilian., MASCOT - II:Linkage at McMaster Health Sciences of Accesss, Clinical Clustering Information, Oscar and the ad hoc Developed Trust Xt Database. Proof of Concept of a Knowledge Translation Need and Impact Assessment Strategy, Grant, HAHSO/OMOHLTC, \$197,162.00.
2015 Mar - 2016 Feb	Chambers, Christine Therese, Poulin, Patricia Anik, Smyth, Catherine Elizabeth, Stevens, Bonnie J. Stinson, Jennifer Nan. Co-Investigators: Busse, Jason Walter, Forgeron, Paula Anne, Iorio, Alfonso, Lalloo, Chitra, Lynch, Mary Elizabeth, McCartney, Colin John Lindsay, Visca, Regina, Improving Chronic Pain for all Canadians: A patient engagement project to identify research priorities., Grant, Canadian Institutes of Health Research,

	Research - New Project, \$45,000.00
2015 Jun - 2015 Dec	Alfonso Iorio, Graduate Student and Recipient of the Award: Abha Athale, 2015 ASH Hematology Opportunities for the Next-Generation of Research Scientists (HONORS), Grant, American Society of Hematology, Research - Prize / Award, \$5,000.00
2014 May – 2015 Dec	Holger Schunemann, Nancy Santesso, Alfonso Iorio, Development of Evidence-Based Practice Guidelines for the Management of Hemophilia. National Hemophilia Foundation - \$275,000.00.
2014 Jul - 2016 Jun	Francesca Fallarino, Co-Investigator: Alfonso Iorio, Re-setting tolerance to FVIII via aryl hydrocarbon receptor ligands., Grant, Bayer Healthcare AG, Research - New Project, \$181,855.00.
2013 Jul - 2016 Jun	Iorio, Alfonso, McKibbin K. Ann, Thabane Lehana, WAPPS-Hemo (Web Accessible Population Pharmacokinetics Service- Hemophilia), Grant, B-CHERP grant competition, AHCDC - New Project, \$221,839.00
2013 Apr - 2014 Mar	Barbara, Angela, Iorio Alfonso, Assessing differential immunogenicities of factor VIII molecules : Do previously treated hemophilia A patients repress valid model? A clinical epidemiology investigational approach, Grant, Canadian Hemophilia Society (CHSOC), Research - New Project, \$72,750.00
2012 Jun - 2015 May	Iorio, Alfonso, CHESS- Canadian Haemophilia Surveillance Scheme, Grant, Association of Hemophilia Clinic Directors of Canada (AHCDC), Research - New Project, \$135,000.00
2012 Apr - 2014 Dec	Iorio, Alfonso, Barty Rebecca, Chan David, Cotoi Chris, Crowther Mark, Gallagher Jason, Haynes Brian, Heddle Nancy, Taggart Karon, MASCOT & Linkage at McMaster Health Sciences of Accessss, Clinical Clustering Information, OSCAR and the ad-hoc developed TRUST-XT database. Proof of concept of a knowledge translation need of impact assessment strategy, Grant, Hamilton Academic Health Sciences Organization (HAHSO), Research - New Project, \$197,054.00.
2012 – 2014	Iorio Alfonso (Mentor) Clinical Scholarship Award awarded to Maura Marcucci (fellow), Bayer Hemophilia Award Program, Grant, Research - New Project, \$160,000.00.
2013 Apr - 2013 Aug	Iorio, Alfonso, Giguere Anik, The Decision-Box and Patient Decision Aids in Hemophilia: tools to facilitate shared decisions-making, Grant, Mathematics of Information Technology and Complex Systems (MITACS), Collab/Partnerships Research - National Networks (e.g. IRIS,CARNET,CEMAID,CITR), \$7,500.00.
2011 - 2013	ACCESSSS to Current Best Evidence to Support Health Care Decision Phase II: Extending coverage to the community and optimizing usefulness. HAHSO/OMOHLTC. Co-investigator., Grant, Research - New Project, \$155,154.00.
2011 - 2013	Modulating the antibody response to exogenous Factor VIII: the role of tryptophan catabolism. Bayer Early Careers Investigator Award. \$210,000. Senior Investigator on the application of the supervised fellow Davide Matino (University of Perugia). Grant, Research - New Project, \$210,000.00.

2011 Nov - 2025 Dec	Iorio, Alfonso, Strategies to Optimize the Use of Prognostic Predictors, Grant, McMaster University (MAC), Research - New Project, \$26,832.00
2016 Jan - 2017 Jan	Co-Principal Investigators: Iorio, A., Chan, A., Co-investigator: Davide Matino., Investigating FIX extravascular localization as a potential new strategy for longer protection in hemophilia B., Grant, Pfizer Inc., \$133,032.00
2008 – present	Management of the National Registry of Congenital Coagulopathies. AICE. Euro 12,000 per year, Grant, Research - New Project
2014 May - 2015 Dec	Holger Schunemann, Alfonso Iorio, Development of Evidence-Based Practice Guidelines for the Management of Hemophilia., Grant, National Hemophilia Foundation, Research - New Project, \$275,000.00
2013 Jun - 2015 Jun	Alfonso Iorio, Surveillance of Safety and Efficacy of Wilate I patients with von Willebrand disease, Grant, Octapharma, Research - New Project, \$11,073.00
2013 Jan - 2015 Jan	Alfonso Iorio, Developing and educational tool to complement the WAPPS website, Grant, Novo Nordisk A/S Denmark, Research - New Project, \$53,000.00
2013 Dec - 2015 Dec	Iorio, Alfonso, WAPPS-Hemo project (Web Accessible Population Pharmacokinetics Service - Hemophilia), Grant, Novo Nordisk Health Care AG (NNHC), Research - First Time, \$53,500.00
2013 Jan - 2014 Dec	Iorio, Alfonso, Haemophilia Experiences Results and Opportunities (HERO) Initiative, Contract, Novo Nordisk Health Care AG (NNHC), Research - New Project, \$35,775.00
2013 Aug - 2014 Aug	Iorio, Alfonso, Assessing differential immunogenicities of factor VII molecules: Do previously treated hemophilia A patients represent a valid model? Grant, Pfizer Canada Inc. (PFIZER), Research - New Project, \$38,697.00
2012 Jul - 2014 Jun	Iorio, Alfonso, Patient Level Meta-Analysis of Prospective/Retrospective Studies Describing Case Cohorts of Hemophilia Patients, Grant, Bayer Inc. (BAYER), Personnel - Postdoctoral Fellowships, \$100,000.00
2011 Nov - 2014 May	Iorio, Alfonso, HERO: Haemophilia Experience Results and Opportunities Initiative, Contract, Novo Nordisk Health Care AG (NNHC), Research - New Project, \$18,610.00
2012 Nov - 2013 Dec	Iorio, Alfonso, Novo Nordisk-Delphi Panel in haemophilia treaters to identify baseline patient characteristics likely to influence choice and success of treatment strategy, Contract, Novo Nordisk Health Care AG (NNHC), Research - New Project, \$1,500.00
2013 Apr - 2013 Aug	Iorio, Alfonso, Giguere Anik, The Decision-Box and Patient Decision Aids in Hemophilia: tools to facilitate shared decisions-making, Grant, Mathematics of

	Information Technology and Complex Systems (MITACS), Collab/Partnerships Research - National Networks (e.g. IRIS,CARNET,CEMAID,CITR), \$7,500.00.
2012 Jul - 2013 Jun	Iorio, Alfonso, Grants 4 Targets, Grant, Bayer AG Corporate Division for Legal Affairs (BAYER AG), Research - New Project, \$37,000.00.
2012 Apr - 2013 Mar	Iorio, Alfonso, ACP Journal Club -Research Start Up Funds, Grant, McMaster University (MAC), Research - Transfer, \$20,000.00
2012 Feb - 2013 Feb	Iorio, Alfonso, Developing a 2-sided intervention to facilitate evidence based practice, Grant, Biogen Idec International GmbH (BIOGEN), Research - New Project, \$76,510.00
2011 Aug - 2012 Jul	Iorio, Alfonso, EUHASS PTP's Metanalysis, Grant, University of Sheffield (UNIVSHEF), Research - New Project, \$19,591.00
2011 Jul - 2012 Jun	Iorio, Alfonso, Knowledge translation and medicinal informatics, Grant, Hamilton Academic Health Sciences Organization (HAHSO), Research - New Project, \$30,000.00
2011 Jul - 2012 Jun	Iorio, Alfonso, EAHAD - Predictors of inhibitor development on hemophilia, Grant, European Association for Haemophilia and Allied Disorders (EAHAD), Research - New Project, \$13,125.82.
2012 Feb - 2012 Apr	Iorio, Alfonso, Modified Delphi - On Line Building, Grant, Novo Nordisk Canada Inc. (NNCI), Research - New Project, \$4,250.00
2012 Mar	Haynes, Brian, Hill Sophie, Iorio Alfonso, Jack Susan, Nieuwlaat Robby, Interventions to enhance patient adherence with prescribed medications: A systematic review and analysis of components of interventions, Grant, Canadian Institutes of Health Research (CIHR), Research - Team, \$93,750.00.
2005 - 2011 Jan	OPERA, On demand Plus Extended FVIII Replacement and Activity trial, EUDRACT 2006-003679-12. Pfizer, euro 120,000. Principal Investigator., Grant
2005 - 2010	AESPERT, Across factor Eight Switch Pharmacokinetic Evaluation of Recombinant Factor Trial, Multicentre Italian Trial, EUDRACT 2006-004426-88. Pfizer. Principal Investigator, Grant, Research - New Project, \$40,000.00
2005 Apr - 2008 Mar	Alfonso Iorio, Management of the National Registry of Congenital Coagulopathies. AICE. Euro 6,000 per year, Grant, Fondazione Paracelso, Research - New Project, \$27,000.00.
2004 - 2005	Carla Silvani, Alfonso Iorio. Ottimizzazione dell'impiego del plasma umano: riduzione delle reazioni avverse evitabili mediante condivisione di linee guida, generazione ed impiego di un sistema di indicatori di efficacia, sicurezza ed appropriatezza terapeutica mediante l'impiego di outcome clinici e gestionali. Ricerca Finalizzata Socio Sanitaria

Regione dell'Umbria. Co-Investigator. \$18,000 Euros., Grant, Research - New Project

- 2004 – 2005 Percorso assistenziale integrato per il monitoraggio della terapia anticoagulante orale: dal medico di base al centro specialistico attraverso i centri di salute e i laboratori dell'Azienda Sanitaria Locale. Ricerca Finalizzata Socio Sanitaria Regione dell'Umbria. Principal Investigator., Grant, Research - New Project, \$25,000.00
- 2001 - 2002 “Percorso di monitoraggio della terapia anticoagulante orale mediante accesso del paziente in centri periferici distribuiti sul territorio per il prelievo e la consegna della proposta di prescrizione terapeutica e valutazione medica centralizzata in tempo reale da parte di personale specializzato del centro per la sorveglianza della terapia anticoagulante orale” Ricerca Finalizzata Socio Sanitaria Regione dell'Umbria, Euro 25,000. Principal Investigator, Grant, Research - New Project, \$25,000.00

LIFETIME PUBLICATIONS (Principal Author is the first name on each of the entries below)

Peer Reviewed Contributions to Books

1. Iorio A, Alatri A, Agnelli G. Non anticoagulant actions of glycosaminoglycans: protein binding studies. In: Non anticoagulant actions of glycosaminoglycans. J. Harenberg, B. Casu, eds. Plenum Press, New York. 101-12. 1996.

Peer Reviewed Contributions to Books (Book Chapters)

1. Alfonso Iorio, Davide Martino “I difetti emostatici nell'insufficienza renale” (“Hemostatic defects in kidney disease”). Clinica e terapia delle malattie emorragiche e trombotiche. G. Castaman, A. Falanga. Piccin, 2018.

Peer Reviewed Journal Articles

1. CHART Collaborative; Huo B, Collins GS, Chartash D, Thirunavukarasu AJ, Flanagan A, Iorio A, Cacciamani G, Chen X, Liu N, Mathur P, Chan AW, Laine C, Pacella D, Berkwits M, Antoniou SA, Camaradou JC, Canfield C, Mittelman M, Feeney T, Loder EW, Agha R, Saha A, Mayol J, Sunjaya A, Harvey H, Ng JY, McKechnie T, Lee Y, Verma N, Stiglic G, McCradden M, Ramji K, Boudreau V, Ortenzi M, Meerpohl JJ, Vandvik PO, Agoritsas T, Samuel D, Frankish H, Anderson M, Yao X, Loeb S, Lokker C, Liu X, Guallar E, Guyatt GH. Reporting Guideline for Chatbot Health Advice Studies: The CHART Statement. JAMA Netw Open. 2025 Aug 1;8(8):e2530220. doi: 10.1001/jamanetworkopen.2025.30220. PMID: 40747871.
2. CHART Collaborative; Huo B, Collins G, Chartash D, Thirunavukarasu A, Flanagan A, Iorio A, Cacciamani G, Chen X, Liu N, Mathur P, Chan AW, Laine C, Pacella D, Berkwits M, Antoniou SA, Camaradou JC, Canfield C, Mittelman M, Feeney T, Loder E, Agha R, Saha A, Mayol J, Sunjaya A, Harvey H, Ng JY, McKechnie T, Lee Y, Verma N, Stiglic G, McCradden M, Ramji K, Boudreau V, Ortenzi M, Meerpohl J, Vandvik PO, Agoritsas T, Samuel D, Frankish H, Anderson M, Yao X, Loeb S, Lokker C, Liu X, Guallar E, Guyatt G. Reporting guideline for chatbot health advice studies: The CHART statement. Artif Intell Med. 2025 Oct;168:103222. doi: 10.1016/j.artmed.2025.103222. Epub 2025 Aug 1. PMID: 40753040.

3. Huo B, Collins G, Chartash D, Thirunavukarasu A, Flanagan A, Iorio A, Cacciamani G, Chen X, Liu N, Mathur P, Chan AW, Laine C, Pacella D, Berkwits M, Antoniou SA, Camaradou JC, Canfield C, Mittelman M, Feeney T, Loder E, Agha R, Saha A, Mayol J, Sunjaya A, Harvey H, Ng JY, McKechnie T, Lee Y, Verma N, Stiglic G, McCradden M, Ramji K, Boudreau V, Ortenzi M, Meerpohl J, Vandvik PO, Agoritsas T, Samuel D, Frankish H, Anderson M, Yao X, Loeb S, Lokker C, Liu X, Guallar E, Guyatt G; CHART Collaborative. Reporting guideline for Chatbot Health Advice studies: the CHART statement. *BMC Med.* 2025 Aug 1;23(1):447. doi: 10.1186/s12916-025-04274-w. PMID: 40745595; PMCID: PMC12315282.
4. Zheng XL, Al-Housni Z, Cataland SR, Coppo P, Geldziler B, Germini F, Iorio A, Keepanasser A, Masias C, Matsumoto M, McCrae KR, McIntyre J, Mustafa RA, Peyvandi F, Russell L, Tarawneh R, Vesely SK; International Society on Thrombosis and Haemostasis. 2025 focused update of the 2020 ISTH guidelines for management of thrombotic thrombocytopenic purpura. *J Thromb Haemost.* 2025 Jun 17:S1538-7836(25)00360-5. doi: 10.1016/j.jtha.2025.06.002. Epub ahead of print. PMID: 40533296.
5. 36: Bhavsar D, Duffy L, Jo H, Lokker C, Haynes RB, Iorio A, Marusic A, Ng JY. Policies on artificial intelligence chatbots among academic publishers: a cross- sectional audit. *Res Integr Peer Rev.* 2025 Feb 28;10(1):1. doi: 10.1186/s41073-025-00158-y. PMID: 40022253; PMCID: PMC11869395.
6. Guyatt G, Vandvik PO, Iorio A, Agarwal A, Yao L, Eachempati P, Zeng L, Chu DK, D'Souza R, Agoritsas T, Murad MH, Schandelmaier S, Rylance J, Djulbegovic B, Montori VM, Hultcrantz M, Brignardello-Petersen R. Core GRADE 7: principles for moving from evidence to recommendations and decisions. *BMJ.* 2025 Jun 3;389:e083867. doi: 10.1136/bmj-2024-083867. PMID: 40461180.
7. Guyatt G, Yao L, Murad MH, Hultcrantz M, Agoritsas T, De Beer H, Schandelmaier S, Iorio A, Zeng L, Prasad M, Vandvik PO, Mustafa RA, Agarwal A, Devji T, Florez ID, Djulbegovic B, Chu DK, Rochweg B, Montori VM, Brignardello- Petersen R. Core GRADE 6: presenting the evidence in summary of findings tables. *BMJ.* 2025 May 27;389:e083866. doi: 10.1136/bmj-2024-083866. PMID: 40425239.
8. Guyatt G, Iorio A, De Beer H, Owen A, Agoritsas T, Murad MH, Karthikeyan G, Cuello C, Prasad M, Kim K, Ali DS, Agarwal A, Hemkens LG, Yao L, Hultcrantz M, Rylance J, Chu DK, Vandvik PO, Djulbegovic B, Mustafa RA, Zeng L, Eachempati P, Rochweg B, Prasad K, Montori VM, Brignardello-Petersen R. Core GRADE 5: rating certainty of evidence-assessing indirectness. *BMJ.* 2025 May 20;389:e083865. doi: 10.1136/bmj-2024-083865. PMID: 40393729.
9. Guyatt G, Wang Y, Eachempati P, Iorio A, Murad MH, Hultcrantz M, Chu DK, Florez ID, Hemkens LG, Agoritsas T, Yao L, Vandvik PO, Montori VM, Brignardello- Petersen R. Core GRADE 4: rating certainty of evidence-risk of bias, publication bias, and reasons for rating up certainty. *BMJ.* 2025 May 13;389:e083864. doi: 10.1136/bmj-2024-083864. Erratum in: *BMJ.* 2025 Jul 29;390:r1468. doi: 10.1136/bmj.r1468. PMID: 40360206.
10. Guyatt G, Schandelmaier S, Brignardello-Petersen R, De Beer H, Prasad M, Murad MH, Eachempati P, Chu DK, D'Souza R, Iorio A, Agoritsas T, Yao L, Mustafa RA, Parpia S, Santaguida P, Vandvik PO, Hultcrantz M, Montori VM. Core GRADE 3: rating certainty of evidence-assessing inconsistency. *BMJ.* 2025 May 6;389:e081905. doi: 10.1136/bmj-2024-081905. PMID: 40328467.
11. Guyatt G, Zeng L, Brignardello-Petersen R, Prasad M, De Beer H, Murad MH, Iorio A, Agarwal A, Yao L, Agoritsas T, Rylance J, Mustafa RA, Vandvik PO, Eachempati P, Zhai C, Zhang L, Montori VM, Hultcrantz M. Core GRADE 2: choosing the target of certainty rating and assessing imprecision. *BMJ.* 2025 Apr 29;389:e081904. doi: 10.1136/bmj-2024-081904. PMID: 40300802.
12. Guyatt G, Agoritsas T, Brignardello-Petersen R, Mustafa RA, Rylance J, Foroutan F, Prasad M, Agarwal A, De Beer H, Murad MH, Schandelmaier S, Iorio A, Yao L, Jaeschke R, Vandvik PO, Zeng L, Parpia S, D'Souza R,

- Rind D, Chu DK, Eachempati P, Prasad K, Hultcrantz M, Montori VM. Core GRADE 1: overview of the Core GRADE approach. *BMJ*. 2025 Apr 22;389:e081903. doi: 10.1136/bmj-2024-081903. PMID: 40262844.
13. Zhou F, Parrish R, Afzal M, Saha A, Haynes RB, Iorio A, Lokker C. Benchmarking domain-specific pretrained language models to identify the best model for methodological rigor in clinical studies. *J Biomed Inform*. 2025 Jun;166:104825. doi: 10.1016/j.jbi.2025.104825. Epub 2025 Apr 15. PMID: 40246186.
14. Guyatt G, Hultcrantz M, Agoritsas T, Iorio A, Vandvik PO, Montori VM. Why Core GRADE is needed: introduction to a new series in The BMJ. *BMJ*. 2025 Apr 15;389:e081902. doi: 10.1136/bmj-2024-081902. PMID: 40233981.
15. Zhou, F., Parrish, R., Afzal, M., Saha, A., Haynes, R. B., Iorio, A., & Lokker, C. (2025). Benchmarking domain-specific pretrained language models to identify the best model for methodological rigor in clinical studies. *Journal of Biomedical Informatics*, 166, 104825. <https://doi.org/10.1016/j.jbi.2025.104825>
16. Hirniak S, Edginton AN, Iorio A, Wong WWL. A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions. *Pharmacoeconomics*. 2025 Apr 1. doi: 10.1007/s40273-025-01484-1. Epub ahead of print. PMID: 40167950.
17. Iorio A, Laine C. What You May Have Missed in 2024: Navigating New Medical Evidence. *Ann Intern Med*. 2025 May;178(5_Supplement):S1. doi: 10.7326/ANNALS-25-01164. Epub 2025 Apr 1. PMID: 40163887.
18. Chelle P, Hajducek D, Iserman E, Iorio A, Edginton A; International Prophylaxis Study Group. Exploring the Impact of Laboratory Reagents on Pharmacokinetic Profiling. *Haemophilia*. 2025 Mar 7. doi: 10.1111/hae.70021. Epub ahead of print. PMID: 40052423.
19. Ng JY, Liu H, Masood M, Farin R, Messih M, Perez A, Aalbersberg IJ, Alperin J, Bryson GL, Chen Q, Ehrlich A, Iorio A, Meester WJN, Willinsky J, Grudniewicz A, Cobo E, Cranston I, Cress PE, Gunn J, Haynes RB, Keenoo BS, Marušić A, Papas ER, Purvis A, Segundo JDB, Shankar PR, Stoev P, Weisflog J, Winker M, Cobey KD, Moher D. Publisher preferences for a journal transparency tool: A modified three-round Delphi study. *F1000Res*. 2025 Jan 31;13:915. doi: 10.12688/f1000research.154408.2. PMID: 40046244; PMCID: PMC11880752.
20. Zeng L, Hultcrantz M, Tovey D, Santesso N, Dahm P, Brignardello-Petersen R, Mustafa RA, Murad MH, Izcovich A, de Beer H, Ragusa MA, Johnston B, Zhang L, Iorio A, Guyatt G. Rating certainty when the target threshold is the null and the point estimate is close to the null. *BMJ Evid Based Med*. 2025 May 20;30(3):202-207. doi: 10.1136/bmjebm-2024-113077. PMID: 40044276.
21. Ng JY, Maduranayagam SG, Suthakar N, Li A, Lokker C, Iorio A, Haynes RB, Moher D. Attitudes and perceptions of medical researchers towards the use of artificial intelligence chatbots in the scientific process: an international cross-sectional survey. *Lancet Digit Health*. 2024 Nov 15:S2589-7500(24)00202-4. doi: 10.1016/S2589-7500(24)00202-4. Epub ahead of print. PMID: 39550312.
22. Lokker C, McKibbin KA, Afzal M, Navarro T, Linkins LA, Haynes RB, Iorio A. The McMaster Health Information Research Unit: Over a Quarter-Century of Health Informatics Supporting Evidence-Based Medicine. *J Med Internet Res*. 2024 Jul 31;26:e58764. doi: 10.2196/58764. PMID: 39083765.
23. Kim MS, Hajducek DM, Gilbert JC, Iorio A, Jilma B, Edginton AN. Kinetic Modeling for BT200 to Predict the Level of Plasma-Derived Coagulation Factor VIII in Humans. *AAPS J*. 2024 Jul 12;26(4):81. doi: 10.1208/s12248-024-00952-4. PMID: 38992298.
24. The Chart Collaborative. Protocol for the development of the Chatbot Assessment Reporting Tool (CHART) for clinical advice. *BMJ Open* 2024;14:e081155. doi: 10.1136/bmjopen-2023-081155

25. Hajducek DM, Chelle P, Iorio A, Iserman E, Edginton AN. Estimated prophylactic dose required to achieve 3% trough as a function of age and concentrate class in multi-country severe WAPPS-Hemo haemophilia patients. *Haemophilia*. 2024; 30: 925–932. <https://doi.org/10.1111/hae.15032>
26. Piggott T, Moja L, Jenei K, Kredo T, Skoetz N, Banzi R, Trapani D, Leong T, McCaul M, Lavis JN, Akl EA, Nonino F, Iorio A, Laurson-Doube J, Huttner BD, Schünemann HJ. GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists. *J Clin Epidemiol*. 2024 Feb;166:111241. doi: 10.1016/j.jclinepi.2023.111241. Epub 2023 Dec 19. PMID: 38123105; PMCID: PMC10939133.
27. Foroutan F, Mayer M, Guyatt G, Riley RD, Mustafa R, Kreuzberger N, Skoetz N, Darzi A, Alba AC, Mowbray F, Rayner DG, Schunemann H, Iorio A. GRADE concept paper 8: judging the certainty of discrimination performance estimates of prognostic models in a body of validation studies. *J Clin Epidemiol*. 2024 Apr 3;170:111344. doi: 10.1016/j.jclinepi.2024.111344. Epub ahead of print. PMID: 38579978.
28. Srivastava A, Iorio A. Lower-dose emicizumab prophylaxis: can less be more? *J Thromb Haemost*. 2024 Apr;22(4):922-925. doi: 10.1016/j.jtha.2024.01.018. PMID: 38521578.
29. Hirniak S, Edginton AN, Iorio A, Alsabbagh MW, Hajducek DM, Wong WW. Health utilities in adults with hemophilia A: A retrospective cohort study. *Haemophilia*. 2024 Mar 20. doi: 10.1111/hae.14979. Epub ahead of print. PMID: 38506967.
30. Curtis R, Wu J, Iorio A, Frick N, Nichol M, Noone D, O'Mahony B, Page D, Stonebraker J, Kucher A, Clearfield E, Skinner MW, Germini F. Test-retest reliability of a mobile application of the patient reported outcomes burdens and experiences (PROBE) study. *Haemophilia*. 2024 Mar 4. doi: 10.1111/hae.14969. Epub ahead of print. PMID: 38439137.
31. Matino D, Germini F, Chan AKC, Decker K, Iserman E, Chelle P, Edginton AN, Oladoyinbo O, Trinari E, Keepanasseril A, Iorio A. Canadian clinical experience on switching from standard half-life recombinant factor VIII (rFVIII), octocog alfa, to extended half-life rFVIII, damoctocog alfa pegol, in persons with haemophilia A ≥ 12 years followed in a Comprehensive Hemophilia Care Program in Canada. *Haemophilia*. 2024 Mar;30(2):345-354. doi: 10.1111/hae.14960. Epub 2024 Feb 20. PMID: 38379181
32. Sun HL, Yang M, Poon MC, Lee A, Robinson KS, Sholzberg M, Wu J, Iorio A, Blanchette V, Carcao M, Klaassen RJ, Jackson S. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes. *Haemophilia*. 2024 Sep;27(5):751-759. doi: 10.1111/hae.14369. Epub 2021 Jun 23. PMID: 34160870.
33. Coffin D, Gouider E, Konkle B, Hermans C, Lambert C, Diop S, Ayoub E, Tootoonchian E, Youttanankorn T, Dakik P, Pereira T, Iorio A, Pierce GF; World Bleeding Disorders Registry Participating Investigators. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients. *Res Pract Thromb Haemost*. 2023 Nov 20;7(8):102264. doi: 10.1016/j.rpth.2023.102264. PMID: 38193052; PMCID: PMC10772874.
34. Fischer K, Lassila R, Peyvandi F, Gatt A, Hollingsworth R, Lambert T, Kaczmarek R, Bettel A, Samji N, Rivard GÉ, Carcao M, Iorio A, Makris M; EUHASS and CHES participants. Inhibitor development according to concentrate in severe hemophilia: reporting on 1392 Previously Untreated Patients from Europe and Canada. *Res Pract Thromb Haemost*. 2023 Nov 20;7(8):102265. doi: 10.1016/j.rpth.2023.102265. PMID: 38193044; PMCID: PMC10772871
35. Coffin, Donna, Abdel Mohsen, M. et al. The World Federation of Hemophilia World Bleeding Disorders Registry: insights from the first 10,000 patients. *Research and Practice in Thrombosis and Haemostasis*, Volume 7, Issue 8, 102264 DOI:<https://doi.org/10.1016/j.rpth.2023.102264>

36. Piggott T, Moja L, Jenei K, Kredo T, Skoetz N, Banzi R, Trapani D, Leong T, McCaul M, Lavis JN, Akl EA, Nonino F, Iorio A, Laurson-Doube J, Huttner BD, Schünemann HJ. Grading of recommendations, assessment, development and evaluations concept 7: issues and insights linking guideline recommendations to trustworthy essential medicine lists. *J Clin Epidemiol*. 2023 Dec 19;166:111241. doi: 10.1016/j.jclinepi.2023.111241. Epub ahead of print. PMID: 38123105.
37. Olasupo OO, Nakar C, Haddix C, Matthew T, Matino D, Malec L, Mbuagbaw L, Tarride JE, Iorio A, Shapiro AD. Inhibitors in hemophilia: association with surgery plans and outcomes in a retrospective cohort study. *Res Pract Thromb Haemost*. 2023 Oct 14;7(7):102228. doi: 10.1016/j.rpth.2023.102228. PMID: 38077822; PMCID: PMC10704510.
38. Wilson MG, Vélez CM, Lavis JN, Misinformation Living Evidence Synthesis Team. Impact of strategies to mitigate misinformation in diverse settings and populations: A protocol for a living evidence synthesis. *BMJ Open* 2023; 13(10).
39. Ng, JY, Maduranayagam S, Lokker C, Iorio A, Haynes, FB, Moher, D. Attitudes and Perceptions of Medical Researchers Towards the Use of Artificial Intelligence Chatbots in the Scientific Process: A Protocol for a Cross-Sectional Survey. *medRxiv* 2023.07.26.23293211; doi: <https://doi.org/10.1101/2023.07.26.23293211>.
40. Shaver N, Katz M, Darko Asamoah G, Linkins LA, Abdelkader W, Beck A, Bennett A, Hughes SE, Smith M, Begin M, Coyle D, Piggott T, Kagina BM, Welch V, Colijn C, Earn DJD, El Emam K, Heffernan J, O'Brien SF, Wilson K, Collins E, Navarro T, Beyene J, Boutron I, Bowdish D, Cooper C, Costa A, Curran J, Griffith L, Hsu A, Grimshaw J, Langlois MA, Li X, Pham-Huy A, Raina P, Rubini M, Thabane L, Wang H, Xu L, Brouwers M, Horsley T, Lavis J, Iorio A, Little J. Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness. *Vaccine*. 2023 Sep 15:S0264-410X(23)01065-4. doi: 10.1016/j.vaccine.2023.09.012. Epub ahead of print. PMID: 37718186.
41. Mannucci PM, Kessler CM, Germini F, Nissen F, Ofori-Asenso R, Brocchieri C, Bendinelli S, Iorio A. Bleeding events in people with congenital haemophilia A without factor VIII inhibitors receiving prophylactic factor VIII treatment: A systematic literature review. *Haemophilia*. 2023 Jun 8. doi: 10.1111/hae.14803. Epub ahead of print.
42. Stonebraker JS, Iorio A, Lavin M, Rezende SM, Srivastava A, Pierce GF, Coffin D, Tootoonchian E, Makris M. Reported prevalence of von Willebrand disease worldwide in relation to income classification. *Haemophilia*. 2023 Jun 5. doi: 10.1111/hae.14810. Epub ahead of print.
43. Lokker C, Bagheri E, Abdelkader W, Parrish R, Afzal M, Navarro T, Cotoi C, Germini F, Linkins L, Brian Haynes R, Chu L, Iorio A. Deep Learning to Refine the Identification of High-Quality Clinical Research Articles from the Biomedical Literature: Performance Evaluation. *J Biomed Inform*. 2023 Jun;142:104384. doi: 10.1016/j.jbi.2023.104384.
44. Ng JY, Cobey KD, Ahmed S, Chow V, Maduranayagam SG, Santoro LJ, Sikora L, Marusic A, Shanahan D, Townsend R, Ehrlich A, Iorio A, Moher D. Recommendations and guidelines for creating scholarly biomedical journals: A scoping review. *PLoS One*. 2023;18(3):e0282168. doi: 10.1371/journal.pone.0282168.
45. Iorio A, MacDonald V, Caillaud A, Luckevich MD, Christoffersen P, Matino D, Keepanasseril A, Iserman E, Germini F, Bentley A, Poon MC. Treatment switch to nonacog beta pegol factor IX in hemophilia B: A Canadian cost-consequence analysis based on real-world factor IX consumption and clinical outcomes. *Res Pract Thromb Haemost*. 2023;7(3):100106. doi: 10.1016/j.rpth.2023.100106.
46. Gordon Guyatt, Yunli Zhao, Martin Mayer, Matthias Briel, Reem Mustafa, Ariel Izcovich, Monica Hultcrantz, Alfonso Iorio, Ana Carolina Alba, Farid Foroutan, Xin Sun, Holger Schunemann, Hans DeBeer, Elie A. Akl,

- Robin Christensen, Stefan Schandelmaier. GRADE guidance 36: updates to GRADE's approach to addressing inconsistency. *Journal of Clinical Epidemiology*. 2023;158:7-83.
47. Ng JY, Cobey KD, Ahmed S, Chow V, Maduranayagam SG, Santoro LJ, Sikora L, Marusic A, Shanahan D, Townsend R, Ehrlich A, Iorio A, Moher D. Recommendations and guidelines for creating scholarly biomedical journals: A scoping review. *PLoS One*. 2023;18(3):e0282168. doi: 10.1371/journal.pone.0282168. eCollection 2023.
48. Guyatt G, Zhao Y, Mayer M, Briel M, Mustafa R, Izcovich A, Hultcrantz M, Iorio A, Alba AC, Foroutan F, Sun X, Schunemann H, DeBeer H, Akl EA, Christensen R, Schandelmaier S. GRADE Guidance 36: Updates to GRADE's approach to addressing inconsistency. *J Clin Epidemiol*. 2023:S0895-4356(23)00046-X. doi: 10.1016/j.jclinepi.2023.03.003. Online ahead of print. PMID: 36898507
49. von Drygalski A, Chowdary P, Kulkarni R, Susen S, Konkole BA, Oldenburg J, Matino D, Klamroth R, Weyand AC, Jimenez-Yuste V, Nogami K, Poloskey S, Winding B, Willemze A, Knobe K; XTEND-1 Trial Group. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A. *N Engl J Med*. 2023 Jan 26;388(4):310-318.
50. Yu JK, Wong WWL, Keepanasseril A, Iorio A, Edginton AN. Cost-utility analysis of emicizumab for the treatment of severe hemophilia A patients in Canada. *Haemophilia*. 2022 Dec 18 *Haemophilia*. 2023;29(2):488-497. doi: 10.1111/hae.14723.
51. Dewidar O, Lotfi T, Langendam M, Parmelli E, Saz Parkinson Z, Solo K, Chu DK, Mathew JL, Akl EA, Brignardello-Petersen R, Mustafa RA, Moja L, Iorio A, Chi Y, Canelo-Aybar C, Kredo T, Karpusheff J, Turgeon AF, Alonso-Coello P, Wiercioch W, Gerritsen A, Klugar M, Rojas MX, Tugwell P, Welch VA, Pottie K, Munn Z, Nieuwlaat R, Ford N, Stevens A, Khabsa J, Nasir Z, Leontiadis GI, Meerpohl JJ, Piggott T, Qaseem A, Matthews M, Schünemann HJ; eCOVID-19 recommendations map collaborators. Which actionable statements qualify as good practice statements In Covid-19 guidelines? A systematic appraisal. *BMJ Evid Based Med*. 2022;27(6):361-369.
52. Shapiro AD, Hardesty BM, Peyvandi F, Iorio A. Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review. *Res Pract Thromb Haemost*. 2022;7(1):100007. doi: 10.1016/j.rpth.2022.100007. eCollection 2023 Jan. PMID: 36891522
53. Iorio A, Königs C, Reding MT, Rotellini D, Skinner MW, Mancuso ME, Berntorp E. Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature. *Haemophilia*. 2023 Jan;29(1):33-44. doi: 10.1111/hae.14676. Epub 2022 Oct 12. PMID: 36224704 Review.
54. Ay C, Kovacevic KD, Kraemmer D, Schoergenhofer C, Gelbenegger G, Firbas CU, Quehenberger P, Jilma-Stohlawetz P, Gilbert JC, Zhu S, Beliveau M, Koenig F, Iorio A, Jilma B, Derhaschnig U, Pabinger I. von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A. *Blood*. 2023;141(10):1147-1158. doi: 10.1182/blood.2022016571.
55. Brignell A, Harwood RC, May T, Woolfenden S, Montgomery A, Iorio A, Williams K. Overall prognosis of preschool autism spectrum disorder diagnoses. *Cochrane Database Syst Rev*. 2022;9(9):CD012749. doi: 10.1002/14651858.CD012749.pub2.
56. Li N, Mahamad S, Parpia S, Iorio A, Foroutan F, Heddle NM, Hsia CC, Sholzberg M, Rimmer E, Shivakumar S, Sun HL, Refaei M, Hamm C, Arnold DM. Development and internal validation of a clinical prediction model for the diagnosis of immune thrombocytopenia. *J Thromb Haemost*. 2022;20(12):2988-2997.
57. Nummi, V, Lehtinen, A-E, Iorio, A, Szanto, T, Lassila, R. Switching from standard to extended half-life FVIII prophylaxis in haemophilia A: Comparison of factor product use, bleed rates and pharmacokinetics. *Haemophilia*. 2022;28(6):e237-e244.

58. Chelle P, Iorio A, Edginton AN. A Personalized Limited Sampling Approach to Better Estimate Terminal Half-life of FVIII concentrates. *J Thromb Haemost.* 2022 Jun 26. doi: 10.1111/jth.15803. Online ahead of print. PMID: 35753074
59. Linkins LA, Iorio A, Little J, Lavis J. Extended reporting guidance for vaccine effectiveness studies for variants of concern for COVID-19. *Vaccine.* 2022;40(22):2986-2987.
60. Mahlangu J, Iorio A, Kenet G. Emicizumab state-of-the-art update. *Haemophilia.* 2022;28 Suppl 4:103-110. doi: 10.1111/hae.14524.
61. Pottie, K., Smith, M., Matthews, M., Santesso, N., Magwood, O., Kredo, T., Scott, S., Bayliss, K., Saad, A., Haridas, R., Detambel, N., Motilall, A., Tan, Y., Steinberg, S., Litynska, J., Dietl, B., Ioiri, A., Reveiz, L., & Schünemann, H. J. A multistakeholder development process to prioritize and translate COVID-19 health recommendations for patients, caregivers and the public. A case study of the COVID-19 recommendation map. *Journal of Clinical Epidemiology.* 2022;148:104-114.
62. Germini F, Noronha N, Abraham Philip B, Olasupo O, Pete D, Navarro T, Keepanasseril A, Matino D, de Wit K, Parpia S, Iorio A. Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature. *J Thromb Haemost.* 2022 Jun;20(6):1364-1375. doi: 10.1111/jth.15723.
63. Bowman, M, Casey, L, Selvam, SN, Lima, D.A, Rawley O, Hinds M, Tuttle A, Grabel J, Iorio A, Walker I, Lillcrap D, James P. von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient-derived endothelial colony-forming cells. *J Thromb Haemost.* 2022;20(7):1599-1609.
64. Germini F, Noronha N, Borg Debono V, Abraham Philip B, Pete D, Navarro T, Keepanasseril A, Parpia S, de Wit K, Iorio A. Accuracy and Acceptability of Wrist-Wearable Activity-Tracking Devices: Systematic Review of the Literature. *J Med Internet Res* 2022;24(1):e30791.
65. Nasir ZH, Mertz D, Nieuwlaat R, Santesso N, Lotfi T, Motilall A, Moja L, Mbuagbaw L, Klugar M, Turgeon AF, Mathew JL, Canelo-Aybar C, Pottie K, Dewidar O, Langendam MW, Iorio A, Vist GE, Meerpohl JJ, Flottorp S, Kredo T, Piggott T, Mathews M, Qaseem A, Chu DK, Tugwell P, Klugarová J, Nelson H, Hussein H, Suvada J, Neumann I, Schünemann HJ; eCOVID-19 recommendations map Collaborators. An evaluation of the eCOVID19 Recommendation Map identified diverging Clinical and Public Health guidance. *J Clin Epidemiol.* 2022;147:83-94.
66. Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens REG, Iorio A, Fischer K. Predicting Individual Changes in Terminal Half-Life After Switching to Extended Half-Life Concentrates in Patients With Severe Hemophilia. *Hemasphere.* 2022 Mar 21;6(4):e694.
67. Germini F, Borg Debono V, Page D, Zuk V, Kucher A, Cotoi C, Hobson N, Sevestre M, Skinner MW, Iorio A; PROBE Investigators. User-Centered Development and Testing of the Online Patient-Reported Outcomes, Burdens, and Experiences (PROBE) Survey and the myPROBE App and Integration With the Canadian Bleeding Disorder Registry: Mixed Methods Study. *JMIR Hum Factors.* 2022;9(1):e30797. doi: 10.2196/30797.
68. Chelle P, Hajducek D, Mahdi M, Young S, Iorio A, Silvertown J, Edginton A. External qualification of the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) models for octocog alfa using real patient data. *Res Pract Thromb Haemost.* 2021;5(7):e12599. doi: 10.1002/rth2.12599.
69. Wiercioch W, Nieuwlaat R, Zhang Y, Alonso-Coello P, Dahm P, Iorio A, Manja V, Mustafa RA, Neumann I, Ortel TL, Rochwerg B, Santesso N, Vesely SK, Akl EA, Schünemann HJ. New methods facilitated the process of prioritizing questions and health outcomes in guideline development. *J Clin Epidemiol.* 2021;143:91-104.
70. Olasupo OO, Haddix C, Nakar C, Maahs J, Greist A, Ghafoor A, Donfield SM, Iorio a, Shapiro AD. Utilization of a surgical database to provide care and assess perioperative treatment and outcomes in patients with bleeding disorders. *Eur J Haematol.* 2021;00:1–12. doi:10.1111/ejh.13731

71. Abdelkader W, Navarro T, Parrish R, Cotoi C, Germini F, Linkins LA, Iorio A, Haynes RB, Ananiadou S, Chu L, Lokker C. A Deep Learning Approach to Refine the Identification of High-Quality Clinical Research Articles From the Biomedical Literature: Protocol for Algorithm Development and Validation. *JMIR Res Protoc.* 2021;10(11):e29398. doi: 10.2196/29398.
72. Lokker C, Gentles SJ, Ganann R, Jezrawi R, Tahir I, Okelana O, Yousif C, Iorio A, Valaitis R. Knowledge translation strategies for sharing evidence-based health information with older adults and their caregivers: findings from a persona-scenario method. *BMC Geriatr.* 2021;21(1):665. doi: 10.1186/s12877-021-02588-x.
73. Blamey G, Van Tassel B, Sagermann E, Stain A, Waterhouse L, Iorio A. Sexual issues in people with haemophilia: awareness and strategies for overcoming communication barriers. *Haemophilia.* 2022;28:36–41. <https://doi.org/10.1111/hae.14447>
74. Foroutan F, Guyatt G, Trivella M, Kreuzberger N, Skoetz N, Riley RD, Roshanov PS, Alba AC, Sekercioglu N, Canelo C, Munn Z, Brignardello-Petersen R, Schünemann HJ, Iorio A. GRADE concept paper 2: Concepts for Judging Certainty on the Calibration of Prognostic Models in a Body of Validation Studies. *J Clin Epidemiol.* 2022;143:202-211.
75. Lotfi T, Hajizadeh A, Moja L, Akl EA, Piggott T, Kredo T, Langendam MW, Iorio A, Klugar M, Klugarová J, Neumann I, Wiercioch W, Leontiadis GI, Mbuagbaw L, Turgeon AF, Meerpohl J, Stevens A, Brozek J, Santesso N, Pottie K, Dewidar O, Flottorp SA, Karpusheff J, Saz-Parkinson Z, Rojas MX, Parmelli E, Chu DK, Tugwell P, Welch V, Avey MT, Brignardello-Petersen R, Mathew JL, Munn Z, Nieuwlaat R, Ford N, Qaseem A, Askie LM, Schünemann HJ. A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations. *J Clin Epidemiol.* 2022;141:161-171.
76. Germini F, Chai-Adisaksopha C, Pete D, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker JS, Thabane L, Crowther MA, Skinner MW, Iorio A. Evaluation of the sexual health in people living with hemophilia. *Haemophilia.* 2021;21:993-1001.
77. Nieuwlaat R, Wiercioch W, Brozek JL, Santesso NAM, Kunkle R, Alonso-Coello P, Anderson DR, Bates S, Cushman M, Dahm P, Iorio A, Lim W, Lyman GH, Middeldorp S, Monagle P, Mustafa RA, Neumann I, Ortel T, Rochwerg B, Vesely SK, Witt DM, Cuker A, Schunemann HJ. How to write a guideline: a proposal for a manuscript template that supports the creation of trustworthy guidelines. *Blood Adv.* 2021;5(22):4721-4726. doi: 10.1182/bloodadvances.2020003577.
78. Olasupo OO, Lowe MS, Krishan A, Collins P, Iorio A, Martino D. Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. *Cochrane Database Syst Rev.* 2021;8(8):CD014201. doi: 10.1002/14651858.CD014201.
79. Abdelkader W, Navarro T, Parrish R, Cotoi C, Germini F, Iorio A, Haynes RB, Lokker C. Machine Learning Approaches to Retrieve High-Quality, Clinically Relevant Evidence From the Biomedical Literature: Systematic Review. *JMIR Med Inform.* 2021;9(9):e30401. doi: 10.2196/30401.
80. Stonebraker JS, O'Mahony B, Noone D, Iorio A. Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time. *Haemophilia.* 2021; 2021;27(5):e596-e608.
81. Sun H, Yang M, Poon M-C, Lee A, Robinson KS, Sholzberg M, Wu J, Iorio A, Blanchette V, Carcao M, Klaassen RJ, Jackson S. Factor product utilization and health outcomes in patients with haemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes. *Haemophilia.* 2021;27(5):751-759
82. Wiercioch W, Nieuwlaat R, Dahm P, Iorio A, Mustafa RA, Neumann I, Rochwerg B, Manja V, Alonso-Coello P, Ortel TL, Santesso N, Vesely SK, Akl EA, Schünemann HJ, Bates SM, Cuker A, Lim W, Monagle P, Kunkle R, Witt DM, Kahn SR, McLintock C, Rezende SM, Zakai NA; ASH VTE Panels Working Group. Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines. *J Clin Epidemiol.* 2021;138:115-127.

83. Versloot O, Iserman E, Chelle P, Germini F, Edginton AN, Schutgens REG, Iorio A, Fischer K; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (IPSG). Terminal half-life of FVIII and FIX according to age, blood group and concentrate type: data from the WAPPS database. *J Thromb Haemost.* 2021;19:1896-1906.
84. van Balen EC, O'Mahony B, Cnossen MH, Dolan G, Blanchette VS, Fischer K, Gue D, O'Hara J, Iorio A, Jackson S, Konkle BA, Nugent DJ, Coffin D, Skinner MW, Smit C, Srivastava A, van Eenennaam F, van der Bom JG, Gouw SC. Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes set. *Res Pract Thromb Haemost.* 2021;5(4):e12488. doi: 10.1002/rth2.12488.
85. Spinella PC, El Kassir N, Cap AP, Kindzelski AL, Almond CS, Barkun A, Gernsheimer TB, Goldstein JN, Holcomb JB, Iorio A, Jensen DM, Key NS, Levy JH, Mayer SA, Moore EE, Stanworth SJ, Lewis RJ, Steiner ME; Hemostasis Trials Outcomes Working Group. Recommended Primary Outcomes for Clinical Trials Evaluating Hemostatic Blood Products and Agents in Patients with Bleeding: Proceedings of a National Heart Lung and Blood Institute and United States Department of Defense Consensus Conference. *J Trauma Acute Care Surg.* 2021 Aug 1;91(2S Suppl 2):S19-S25. doi: 10.1097/TA.0000000000003300.
86. Astermark J, Olsson A, Chelle P, Täckström K, Walger M, Magnusson M, Iorio A. Comparison of single subject and population-based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A. *Haemophilia.* 2021;27(4):626-633.
87. Teitel J, Sholzberg M, Iorio A. Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products. *Res Pract Thromb Haemost.* 2021 Feb 23;5(2):349-355.
88. Aquino CC, Borg Debono V, Germini F, Pete D, Kempton CL, Young G, Sidonio R, Croteau SE, Dunn AL, Key NS, Iorio A. Outcomes for studies assessing the efficacy of hemostatic therapies in persons with congenital bleeding disorders. *Haemophilia.* 2021;27(2):211-220.
89. Yu JK, Iorio A, Chelle P, Edginton AN. Pharmacokinetic implications of dosing emicizumab based on vial size: A simulation study. *Haemophilia.* 2021;27(3):358-365.
90. Riva S, Marchesini E, Olioecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre CP, Zanon E, Barillari G, Cantori I, Caimi TM, Sottillotta G, Iorio A, Mannucci PM. Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. *Haemophilia.* 2021 Jul;27(4):e525-e529.
91. Kavanagh PL, Frater F, Navarro T, LaVita P, Parrish R, Iorio A. Optimizing a literature surveillance strategy to retrieve sound overall prognosis and risk assessment model papers. *J Am Med Inform Assoc.* 2021;28(4):766-771. doi: 10.1093/jamia/ocaa232.
92. Asamoah-Boaheng M, Badejo OA, Bell LV, Buckley N, Busse JW, Campbell TS, Corace K, Cooper L, Flusk D, Garcia DA, Hossain MA, Iorio A, Lavoie KL, Poulin PA, Skidmore B, Rash JA. Interventions to Influence Opioid Prescribing Practices for Chronic Noncancer Pain: A Systematic Review and Meta-Analysis. *Am J Prev Med.* 2021;60(1):e15-e26. doi: 10.1016/j.amepre.2020.07.012.
93. Lotfi T, Stevens A, Akl EA, Falavigna M, Kredo T, Mathew JL, Schünemann HJ; eCOVID Collaborators. Getting trustworthy guidelines into the hands of decision-makers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines. *J Clin Epidemiol.* 2021;135:182-186. doi: 10.1016/j.jclinepi.2021.03.034.
94. Barco S, Valerio L, Ageno W, Cohen AT, Goldhaber SZ, Hunt BJ, Iorio A, Jimenez D, Klok FA, Kucher N, Mahmoudpour SH, Middeldorp S, Münzel T, Tagalakakis V, Wendelboe AM, Konstantinides SV. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000-18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database. *Lancet Respir Med.* 2021(1):33-42. doi: 10.1016/S2213-2600(20)30417-3.

95. Chai-Adisaksopha C, Noone D, Curtis R, Frick N, Nichol MB, Germini F, O'Mahony B, Page D, Stonebraker JS, Skinner MW, Iorio A. Non-severe haemophilia: Is it benign? - Insights from the PROBE study. *Haemophilia*. 2021;27(1):17-24.
96. Konkle B, Pierce G, Coffin D, Naccache M, Clark RC, George L, Iorio A, O'Mahony B, Pipe S, Skinner M, Watson C, Peyvandi F, Mahlangu J; ISTH subcommittee on Factor VIII, Factor IX, rare bleeding disorders. Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. *J Thromb Haemost*. 2020;18(11):3074-3077.
97. Pottie K, Magwood O, Rahman P, Concannon T, Alonso-Coello P, Jaramillo Garcia A, Santesso N, Thombs B, Welch V, Wells GA, Saad A, Archibald D, Grad R, Moore A, Ximena Rojas M, Iorio A, Pinto N, Doull M, Morton R, Santesso N, Akl EA, Schünemann HJ, Tugwell P. GRADE Concept Paper 1: Validating the "F.A.C.E" instrument using stakeholder perceptions of feasibility, acceptability, cost, and equity in guideline implement.. *J Clin Epidemiol*. 2020;1;131:133-140.
98. Darzi AJ, Repp AB, Spencer FA, Morsi RZ, Charide R, Etxeandia-Ikobaltzeta I, Bauer KA, Burnett AE, Cushman M, Dentali F, Kahn SR, Rezende SM, Zakai NA, Agarwal A, Karam SG, Lotfi T, Wiercioch W, Waziry R, Iorio A, Akl EA, Schünemann HJ. Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews. *Blood Adv*. 2020 Oct 13;4(19):4929-4944.
99. Schünemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, Noble S, Macbeth F, Griffiths G, Garcia D, Lyman GH, Di Nisio M, Iorio A, Mbuagbaw L, Neumann I, van Es N, Brouwers M, Guyatt G, Streiff MB, Marcucci M, Baldeh T, Florez ID, Alma OG, Solh Z, Bossuyt PM, Kahale LA, Ageno W, Bozas G, Büller HR, Lebeau B, Lecumberri R, Loprinzi C, McBane R, Sideras K, Maraveyas A, Pelzer U, Perry J, Klerk C, Agnelli G, Akl EA. Evaluating prophylactic heparin in ambulatory patients with solid tumours: a systematic review and individual participant data meta-analysis. *Lancet Haematol*. 2020 Oct;7(10):e746-e755. doi: 10.1016/S2352-3026(20)30293-3. PMID: 32976752.
100. Solms A, Shah A, Berntorp E, Tiede A, Iorio A, Linardi C, Ahsman M, Mancuso ME, Zhivkov T, Lissitchkov T. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. *Ann Hematol*. 2020 Nov;99(11):2689-2698. doi: 10.1007/s00277-020-04280-3. Epub 2020 Sep 24. PMID: 32974838; PMCID: PMC7536163.
101. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2020 Oct;18(10):2486-2495.
102. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2020 Oct;18(10):2503-2512.
103. Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, Matsumoto M, Mustafa RA, Pai M, Rock G, Russell L, Tarawneh R, Valdes J, Peyvandi F. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2020 Oct;18(10):2496-2502.
104. Darzi AJ, Karam SG, Spencer FA, Spyropoulos AC, Mbuagbaw L, Woller SC, Zakai NA, Streiff MB, Gould MK, Cushman M, Charide R, Etxeandia-Ikobaltzeta I, Germini F, Rigoni M, Agarwal A, Morsi RZ, Akl EA, Iorio A, Schünemann HJ. Risk models for VTE and bleeding in medical inpatients: systematic identification and expert assessment. *Blood Adv*. 2020 Jun 23;4(12):2557-2566.
105. Stonebraker JS, Bolton-Maggs PHB, Brooker M, Evatt B, Iorio A, Makris M, O'Mahony B, Skinner MW, Coffin D, Pierce GF, Tootoonchian E. The World Federation of Hemophilia Annual Global Survey 1999-2018. *Haemophilia*. 2020 Jul;26(4):591-600.
106. Konkle BA, Coffin D, Pierce GF, Clark C, George L, Iorio A, Mahlangu J, Naccache M, O'Mahony B, Peyvandi F, Pipe S, Quartel A, Sawyer EK, Skinner MW, Tortella B, Watson C, Winburn I; Members of the

- WFH Gene Therapy Registry Steering Committee. World Federation of Hemophilia Gene Therapy Registry. *Haemophilia*. 2020 Jul;26(4):563-564. doi: 10.1111/hae.14015. Epub 2020 May 27. PMID: 32462720.
107. Wiercioch W, Nieuwlaat R, Akl EA, Kunkle R, Alexander KE, Cuker A, Rajasekhar A, Alonso-Coello P, Anderson DR, Bates SM, Cushman M, Dahm P, Guyatt G, Iorio A, Lim W, Lyman GH, Middeldorp S, Monagle P, Mustafa RA, Neumann I, Ortel TL, Rochwerg B, Santesso N, Vesely SK, Witt DM, Schünemann HJ. Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences. *Blood Adv*. 2020 May 26;4(10):2351-2365.
108. Paquette M, Mbuagbaw L, Iorio A, Nieuwlaat R. Methodological Considerations for Investigating Oral Anticoagulation Persistence in Atrial Fibrillation. *Eur Heart J Cardiovasc Pharmacother*. 2021 May 23;7(3):251-260.
109. Ventresca M, Schünemann HJ, Macbeth F, Clarke M, Thabane L, Griffiths G, Noble S, Garcia D, Marcucci M, Iorio A, Zhou Q, Crowther M, Akl EA, Lyman GH, Gloy V, DiNisio M, Briel M. Obtaining and managing data sets for individual participant data meta-analysis: scoping review and practical guide. *BMC Med Res Methodol*. 2020 May 12;20(1):113. doi: 10.1186/s12874-020-00964-6.
110. Matino D, Afraz S, Zhao G, Tieu P, Gargaro M, Fallarino F, Iorio A. Tolerance to FVIII: Role of the Immune Metabolic Enzymes Indoleamine 2,3 Dioxygenase-1 and Heme Oxygenase-1. *Front Immunol*. 2020 Apr 15;11:620. doi: 10.3389/fimmu.2020.00620. eCollection 2020.
111. Alexander PE, Debono VB, Mammen MJ, Iorio A, Aryal K, Deng D, Brocard E, Alhazzani W. COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine. *J Clin Epidemiol*. 2020 Jul;123:120-126. doi: 10.1016/j.jclinepi.2020.04.016. Epub 2020 Apr 21. PMID: 32330521; PMCID: PMC7194626.
112. Hajducek DM, Chelle P, Hermans C, Iorio A, McEneny-King A, Yu J, Edginton A. Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS-Hemo project. *Haemophilia*. 2020 May;26(3):384-400. doi: 10.1111/hae.13977. Epub 2020 Apr 13. PMID: 32281726.
113. Croteau SE, Wheeler AP, Khan O, Haley KM, Borst AJ, Lattimore S, Yeung CHT, Iorio A. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. *Res Pract Thromb Haemost*. 2020 Feb 6;4(2):326-333. doi: 10.1002/rth2.12305. PMID: 32110764; PMCID: PMC7040534.
114. Darzi AJ, Karam SG, Charide R, Etxeandia-Ikobaltzeta I, Cushman M, Gould MK, Mbuagbaw L, Spencer FA, Spyropoulos AC, Streiff MB, Woller S, Zakai NA, Germini F, Rigoni M, Agarwal A, Morsi RZ, Iorio A, Akl EA, Schünemann HJ. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. *Blood*. 2020 May 14;135(20):1788-1810. doi: 10.1182/blood.2019003603. PMID: 32092132;
115. Solms A, Iorio A, Ahsman MJ, Vis P, Shah A, Berntorp E, Garmann D. Favorable Pharmacokinetic Characteristics of Extended-Half-Life Recombinant Factor VIII BAY 94-9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. *Clin Pharmacokinet*. 2020 May;59(5):605-616.
116. McEneny-King A, Yeung CH, Edginton AN, Iorio A, Croteau SE. Clinical application of Web Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Patterns of blood sampling and patient characteristics among clinician users. *Haemophilia*. 2020 Jan;26(1):56-63. doi: 10.1111/hae.13882. Epub 2019 Nov 19. PMID: 31742831.
117. Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Megías-Vericat JE, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. *Clin Pharmacokinet*. 2020 Feb;59(2):245-256. doi: 10.1007/s40262-019-00809-6. PMID: 31435896.

118. Tritschler T, Langlois N, Hutton B, Shea BJ, Shorr R, Ng S, Dubois S, West C, Iorio A, Tugwell P, Le Gal G. Protocol for a scoping review of outcomes in clinical studies of interventions for venous thromboembolism in adults. *BMJ Open* . 2020 Dec 7;10(12):e040122. doi: 10.1136/bmjopen-2020-040122.
119. Yu JK, Iorio A, Edginton AN. A comparison of methods for prediction of pharmacokinetics when switching to extended half-life products in hemophilia A patients. *Thromb Res*. 2020 Dec;196:550-558. doi: 10.1016/j.thromres.2020.10.024.
120. Grimshaw JM, Tovey DI, Lavis JN, on behalf of COVID-END. COVID-END: an international network to better co-ordinate and maximize the impact of the global evidence synthesis and guidance response to COVID-19. In: Collaborating in response to COVID-19: editorial and methods initiatives across Cochrane. *Cochrane Database of Systematic Reviews* 2020;(12 Suppl 1):[4-8]. <https://doi.org/10.1002/14651858.CD202002>
121. Stevens A, Lotfi T, Akl EA, Falavigna M, Kredt T, Mathew JL, Avey MT, Brignardello-Petersen R, Chu DK, Dewidar O, Duda S, Diet B, Flottorp S, Hajizadeh A, Iorio A, Klugar M, et al. The eCOVID-19 living recommendations map and gateway to contextualization. In: Collaborating in response to COVID-19: editorial and methods initiatives across Cochrane. *Cochrane Database of Systematic Reviews* 2020;(12 Suppl 1):[54-57]. <https://doi.org/10.1002/14651858.CD202002>
122. Hay CRM, Shima M, Makris M, Jiménez-Yuste V, Oldenburg J, Fischer K, Iorio A, Skinner MW, Santagostino E, von Mackensen S, Kessler CM. Challenges and key lessons from the design and implementation of an international haemophilia registry supported by a pharmaceutical company. *Haemophilia*. 2020 Nov;26(6):966-974
123. Haynes RB, Del Fiore G, Michelson M, Iorio A. Context and Approach in Reporting Evaluations of Electronic Health Record-Based Implementation Projects. *Ann Intern Med*. 2020 Jun 2;172(11 Suppl):S73-S78. doi: 10.7326/M19-0874.
124. van Es N, Ventresca M, Di Nisio M, Zhou Q, Noble S, Crowther M, Briel M, Garcia D, Lyman GH, Macbeth F, Griffiths G, Iorio A, Lawrence M, Neumann I, Brozek J, Guyatt G, Streiff MB, Baldeh T, Florez ID, Alma OG, Agnelli G, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Lecumberri R, Sideras K, Loprinzi C, McBane R, Pelzer U, Riess H, Solh Z, Perry J, Kahale LA, Bossuyt PM, Klerk C, Büller HR, Akl EA, Schünemann HJ; IPDMA heparin use in cancer patients research group. The Khorana score prediction for venous thromboembolism in cancer patients: an individual patient data meta-analysis. *J Thromb Haemost*. 2020 Aug;18(8):1940-1951.
125. Seguin A, Haynes RB, Carballo S, Iorio A, Perrier A, Agoritsas T. Translating Clinical Questions by Physicians into Searchable Queries: Analytical Survey Study. *JMIR Med Educ*. 2020 Apr 20;6(1)e16777. Doi: 10.2196/16777.
126. Poupard C, Sattler L, Ryman A, Eschwege V, De Maistre E, Flaujac C, Szymezak J, Grand F, Repesse Y, Galinat H, Donnard M, Ternisien C, Iorio A, Chelle P, Jeanpierre E; 'Biology Study Group on Haemorrhagic Diseases' (Group BIMHO - GFHT). Multicentre pharmacokinetic evaluation of rFVIII-Fc (efmoroctocog alfa) in a real life and comparison with non-extended half-life FVII concentrates. *Haemophilia*. 2020. Mar;26(2):282-289. Doi: 10.1111/hae.13946. Epub 2020 Feb 27.
127. Palareti L, Melotti G, Cassis F, Nevitt SJ, Iorio A. Psychological interventions for people with hemophilia. *Cochrane Database Syst Rev*. 2020 Mar 18;3:CD010215. doi: 10.1002/14651858.CD010215.pub2. Review.
128. Hossain MA, Asamoah-Boaheng M, Badejo OA, Bell LV, Buckley N, Busse JW, Campbell TS, Corace K, Cooper LK, Flusk D, Garcia DA, Iorio A, Lavoie KL, Poulin PA, Skidmore B, Rash JA. Prescriber adherence to guidelines for chronic noncancer pain management with opioids: Systematic review and meta-analysis. *Health Psychol*. 2020 May;39(5):430-451. Doi: 10.1037/hea0000830. PMID: 3199179.
129. Foroutan F, Guyatt G, Zuk V, Vandvik PO, Alba AC, Mustafa R, Vernooij R, Arevalo-Rodriguez I, Munn Z, Roshanov P, Riley R, Schandelmaier S, Kuijpers T, Siemieniuk R, Canelo-Aybar C, Schunemann H, Iorio A. GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating

- certainty in identification of groups of patients with different absolute risks. *J Clin Epidemiol*. 2020 Jan 23;121:62-70. Doi: 10.1016/j.jclinepi.2019.12.023.
130. Yu JK, Iorio A, Chelle P, Edginton AN. A comparison of methods for prediction of pharmacokinetics across factor concentrate switching in hemophilia patients. *Thromb Res* 2019 Dec; 184: 31-37. Doi: 10.1016/j.thromres.2019. 10.023. Epub 2019 Oct 29. PMID: 31689604.
131. Foroutan F, Iorio A, Thabane L, Guyatt, G. Calculation of absolute risk for important outcomes in patients with and without a prognostic factor of interest. *J Clin Epidemiol*. 2020 Jan;117:46-51. Doi 10.1016/j.jclinepi.2019.08.012. Epub 2019 Oct 4. PMID 31589954.
132. Alfonso Iorio, Jeffrey S. Stonebraker, Herve Chambost, Michael Makris, Donna Coffin, Christine Herr, Federico Germini for the Data and Demographics Committee of the World Federation of Hemophilia. Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-analytic Approach Using National Registries. *Ann Intern Med*. 2019;171(8):540-547. Doi: 10.7326/M19-1208. [Epub ahead of print].
133. Hua BL, Chelle P, Yeung C, Gu J, Zhao YQ, Iorio A. *Zhonghua Xue Ye Xue Za Zhi*. 2019 Aug 14;40(8):673-677. [Population pharmacokinetics of two recombinant human coagulant factor VIII preparations in patients with hemophilia A]. Doi: 10.3760/cma.j.issn.0253-2727.2019.08.009. Chinese. PMID: 31495135.
134. Chelle P, Yeung CHT, Croteau SE, Lissick J, Balasa V, Ashburner C, Park YS, Bonanad S, Megias-Vericat JE, Nagao A, Wynn T, Corrales-Medina F, Tran H, Sharathkumar A, Chitlur M, Sarmiento S, Edginton A, Iorio A. Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup. *Clin Pharmacokinet*. 2020 Feb;59(2):245-256.
135. Makris M, Iorio A. Emicizumab and thrombosis: The story so far. *J Thromb Haemost*. 2019 Aug;17(8): 1269-1272. Doi: 10.1111/jth.14556. PMID: 31368220. PMID: 31302829 [Pubmed – indexed for MEDLINE].
136. Chelle P, Yeung CHT, Bonanad S, Morales Munoz JC, Ozelo MC, Megias Vericat JE, Iorio A, Spears J, Mir R, Edginton A. Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients. *J Pharmacokinet Pharmacodyn* 2019 Oct;46(5):439. Doi: 10.1007/s10928-019-09647-2.
137. Schunemann HJ, Zhang Y, Oxman AD; Expert Evidence in Guidelines Group: Holger J. Schünemann, Yuping Zhang, Andrew D. Oxman, Antonio Bognanni, Jan Brozek, Mark Crowther, Carlos Cuello, Adam Cuker, Maicon Falavigna, Itziar Etxeandia Ikobaltzeta, Alfonso Iorio, Kim Legault, Joerg Meerpohl, Jill Lansing, Nancy Santesso, Reem Mustafa, Ben Djulbegovic, Jun Xia, Wojtek Wiercioch. Distinguishing opinion from evidence in guidelines. *BMJ* 2019 Jul 19;366:14606. Doi: 1136/bmj.14606.
138. Zhou JY, Barnes RFW, Foster G, Iorio A, Cramer TJ, von Drygalski A. Joint Bleeding Tendencies in Adult Patients with Hemophilia: It's Not All Pharmacokinetics. *Clin Appl Thromb Hemost*. 2019 Jan-Dec25: 1076029619862052. Doi: 10.1177/1076029619862052.
139. Mahlangu, J., Naidoo, Y., Goga, Y., Vaithlingum, M., Joubert, J., Sutton, C., Potgieter, J., Cruickshank, A-L., Iorio A. Home therapy for inherited bleeding disorders in South Africa: Results of a modified Delphi consensus process. *S Afr Med J*. 2019 Aug 28;109(9):639-644. doi: 10.7196/SAMJ.2019.v109i9.13637.
140. Shah, A, Solms A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME, Zhivkov T, Lissitchkov T. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. *Ann Hematol*. 2019 Sep;98(9):2035-2044. doi: 10.1007/s00277-019-03747-2.
141. Alper BS, Oettgen P, Kunnamo I, Iorio A, Ansari MT, Murad MH, Meerpohl JJ, Qaseem A, Hultcrantz M, Schünemann HJ, Guyatt G; GRADE Working Group. Defining certainty of net benefit: a GRADE concept paper. *BMJ Open*. 2019 Jun 4;9(6):e027445. Doi: 10.1136/bmjopen-2018-027445. PMID: 31167868 [PubMed – in process] Free PMC Article.

142. Alanna McEneny-King, Pierre Chelle, Gary Foster, Arun Keepanasseril, Alfonso Iorio, Andrea N. Edginton. Development and evaluation of generic population pharmacokinetic model for standard half-life factor VIII for use in dose individualization. *Journal of Pharmacokinetics and Pharmacodynamics*. 2019 May 18. doi: 10.1007/s10928-019-09634-7. [Epub ahead of print].
143. Yu JK, Iorio A, Edginton AN; WAPPS co-investigators. Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. *Res Pract Thromb Haemost*. 2019 May 20;3(3):528-541. Doi: 10.1002/rth2.12204. eCollection 2019 Jul. Review. Erratum in: *Res Pract Thromb Haemost*. 2019 Sep 16;3(4):771.
144. Carcao MD, Chelle P, Clarke E, Kim L, Tiseo L, Morfini M, Hossain T, Rand ML, Brown C, Edginton A, Lillicrap D, Iorio A, Blanchette VS. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: is there a difference? *J Thromb Haemost*. 2019 Apr 30. doi: 10.1111/jth.14469. [Epub ahead of print] PubMed PMID: 31038793.
145. Escobar M, Santagostino E, Mancuso ME, Coppens M, Balasa V, Taylor JA, Iorio A, Negrier C. Switching patients in the age of long-acting recombinant products? *Expert Rev Hematol*. 2019;12(sup1):1-13. Doi: 10.1080/17474086.2018.1564032. PMID:31282771.
146. Konkle BA, Skinner M, Iorio A. Hemophilia trials in the twenty-first century: Defining patient important outcomes. *Res Pract Thromb Haemost*. 2019 Mar 12;3(2):184-192. doi: 10.1002/rth2.12195. eCollection 2019 Apr. Review. PubMed PMID: 31011702; PubMed Central PMCID: PMC6462740.
147. Ning S, Liu Y, Barty R, Cook R, Rochwerg B, Iorio A, Warkentin TE, Heddle NM, Arnold DM. The association between platelet transfusions and mortality in patients with critical illness. *Transfusion*. 2019 Apr 1. doi: 10.1111/trf.15277.[Epub ahead of print] PubMed PMID: 30934133.
148. Pai M, Yeung CHT, Akl EA, Darzi A, Hillis C, Legault K, Meerpohl JJ, Santesso N, Taruscio D, Verhovsek M, Schünemann HJ, Iorio A. Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. *BMC Med Res Methodol*. 2019 Mar 28;19(1):67. doi: 10.1186/s12874-019-0713-0. PubMed PMID: 30922227; PubMed Central PMCID: PMC6437842.
149. Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther MA, Iorio A. Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study. *Haemophilia*. 2019 Mar 12. doi: 10.1111/hae.13703. [Epub ahead of print] PubMed PMID: 30861270.
150. Peyvandi F, Castaman G, Gresele P, De Cristofaro R, Schinco P, Bertomoro A, Morfini M, Gamba G, Barillari G, Jiménez-Yuste V, Königs C, Iorio A, Federici AB. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease. *Blood Transfus*. 2019 Feb 4;1-8. doi: 10.2450/2019.0183-18. [Epub ahead of print] PubMed PMID: 30747707.
151. Haynes RB, Budhram D, Cherian J, Iserman E, Iorio A, Lokker C. An evidence rating service provided valid correlates of the clinical importance of medical articles and journals. *J Clin Epidemiol*. 2019 May;109:80-89. doi: 10.1016/j.jclinepi.2019.01.010. Epub 2019 Feb 5. PubMed PMID: 30731116.
152. Stemmerger M, Kallenbach F, Schmit E, McEneny-King A, Germini F, Yeung CHT, Edginton AN, von Mackensen S, Kurnik K, Iorio A. Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study. *Thromb Haemost*. 2019 Mar;119(3):368-376. doi: 10.1055/s-0039-1677700. Epub 2019 Jan 27. PubMed PMID: 30685872.
153. Makris M, Iorio A. Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population? *Res Pract Thromb Haemost*. 2018 Dec 12;3(1):12-14. doi: 10.1002/rth2.12172. eCollection 2019 Jan. PubMed PMID: 30656270; PubMed Central PMCID: PMC6332771.

154. Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther MA, Iorio A. Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. *Haemophilia*. 2019 Jan;25(1):75-83. doi: 10.1111/hae.13649. Epub 2018 Dec 6. PubMed PMID: 30520534.
155. Amir Qaseem, Timothy J. Wilt, Devan Kansagara, Carrie Horwitch, Michael J. Barry, and Mary Ann Forciea for the Clinical Guidelines Committee of the American College of Physicians. Hemoglobin A1c Targets for Glycemic Control with Pharmacologic Therapy for Nonpregnant Adults with Type 2 Diabetes Mellitus: A Guidance Statement Update from the American College of Physicians. *Ann Intern Med*. 2018;168:569-576. Doi:10.7326/M17-0939.
156. Amir Qaseem, Jennifer Lin, Reem A. Mustafa, Carrie A. Horwitch and Timothy J. Wilt for the Clinical Guidelines Committee of the American College of Physicians. Screening for Breast Cancer in Average-Risk Women: A Guidance Statement from the American College of Physicians. *Ann Intern Med*. 2019 Apr 9. doi: 10.7326/M18-2147. [Epub ahead of print]
157. Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A. McMaster RARE-Best practices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. *Journal of Thrombosis and Haemostasis* 2018; 16(8): 1656-64.
158. Patricia Poulin, Yaadwinder Shergill, Heather Romanow, Jason W. Busse, Christine T. Chambers, Lynn Cooper, Paula A. Forgeron, Anita Olsen Harper, Maria Hudspith, Alfonso Iorio, Chitra Lalloo, Carley Ouellette, Rosalind Robertson, Sandy Smeenk, Bonnie Stevens & Jennifer Stinson (2018) Researching what matters to improve chronic pain care in Canada: A priority-setting partnership process to support patient-oriented research, *Canadian Journal of Pain*, 2:1, 191-204, DOI: 10.1080/24740527.2018.1433959 To link to this article: <https://doi.org/10.1080/24740527.2018.1433959>.
159. Rash JA, Buckley N, Busse JW, Campbell TS, Corace K, Cooper L, Flusk D, Iorio A, Lavoie KL, Poulin PA, Skidmore B. Healthcare provider knowledge, attitudes, beliefs, and practices surrounding the prescription of opioids for chronic non-cancer pain in North America: a protocol for a mixed-method systematic review. *Syst Rev*. 2018 Nov 13;7(1): 189. Doi: 10.1186/s13643-018-0858-7. PMID: 30424800.
160. McEneny-King A, Chelle P, Iorio A, Edginton AN. The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. *Thromb Res*. 2018 Aug 9;170:53-59. doi:10.1016/j.thromres.2018.08.004. [Epub ahead of print] PubMed PMID: 30118868.
161. Mannucci PM, Nobili A, Marchesini E, Olivioecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotto G, Peyvandi F, Iorio A. Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls. *Haemophilia*. 2018 Aug 16. doi: 10.1111/hae.13595. [Epub ahead of print] PubMed PMID: 30112863.
162. Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther M, Iorio A. Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. *BMJ Open*. 2018 Aug 8;8(8):e021900. doi: 10.1136/bmjopen-2018-021900. PubMed PMID: 30093520; PubMed Central PMCID: PMC6089314.
163. Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, et al. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. *Haemophilia* [Internet]. 2018 Jul 20;24(4):e167-72.
164. Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. *Res Pract Thromb Haemost*. 2018 May 27;2(3):607-614. doi: 10.1002/rth2.12118. eCollection 2018 Jul. PubMed PMID 30046766; PubMed Central PMCID: PMC6046597.

165. Iorio A, Edginton AN, Blanchette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathôt R, Morfini M, Neufeld EJ, Spears J. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. *Res Pract Thromb Haemost*. 2018 May 20;2(3):535-548. doi: 10.1002/rth2.12106. eCollection 2018 Jul. Review. PubMed PMID: 30046759; PubMed Central PMCID: PMC6046594.
166. Del Fiol G, Michelson M, Iorio A, Cotoi C, Haynes RB. A Deep Learning Method to Automatically Identify Reports of Scientifically Rigorous Clinical Research from the Biomedical Literature: Comparative Analytic Study. *J Med Internet Res*. 2018 Jun 25;20(6):e10281. doi: 10.2196/10281. PubMed PMID: 29941415; PubMed Central PMCID: PMC6037944.
167. Kahale LA, Diab B, Brignardello-Petersen R, Agarwal A, Mustafa RA, Kwong J, Neumann I, Li L, Lopes LC, Briel M, Busse JW, Iorio A, Vandvik PO, Alexander PE, Guyatt G, Akl EA. Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey. *J Clin Epidemiol*. 2018 Jul;99:14-23. doi: 10.1016/j.jclinepi.2018.02.016. Epub 2018 Mar 2. Review. PubMed PMID: 29505859.
168. Chai-Adisaksopha C, Iorio A, Crowther MA, de Miguel J, Salgado E, Zdraveska M, Fernández-Capitán C, Nieto JA, Barillari G, Bertolotti L, Monreal M; RIETE investigators. Vitamin K Antagonists after 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. *Am J Med*. 2017 Dec 20. pii: S0002-9343(17)31277-9. doi: 10.1016/j.amjmed.2017.11.042. [Epub ahead of print]. PMID: 29274307.
169. Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottolotta G, Iorio A, Mannucci PM. Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. *Haemophilia*. 2017 Dec 22. Doi: 10.1111/hae.13379. PMID: 29271531.
170. Iorio A. Using pharmacokinetics to individualize hemophilia therapy. *Hematology. Am Soc Hematol Educ Program*. 2017 Dec 8;2017(1):595-604. doi: 10.1182/asheducation-2017.1.595. Review. Pubmed PMID: 29222309.
171. Neil-Sztramko SE, Farran R, Watson S, Levinson AJ, Lavis JN, Iorio A, Dobbins M. If You Build It, Who Will Come? A Description of User Characteristics and Experiences with the McMaster Optimal Aging Portal. *Gerontol Geriatr Med*. 2017 Nov 8;3:2333721417737681. doi: 10.1177/2333721417737681. eCollection 2017 Jan-Dec. PMID: 29152540.
172. Chai-Adisaksopha C, Iorio A, Hillis C, Siegal D, Witt DM, Schulman S, Crowther M. Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. *Thromb Res*. 2017 Dec;160:97-104. doi: 10.1016/j.thromres.2017.11.001. Epub 2017 Nov 11. PMID: 29136562.
173. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with haemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. *J Thromb Haemost*. 2017 Dec;15(12):2461-2465. Doi: 10.1111/jth.13867. Epub 2017 Nov 9. No abstract available. PMID: 29119666.
174. Alba AC, Agoritsas T, Walsh M, Hanna S, Iorio A, Devereaux PJ, McGinn T, Guyatt G. Discrimination and Calibration of Clinical Prediction Models: Users' Guides to the Medical Literature. *JAMA*. 2017 Oct 10;318(14):1377-1384. doi: 10.1001/jama.2017.12126. PMID: 29049590.
175. McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. *Pharmaceutics*. 2017 Oct 17;9(4). pii: E47. doi: 10.3390/pharmaceutics9040047. PMID: 29039750.
176. Peyvandi F, Makris M, Collins P, Lillicrap D, Pipe SW, Iorio A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Minimal dataset for post-registration surveillance of new drugs in hemophilia: a communication from the SSC of the ISTH. *J Thromb Haemost*. 2017 Sep;15(9): 1878-1881. Doi: 10.1111/jth.13762. Epub 2017 Aug 2. No abstract available. PMID: 28767195.

177. Barbara AM, Dobbins M, Brian Haynes R, Iorio A, Lavis JN, Raina P, Levinson AJ. McMaster Optimal Aging Portal: an evidence-based database for geriatrics-focused health professionals. *BMC Res Notes*. 2017 Jul 11;10(1):271. doi: 10.1186/s13104-017-2595-8. PMID: 28693544.
178. Hemens BJ, Iorio A. Computer-Aided Systematic Review Screening Comes of Age. *Ann Intern Med*. 2017 June 13. Doi: 10.7326/M17-1295. [Epub ahead of print] No abstract available. PMID: 28605802.
179. Lawson W, Uy M, Strike K, Iorio A, Stein N, Koziol L, Chan A. Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation. *Haemophilia*. 2017 June 2. Doi: 10.1111/hae.13269. [Epub ahead of print] PMID: 28574191.
180. Keepanasseril A, Stoffman J, Bouskill V, Carcao M, Iorio A, Jackson S; Association of Haemophilia Centre Directors of Canada (AHCDC). Switching to extended half-life products in Canada – preliminary data. *Haemophilia*. 2017 May 26. Doi: 10.1111/hae.13245. PMID: 28548284.
181. Guyatt GH, Ebrahim S, Alonso-Coello P, Johnston BC, Mathioudakis AG, Briel M, Mustafa RA, Sun X, Walter SD, Heels-Ansdell D, Neumann I, Kahale LA, Iorio A, Meerpohl J, Schunemann HJ, Akl EA. GRADE guidelines 17: Assessing the Risk of Bias associated with missing participant outcome data in a body of evidence. *J Clin Epidemiol*. 2017 May 18. Pii: S0895-4356(16)30811-3. Doi:10.1016/j.jclinepi.2017.05.005. [Epub ahead of print]. PMID: 28529188.
182. Hultcrantz M, Rind D, Akl EA, Treweek S, Mustafa RA, Iorio A, Alper BS, Meerpohl JJ, Murad MH, Ansari MT, Katikireddi SV, Ostlund P, Tranaeus S, Christensen R, Gartlehner G, Brozek J, Izcovich A, Schunemann H, Guyatt G. The GRADE Working Group clarifies the construct of certainty of evidence. *J Clin Epidemiol*. 2017 May 18. Pii: S0895-4356(16)30703-X. Doi: 10.1016/j.jclindpi.201705.006. [Epub ahead of print]. PMID: 28529184.
183. Korte W, Poon MC, Iorio A, Makris M. Thrombosis in Inherited Fibrinogen Disorders. *Transfus Med Hemother*. 2017 Apr;44(2): 70-76. Doi: 10.1159/000452864. Epub 2017 Mar 14. Review. PMID: 28503122.
184. Matino D, Chai-Adisaksopha C, Iorio A. Systematic reviews of prognosis studies: a critical appraisal of five core clinical journals. *Diagn Progn Res* 1, 9 (2017). <https://doi.org/10.1186/s41512-017-0008-z>.
185. Busse JW, Craigie S, Juurlink DN, Buckley DN, Wang L, Couban RJ, Agoritsas T, Akl EA, Carrasco-Labra A, Cooper L, Cull C, da Costa BR, Frank JW, Grant G, Iorio A, Persaud N, Stern S, Tugwell P, Vandvik PO, Guyatt G. Guideline for opioid therapy and chronic noncancer pain. *CMAJ*. 2017 May 8;189(18): E659-E666. Doi: 10.1503/cmaj.170363. PMID: 28483845.
186. Middeldorp S, Iorio A. Oral contraceptive use is a provoking factor for venous thromboembolism. *BMJ*. 2017 Apr 27;357:j2073. Doi:10.1136/bmj.j2073. PubMed PMID: 28450404.
187. Sekercioglu N, Angeliki Veroniki A, Thabane L, Busse JW, Akhtar-Danesh N, Iorio A, Cruz Lopes L, Guyatt GH. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. *PLoS One*. 2017 Mar 1;12(3): e0171028. doi:10.1371/journal.pone.0171028. eCollection 2017.
188. Iorio A, Edginton AN. Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics – impact of recent advances in haemophilia study design on our understanding of

- optimal haemophilia treatment. *Haemophilia*. 2017 Mar 21. Doi: 10.1111/hae.13210. [Epub ahead of print] No abstract available. PMID: 28326647.
189. Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. *Haemophilia*. 2017 May;23(3):e170-e179. Doi:10.1111/hae.13215. Epub 2017 Mar 26. PMID: 28345268.
190. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M; Pharmacokinetic (PK) Expert Working Group of the International Prophylaxis Study Group (the IPSG). Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. *Thromb Haemost*. 2017 Jun 2;117(6): 1023-1030. Doi: 10.1160/TH16-12-0942. Epub 2017 Mar 30. PMID: 28357444 [PubMed-in process].
191. Iorio A, Fischer K, Makris M. Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. *Br J Haematol*. 2017 Apr 7. Doi: 10.1111/bjh.14610. [Epub ahead of print] Review.
192. Iorio A, Barbara AM, Makris M, Fischer K, Castaman G, Catarino C, Gilman E, Kavakli K, Lambert T, Lassila R, Lissitchkov T, Mauser-Bunschoen E, Mingot-Castellano ME, Ozdemir N, Pabinger I, Parra R, Pasi J, Peerlinck, Rauch A, Roussel-Robert V, Serban M, Tagliaferri A, Windyga J, Zanon E. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. *Haemophilia*. 2017 Mar;23(2):255-263. Doi: 10.1111/hae.13167. Epub 2017 Feb 15.
193. Sun J, Zhao Y, Yang R, Guan T, Iorio A; Chinese HERO study group. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China – results from the HERO Study. *Haemophilia*. 2017 Jan;23(1):89-97.
194. Van Vulpen L.F, Saccullo G, Iorio A, Makris M. The current state of adverse event reporting in hemophilia. *Expert Rev Hematol*. 2016 Dec 26:1-8. Doi: 10.1080/17474086.2017.1272410. [Epub ahead of print]. PMID: 28013565.
195. Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L; WAPPS-Hemo co-investigator network. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. *JMIR Res Protoc* 2016 Dec 15;5(4): e239.
196. Iorio A, Stonebraker JS, Brooker M, Soucie JM; Data and Demographics Committee of the World Federation of Hemophilia. Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. *Haemophilia*. 2016 Dec 8. Doi: 10.1111/hae.13127. [Epub ahead of print] PMID: 27928881.
197. McEneny-King A, Foster G, Iorio A, Edginton AN. Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation into the Web-Accessible Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo). *JMIR Res Protoc*. 2016 Dec 7;5(4): e232.

198. Fischer K, Iorio A, Hollingsworth R, Makris M; EUHASS collaborators. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. *Haemophilia*. 2016 Jan;22(1): e36-8. Doi:10.1111/hae.12764. PMID: 26208036.
199. Yeung CH, Santesso N, Zeraatkar D, Wang A, Pai M, Scholzberg M, Schunemann HJ, Iorio A. Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases. *Haemophilia*. 2016 Jul;22 Suppl 3:41-50. doi: 10.1111/hae.13010.
200. Lane SJ, Sholapur NS, Yeung CH, Iorio A, Heddle NM, Scholzberg M, Pai M. Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: a qualitative study. *Hemophilia*, 2016 Jul;22 Suppl 3: 23-30. Doi: 10.1111/hae.13009.
201. Pai M, Santesso N, Yeung CH, Lane SJ, Schunemann HJ, Iorio A. Methodology for the development of the NHF-McMaster Guideline on Care Models for Haemophilia Management. *Haemophilia*. 2016 Jul;22 Suppl 3:17-22. doi: 10.1111/hae.13007
202. Pai M, Key NS, Skinner M, Curtis R, Feinstein M, Kessler C, Lane SJ, Makris M, Riker E, Santesso N, Soucie JM, Yeung CH, Iorio A, Schunemann HJ. NHF-McMaster Guideline on Care Models for Haemophilia Management. *Haemophilia*. 2016 Jul;22 Suppl 3:6-16. doi: 10.1111/hae.13008.
203. Yeung CH, Santesso N, Pai M, Kessler C, Key NS, Makris M, Navarro-Ruan T, Soucie JM, Schunemann HJ, Iorio A. Care models in the management of haemophilia: a systematic review. *Haemophilia*. 2016 Jul;22 Suppl 3:31-40. doi: 10.1111/hae.13000.
204. Schünemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, Garcia D, Lyman G, Noble S, Macbeth F, Griffiths G, DiNisio M, Iorio A, Beyene J, Mbuagbaw L, Neumann I, Van Es N, Brouwers M, Brozek J, Guyatt G, Levine M, Moll S, Santesso N, Streiff M, Baldeh T, Florez I, Gurunlu Alma O, Solh Z, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Buller H, Evans J, McBane R, Bleker S, Pelzer U, Akl EA; IPDMA heparin use in cancer patients research group. Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. *BMJ Open*. 2016 Apr 29;6(4): e010569. doi: 10.1136/bmjopen-2015-010569. PubMed PMID: 27130164.
205. Dolan G, Iorio A, Jokela V, Juusola K, Lassila R. Haemophilia in a real-world setting: the value of clinical experience in data collection. *Eur J Haematol*. 2016 Feb;96 Suppl 82:3-9. doi: 10.1111/ejh.12715. PubMed PMID: 26809546.
206. Marcucci M, Skjøth F, Lip GY, Iorio A, Larsen TB. A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. *Int J Cardiol*. 2016 Jan 15;203:785-90. doi: 10.1016/j.ijcard.2015.11.035. Epub 2015 Nov 6. PubMed PMID: 26595784.
207. Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl EA, Vernooij RW, Johnston BC, Sun X, Briel M, Busse JW, Ebrahim S, Granados CE, Iorio A, Irfan A, Martínez García L, Mustafa RA, Ramírez-Morera A, Selva A, Solà I, Sanabria AJ, Tikkinen KA, Vandvik PO, Zazueta OE, Zhang Y, Zhou Q, Schünemann H, Guyatt GH. Systematic reviews experience major limitations in reporting absolute effects. *J Clin Epidemiol*. 2016 Apr;72:16-26. doi: 10.1016/j.jclinepi.2015.11.002. Epub 2015 Nov 10. PubMed PMID: 26560992.
208. Fischer K, Iorio A, Hollingsworth R, Makris M; all EUHASS collaborators. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. *Haemophilia*. 2016 Jan;22(1):e36-8. doi: 10.1111/hae.12764. Epub 2015 Jul 24. PubMed PMID: 26208036.

209. Romanov V, Marcucci M, Cheng J, Thabane L, Iorio A. Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient data meta-analysis of rAFH-PFM post authorization safety studies. *Thromb Haemost.* 2015 Jul;114(1):5664. doi: 10.1160/TH14100882. Epub 2015 May 28. PMID: 26017627.
210. Franchi C, Ardoino I, Rossio R, Nobili A, Biganzoli EM, Marengoni A, Marcucci M, Pasina L, Tettamanti M, Corrao S, Mannucci PM; REPOSI Investigators (Iorio A in the REPOSI team author list). Prevalence and risk factors associated with use of QT-prolonging drugs in hospitalized older people. *Drugs Aging.* 2015 Dec 22. [Epub ahead of print] PubMed PMID: 26693921.
211. Matino D, Makris M, Dwan K, D'Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. *Cochrane Database Syst Rev.* 2015 Dec 16;12:CD004449. [Epub ahead of print] Review. PMID: 26677005.
212. Marcucci M, Skjøth F, Lip GY, Iorio A, Larsen TB. A decisional model to individualize warfarin recommendations: expected impact on treatment and outcome rates in real-world population with atrial fibrillation. *Int J Cardiol.* 2015 Nov 6;203:785-790. Doi: 10.1016/j.ijcard.2015.11.035 PMID: 26595784.
213. Palareti L, Poti S, Cassis F, Emiliani F, Matino D, Iorio A. Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: results from the HERO qualitative study. *Int J Qual Stud Health Well-Being.* 2015 Nov 16;10:28915. Doi: 10.3402/qhw.v10.28915. eCollection 2015. PMID: 2657860 [PubMed – in process].
214. Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl EA, Vernooij RW, Johnston BC, Sun X, Briel M, Busse JW, Ebrahim S, Granados CE, Iorio A, Irfan A, Martinez Garcia L, Mustafa RA, Ramirez-Morera A, Selva A, Sola I, Sanabria AJ, Tikkinen KA, Vandvik PO, Zazueta OE, Zhou Q, Schunemann H, Guyatt GH. Systematic reviews suffer from major limitations in reporting absolute effects. *J Clin Epidemiol.* 2015 Nov 8. Pii: S0895-4356(15)00505-3. Doi: 10.1016/j.jclinepi.2015.11.002. [Epub ahead of print] PMID: 26560992.
215. Carcao MD, Iorio A. Individualizing factor replacement therapy in severe hemophilia. *Semin Thromb Hemost.* 2015 Nov;41(8):86471. doi: 10.1055/s00351552563. Epub 2015 Aug 13. PMID: 26270111.
216. Chai-Adisaksopa C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. *J Thromb Haemost.* 2015 Nov;13(11):201220. doi: 10.1111/jth.13139. Epub 2015 Oct 5. PMID: 26356595.
217. Bellelli G, Nobili A, Annoni G, Morandi A, Djade CD, Meagher DJ, MacLulich AM, Davis D, Mazzone A, Tettamanti M, Mannucci PM; REPOSI (REgistro POLiterapie SIMI) Investigators (Iorio A in the REPOSI team author list). Under-detection of delirium and impact of neurocognitive deficits on in-hospital mortality among acute geriatric and medical wards. *Eur J Intern Med.* 2015 Nov;26(9):696-704. doi: 10.1016/j.ejim.2015.08.006. Epub 2015 Aug 31. PubMed PMID: 26333532.
218. Chai-Adisaksopha C, Hillis C, Thabane L, Iorio A. A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. *Haemophilia.* 2015 Nov;21(6):7315. doi: 10.1111/hae.12750. Epub 2015 Jul 14. PMID: 26179330.
219. Minuk L, Jackson S, Iorio A, Poon MC, Dilworth E, Brose K, Card R, Rizwan I, ChinYee B, Louzada M. Cardiovascular disease (CVD) in Canadians with haemophilia: Age Related CVD in Haemophilia Epidemiological Research (ARCHER study). *Haemophilia.* 2015 Nov;21(6):73641. doi: 10.1111/hae.12768. Epub 2015 Jul 29. PMID: 26222883.

220. Martino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. *J Clin Invest*. 2015 Oct 1;125(10):376681. doi: 10.1172/JCI81859. Epub 2015 Aug 31. PMID: 26426076.
221. Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Makris M; EUHASS Participants. Inhibitor development in nonsevere haemophilia across Europe. *Thromb Haemost*. 2015 Oct;114(4):6705. doi: 10.1160/TH14121044. Epub 2015 Aug 13. PMID: 26293381.
222. Akl EA, Carrasco Labra A, Brignardello Petersen R, Neumann I, Johnston BC, Sun X, Briel M, Busse JW, Ebrahim S, Granados CE, Iorio A, Irfan A, Martínez García L, Mustafa RA, Ramírez Morera A, Selva A, Solà I, Sanabria AJ, Tikkinen KA, Vandvik PO, Vernooij RW, Zazueta OE, Zhou Q, Guyatt GH, Alonso Coello P. Reporting, handling and assessing the risk of bias associated with missing participant data in systematic reviews: a methodological survey. *BMJ Open*. 2015 Sep 30;5(9):e009368. doi: 10.1136/bmjopen2015009368. PMID: 26423858 Free PMC Article.
223. Santalucia P, Franchi C, Djade CD, Tettamanti M, Pasina L, Corrao S, Salerno F, Marengoni A, Marcucci M, Nobili A, Mannucci PM; REPOSI Investigators (Iorio A in the REPOSI team author list). Gender difference in drug use in hospitalized elderly patients. *Eur J Intern Med*. 2015 Sep;26(7):483-90. doi: 10.1016/j.ejim.2015.07.006. Epub 2015 Jul 22. PubMed PMID: 26209883.
224. Strike KL, Iorio A, Jackson S, Lawson W, Scott L, Squire S, Chan AK. Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation. *Haemophilia*. 2015 Nov;21(6):82831. doi: 10.1111/hae.12767. Epub 2015 Jul 24. No abstract available. PMID: 26208178.
225. Rossio R, Franchi C, Ardoino I, Djade CD, Tettamanti M, Pasina L, Salerno F, Marengoni A, Corrao S, Marcucci M, Peyvandi F, Biganzoli EM, Nobili A, Mannucci PM; REPOSI Investigators (Iorio A in the REPOSI team author list). Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. *Eur J Intern Med*. 2015 Jun;26(5):330-7. doi: 10.1016/j.ejim.2015.04.002. Epub 2015 Apr 18. PubMed PMID: 25898778.
226. Berntorp E, Iorio A. Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. *Blood*. 2015 Jun 11;125(24):3816-7. doi: 10.1182/blood-2014-10-608471. No abstract available. PMID: 26069334 [PubMed - in process] Free PMC Article.
227. Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M; EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. *Thromb Haemost*. 2015 May;113(5):968-75. doi: 10.1160/TH14-10-0826. Epub 2015 Jan 8. PMID: 25567324 [PubMed - in process].
228. Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauser S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. *Thromb Haemost*. 2015 May;113(5):958-67. doi: 10.1160/TH14-07-0621. Epub 2015 Jan 29. PMID: 25631402 [PubMed - in process].
229. Nieuwlaat, R., Wilczynski, N., Navarro, T., Hobson, N., Jeffery, R., Keeganasseril, A., Agoritsas, T., Mistry, N., Iorio, A., Jack, S., Sivaramalingam, B., Iserman, E., Mustafa, R. A., Jedraszewski, D., Cotoi, C., & Haynes, R. B. B. Interventions for enhancing medication adherence. *Cochrane Database of Systematic Reviews*, 2014, 11, CD000011. <https://doi.org/10.1002/14651858.CD000011.pub4>

230. Mbuagbaw L, Sivaramalingam B, Navarro T, Hobson N, Keepanasseril A, Wilczynski NJ, Haynes RB; Patient Adherence Review (PAR) Team. (Iorio A listed in the PAR team members). Interventions for enhancing adherence to AntiRetroviral Therapy (ART): a systematic review of high-quality studies. *AIDS Patient Care STDS*. 2015 May;29(5):248-66. doi: 10.1089/apc.2014.0308. Epub 2015 Mar 31. Review. PMID: 25825938.
231. Corrao S, Argano C, Nobili A, Marcucci M, Djade CD, Tettamanti M, Pasina L, Franchi C, Marengoni A, Salerno F, Violi F, Mannucci PM, Perticone F; REPOSI Investigators. Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study. *Eur J Intern Med*. 2015 May;26(4):243-9. doi: 10.1016/j.ejim.2015.02.018. Epub 2015 Mar 5. PMID: 25749554.
232. Marcucci M, Iorio A, Douketis JD, Eichinger S, Tosetto A, Baglin T, Cushman M, Palareti G, Poli D, Tait RC, Kyrle PA. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. *Thromb Haemost*. 2015 May;13(5):77581. doi: 10.1111/jth.12871. Epub 2015 Mar 12. PMID: 25660555.
233. Rizwan I, Minuk L, Jackson S, Iorio A. Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. *Haemophilia*. 2015 May;21(3):e15666. doi: 10.1111/hae.12596. Epub 2014 Nov 24 PMID: 25420604.
234. Marcucci M, Iorio A, Douketis JD, Eichinger S, Tosetto A, Baglin T, Cushman M, Palareti G, Poli D, Tait RC, Kyrle PA. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna prediction model with pooled individual patient data. *Thromb Haemost*. 2015 May;13(5):77581. doi: 10.1111/jth.12871. Epub 2015 Mar 12. PMID: 25660555.
235. Marengoni A, Nobili A, Corli O, Djade CD, Bertoni D, Tettamanti M, Pasina L, Corrao S, Salerno F, Marcucci M, Mannucci PM; REPOSI investigators. (Iorio A in the REPOSI team author list). The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy. *Intern Emerg Med*. 2015 Apr;10(3):305-13. doi: 10.1007/s11739-014-1131-2. Epub 2014 Sep 24. PubMed PMID: 25248643.
236. Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. *Haemophilia*. 2015 Mar;21(2):204-9. Doi: 10.1111/hae.12550. Epub 2014 Oct 2. PMID: 25274155.
237. Iorio A, Spencer FA, Falavigna M, Alba C, Lang E, Burnand B, McGinn T, Hayden J, Williams K, Shea B, Wolff R, Kujpers T, Perel P, Vandvik PO, Glasziou P, Schunemann H, Guyatt G. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. *BMJ*. 2015 Mar 16;350:h870. doi: 10.1136/bmj.h870. No abstract available. PMID: 25775931 [PubMed - indexed for MEDLINE].
238. Jackson SC, Yang M, Minuk L, Sholzberg M, St-Louis J, Iorio A, Card R, Poon MC. Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. *BMC Hematol*. 2015 Feb 14;15:4. doi: 10.1186/s12878-015-0022-8. eCollection 2015. PMID: 25692030 [PubMed].
239. McCarthy A, Moore A, Redhead L, McLaughlin P, Iorio A, Chowdary P. Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors. *Haemophilia*. 2015 Jan;21(1):11623. doi: 10.1111/hae.12500. Epub 2014 Nov 24. PMID: 25421726.
240. Nugent D, Kalnins W, Querol F, Gregory M, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population. *Haemophilia*. 2015 Jan;21(1):e26-38. doi: 10.1111/hae.12545. Epub 2014 Nov 7. PMID: 25377442.

241. Moja L, Kwag KH, Lytras T, Bertizzolo L, Brandt L, Pecoraro V, Rigon G, Vaona A, Ruggiero F, Mangia M, Iorio A, Kunnamo I, Bonovas S. Effectiveness of computerized decision support systems linked to electronic health records: a systematic review and meta-analysis. *Am J Public Health*. 2014 Dec;104(12):e12-22. doi: 10.2105/AJPH.2014.302164. Epub 2014 Oct 16. Review. PMID: 25322302 [PubMed - indexed for MEDLINE].
242. Akl EA, Kahale LA, Agarwal A, Al-Matari N, Ebrahim S, Alexander PE, Briel M, Brignardello-Petersen R, Busse JW, Diab B, Iorio A, Kwong J, Li L, Lopes LC, Mustafa R, Neumann I, Tikkinen KA, Vandvik PO, Zhang Y, Alonso-Coello P, Guyatt G. Impact of missing participant data for dichotomous outcomes on pooled effect estimates in systematic reviews: a protocol for a methodological study. *Syst Rev*. 2014 Nov 26;3:137. doi: 10.1186/2046-4053-3-137. PMID: 25423894 [PubMed - in process] Free PMC Article.
243. Marcucci M, Lip GY, Nieuwlaet R, Pisters R, Crijns HJ, Iorio A. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. *Am J Med*. 2014 Oct;127(10):979-986.e2. doi: 10.1016/j.amjmed.2014.05.003. Epub 2014 May 13. PMID: 24838192 [PubMed - indexed for MEDLINE].
244. Agoritsas T, Iserman E, Hobson N, Cohen N, Cohen A, Roshanov PS, Perez M, Cotoi C, Parrish R, Pullenayegum E, Wilczynski NL, Iorio A, Haynes RB. Increasing the quantity and quality of searching for current best evidence to answer clinical questions: protocol and intervention design of the MacPLUS FS Factorial Randomized Controlled Trials. *Implement Sci*. 2014 Sep 20;9:125. doi: 10.1186/s13012-014-0125-9. PMID: 25239537 [PubMed - indexed for MEDLINE].
245. Matino D, Iorio A. Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward. *Haemophilia*. 2014 Sep;20(5):604-6. doi: 10.1111/hae.12511. Epub 2014 Aug 25. PubMed PMID: 25154445.
246. Cassis FR, Buzzi A, Forsyth A, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) Study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. *Haemophilia*. 2014 Jul;20(4):e287-95. doi: 10.1111/hae.12454. Epub 2014 May 7. PubMed PMID: 24800872.
247. Bessede A, Gargaro M, Pallotta MT, Matino D, Servillo G, Brunacci C, Biciato S, Mazza EM, Macchiarulo A, Vacca C, Iannitti R, Tissi L, Volpi C, Belladonna ML, Orabona C, Bianchi R, Lanz TV, Platten M, Della Fazio MA, Piobbico D, Zelante T, Funakoshi H, Nakamura T, Gilot D, Denison MS, Guillemin GJ, DuHadaway JB, Prendergast GC, Metz R, Geffard M, Boon L, Pirro M, Iorio A, Veyret B, Romani L, Grohmann U, Fallarino F, Puccetti P. Aryl hydrocarbon receptor control of a disease tolerance defense pathway. *Nature*. 2014 Jul 10;511(7508):184-90. doi: 10.1038/nature13323. PMID: 24930766 [PubMed - indexed for MEDLINE].
248. Athale AH, Marcucci M, Iorio A. Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. *Cochrane Database Syst Rev*. 2014 Apr 24;4:CD010561. doi: 10.1002/14651858.CD010561.pub2. Review. PMID: 24763974 [PubMed - in process].
249. Athale, A., Giguere, A., Barbara, A., Krassova, S., & Iorio, A. Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes for clinicians and patient decision aids for patients. *Haemophilia*, 2014; 20(6), 800–806. <https://doi.org/10.1111/hae.12495>
250. Matino D, Teitel J, Page D, Keepanasseril A, Iorio A, Walker I. The haemophilia certification system in Canada. *Blood Transfus*. 2014 Apr;12 Suppl 3:e531-41. doi: 10.2450/2014.0032-14s. Review. No abstract available. PMID: 24922284 [PubMed - indexed for MEDLINE].
251. Iorio A, Douketis JD. Ruling out DVT using the Wells rule and a D-dimer test. *BMJ*. 2014 Mar 10;348:g1637. doi: 10.1136/bmj.g1637. No abstract available. PMID: 24615174 [PubMed - indexed for MEDLINE].

252. Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le Gal G, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. *Thromb Haemost.* 2014 Jan;111(1):172-9. doi: 10.1160/TH13-04-0336. Epub 2013 Oct 24. PMID: 24154729 [PubMed - indexed for MEDLINE].
253. Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le Gal G, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. *Thromb Haemost.* 2014 Jan;111(1):172-9. doi: 10.1160/TH13-04-0336. Epub 2013 Oct 24. PubMed PMID: 24154729.
254. Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. *Haemophilia.* 2014 Jul;20(4):527-34. doi: 10.1111/hae.12371. Epub 2014 Jan 29. PubMed PMID: 24471912.
255. Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A and Nowak-Gottl U. Effect of type and intensity of FVIII exposure on inhibitors development in hemophilia A: first results of an individual patient data meta-analytic project. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. AS 22.2.
256. Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, Makris M, O'Donnell J, Pipe S, Santagostino E, Saint-Remy JM, Schramm W, Iorio A. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. *Haemophilia.* 2014 Mar;20(2):200-6. doi: 10.1111/hae.12283. Epub 2013 Oct 29. PubMed PMID: 24533949.
257. Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Djade CD, Marengoni A, Salerno F, Corrao S, Mannucci PM; REPOSI (Registro Politerapie Societa Italiana di Medicina Interna) Investigators. Prophylaxis of venous thromboembolism in elderly patients with multimorbidity. *Intern Emerg Med.* 2013;Sep;8(6):509-20. doi: 10.1007/s1173901309448. Epub 2013†May 8. PMID: 23653407.
258. Forsyth AL, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. *Haemophilia.* 2014 Jan;20(1):44-51. doi: 10.1111/hae.12239. Epub 2013 Aug 1. PubMed PMID: 23902228.
259. Marcucci M, Iorio A, Douketis J. Management of patients with unprovoked venous thromboembolism: an evidence-based and practical approach. *Curr Treat Options Cardiovasc Med.* 2013 Apr;15 (2): 224-39. Doi: 10.1007/s11936-012-0225-2. PubMed PMID: 23344704; PubMed Central PMID: PMC3608888.
260. Iorio A, Skinner MW, Makris M. Factor VIII products and inhibitors in severe hemophilia A. *N. Engl J Med.* 2013 Apr 11;368(15): 1456. Doi: 10.1056/NEJMc1301995#SA1. PubMed PMID: 2374132.
261. Santagostino E, Messina M, Tagliaferri A, Iorio A, Morfini M. Haemophilia at various states of life: design of new therapeutic strategies through an interactive course – the Kogeniale project. *Blood Transfus.* 2013 Apr;11(2): 272-80. Doi: 10.2450/2012.0158-12. Epub 2013 Jan 23. PubMed PMID: 23399360; PubMed Central PMCID: PMC3626480.
262. Marcucci M, Smith CT, Douketis JD, Tosetto A, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. *J Clin Epidemiol.* 2013 Apr;66(4) : 415-25. Doi: 10.1016/j.jclinepi.2012.08.007. Epub 2013 Feb 8. PubMed PMID: 23395515.

263. Marengoni A, Nobili A, Pirali C, Tettamanti M, Pasina L, Salerno F, Corrao S, Iorio A, Marcucci M, Franchi C, Mannucci PM. Comparison of disease clusters in two elderly populations hospitalized in 2008 and 2010. *Gerontology*. 2013;59(4):307-15. doi: 10.1159/000346353. Epub 2013 Jan 25. PMID: 23364029.
264. Cassis FR, Querol F, Forsyth A, Iorio A; on behalf of the HERO International Advisory Board. Psychosocial aspects of haemophilia: a systematic review of methodologies and findings. *Haemophilia*. 2012 May;18(3):e101-e114. doi: 10.1111/j.1365-2516.2011.02683.x. Epub 2011 Nov 8. PubMed PMID: 22059839.
265. Knoebl P, Marco P, Baudo F, Collins P, Huth-Kühne A, Nemes L, Pellegrini F, Tengborn L, Lévesque H; EACH2 Registry Contributors (Iorio A listed). Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). *J Thromb Haemost*. 2012 Apr;10(4):622-31. doi:10.1111/j.1538-7836.2012.04654.x. PubMed PMID: 22321904.
266. Zanon E, Iorio A, Rocino A, Artoni A, Santoro R, Tagliaferri A, Coppola A, Castaman G, Mannucci PM; Italian Association of Hemophilia Centers, Barillari G, Dragani A, Gamba G, Giuffrida A, Lapcorella M, Mancuso G, Lucia L, Mazzucconi MG, Messina M, Musso R, De Martis F, Rossetti G, Schinco P, Spiezia L, Valdrè L. Intracranial haemorrhage in the Italian population of haemophilia patients with and without inhibitors. *Haemophilia*. 2012 Jan;18(1):39-45. doi: 10.1111/j.1365-2516.2011.02611.x. Epub 2011 Jul 14. PubMed PMID: 21752159.
267. Siboni SM, Zanon E, Sottilotta G, Consonni D, Castaman G, Mikovic D, Biondo F, Tagliaferri A, Iorio A, Mannucci PM, Peyvandi F. Central nervous system bleeding in patients with rare bleeding disorders. *Haemophilia*. 2012 Jan;18(1):34-8. doi: 10.1111/j.1365-2516.2011.02545.x. Epub 2011 May 4. PubMed PMID: 21539694.
268. Tositto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). *J Thromb Haemost* 2012;10:1019-5.
269. Marengoni A, Corrao S, Nobili A, Tettamanti M, Pasina L, Salerno F, Iorio A, Marcucci M, Bonometti F, Mannucci PM; on behalf of SIMI Investigators (SIMI denotes the Italian Society of Internal Medicine. The participating units and co-authors are listed in the Appendix). In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. *Int J Geriatr Psychiatry*. 2011 Sep;26(9):930-6. doi: 10.1002/gps.2627. Epub 2010 Nov 9. PubMed PMID: 21061413.
270. Marcucci M, Nobili A, Iorio A. More about optimal choices in cardioembolism prevention. *Eur J Intern Med* 2011;22:e-19.
271. Iorio A, Marcucci M, Makris M. Concentrate-related inhibitor risk: is a difference always real? *J Thromb Haemost*. 2011 Nov;9(11):2176-9. doi: 10.1111/j.1538-7836.2011.04480.x. PubMed PMID: 21854537.
272. Federici AB, Bucciarelli P, Castaman G, Baronciani L, Canciani MT, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Olivioecchio E, Iorio A, Mannucci PM. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients. *Semin Thromb Hemost*. 2011 Jul;37(5):511-21. Epub 2011 Nov 18. PubMed PMID: 22102194.
273. Siragusa S, Malato A, Saccullo G, Iorio A, Di Ianni M, Caracciolo C, Coco LL, Raso S, Santoro M, Guarneri FP, Tuttolomondo A, Pinto A, Pepe I, Casuccio A, Abbadessa V, Licata G, Battista Rini G, Mariani G, Di Fede G. Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. *Am J Hematol*. 2011 Nov;86(11):914-7. doi: 10.1002/ajh.22156. Epub 2011 Sep 22. PubMed PMID: 21953853.

274. Kenet G, Aronis S, Berkun Y, Bonduel M, Chan A, Goldenberg NA, Holzhauer S, Iorio A, Journeycake J, Junker R, Male C, Manco-Johnson M, Massicotte P, Mesters R, Monagle P, van Ommen H, Rafini L, Simioni P, Young G, Nowak-Göttl U. Impact of persistent antiphospholipid antibodies on risk of incident symptomatic thromboembolism in children: a systematic review and meta-analysis. *Semin Thromb Hemost.* 2011 Oct;37(7):802-9. Epub 2011 Dec 20. Review. PubMed PMID: 22187403.
275. Nobili A, Marengoni A, Tettamanti M, Salerno F, Pasina L, Franchi C, Iorio A, Marcucci M, Corrao S, Licata G, Mannucci PM. Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. *Eur J Intern Med.* 2011 Dec;22(6):597-602. Epub 2011 Sep 29. PubMed PMID: 22075287.
276. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. *Cochrane Database Syst Rev.* 2011 Sep 7;(9):CD003429. Review. PubMed PMID: 21901684.
277. Marengoni A, Corrao S, Nobili A, Tettamanti M, Pasina L, Salerno F, Iorio A, Marcucci M, Bonometti F, Mannucci PM; SIMI Investigators. In-hospital death according to dementia diagnosis in acutely ill elderly patients: the REPOSI study. *Int J Geriatr Psychiatry.* 2011 Sep;26(9):930-6. doi: 10.1002/gps.2627. Epub 2010 Nov 9. PubMed PMID: 21845595.
278. Giampaolo A, Abbonizio F, Puopolo M, Arcieri R, Mannucci PM; Italian Association of Haemophilia Centres, Hassan HJ, Accorsi A, Ettorre PC, Schiavoni M, Palareti G, Rodorigo G, Valdré L, Amaddii G, Billio A, Notarangelo L, Iannacaro P, Muleo P, Biasioli C, Rossi V, Alatri A, Testa S, Vincenzi D, Scapoli G, Morfini M, Molinari AC, Lapecorella M, Mariani G, Baudo F, Caimi MT, Federici AB, Gringeri A, Mannucci PM, Santagostino E, Marietta M, Coppola A, Di Minno G, Perricone C, Schiavulli. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. *Transfus Med.* 2011 Aug;21(4):280-4. doi: 10.1111/j.1365-3148.2011.01074.x. Epub 2011 Mar 30. PubMed PMID: 21733006.
279. Douketis JD, Iorio A. The association between venous thromboembolism and physical inactivity in everyday life. *BMJ.* 2011 Jul 4;343:d3865. doi: 10.1136/bmj.d3865. PubMed PMID: 21727168.
280. Marchesini E, Prisco D, Iorio A. Recombinant Factor VIIa concentrate versus plasma-derived concentrates for the treatment of acute bleeding episodes in persons with haemophilia and inhibitors. *European Oncology and Haematology.* 2011, 7:Summer(2)140-142.
281. Iorio A. ACP Journal Club. The Wells rule and a primary care rule were useful for ruling out deep venous thrombosis in primary care. *Ann Intern Med.* 2011 Jun 21;154(12):JC6-13. PubMed PMID: 21690591.
282. Nobili A, Licata G, Salerno F, Pasina L, Tettamanti M, Franchi C, De Vittorio L, Marengoni A, Corrao S, Iorio A, Marcucci M, Mannucci PM; SIMI Investigators. Polypharmacy, length of hospital stay, and in-hospital mortality among elderly patients in internal medicine wards. The REPOSI study. *Eur J Clin Pharmacol.* 2011 May;67(5):507-19. Epub 2011 Jan 11. PubMed PMID: 21221958.
283. Pasina L, Nobili A, Tettamanti M, Salerno F, Corrao S, Marengoni A, Iorio A, Marcucci M, Mannucci PM; REPOSI Investigators. Prevalence and appropriateness of drug prescriptions for peptic ulcer and gastro-esophageal reflux disease in a cohort of hospitalized elderly. *Eur J Intern Med.* 2011 Apr;22(2):205-10. Epub 2010 Dec 21. PubMed PMID: 21402255.
284. Douketis J, Tosetto A, Marcucci M, Bagli T, Cushman M, Kryle P, Cosmi B, Poli D, Tait RC, Iorio A. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. *BMJ.* 2011 Feb 24;342:d813. Review. PubMed PMID: 21349898; PubMed Central PMCID: PMC3044449.

285. Rocca A, Pizzinelli S, Oliovecchio E, Santagostino E, Rocino A, Iorio A. An Italian ad hoc study group. Replacement therapy with recombinant factor IX. A multicentre evaluation of current dosing practices in Italy. *Blood Transfus.* 2011 Jan 9(1):60-9.
286. Malato A, Saccullo G, Iorio A, Ageno W, Siragusa S. Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. *Curr Pharm Des.* 2010;16(31):3483-6. Review. PubMed PMID: 20858182.
287. Marcucci M, Iorio A, Nobili A, Tettamanti M, Pasina L, Marengoni A, Salerno F, Corrao S, Mannucci PM; REPOSI Investigators. Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards. *Eur J Intern Med.* 2010 Dec;21(6):516-23.
288. Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, Palareti G, Poli D, Tait RC, Iorio A. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. *J Thromb Haemost.* 2010 Nov;8(11):2436-42. doi:10.1111/j.1538-7836.2010.04022.x. PubMed PMID: 20723032.
289. Kearon C, Iorio A, Palareti G; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting. *J Thromb Haemost.* 2010 Oct;8(10):2313-5. doi:10.1111/j.1538-7836.2010.03991.x. PubMed PMID: 20738761.
290. Iorio A, Kearon C, Filippucci E, Marcucci M, Macura A, Pengo V, Siragusa S, Palareti G. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. *Arch Intern Med.* 2010 Oct 25;170(19):1710-6. Review. PubMed PMID: 20975016.
291. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Iorio A. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. *Ann Intern Med.* 2010 Oct 19;153(8):523-31. Review. PubMed PMID: 20956709.
292. Iorio A. ACP Journal Club. A 9-factor score predicted 2-year risk for bleeding in outpatients with, or at high risk for, atherothrombosis. *Ann Intern Med.* 2010 Oct 19;153(8):JC4-13. PubMed PMID: 20956697.
293. Iorio A, Matino D, D'Amico R, Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. *Cochrane Database Syst Rev.* 2010 Aug 4;(8):CD004449. Review. PubMed PMID: 20687076.
294. Marengoni A, Bonometti F, Nobili A, Tettamanti M, Salerno F, Corrao S, Iorio A, Marcucci M, Mannucci PM; Italian Society of Internal Medicine (SIMI) Investigators. In-hospital death and adverse clinical events in elderly patients according to disease clustering: the REPOSI study. *Rejuvenation Res.* 2010 Aug;13(4):469-77. PubMed PMID: 20586646.
295. Giuliano V, Bassotti G, Mourvaki E, Castellani D, Filippucci E, Sabatino G, Gizzi S, Palmerini F, Galli F, Morelli O, Baldoni M, Morelli A, Iorio A. Small intestinal bacterial overgrowth and warfarin dose requirement variability. *Thromb Res.* 2010 Jul;126(1):12-7. Epub 2010 Jan 3. PubMed PMID: 20051286.
296. Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. *J Thromb Haemost.* 2010 Jun;8(6):1256-65. Epub 2010 Mar 17. Review. PubMed PMID: 20345722.

297. Tagliaferri A, Rivolta GF, Iorio A, Olivoecchio E, Mancuso ME, Morfini M, Rocino A, Mazzucconi MG, Franchini M; Italian Association of Hemophilia Centers, Ciavarella N, Scaraggi A, Valdrè L, Tagariello G, Radossi P, Muleo G, Iannaccaro PG, Biasoli C, Vincenzi D, Serino ML, Linari S, Molinari C, Boeri E, La Pecorella M, Carloni MT, Santagostino E, Di Minno G, Coppola A, Rocino A, Zanon E, Spiezia L, Di Perna C, Marchesini M, Marcucci M, Dragani A, Macchi S, Albertini P, D'Inca M. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. *Haemophilia*. 2010 May 16(3):437-46. Epub 2010 Feb 9. PubMed PMID: 20148978.
298. Macura A, Abraha I, Kirkham J, Gensini GF, Moja L, Iorio A. Selective outcome reporting: telling and detecting true lies. The state of the science. *Intern Emerg Med*. 2010 Apr;5(2):151-5. Epub 2010 Mar 19. PubMed PMID: 20300879.
299. Iorio A, Basileo M, Marcucci M, Guercini F, Camilloni B, Paccamiccio E, Vecchioli M, Iorio AM. Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, double-blind crossover study. *Arch Intern Med*. 2010 Apr 12;170(7):609-16. PubMed PMID: 20386004.
300. Kenet G, Lütkehoff LK, Albisetti M, Bernard T, Bonduel M, Brandao L, Chabrier S, Chan A, deVeber G, Fiedler B, Fullerton HJ, Goldenberg NA, Grabowski E, Günther G, Heller C, Holzhauer S, Iorio A, Journeycake J, Junker R, Kirkham FJ, Kurnik K, Lynch JK, Male C, Manco-Johnson M, Mesters R, Monagle P, van Ommen CH, Raffini L, Rostásy K, Simioni P, Sträter RD, Young G, Nowak-Göttl U. Impact of thrombophilia on risk of arterial ischemic stroke or cerebral sinovenous thrombosis in neonates and children: a systematic review and meta-analysis of observational studies. *Circulation*. 2010 Apr 27;121(16):1838-47. Epub 2010 Apr 12. Review. PubMed PMID: 20385928.
301. Cosmi B, Legnani C, Iorio A, Pengo V, Ghirarduzzi A, Testa S, Poli D, Tripodi A, Palareti G; PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. *Eur J Vasc Endovasc Surg*. 2010 Mar;39(3):356-65. Epub 2010 Jan 19. PubMed PMID: 20034816.
302. Iorio A, Fabbriani G, Marcucci M, Brozzetti M, Filipponi P. Bone mineral density in haemophilia patients. A meta-analysis. *Thromb Haemost*. 2010 Mar;103(3):596-603. Epub 2010 Jan 13. PubMed PMID: 20076854.
303. Iorio A, Marchesini E, Awad T, Gluud LL. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. *Cochrane Database Syst Rev*. 2010 Jan 20;(1):CD004888. Review. PubMed PMID: 20091566.
304. G. Tagariello, A. Iorio, P.M. Mannucci. Author Response: Insufficient evidence to suggest less stringent therapy in haemophilia B? *Blood* 2009;114(23):4907.
305. A. Iorio. International clinical trials are the best way to improve global haemophilia care? No. *Haemophilia* 2009; 15(Suppl1),13.
306. Siboni SM, Mannucci PM, Gringeri A, Franchini M, Tagliaferri, Ferretti M, Tradati FC, Santagostino E and Von Mackensen S for the Italian Association of Hemophilia Centres (AICE). Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. *Journal of Thrombosis and Haemostasis*. 7:780-786. DOI: 10.1111/j.1538-7836.2009.03318.x (A. Iorio in the Medline published coauthors list) (IF = 5,947).
307. A. Coppola, M. Margaglione, E. Santagostino, A. Rocino, E. Grandone, P.M. Mannucci, G. Di Minno for the AICE PROFIT Study Group. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction (ITI) of hemophilia A patients with high-responding inhibitors. *J Thromb Haemost*. 2009 Nov;7(11):1809-15. Epub 2009 Sep 9.

308. Iorio A, Ageno W, Cosmi B, Imberti D, Lussana F, Siragusa S, Tormene D, Tosetto A, Cattaneo M. Objectives and methodology: guidelines of the Italian Society for Haemostasis and Thrombosis (SISST). *Thromb Res*. 2009 Nov;124(5):e1-5. Epub 2009 Jun 26. PubMed PMID: 19559468.
309. Gluud LL, Marchesini E, Iorio A. Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. *Am J Gastroenterol*. 2009 Sep;104(9):2335-41; quiz 2342. Epub 2009 Jun 9. Review. PubMed PMID:19513022.
310. Ageno W, Garcia D, Aguilar MI, Douketis J, Finazzi G, Imberti D, Iorio A, Key NS, Lim W, Marietta M, Prisco D, Sarode R, Testa S, Tosetto A, Crowther M. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment. *Am J Hematol*. 2009 Sep;84(9):584-8. Review. PubMed PMID: 19610020.
311. Iorio A, Marcucci M. Clinical trials and haemophilia: does the Bayesian approach make the ideal and desirable good friends? *Haemophilia*. 2009 Jul;15(4):900-3. Epub 2009 Apr 7. Review. PubMed PMID: 19473413.
312. Tagariello G, Iorio A, Santagostino E, Morfini M, Bisson R, Innocenti M, Mancuso ME, Mazzucconi MG, Pasta GL, Radossi P, Rodorigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP, Mannucci PM; Italian Association Hemophilia Centre (AICE). Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. *Blood*. 2009 Jul 23;114(4):779-84. Epub 2009 Apr 8. Review. PubMed PMID: 19357395.
313. Santoro C, Iorio A, Ferrante F, Pallotta A, Pignoloni P, Biondo F, Agnelli G, Mazzucconi MG. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII). *Haemophilia*. 2009 May;15(3):779-87. Epub 2009 Feb 27. PubMed PMID:19298379.
314. Iorio A, Oliovecchio E, Morfini M, Mannucci PM; Association of Italian Hemophilia Centres Directors. Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis. *Haemophilia*. 2008 May;14(3):444-53. Epub 2008 Mar 18. Erratum in: *Haemophilia*. 2009 Mar;15(2):637. PubMed PMID: 18355268.
315. Iorio A, Barnes C, Vedovati MC, Favalaro EJ. Thrombophilia and cerebral vein thrombosis. *Front Neurol Neurosci*. 2008;23:55-76. Review. PubMed PMID: 18004053.
316. Iorio A. Iatrogenic causes of an ICH: OAT therapy. *Eur J Anaesthesiol Suppl*. 2008;42:8-11. Review. PubMed PMID: 18289410.
317. Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E; for the KOGENATE® Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: Experience in the standard clinical setting. *Thromb Haemost*. 2008; 99(1): 52-58.
318. Verso M, Iorio A. Review: Perioperative LMW heparin does not reduce mortality after surgery more than unfractionated heparin in patients with cancer. *ACP J Club*. 2008 Dec 16;149(6):11. PubMed PMID: 19071877.
319. Iorio A, Basileo M, Marchesini E, Palazzesi GP, Materazzi M, Marchesi M, Esposito A, Pellegrini L, Germani A, Rocchetti L, Silvani CM. Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results of the pilot phase. *Blood Transfus*. 2008 Oct;6(4):211-9. PubMed PMID: 19112736; PubMed Central PMCID: PMC2626902.
320. Iorio A, Moja L, Liberati A, Gensini GF, Gusinu R, Conti AA. Selecting references that match constructs: the difficult job of citing the parachute hyperbole. *Intern Emerg Med*. 2008 Jun;3(2):151-4. PubMed PMID: 18437290.

321. Iorio A, Basileo M, Marchesini E, Materazzi M, Marchesi M, Esposito A, Palazzesi GP, Pellegrini L, Pasqua BL, Rocchetti L, Silvani CM. The good use of plasma. A critical analysis of five international guidelines. *Blood Transfus.* 2008 Jan;6(1):18-24. PubMed PMID: 18661920; PubMed Central PMCID: PMC2626858.
322. Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E; KOGENATE Bayer European PMS Study Group. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. *Thromb Haemost.* 2008 Jan;99(1):52-8. PubMed PMID: 18217134.
323. Palareti G, Cosmi B, Iorio A. D-Dimer and duration of anticoagulation. *New England Journal of Medicine*, 2007; 356 (4): 421-3.
324. Iorio A, Vedovati MC, Filippucci E, Agnelli G. Seizures, headache and thrombocytopenia: diagnosis and treatment do not always come in a standard sequence. *Intern Emerg Med.* 2007 Oct;2(3):202-6. PubMed PMID: 17909704.
325. Iorio A, Federici MO, Mourvaki E, Ferolla P, Piroddi M, Stabile A, Timi A, Celleno R, Benedetti MM. Impaired endothelial antithrombotic activity following short-term interruption of continuous subcutaneous insulin infusion in type 1 diabetic patients. *Thromb Haemost.* 2007 Sep;98(3):635-41. PubMed PMID: 17849053.
326. Baldi G, Altomonte F, Altomonte M, Ghirarduzzi A, Brusasco C, Parodi RC, Ricciardi A, Remollino V, Spisni V, Saporito A, Caiazza A, Musso G, Cervellin G, Lamberti S, Buzzalino M, De Giorgi F, Del Prato C, Golinelli MP, Gai V, Monsù R, Gioffre' M, Giovanardi D, Cattaneo S, Frumento F, Caporrella A, Re G, De Iaco F, Bologna G, Nocenti F, Lorenzi C, Zoratti R, Sciolla A, Tiscione V, Pastorello M, Vandelli A, Villa A, Zanna M, De Palma A, Iorio A. Intracranial haemorrhage in patients on antithrombotics: clinical presentation and determinants of outcome in a prospective multicentric study in Italian emergency departments. *Cerebrovasc Dis.* 2006;22(4):286-93. Epub 2006 Jul 17. PubMed PMID: 16847397.
327. Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, The Emoclot 15 Study Members. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. *Haemophilia* 2006, 12(2):128-32. (Iorio A listed in the Appendix as Emoclot 15 study member).
328. Mancuso ME, Rumi MG, Santagostino E, Linari S, Coppola A, Mannucci PM, Colombo M, Hepatitis Study Group of the Association of Italian Hemophilia Centers. High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C. *Haematologica.* 2006, 91: 1367-1371 (Iorio A in the Appendix as member of the study group).
329. Iorio AM, Camilloni B, Basileo M, Guercini F, Conti S, Ferrante F, Paccamiccio E, Iaboni S, Vecchioli M, Iorio A. Influenza vaccination in patients on long-term anticoagulant therapy. *Vaccine.* 2006 Nov 10;24(44-46):6624-8. Epub 2006 Jun 8. PubMed PMID: 16828939.
330. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A, PROLONG Investigators. D-dimer testing to determine the duration of anticoagulation therapy. *N Engl J Med.* 2006 Oct 26;355(17):1780-9. Erratum in: *N Engl J Med.* 2006 Dec 28;355(26):2797. PubMed PMID: 17065639.
331. Iorio A, Agnelli G. Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? No. *J Thromb Haemost.* 2006 Oct;4(10):2133-6. Epub 2006 Jul 17. PubMed PMID: 16848864.
332. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. *Cochrane Database Syst Rev.* 2006 Apr 19;(2):CD003429. Review. Update in: *Cochrane Database Syst Rev.* 2011;9:CD003429. PubMed PMID: 16625581.

333. Iorio A, Stobart K, Bolton-Maggs P. Can evidence harm? Certainly not hemophilia treatment and community. *J Thromb Haemost.* 2006 Mar;4(3):505-6. PubMed PMID: 16460430.
334. Iorio A, Guercini F, Ferrante F, Nenci GG. Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. *Curr Pharm Des.* 2005;11(30):3893-918. PubMed PMID: 16305520.
335. Iorio A., Ferrante F. Gestione ed organizzazione di un centro di sorveglianza della terapia anticoagulante. *Annali della Facoltà di Medicina e Chirurgia della Università di Perugia che pubblicano gli Atti della Accademia Anatomico-Chirurgica* (0365-2270) 2005, vol.96 supp. 1.
336. Mantovani L., Monzini M., Mannucci P., Scalone L., Villa M., Gringeri A., for the Conan Study Group. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. *Haemophilia* (Oxford. Print). 2005.
337. Belvini D., Salviato R., Radossi P., Pierobon F., Mori P., Castaldo G., Tagariello G., AICE HB study group. Molecular genotyping of the Italian cohort of patients with hemophilia B. *Haematologica* (0390-6078) 2005, 90: 635-642. (Iorio A listed as Head of the Centro Emofil di Perugia.).
338. Mourvaki E, Ferrante F, Ghirarduzzi A, Brini M, Depunzio I, Iorio A. Performance comparison of three assay methods used in fasting and postmethionine load plasma homocysteine determinations from patients with vascular disease. *Am J Clin Pathol.* 2005 Nov;124(5):675-81. PubMed PMID: 16203288.
339. Conti S, La Torre D, Gambelunghe G, Ciorba E, Iorio A. Successful treatment with rFVIIa of spontaneous intracerebral hemorrhage in a patient with mechanical prosthetic heart valves. *Clin Lab Haematol.* 2005 Aug;27(4):283-5. PubMed PMID: 16048499.
340. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. *Cochrane Database Syst Rev.* 2005 Apr 18;(2):CD003429. Review. Update in: *Cochrane Database Syst Rev.* 2006;(2):CD003429. PubMed PMID: 15846666.
341. Iorio A. Prevention of venous thromboembolism after major orthopedic surgery: summing up evidence about old and new antithrombotic agents. *J Thromb Haemost.* 2004 Jul;2(7):1055-7. Review. Erratum in: *J Thromb Haemost.* 2004 Aug;2(8):1504. PubMed PMID: 15219186.
342. Silingardi M, Salvarani C, Boiardi L, Accardo P, Iorio A, Olivieri I, Cantini F, Salvi F, La Corte R, Triolo G, Ciccia F, Ghirarduzzi A, Filippini D, Paolazzi G, Iori I. Factor V Leiden and prothrombin gene G20210A mutations in Italian patients with Behçet's disease and deep vein thrombosis. *Arthritis Rheum.* 2004 Apr 15;51(2):177-83. PubMed PMID: 15077257.
343. Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. *J Thromb Haemost.* 2003 Sep;1(9):1906-13. PubMed PMID: 12941030.
344. Conti S, Guercini F, Iorio A. Low-molecular-weight heparin and cancer survival: review of the literature and pooled analysis of 1,726 patients treated for at least three months. *Pathophysiol Haemost Thromb.* 2003 Jul-2004 Aug;33(4):197-201. PubMed PMID: 15583449.
345. Iorio A. Applied pharmacoeconomics: considerations to drive the choice of a prophylactic antithrombotic regimen. *J Thromb Haemost.* 2003 May;1(5):881-3. Review. PubMed PMID: 12871350.

346. Testa S., Iorio A., Alatri A., Parisoli A., Ghirarduzzi A., Berrettini M., Rinaldi G., per il Gruppo di Studio di Centri aderenti all'FCSA e per il Gruppo di Studio Coagulazione della SIMEL. Gli standard di accreditamento dei centri per la sorveglianza dei pazienti in terapia anticoagulante orale (TAO). *Journal of Laboratory Medicine* 2002 3 (2-s1): 52-56.
347. Nicolini A, Ghirarduzzi A, Iorio A, Silingardi M, Malferrari G, Baldi G. Intracranial bleeding: epidemiology and relationships with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. *Haematologica*. 2002 Sep;87(9):948-56. PubMed PMID: 12217807.
348. Goracci S, Filippucci E, Guercini F, Santucci L, Iorio A. Successful treatment of Dieulafoy's disease in a von Willebrand patient. *Haematologica*. 2002 Jul;87(7):ECR23. PubMed PMID: 12091139.
349. Iorio A., Agnelli G. Heparin reduces venous thromboembolism in neurosurgery but increases the risk of bleeding. (Iorio A, Agnelli G. Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a metanalysis. *Arch Intern Med*. 2000;160:2327-2332). *ACP journal club* (1056-8751) 2001: 55.
350. Tripodi A., Chantarangkul V., Lombardi R., Lecchi A., Mannucci P., Cattaneo M., for the ad hoc study group. Multicenter study of homocysteine measurement – performance characteristic of different methods, influence of standards on interlaboratory agreement results. *Thrombosis and Haemostasis* (0340-6245) 2001, 85: 291-5, (Iorio A. listed as author in the ad hoc study group) (IF = 3,723).
351. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Iorio A, Bazzan M, Moia M, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W; Warfarin Optimal Duration Italian Trial Investigators. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. *N Engl J Med*. 2001 Jul 19;345(3):165-9. PubMed PMID: 11463010.
352. Silingardi M, Ghirarduzzi A, Galimberti D, Iorio A, Iori I. Mesenteric-portal vein thrombosis in a patient with hyperhomocysteinemia and heterozygous for 20210A prothrombin allele. *Thromb Haemost*. 2000 Aug;84(2):358-9. PubMed PMID: 10959718.
353. Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Arch Intern Med*. 2000 Aug 14-28;160(15):2327-32. PubMed PMID: 10927730.
354. Silingardi M, Ghirarduzzi A, Tincani E, Iorio A, Iori I. Miconazole oral gel potentiates warfarin anticoagulant activity. *Thromb Haemost*. 2000 May;83(5):794-5. Review. PubMed PMID: 10823285.
355. Buratta S, Andreoli V, Mambrini R, Iorio A, Porcellati S, Mozzi R. Serine base exchange enzyme in porcine lyophilised platelets: enzyme properties and modulation by A1F4- and different types of heparin. *Mol Cell Biochem*. 2000 Jan;203(1-2):177-84. PubMed PMID: 10724347.
356. Ascani A, Iorio A, Agnelli G. Withdrawal of warfarin after deep vein thrombosis: effects of a low fixed dose on rebound thrombin generation. *Blood Coagul Fibrinolysis*. 1999 Jul;10(5):291-5. PubMed PMID: 10456621.
357. M. D'Inca, A. Ghirarduzzi, I. Iori, A. Iorio, G. Rinaldi, C. Salvarani, M. Silingardi. Sindrome da anticorpi antifosfolipidi. *L'internista ospedaliero* 1998;3:12-22.
358. G. Agnelli, A. Iorio. Enoxaparin in Neurosurgical patients. *N Eng J Med* 1998, 339: 1639-40. (IF = 28,660).
359. Cattabiani ML, Dallari A, Gaddi O, Giovanardi F, Troiso A, Guidetti D, Iorio A, Lo G, Manzini L, Baldi G, Parmiggiani G, Proccichiani D, Tincani E, Iori I. Indicazioni al trattamento dell'ictus ischemico. *Geriatrics* 1998;4(suppl):21-28.

360. Agnelli G, Piovella F, Buoncristiani P, Severi P, Pini M, D'Angelo A, Beltrametti C, Damiani M, Andrioli GC, Pugliese R, Iorio A, Brambilla G. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. *N Engl J Med*. 1998 Jul 9;339(2):80-5. PubMed PMID: 9654538.
361. Alatri A, Iorio A, Agnelli G. Choice of end-points in assessing the efficacy of post-discharge prophylaxis for venous thromboembolism. *Thromb Haemost*. 1998 Jan;79(1):234. PubMed PMID: 9459353.
362. Agnelli G, Iorio A, Parise P, Goldhaber SZ, Levine MN. Fibrinogenolysis and thrombin generation after reduced dose bolus or conventional rt-PA for pulmonary embolism. The Coagulation Project Investigators of the Bolus Alteplase Pulmonary Embolism Group. *Blood Coagul Fibrinolysis*. 1997 Jun;8(4):216-22. PubMed PMID: 9199818.
363. Iorio A, Nucciarelli F, Renga C, Nenci GG, Gianese F, Agnelli G. Effect of dermatan sulphate on activated partial thromboplastin time determined with different reagents. *Haemostasis*. 1997 Mar-Apr;27(2):85-90. PubMed PMID: 9212356.
364. Mozzi R, Andreoli V, Buratta S, Iorio A. Different mechanisms regulate phosphatidylserine synthesis in rat cerebral cortex. *Mol Cell Biochem*. 1997 Mar;168(1-2):41-9. PubMed PMID: 9062892.
365. Iorio A, Agnelli G. Pharmacokinetic optimisation of the treatment of deep vein thrombosis. *Clin Pharmacokinet*. 1997 Feb;32(2):145-72. Review. PubMed PMID: 9068929.
366. Ricotta S, Iorio A, Parise P, Nenci GG, Agnelli G. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography-an overview analysis. *Thromb Haemost*. 1996 Dec;76(6):887-92. Review. PubMed PMID: 8972006.
367. Ricotta S, Iorio A, Parise P, Nenci GG, Agnelli G. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography - an overview analysis. *Thromb Haemost* 1996;76:887-92.
368. Agnelli G, Iorio A, Ricotta S, Parise P, Nenci GG. Post-discharge deep-vein thrombosis after orthopaedic surgery. *Lancet*. 1996 Oct 26;348:1179-1180. PubMed PMID: 8888208.
369. Berrettini M, Parise P, Ricotta S, Iorio A, Peirone C, Nenci GG. Increased plasma levels of tissue factor pathway inhibitor (TFPI) after n-3 polyunsaturated fatty acids supplementation in patients with chronic atherosclerotic disease. *Thromb Haemost*. 1996 Mar;75(3):395-400. PubMed PMID: 8701396.
370. Muscat C, Bertotto A, Ercolani R, Bistoni O, Agea E, Cesarotti M, Fiorucci G, Spinozzi F, Gerli R. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. *Annals of Rheumatic Diseases*. 1995;5:382-85 (Iorio A. did statistical analysis, as stated in the acknowledgements).
371. Agnelli G, Iorio A, Renga C, Boschetti E, Nenci GG, Ofosu FA, Hirsh J. Prolonged antithrombin activity of low-molecular-weight heparins. Clinical implications for the treatment of thromboembolic diseases. *Circulation*. 1995 Nov 15;92(10):2819-24. PubMed PMID: 7586247.
372. Parise P, Hauert J, Iorio A, Callegari P, Agnelli G. Streptokinase and rt-PA activate platelets by a different way: implications on the rethrombosis rate after their administration in myocardial infarction. *J Lab Clin Med*. 1995 Feb;125(2):212-21. PubMed PMID: 7531212.
373. Iorio A, Alatri A, Mazzolai L, Agnelli G. Plasma thrombin neutralization assay: pharmacokinetic applications. *Semin Thromb Hemost*. 1994;20(3):266-73. PubMed PMID: 7824961.

374. Agnelli G, Iorio A, de Angelis V, Nenci GG. Dermatan sulphate in heparin-induced thrombocytopenia. *Lancet*. 1994 Nov 5;344(8932):1295-6. PubMed PMID: 7968002.
375. Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Fibrinogen degradation products generation is the major determinant of platelet inhibition induced by plasminogen activators in platelet rich plasma. *Fibrinolysis* 1993; 7, 379-385. (IF = 0,845).
376. Paglicci Reattelli L, Lalli L, Iorio A. La valutazione dell'idoneità allo sport agonistico nella casistica dei Servizi di Medicina Sportiva delle U.S.L. e della Commissione d'Appello della Regione Umbria. (1982-1990). *Medicina Legale - Quaderni Camerti* 1992, XIV(2), 199-213.

Peer Reviewed Journal Abstracts

1. E. Ayoub, D. Coffin, C. Lambert, B. Konkle, C. Hermans, J.O'Hara, S.Diop, G.F.Pierce, E. Gouider, A.Iorio. International data integration program of the WFHworld bleeding disorders registry: bringing europe data to the global stage. *Haemophilia* Volume 30: 17th Annual Congress of the European Association for Haemophilia and Allied Disorders 2024, 6-9, February 2024, Messe Frankfurt, Germany PO044
2. Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Letizia Polito, Katya Moreno, Michelle Santos, Emma Iserman, Davide Martino, and Alfonso Iorio. Experience with Emicizumab Among People with Hemophilia A in the Canadian Hemophilia Bleeding Disorders Registry. *Blood* (2023) 142 (Supplement 1): P1240
3. P. Chelle E. Iserman A. Iorio A. Edginton Impact of Reagent on the Estimation of Elocate and Adynovate Pharmacokinetic (PK) Parameters? *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 PB0175
4. D. Martino A. Iorio A. Chan N. Samji. Real-World Effectiveness and Safety of Damoctocog Alfa Pegol in Canadian Patients with Hemophilia A: Interim Results from the HEM-POWR Study. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 PB0661
5. E. AlTowyan A. Valenzuela Suárez Z. Al Housni A. Iorio D. Martino. Late Diagnosis of Two Adult Siblings with Bernard Soulier Syndrome (BSS). *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 PB1392
6. Z. Al Housni A. Valenzuela Suárez E. AlTowyan A. Iorio D. Martino. Use of Emicizumab for the Treatment of Acquired Hemophilia A: A Systematic Review. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 OC 06.5
7. F. Germini Z. Al Housni A. Chan K. Decker A. Iorio D. Martino. Effect of F8 Mutations and Von Willebrand Factor on Pharmacokinetics of FVIII Concentrates in Severe Hemophilia A. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 OC 24.4
8. F. Germini C. Chai-Adisaksopha Q. Ibrahim E. Iserman M. Rattle A. Keepanasseril A. Iorio. Evaluation of the Burden of Bone Fractures in People Living with Hemophilia: A Registry-Based Case-Control Study. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 PB0644
9. P. Chelle D. Hajducek N. Daoud E. Iserman C. Gerber F. Germini A. Edginton A. Iorio M Recht. Estimated Factor VIII Activity Levels at the Time of Bleeding Events in Individuals with Hemophilia a Without Inhibitors. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 OC 24.2
10. D. Martino P. Chelle S. Jackson J. Teitel G. Castaman A. Keepanasseril A Iorio. Effect of the Type of F9 Mutation on the Pharmacokinetic Profile of Patients with Hemophilia B Treated with Extended Half-Life FIX Concentrates. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 OC 24.1

11. E. Tootoonchian J. Stonebraker A. Iorio M. El-Ekiaby E. Gouider M. Makris and others. Analysis of the Change in Diagnosis of von Willebrand Disease by Region and Economic Status. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 PB0837
12. T. Youttanankorn B. Konkle D. Coffin M. Naccache C. Clark L. George A. Iorio and others myGTR: A Patient Engagement Tool from the World Federation of Hemophilia Gene Therapy Registry. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 PB0191
13. E. Ayoub D. Coffin B. Konkle N. Connell J. Sathar S. Diop A Iorio and others. WFH World Bleeding Disorders Registry Launches the First Global Data Collection on People with von Willebrand Disease. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 PB0827
14. B. Konkle D. Coffin M. Naccache T. Youttanankorn C. Clark L. George A Iorio and others. The WFH Gene Therapy Registry: A Collaborative Approach Towards a Global Resource for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy. *Research and Practice in Thrombosis and Haemostasis* Vol. 7 Supplement October, 2023 OC 20.5
15. R.Curtis¹, J.Wu, A.Iorio, M.B.Nichol, F.Germini, A.Kucher, M.W.Skinner. TEST-RETEST RELIABILITY ANALYSIS OF THE PATIENT REPORTED OUTCOMES BURDENS AND EXPERIENCES (PROBE) STUDY. *Haemophilia*, Volume 29: 16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester, Pages1-220 PO077
16. B.A.Konkle, D.Coffin, M.Naccache, C.Clark, L.George, A.Iorio, W.Miesbach, D.Noone, F.Peyvandi, S.W.Pipe, M.Recht, M.W.Skinner, L.A.Valentino, J.N.Mahlangu, G.F.Pierce. BUILDING A GLOBAL RESOURCE FOR THE LONG-TERM FOLLOW-UP OF HEMOPHILIA PATIENTS TREATED WITH GENE THERAPY: COLLABORATION BETWEEN THE WORLD FEDERATION OF HEMOPHILIA AND NATIONAL REGISTRIES. *Haemophilia*, Volume 29: 16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023, 7–10 February 2023, Manchester, Pages1-220 PO148
17. Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Francis Nissen, Katya Moreno, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio. Real-World Outcomes of Emicizumab in Hemophilia A with or without FVIII Inhibitors from the Canadian Hemophilia Bleeding Disorder Registry. *Blood* (2022) 140 (Supplement 1): 8465–8467. <https://doi.org/10.1182/blood-2022-157531>
18. Man-Chiu Poon, Adrienne Lee, Federico Germini, Arun Keepanasseril, Quazi Ibrahim, Francis Nissen, Fabian Sanabria, Michelle Santos, Emma Iserman, Davide Matino, Alfonso Iorio. Emicizumab Outcomes in Hemophilia A Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. *Blood* (2021) 138 (Supplement 1): 347. <https://doi.org/10.1182/blood-2021-147195>
19. D. Matino, K. Decker, E. Iserman, A. Keepanasseril, F. Germini, A. Chan, L. Walsh, A. Iorio. Canadian Patient Experience on Switching from Octocog Alfa to Extended Half-Life FVIII Damoctocog Alfa Pegol in Patients with Severe Hemophilia A *Res Pract Thromb Haemost.* 2022; 6 (Suppl 1). PB1142
20. F. Germini, N. Noronha, A. Binu, O. Olasupo, D. Pete, T. Navarro, A. Keepanasseril, D. Matino, K. de Wit, S. Parpia, A. Iorio Risk factors for bleeding in people living with Hemophilia A and B treated with regular prophylaxis: a systematic review of the literature. *Res Pract Thromb Haemost.* 2022; 6 (Suppl 1) PB0676
21. T. Szanto, R. Lassila, V. Nummi, A. Iorio, A. Leithinen. WAPPS-Hemo as a tool for optimizing prophylaxis with extended half-life FIX in patients with severe or moderate hemophilia B. *Res Pract Thromb Haemost.* 2022; 6 (Suppl 1) PB1160
22. M. Naccache, B. Konkle, D. Coffin, C. Clark, L. George, A. Iorio, W. Miesbach, D. Noone, F. Peyvandi, S. Pipe, M. Recht, M. Skinner, L. Valentino, J. Mahlangu, G. Pierce, F. Leebeek. Collaboration between the World Federation of Hemophilia and National Registries for the Long-Term Follow-up of People with Hemophilia Treated with Gene Therapy. *Res Pract Thromb Haemost.* 2022; 6 (Suppl 1) PB0212

23. Alexandra Kucher, Ricardo Carlos Gaitán Fitch, Mark Skinner, Minerva Cruz Álvaro, Escobar Ofir, Alfonso, Alfonso Iorio, Federico Germini, Rick Parrish, Michael Sevestre. Integration of the Mexican Registry of Coagulopathies (RMC) with PROBE. Haemophilia, Volume 28: Abstracts of the World Federation of Hemophilia World Congress 2022, 8–11 May 2022, Montreal and Virtual, Pages1-113 LR-07.01 (1160466)
24. Amy Shapiro, Brandon Hardesty, Flora Peyvandi, Alfonso Iorio. Prevalence of selected bleeding and thrombotic events in persons with congenital haemophilia versus the general non-haemophilia population. Haemophilia, Volume 28: Abstracts of the World Federation of Hemophilia World Congress 2022, 8–11 May 2022, Montreal and Virtual, Pages1-113 FP-08.03 (1160133)
25. Emily Ayoub, Donna Coffin, Saliou Diop, Cédric Hermans, Barbara A. Konkle, Declan Noone, Jamie O'Hara, Glenn F. Pierce, Ellia Tootonchian. WFH world bleeding disorders registry highlights gaps in haemophilia diagnosis and management. Haemophilia, Volume 28: Abstracts of the World Federation of Hemophilia World Congress 2022, 8–11 May 2022, Montreal and Virtual, Pages1-113 FP-07.03 (1161132)
26. Barbara A. Konkle, Donna Coffin, Mayss Naccache, Cary Clark, Lindsey A. George, Alfonso Iorio, Wolfgang Miesbach, Declan Noone, Flora Peyvandi, Steven Pipe, Michael Recht, Mark Skinner, Leonard Valentino, Johnny N. Mahlangu, Glenn F. Pierce. Using the World Federation of Haemophilia gene therapy registry for the long-term follow-up of haemophilia patients treated with gene therapy. Haemophilia, Volume 28: Abstracts of the World Federation of Hemophilia World Congress 2022, 8–11 May 2022, Montreal and Virtual, Pages 1-113 P-17 (1158015)
27. Ellia Tootonchian, Magdy El Ekiaby, Emna Gouider, Alfonso Iorio, Mike Makris, Jamie O'Hara, Michael Recht, Glenn F. Pierce, Donna Coffin, Jeffrey Stonebraker. Comparison of change in number of identified people with haemophilia A and factor VIII use per patient over time. Haemophilia, Volume 28: Abstracts of the World Federation of Hemophilia World Congress 2022, 8–11 May 2022, Montreal and Virtual, Pages1-113 P-78 (1162340)
28. Toong Youttanankorn, Donna Coffin, Saliou Diop, Cédric Hermans, Barbara A. Konkle, Catherine Lambert, Declan Noone, Jamie O'Hara, Glenn F. Pierce, Mark Skinner, Alfonso Iorio. Empowering people with haemophilia to take control of their care and treatment through my WBDR and my PROBE—A patient-reported outcomes tool for achieving a 360-degree patient-centred evaluation. Haemophilia, Volume 28: Abstracts of the World Federation of Hemophilia World Congress 2022, 8–11 May 2022, Montreal and Virtual, Pages1-113 FP-02.01 (1160929)
29. Shannon Jackson, Barbara Sheridan, Deborah Gue, Scott Lyons, Rick Waines, Tim Ireland, Drashti Pete, Alfonso Iorio, Leo Walsh, Mark Skinner, Federico Germini. Feasibility of integrating PROBE (patient reported outcomes, burdens and experiences) into a clinical care pathway to facilitate transformation to a value-based health care model in haemophilia. Haemophilia, Volume 28: Abstracts of the World Federation of Hemophilia World Congress 2022, 8–11 May 2022, Montreal and Virtual, Pages1-113 PP-60 (1160288)
30. A. Iorio, D. Matino, K. Decker, E. Iserman, A. Keepanasseril, F. Germini, A.K.C.Chan, L. Walsh CLINICAL EXPERIENCE ON SWITCHING FROM OCTOCOG ALFA TO EXTENDED-HALF-LIFE FVIII DAMOCTOCOG ALFA PEGOL IN PATIENTS WITH SEVERE HAEMOPHILIA, Haemophilia, Volume 28: 15th Annual Congress of European Association for Haemophilia and Allied Disorders 2022, 2–4 February 2022, Virtual Meeting, Pages1-134
31. B. Konkle, D Coffin, M. Naccache, C. Clark, L. A. George, A. Iorio, W. Miesbach, D.Noone, F. Peyvandi, S. Pipe, M. Recht, M. W.Skinner, L. A. Valentino, J.N. Mahlangu, G.F.Pierce. THE WORLD FEDERATION OF HEMOPHILIA GENE THERAPY REGISTRY – A GLOBAL RESOURCE FOR THE LONG-TERM FOLLOW-UP OF HEMOPHILIA PATIENTS TREATED WITH GENE THERAPY. Haemophilia, Volume 28: 15th Annual Congress of European Association for Haemophilia and Allied Disorders 2022, 2–4 February 2022, Virtual Meeting, Pages1-134 PO139

32. Omotola O. Olasupo, Charles Nakar, Alfonso Iorio, Craig Haddix, Thushara Mathew, Lynn M Malec, Davide Matino, Lawrence Mbuagbaw, Jean-Eric Tarride, Amy D. Shapiro. Perioperative Outcomes Associated with Inhibitor Status in Patients with Hemophilia - a Retrospective Cohort Study. *Blood* (2021) 138 (Supplement 1): 4990. <https://doi.org/10.1182/blood-2021-147550>
33. C. Ay, U. Derhaschnig, B. Jilma, C. Schoergenhofer, K. Kovacevic, P. Quehenberger, P. Jilma, J.C. Gilbert, S. Zhu, D. Kraemmer, A. Iorio, I. Pabinger. The VWF-A1 domain binding aptamer BT200 prolongs the half-lives of different factor VIII (FVIII) products in patients with severe hemophilia A and increases FVIII levels in non-severe hemophilia A. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) LB 02.1
34. A. Solms, A. Shah, E. Berntorp, A. Tiede, A. Iorio, A. Bröcker, M.E. Mancuso. Predicted FVIII Consumption of BAY 94-9027 Compared with Standard- and Extended-half-Life FVIII Products in Patients with Severe Hemophilia A. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) PB0559
35. A. Iorio, F. Leebeek, S. Susen, A. Shapiro, G. Özen, B. Mellgård, Y. Wang. Pharmacokinetics/Pharmacodynamics (PK/PD) of Recombinant von Willebrand Factor (Vonicog Alfa) in Adult Patients with von Willebrand Disease (VWD) during Prophylactic Treatment. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) PB0917
36. S. Jackson, B. Sheridan, D. Gue, S. Lyons, R. Waines, T. Ireland, D. Pete, A. Iorio, L. Walsh, M. Skinner, F. Germini. Feasibility of Integrating PROBE (Patient Reported Outcomes, Burdens and Experiences) into a Clinical Care Pathway to Facilitate Transformation to a Value-based Health Care Model in Hemophilia. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) PB0626
37. E. Tootoonchian, J. Stonebraker, M. El Ekiaby, E. Gouider, A. Iorio, M. Makris, J. O'Hara, M. Recht, G. Pierce, D. Coffin. Analysis of the Percentage of Persons with Severe Hemophilia A as an Indicator of Care. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) PB0481
38. B.A. Konkle, D. Coffin, M. Naccache, C. Clark, L.A. George, A. Iorio, W. Miesbach, D. Noone, F. Peyvandi, S.W. Pipe, M. Recht, M. Skinner, L.A. Valentino, J.N. Mahlangu, G.F. Pierce. The World Federation of Hemophilia Gene Therapy Registry. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) PB0661
39. M.E. Mancuso, P. Chelle, E. Iserman, T. Matthew, A. Keepanasseril, A. Edginton, A. Iorio, WAPPS-Hemo Investigators. Real-world Use of Damoctocog Alfa Pegol in Patients with Hemophilia A: Analysis of PK Profiles and Treatment Regimen Data from the WAPPS-Hemo Database. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) OC 08.4
40. A. Iorio, A. Srivastava, P. James and others. Plasma-derived VWF/FVIII Concentrate (wilate®) for Haemostasis in Women with VWD during Childbirth. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) PB0939
41. T. Youttanankorn, D. Coffin, S. Diop, C. Hermans, B. Konkle, C. Lambert, D. Noone, J. O'Hara, G. Pierce, M.W Skinner, A. Iorio. Incorporating Patient Reported Outcomes into Clinical Practice: A 360-degree Clinical Evaluation for Better Care and Treatment of People with Hemophilia through myWBDR and myPROBE. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) PB0505
42. E. Clearfield, H.-Y. Chang, T. Majid, M.W. Skinner A Iorio. Responses to Anxiety and Depression Items in People with Hemophilia who Tested a Patient Reported Outcome Measure: The coreHEM MH Study. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 1) PB0662
43. Mark Skinner, Declan Noone, Randall Curtis, Neil Frick, Federico Germini, Alexandra Kucher, Michael Nichol, Brian O'Mahony, David Page, Jeff Stonebraker, Alfonso Iorio. Relationship of EQ-5D Pain Domain and Bleeds - Insights from the PROBE Study. *Haemophilia Volume 27: Abstracts of the WFH 17th International Musculoskeletal Congress, 3-7, May 2021, Virtual Meeting, Pages 1-22 P-019 (1035680)*

44. E. Tootoonchian, J. Stonebraker, M. El Ekiaby, E. Gouider, A. Iorio, M. Makris, J. O'Hara, M. Recht, G. Pierce, D. Coffin. ANALYSIS OF HEMOPHILIA PATIENT IDENTIFICATION IN DIFFERENT ECONOMIC SETTINGS. *Haemophilia*, Volume 27: Virtual Congress of the European Association for Haemophilia and Allied Disorders 2021 3-5 February 2021 Pages 1-192 ABS002
45. E. Tootoonchian, J. Stonebraker, M. El Ekiaby, E. Gouider, A. Iorio, M. Makris, J. O'Hara, M. Recht, G. Pierce, D. Coffin. EQUITY IN THE USE OF PROPHYLAXIS IN CHILDREN WITH SEVERE HEMOPHILIA. *Haemophilia*, Volume 27: Virtual Congress of the European Association for Haemophilia and Allied Disorders 2021 3-5 February 2021 Pages 1-192 ABS005
46. J. Yu, A. Iorio, P. Chelle, A. Edginton. PHARMACOKINETIC IMPLICATIONS OF DOSING EMICIZUMAB BASED ON VIAL SIZE: A SIMULATION STUDY. *Haemophilia*, Volume 27: Virtual Congress of the European Association for Haemophilia and Allied Disorders 2021 3-5 February 2021 Pages 1-192 ABS161
47. B. A. Konkle, D. Coffin, M. Naccache, C. Clark, L. George, A. Iorio, W. Miesbach, B. O'Mahony, F. Peyvandi, S. W. Pipe, M. Recht, M. W. Skinner, L. A. Valentino, J. N. Mahlangu, G. F. Pierce. THE WORLD FEDERATION OF HEMOPHILIA GENE THERAPY REGISTRY. *Haemophilia*, Volume 27: Virtual Congress of the European Association for Haemophilia and Allied Disorders 2021 3-5 February 2021 Pages 1-192 ABS203
48. E. Ayoub, D. Coffin, C. Hermans, J. O'Hara, D. Noone, G. Pierce, S. Diop, E. Tootoonchian, T. Youttanankorn, B. Konkle, A. Iorio. WORLD BLEEDING DISORDERS REGISTRY SHOWCASES DISPARITIES IN HEMOPHILIA CARE AROUND THE WORLD. *Haemophilia*, Volume 27: Virtual Congress of the European Association for Haemophilia and Allied Disorders 2021 3-5 February 2021 Pages 1-192 ABS209
49. Lee A, Germini F, Poon M-C, Keepanasseril A, Ibrahim Q, Shang A, Nissen F, Meier O, Sima CS, Matino D, Iorio A. Analysis of Hemophilia a Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. *Blood* (2020) 136 (Supplement 1): 37–38. <https://doi.org/10.1182/blood-2020-137320>.
50. Versloot O, Iserman E, Chelle P, Germini F, Mathew T, Iorio A, Fischer K. Terminal Half-Life of Factor VIII/IX According to Age and Blood Group Based on 8550 Assessments. *Blood* (2020) 136 (Supplement 1): 22–23. <https://doi.org/10.1182/blood-2020-141801>.
51. Versloot O, Iserman E, Chelle P, Germini F, Mathew T, Iorio A, Fischer K. Not All Patients Benefit from Switching to Ehl: Results from the Wapps Database. *Blood* (2020) 136 (Supplement 1): 21–22. <https://doi.org/10.1182/blood-2020-142816>.
52. Solms A, Shah A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME, Zhivkov T, Lissitchkov T. Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Dacotocog Alfa Pegol (BAY 94-9027) and Efmoroctocog Alfa (rFVIII Fc) in Patients with Severe Hemophilia A. *Blood* (2020) 136 (Supplement 1): 24–25. <https://doi.org/10.1182/blood-2020-136586>.
53. M. Naccache, D. Coffin, W. Youttanankorn, E. Tootoonchian, V. Byams, S. Diop, C. Hermans, D. Noone, J. O'Hara, G.F. Pierce, A. Iorio, B. Konkle, E. Ayoub. Two-year Update on the WFH World Bleeding Disorders Registry. *Res Pract Thromb Haemost.* 2020; 4 (Suppl 1) PB0837
54. E. Tootoonchian, J. Stonebraker, A. Iorio, V. Byams, M. El Ekiaby, M. Makris, J. O'Hara, H. Chambost, A. Weill, G. Pierce, A. Baumann, D. Coffin. The Annual Global Survey Continues to Close the Gap in Data Collection of Bleeding Disorders. *Res Pract Thromb Haemost.* 2020; 4 (Suppl 1) PB0854
55. D. Matino, A. Iorio, A. Keepanasseril, F. Germini, A.C. Birkegård, A. Caillaud, M. Carcao, J. Hews-Girard, E. Iserman, P. James, A. Lee, C. Phua, H. Sun, J. Teitel, M.-C. Poon. A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting. *Res Pract Thromb Haemost.* 2020; 4 (Suppl 1) PB0905

56. K. de Repentigny, M. Hinds, J. Grabell, A. Keepanasseril, A. Iorio, N. Rydz, S. Jackson, S. Robinson, L. Sun, M. Belletrutti, P. James. The CHiC Study: The Canadian Hemophilia Carriers Study – Preliminary Results. *Res Pract Thromb Haemost.* 2020; 4 (Suppl 1) PB0982
57. C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, D. Noone, F. Germini, B. O'Mahony, D. Page, J. Stonebraker, M. Skinner, A. Iorio, PROBE investigators. Non-Severe Hemophilia Is Not Benign? – Insights from the PROBE Study. *Res Pract Thromb Haemost.* 2020; 4 (Suppl 1) PB1005
58. F. Germini, S. O'Callaghan, C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, D. Noone, B. O'Mahony, D. Page, J. Stonebraker, M. Skinner, A. Iorio, PROBE investigators. Association Between Aging and Health Status in Persons Leaving with Hemophilia and Controls Without a Bleeding Disorder – Insights from the PROBE Study. *Res Pract Thromb Haemost.* 2020; 4 (Suppl 1) PB1012
59. B. Konkle, D. Coffin, M. Naccache, C. Cary, L.A. George, A. Iorio, B. O'Mahony, S.W. Pipe, M.W. Skinner, C. Watson, F. Peyvandi, J.N. Mahlangu, G.F. Pierce. The World Federation of Hemophilia Gene Therapy Registry. *Res Pract Thromb Haemost.* 2020; 4 (Suppl 1) PB1098
60. Juan Eduardo Megías-Vericat, Santiago Bonanad, María Fernanda Martínez García, Ruben Berrueco Moreno, Eva María Mingot-Castellano, Manuel Rodríguez López, Mariana Canaro Hirnyk, José Mateo Arranz, José Manuel Calvo Villas, Saturnino Haya, Ana Rosa Cid, Alfonso Iorio. PK-guided switch from standard half-life to extended half-life factor VIII products. *Haemophilia*, Volume 26: Abstracts of the World Federation of Hemophilia, Virtual Summit – Connecting the Global Bleeding Disorders Community, June 2020, Pages 1-159 MED-PP-012 (148)
61. Erna C. van Balen, Brian O'Mahony, Marjon H. Cnossen, Victor Blanchette, Kathelijn Fischer, Alfonso Iorio, Shannon Jackson, Donna Coffin, Mark Skinner, Alok Srivastava, Johanna G. van der Bom, Samantha C. Gouw on behalf of the HaemoValue Steering committee. International Standard Set of Health Outcomes that matter for people living with hemophilia. *Haemophilia*, Volume 26: Abstracts of the World Federation of Hemophilia, Virtual Summit – Connecting the Global Bleeding Disorders Community, June 2020, Pages 1-159 MED-MP-020 (658)
62. Maria Elisa Mancuso, Massimo Morfini, Alfonso Iorio, Arathi Arun, Cristina Novembrino, Massimo Boscolo, Flora Peyvandi, Elena Santagostino. Comparative PK evaluation of SHL vs EHL by non-compartmental and compartmental population PK analysis in patients with severe and moderate HA. *Haemophilia*, Volume 26: Abstracts of the World Federation of Hemophilia, Virtual Summit – Connecting the Global Bleeding Disorders Community, June 2020, Pages 1-159 MED-PP-060 (414)
63. Mayss Naccache, Donna Coffin, Vanessa Byams, Saliou Diop, Cedric Hermans, Declan Noone, Jamie O'Hara, Glenn F. Pierce, Hendrika Marianne van den Berg, Alfonso Iorio, Barbara Konkle. The World Federation of Hemophilia World Bleeding Disorders Registry – 2 years update. *Haemophilia*, Volume 26: Abstracts of the World Federation of Hemophilia, Virtual Summit – Connecting the Global Bleeding Disorders Community, June 2020, Pages 1-159 MTD-MP-011 (140)

64. Toong Youttanankorn, Donna Coffin, Vanessa Byams, Saliou Diop, Cedric Hermans, Declan Noone, Jamie O'Hara, Glenn F. Pierce, Hendrika Marianne van den Berg, Alfonso Iorio, Barbara Konkle. Data is the new currency: The World Bleeding Disorders Registry Data Quality Accreditation Program. Haemophilia, Volume 26: Abstracts of the World Federation of Hemophilia, Virtual Summit – Connecting the Global Bleeding Disorders Community, June 2020, Pages 1-159 MTD-MP-013 (628)

65. D. Hadjucsek, F. Primacakti, N. Chozie, R. Mir, A. Iorio, A. McEneny-King, A. Edginton. ASSESSING A POPULATION PHARMACOKINETIC MODEL OF A PLASMA-DERIVED, VON WILLEBRAND FACTOR-CONTAINING FVIII CONCENTRATE FOR BAYESIAN FORECASTING IN LOW DOSE SCENARIOS. Haemophilia, Volume 26: 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5–7 February 2020, The Hague, The Netherlands, Pages 1-196 P044

66. F. Germini, V. Borg Debono, D. Page, M. W. Skinner, V. Zuk, A. Kucher, M. Sevestre, A. Iorio on behalf of PROBE investigators. DEVELOPMENT AND TESTING OF THE ONLINE PROBE SURVEY AND THE MYPROBE APP AND INTEGRATION WITH THE CANADIAN BLEEDING DISORDER REGISTRY Haemophilia, Volume 26: 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5–7 February 2020, The Hague, The Netherlands, Pages 1-196 P097

67. J. E. Megías Vericat¹, S. Bonanad-Boix, M. F. Martínez García, R. Berrueto, M. E. Mingot-Castellano, M. Rodríguez, M. Canaro, J. Mateu, I. Larrode, S. Haya, A. Santamaría, M. Mesegué, C. Albo, A. Palomero, N. Vilalta, J. M. Calvo, A. R. Cid, J. L. Poveda, A. Iorio. PK-GUIDED SWITCH BETWEEN STANDARD HALF-LIFE AND EXTENDED HALF-LIFE FACTOR VIII PRODUCTS. Haemophilia, Volume 26: 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5–7 February 2020, The Hague, The Netherlands, Pages 1-196 P117

68. M. Naccache, D. Coffin, T. Youttanankorn, E. Tootoonchian, V. Byams, S. Diop, C. Hermans, D. Noone, J. O'Hara, G. F. Pierce, H. van den Berg, A. Iorio, B. Konkle. THE WORLD BLEEDING DISORDERS REGISTRY CELEBRATES 2 YEARS! Haemophilia, Volume 26: 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5–7 February 2020, The Hague, The Netherlands, Pages 1-196 P147

69. E. vanBalen, B. O'Mahony, M. H. Cnossen, G. Dolan, V. Blanchette, K. Fischer, D. Gue, J. O'Hara, A. Iorio, S. Jackson, B. A. Konkle, D. Nugent, D. Coffin, G. Pierce, M. Skinner, C. Smit, A. Srivastava, F. vanEenenaaam, J. van derBom, S. Gouw. INTERNATIONAL STANDARD SET OF HEALTH OUTCOMES THAT MATTER FOR PEOPLE LIVING WITH HEMOPHILIA. Haemophilia, Volume 26: 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5–7 February 2020, The Hague, The Netherlands, Pages 1-196 P177

70. E. Tootoonchian, J. S. Stonebraker, A. Iorio, M. El Ekiaby, M. Makris, V. Byams, J. O'Hara, H. Chambost, A. Weill, G. Pierce, D. Coffin. REPORT ON THE ANNUAL GLOBAL SURVEY – 20 YEARS ON AND MORE INFORMATIVE. Haemophilia, Volume 26: 13th Annual Congress of European Association for Haemophilia and Allied Disorders 2020, 5–7 February 2020, The Hague, The Netherlands, Pages 1-196 OR04

71. C. Chai-Adisaksopha, S. Afraz, T. Rattanathamthee, A. Iorio. Perioperative management of patients with congenital factor XI deficiency. Haemophilia 2018, 24 (Suppl 1); OR06.

72. D. Noone, C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, B. O'Mahony, D. Page, J. Stonebraker, A. Iorio, M.W. Skinner on behalf of Patient Reported Outcomes and Experiences (PROBE) Investigator Group. Haemophilia 2018, 24 (Suppl 1); OR07.

73. P. Staibano, A. McEnenyKing, M. Morfini, G. Foster, N. Hobson, T. Navarro Ruan, A.N. Edginton, A. Iorio. Comparative assessment of the performance of pharmacokinetic tools for prophylactic dosing of factor VIII concentrate in patients with hemophilia A. *Haemophilia* 2018, 24 (Suppl 1); PO42.
74. G. Pierce, A. Iorio, J. O'Hara, S. Diop, R. Hollingsworth, A. Srivastava, D. Lillicrap, H.M. van den Berg, M. Soucie, C. Hermans, C. Upshaw, M. Naccache, C. Herr, D. Coffin. *Haemophilia* 2018, 24 (Suppl 1); PO75.
75. S. Bonanad, J.E. Megías Vericat, A. Iorio, T. Navarro, J.L. Poveda. Online course of pharmacokinetic monitoring in hemophilia with application in the clinical practice. *Haemophilia* 2018, 24 (Suppl 1); P125.
76. R.F. Barnes, E.J. Cooke, T.J. Cramer, J.Y. Zhou, G. Foster, A. Iorio, A. von Drygalski. The role of vascular remodeling and clotting factor thresholds in the context of hemophilic joint bleeding: results from a prospective imaging study in patients with hemophilia and advanced arthropathy. *Research and Practice in Thrombosis and Haemostasis* 2017, 1, (Suppl S1); OC 37.3.
77. Iorio A, Cheng J, Marcucci M, Romanov V and Thabane L. Bayesian approach to the assessment of the population specific risk of inhibitors. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO261-Mon.
78. Iorio A, Krishnan S, Myren K-J, Lethagen S, McCormick N and Karner P. Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO171-Mon.
79. Iorio A, Krishnan S, Myren K-J, Lethagen S, McCormick N and Karner P. Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products. 2015 International Society on Thrombosis and Haemostasis 2015, 13 (Suppl. 2); 1–997. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO170-Mon.
80. Iorio A, Blanchette V, Blatny J, Collins P, Croteau S, Dunn A, Fischer K, Hermans C, Kavakli K, Jackson S, James P, Mammen S, Morfini M, Navarro-Ruan T, Neufeld EJ, Ozelo M, Radossi P, Rangarajan S, Ruiz- Saez A, Teitel J, Thabane L, Young G and Xi M. A population approach to hemophilia pharmacokinetics. Wapps: a web-service for bayesian post hoc estimation. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. AS122.
81. Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S. Indirect comparison of the efficacy of recombinant factor IX Fc fusion protein and other factor IX products for prophylaxis: simulating the effect of compliance on real-world effectiveness. *Value in Health* 2014, 17: A1-A295. PSY41.
82. Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S. Indirect comparison of the efficacy of recombinant factor VIII Fc fusion protein and other factor VIII products for prophylaxis: modeling the effect of compliance. *Value in Health* 2014, 17: A1-A295. PSY40.
83. Khair K, Cruz MS, Werner S, Knaub S, Iorio A and on behalf of Wil-20 working group. Surveillance study of safety and efficacy of aVWF/ FVIII concentrate in patients with von willebrand disease (WIL-20) – a planned interim analysis. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO662-Mon.
84. Traore A, Chan A, Iorio A, Heddle N, Walker I and on behalf of Association of Hemophilia Clinic Directors of Canada. Utilization of anti-inhibitors products and inhibitors status of severe hemophilia patients: 5 years national data from the Canadian hemophilia assessment and resource management system. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl. 2); 1–997. PO276-Mon.

85. Kahale LA, Diab B, Brignardello-Peterson R, Mustafa R, Busse JW, Agarwal A, Kwong J, Li L, Neumann I, Lopes LC, Olav Vandvik P, Briel M, Iorio A, Guyatt GH, Akl E. Extent and handling of missing dichotomous outcome data in 100 Cochrane and non-Cochrane systematic reviews. *Cochrane Database Syst Rev Suppl* 1-327 (2015). O 9.1.
86. Iorio A, Matovinovic E, Hayden J. Systematic reviews of prognostic studies 5: using GRADE in systematic reviews of studies on overall prognosis. *Cochrane Database Syst Rev Suppl* 1-327 (2015). W 91.
87. Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII. *Value Health*. 2015 Nov;18(7):A660. doi: 10.1016/j.jval.2015.09.2393. Epub 2015 Oct 20. PMID: 26533703.
88. Chai-Adisaksopha C, Iorio A, Crowther MA, de Miguel J, Salgado E, Zdraveska M, Monreal M. Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Clinically Relevant Thrombosis. *Blood* 2015;126 (23). Abs 430 (oral).
89. Federici AB, Castaman G, Iorio A, Oliovecchio E, and Prodeswil Investigators. Safety and Effectiveness of Desmopressin for the management and delivery and major surgery in patients with mild-moderate von willebrand disease: Final analysis of the Prodeswil Study. *Blood* 2015: 126(23). Abs 759 (oral).
90. Chai-Adisaksopha C, Said Y. AlKindi, Matthew Cheah, Alfonso Iorio, Mark A. Crowther, and Lori Ann Linkins. Outcomes of Low-Molecular-Weight Heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumors. *Blood* 2015: 126 (23). Abs 428 (oral).
91. Chatree Chai-Adisaksopha, Matthew Cheah, Said Y. AlKindi, Alfonso Iorio, Mark A. Crowther, and Lori Ann Linkins. Bleeding in patients receiving Low-Molecular-Weight Heparin for cancer-associated thrombosis. *Blood* 2015;126 (23). Abs 1120.
92. Matino D, Gargaro M, Santoro C, Castaman G, Fallarino F, Iorio A. Investigating potential determinants of ITI success using immune gene expression profiling: a preliminary study. *Journal of Thrombosis and Haemostasis*. 2015, 13(Suppl 2); 1-997. PO162-Tue.
93. Iorio A, Rentz A, Balantac Z, Hoxer CS. Assessing the indication and success of treatment for haemophilia patients: results from a Delphi panel. *Journal of Thrombosis and Haemostasis* 2015, 13 (Suppl 2); 1-997. PO138-Tue.
94. Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Factor consumption for prophylaxis and treatment of bleeding: recombinant factor IX Fc fusion compared with conventional recombinant Factor IX. *Value Health*. 2015 Nov;18(7):A660. doi: 10.1016/j.jval.2015.09.2396. Epub 2015 Oct 20. PMID: 26533702.
95. Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Modeling the impact of potential differences in real-world adherence with extended-half-life conventional factor VII and IX on bleeding. P. *Value Health*. 2015 Nov;18(7):A660-1. Doi: 10.1016/j.val.2015.09.2397. Epub 2015 Oct 20. PMID: 26533698.
96. Menchen Xi, Tamara Navarro-Ruan, Sunil Mammen, Victor S. Blanchette, Cedric R. Hermans, Massimo Morfini, Peter W. Collins, Kathelijin Fischer, Ellis J. Neufeld, Guy Young, Kaan Kavakli, Paolo Radossi, Amy Dunn, Lehana Thabane, Alfonso Iorio. Systematic review of the published evidence on the pharmacokinetic characteristics of factor VIII and IX concentrates. *Blood* 2014 (ASH Annual Abstracts) 124 (21).
97. Chatree Chai-Adisaksopha, Christopher M. Hillis, Lehana Thabane, Alfonso Iorio. A Systematic review of definitions and reporting of bleeding outcome measures in hemophilia. *Blood* 2014 (ASH Annual Abstracts) 124 (21) 2821;.

98. Jing Sun, Renchi Yan, Yongqiang Zhao, Xuefeng Wang, Jingsheng Wu, Xinsheng Zhang, Bin Teng, Tao Guan, Kuixing Li and Alfonso Iorio. Factors influencing quality of life in Chinese adults with hemophilia: Results from the HERO study. *Haemophilia* (2014), 20 (Suppl. 3), 1-186.
99. Leonard Minuk, Erinne Dilworth, Shannon Jackson, Alfonso Iorio, Man-Chiu Poon, Robert Card, Irum Rizwan and Martha Louzada. Cardiac risk factors in older patients with hemophilia: Report of the age related cardiovascular disease in hemophilia epidemiologic research (ARCHER) study. *Haemophilia* (2014), 20 (Suppl. 3), 1-186.
100. A. Iorio. Does product type influence the development on inhibitor in PTPs and PUPs? *Haemophilia* (2014), 20 (Suppl. 2), 18-91. PO121.
101. M. Marcucci, J. Cheng, V. Romanov, L. Thabane, A. Iorio. The use of FVIII concentrate in hemophilia A patients with low titer inhibitors or a personal history of inhibitor: a meta-analysis of advance post-authorization safety studies in different countries. *Haemophilia* (2014), 20 (Suppl. 2), 18-91. PO044.
102. A Iorio, MG Barbara, P Mathew, GF Rivolta, VV Romanov, V Roussel- Roberts, A Tagliaferri, J Windyga. Investigating determinants of inhibitor development to factor VIII molecules in previously treated hemophilia A patients. *Haemophilia* (2014), 20 (Suppl. 2), 18-91. PO-037.
103. Marcucci M, Fisher K, Kenet G, Young G, Walker I, Thabane L. Risk of inhibitor development in previously treated patients with positive inhibitor history or low titer of inhibitor at baseline: results of a survey of hemophilia experts. Abstracts of the 60th Annual Meeting of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis June 23-26, 2014. *Journal of Thrombosis and Haemostasis* 2014; 12 (Suppl. 1) 1–106.
104. Karen Strike, Frank Smith, Anthony Chan, Theresa Almonte, Christine Chaston, Kay Decker, Rebecca Goldsmith, Naomi Matsui, Kim Nagel, Christa Orschel, Irwin Walker, Linda Waterhouse and Alfonso Iorio. Assessment of patient preferences and perceived value of the comprehensive interdisciplinary combined hemophilia and orthopedic clinic using a validated questionnaire. *Haemophilia* (2014), 20 (Suppl. 3), 1-186.
105. Alfonso Iorio, Sangeeta Krishnan, Lynn Huynh, Paul Karner, Mei Sheng Duh And Sander Yermakov. An indirect comparison of the efficacy of prophylactic use of rFVIII-Fc and other rFVIII products and model of the effect of compliance. *Haemophilia* (2014), 20 (Suppl. 3), 1-186.
106. Alfonso Iorio, Sangeeta Krishnan, Lynn Huynh, Paul Karner, Mei Sheng Duh And Sander Yermakov. An indirect comparison of the efficacy of prophylactic use of rFIX-Fc and other rFIX products and simulation of the effect of compliance on effectiveness. *Haemophilia* (2014), 20 (Suppl. 3), 1-186.
107. Aicha Traore, Anthony Chan, Margaret Warner, Alfonso Iorio, John Wu, Jayson Stoffman, Alan Tinmouth, Jerry Teitel, Nancy Heddle and Irwin Walker. Factor VII deficiency patients: 5-year factor concentrates utilization trend based on the Canadian Hemophilia Assessment and Resource Management System (CHARMS). *Haemophilia* (2014), 20 (Suppl. 3), 1-186.
108. Shannon Jackson, Ming Yang, Len Minuk, Jean St-Louis, Michelle Sholzberg, Robert Card, Alfonso Iorio and Man-Chiu Poon. An evaluation of whether the ankle is now the dominant site of chronic hemophilic arthropathy in young adults with severe hemophilia. *Haemophilia* (2014), 20 (Suppl. 3), 1-186.
109. Iorio A, Forsyth A, Querol F, Stain AM, Pericleous L and Cooper D. Does higher risk activity change bleed frequency and haemophilia treatment center/provider utilisation in children with haemophilia: an analysis from the HERO Study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PO 126.

110. Iorio A, Forsyth A, Guelcher C, Buzzi A, Wisniewski T and Cooper D. Relationship of quality of life, pain and self-reported arthritis with activity, bleed rate and haemophilia treatment centre/provider utilisation: results from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PO 125.
111. Iorio A, Cassis F, Gregory M, Kalnins W, Wisniewski T and Cooper D. Potential relationships between negative impacts on employment or relationships and haemophilia treatment centre/provider utilisation: an analysis of adults with haemophilia from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PO 124.
112. Iorio A, Cassis F, Gregory M, Kalnins W, Wisniewski T and Cooper D. Potential relationships between negative impacts on employment or relationships with haemophilia centre/provider utilisation: An analysis of parents of children with haemophilia from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PO 123.
113. Iorio A, Nugent D, Stain AM, Gregory M, Pericleous L and Cooper D. Do inhibitors, treatment regimen and bleed frequency impact parent-directed haemophilia treatment centre and provider utilisation: An analysis of parents of children with haemophilia in the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PO 122.
114. Marcucci M, Eichinger S, Iorio A, Douketis JD, Tositto A, Baglin TPT, Cushman M, Palareti G, Poli D, Campbell TR and Kyrle PA. External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PB 3.70-3.
115. Iorio A, Nugent D, Stain AM, Gregory M, Pericleous L and Cooper D. Do inhibitors, treatment regimen and bleed frequency impact haemophilia treatment centre and provider utilisation: an analysis of adults with haemophilia in the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PB 3.36-6.
116. Federici AB, Castaman G, Iorio A, Bonduel M, D'Amico EA, Olivovichio E, Santoro C, Siboni SM, Zieger B and Mannucci PM. Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PA 2.08-1.
117. Matino D, Iorio A, Gargaro M, Santagostino E, Santoro C, Di Minno G, Morfini M, Puccetti P and Fallarino F. Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. AS 22.3.
118. F Cassis, M Gregory, W Kalnins, T Wisniewski, DL Cooper, A Iorio. Associations between negative impact on employment or relationships and haemophilia treatment centre and healthcare practitioner utilisation: Global Results from the HERO Study. *Value in Health* 16 (2013) A1-A298. PSY87.
119. Nugent, AM Stain, M Gregory, L Pericleous, DL Cooper, A Iorio. Associations between inhibitors, treatment regimen, bleed frequency and healthcare practitioner utilisation in the haemophilia treatment centre: global results from the HERO study. *Value in Health* 16 (2013) A1-A298. PSY86.
120. Akl EA, Johnston B, Carrasco A, Brignardello Petersen R, Neumann I, Sun X, Briel M, Busse J, Granados C, Iorio A, Irfan A, Martinez L, Mustafa RA, Ramirez A, Sola I, Martinez Garcia L, Selva A, Sanabria AJ, Zazueta OE, Vernooij R, Tikkinen KA, Ebrahim S, Vandvik PO, Guyatt GH, Alonso Coello P. Reporting, dealing with, and judging risk of bias associated with missing participant data in systematic reviews: a methodological survey. *Cochrane Database Syst Rev* 213-222 (2013) DOI:10.1002/14651858.CD201300.

121. Pardo J, Lawson J, Rader T, Parrish R, Cotoi C, Tugwell P, Haynes B, Iorio A. Improving the efficiency of updating Cochrane Reviews: a joint pilot project of the McMaster PLUS database team and the musculoskeletal review group. *Cochrane Database Syst Rev Suppl* 213–222 (2013) DOI:10.1002/14651858.CD201300.
122. Athale A, Iorio A. Investigating the use of the McMaster Premium Literature Service (PLUS) as a method to efficiently update systematic reviews. *Cochrane Database Syst Rev Suppl* 213–222 (2013) DOI:10.1002/14651858.CD201300.
123. Abha Athale, Anik Giguere, Angela Barbara, Emma Iserman, and Alfonso Iorio. Developing a two-sided intervention to facilitate shared decision making in haemophilia: Decision Boxes for clinicians and brief patient decision aids for patients. *Blood* 2013 (ASH Annual Meeting Abstracts), 122 (21).
124. Sun J, Yang R, Zhao Y, Wang X, Wu J, Zhang X, Guan T and Iorio A. Quality of life and well-being of haemophilia patients and parents in China: subgroup analysis of the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PO 166.
125. Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L and Iorio A. Meta-analysis of post authorization safety studies: worldwide postmarketing surveillance of hemophilia A patients treated with antihemophilic factor recombinant plasma/albumin-free method rAHF-PFM. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PO 148.
126. Iorio A, Buzzi A, Benchikh El Fegoun S and Cooper D. Association between treatment regimen and quality of life assessed by EQ-5D-3L and pain interference in adults with haemophilia with and without inhibitors in the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 129.
127. Iorio A and Buzzi A. Association of treatment regimen and location with bleed frequency, quality of life and comorbidities in adults and children with haemophilia from the HERO study. *Journal of Thrombosis and Haemostasis* 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 128.
128. Alfonso Iorio, Felipe Querol, Trine Pilgaard. Quality of Life in adults with haemophilia: European results From the HERO Study. *Haemophilia* (2013), 19 (Suppl. 2), 10-82PO043.
129. Alfonso Iorio, Felipe Querol, Werner Kalnins, Trine Pilgaard. Access to Haemophilia Treatment Centres, treatment and information sources: European results from the HERO Study. *Haemophilia* (2013), 19 (Suppl. 2), 10-82PO044.
130. Alfonso Iorio, Frederica Cassis, Felipe Querol, Werner Kalnins, Trine Pilgaard. Effects of Haemophilia on relationships, intimacy and family: European results from the HERO Study. *Haemophilia* (2013), 19 (Suppl. 2), 10--82PO031.
131. Alfonso Iorio, Frederica Cassis, Felipe Querol, Trine Pilgaard. Demographic characteristics of European respondents in the HERO study. *Haemophilia* (2013), 19 (Suppl. 2), 10--82 PO030.
132. E. Santagostino, S. Lentz, A. Iorio, A. K. Busk, L. Adab-Franch, J. Meunier, A. Regnault. Effect of turoctocog alfa on quality of life of children, adolescents and adults with haemophilia A: results from two clinical trials. *Haemophilia* (2013), 19 (Suppl. 2), 10-82 PO024.
133. F. Cassis, A. Forsyth, M. Gregory and A. Iorio. Qualitative and quantitative assessment of sexual intimacy in adult patients in the hemophilia experiences results opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-148. *Haemophilia* 2012, 18 (Suppl. 3), 1–208.

134. K. Strike, A. Chan, K. Ross, C. Bos, T. Almonte, K. Decker, R. Goldsmith, A. Iorio, I. Walker, K. Webert and L. Waterhouse. Osteochondral lesions of the ankle joint in patients with Hemophilia A: a retrospective case series. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-212. Haemophilia 2012, 18 (Suppl. 3), 1–208.
135. M. Marcucci, G. Kenet, S. Holzhauer, C. Bidlingmaier, C. Escuriola Ettingshausen, A. Iorio And U. Nowak-Gottl. Assessment of treatment-related risk factors for inhibitor development in previously untreated hemophilia A patients: different statistical approaches. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-WE-04.2-3. Haemophilia 2012, 18 (Suppl. 3), 1–208.
136. A. Coppola, M. Margaglione, E. Santagostino, A. Rocino, A. Tagliaferri, M. Messina, E. Zanon, S. Linari, A. Iorio, L. Valdre, M. Mancuso and G. Di Minno. Predictors of success of immune tolerance induction in hemophilia A patients with high-responding inhibitors: a score from the Italian registry. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France. Haemophilia 2012, 18 (Suppl. 3), 1–208.
137. D. Nugent, C. Garrido, K. Halter, A. Buzzi and A. Iorio. Impact of hemophilia on interpersonal relationships: assessment of parent/caregiver respondents in the hemophilia experiences, results, opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-WE-04.2-2. Haemophilia 2012, 18 (Suppl. 3), 1–208.
138. F. Cassis, A. Buzzi, A. Forsyth, M. Gregory and A. Iorio. Impact of hemophilia on relationships with partners, family, and friends: assessment of adult patient respondents in the hemophilia experiences, results, opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-087. Haemophilia 2012, 18 (Suppl. 3), 1–208.
139. A. Stain, E. Sandoval, K. Halter, and A. Iorio. Hemophilia knowledge and frequently used and valued information sources: patient/parent perceptions from the Hero study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-088. Haemophilia 2012, 18 (Suppl. 3), 1–208.
140. C. Bos, A. Chan, C. Webber, A. Iorio, K. Nagel, I. Walker and K. Webert. Low bone mineral density and increased fat mass in boys with severe Hemophilia. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-048. Haemophilia 2012, 18 (Suppl. 3), 1–208.
141. C. Bos, A. Chan, S. Atkinson, K. Bandosz, K. Nagel, K. Strike, C. Webber, K. Webert, A. Iorio And I. Walker. Nutritional intake and bone mineral density in boys with severe hemophilia. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-047. Haemophilia 2012, 18 (Suppl. 3), 1–208.
142. W. Kalnins, F. Querol, K. Halter and A. Iorio. Clinical presentation and management of pediatric hemophilia patients as reported by parents surveyed in the Haemophilia Experiences Results Opportunities (HERO) survey. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-022. Haemophilia 2012, 18 (Suppl. 3), 1–208.
143. W. Kalnins, F. Querol, M. Gregory and A. Iorio. Clinical presentation and management of adult patients responding to the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France FP-MO-04.4-1. Haemophilia 2012, 18 (Suppl. 3), 1–208.
144. M. Marcucci, G. Kenet, S. Holzhauer, C. Bidlingmaier, C. Escuriola Ettingshausen, A. Iorio, and U. Nowak-Gottl. Concentrate type and dose in hemophilia A patients: Is there an independent effect on risk of inhibitor formation? Oral communication. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 2, page 1 Haemophilia 2012, 18 (Suppl. 1), 11–51.

145. Diane J Nugent, Chris Guelcher, Angela Forsyth, Neil Frick, Michelle Rice, Alfonso Iorio, Tami Wisniewski, and David L. Cooper. Hemophilia Experiences, Results and Opportunities (HERO) Study: US respondent demographics and impact of diagnosis on career and lifestyle decisions and quality of life. *Blood* 2012 (ASH Annual Meeting Abstracts):120 (21).
146. Irwin Walker, Aicha N Traore, Alfonso Iorio, Bruce Ritchie, Nancy Heddle, Kathryn E Webert, Jean St. Louis, David Lillierap, Jerome M. Teitel, and Anthony KC. Chan. Ten-Year Canadian national prospective data on utilization of anti-hemophilic concentrates: indications and trends. *Blood* 2012 (ASH Annual Meeting Abstracts):120 (21).
147. Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl E, Sun X, Johnston B, Busse J, Dahm P, Glujovsky D, Iorio A, Irfan A, Martinez L, , Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Briel M, Granados C, Mustafa R, Guyatt G. Risk difference estimation and reporting in systematic reviews. Abstracts of the 2012 Cochrane Colloquium. *Cochrane Database Syst Rev* 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200.
148. Akl E, Alonso-Coello P, Neumann I, Brignardello-Petersen R, Carrasco-Labra A, Johnston B, Sun X, Briel M, Busse J, Dahm P, Granados C, Glujovsky D, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. Reporting, handling and judging risk of bias associated with missing participant data in systematic reviews. Abstracts of the 2012 Cochrane Colloquium. *Cochrane Database Syst Rev* 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200.
149. Johnston B, Alonso-Coello P, Neumann I, Carrasco-Labra A, Brignardello-Petersen R, Sun X, Akl E, Briel M, Busse J, Dahm P, Glujovsky D, Granados C, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. Reporting of absolute estimates of effect of patient important benefits and harms in abstract of systematic reviews. Abstracts of the 2012 Cochrane Colloquium. *Cochrane Database Syst Rev* 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200.
150. Sun X, Brignardello-Petersen R, Carrasco-Labra A, Neumann I, Alonso-Coello P, Akl E, Johnston B, Briel M, Busse J, Dahm P, Granados C, Glujovsky D, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. Subgroup analyses in systematic reviews: a survey of Cochrane and non-Cochrane reviews. Abstracts of the 2012 Cochrane Colloquium. *Cochrane Database Syst Rev* 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200.
151. Guyatt G, Spencer F, Iorio A, Vandvik P, You J. Uncertainty in baseline risk can reduce confidence in estimates of effect. Abstracts of the 2012 Cochrane Colloquium. *Cochrane Database Syst Rev* 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200.
152. D. Nugent, C. Garrido, K. Halter and A. Iorio. Demographic characteristics of parents of children/adolescents with hemophilia responding in the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-MO-200. *Haemophilia* 2012, 18 (Suppl. 3), 1–208.
153. A. Forsyth, M. Gregory and A. Iorio. Demographic characteristics of adult patient respondents in the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-MO-199. *Haemophilia* 2012, 18 (Suppl. 3), 1–208.
154. Iorio A. IPD meta-analysis to investigate the risk factor for inhibitor development. *Hemophilia*. Perugia Hemophilia Centre, University of Perugia, Italy, Health Information Research Unit, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada (2012), 18 (Suppl 1), 1-10.
155. Iorio A. The use of the clinical trial design in hemophilia: methodological considerations. *Hemophilia*. Perugia Hemophilia Centre, University of Perugia, Italy, Health Information Research Unit, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. (2012), 18 (Suppl 1), 1-10.

156. Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Sabine E, Palareti G, Poli D, Tait CR, Douketis, JD. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: The DASH Prediction Score. *Blood*, 2012, 118;21.
157. Matino D, Iorio A, Gargaro M, Tagariello G, Luciani M, Di Minno G, Coppola A, Di Gennaro L, Puccetti P, Fallarino F. Indoleamine 2,3-Dioxygenase and peripheral tolerance to exogenous Factor VIII: a multi-centre pilot study. *Blood*, 2012, 118;21.
158. Federici AB, Bucciarelli P, Iorio A, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Oliovecchio E, Mannucci, PM. Clinical laboratory and molecular markers of Von Willebrand Disease Type 3 (VWD3): results from the retro/prospective studies on 105/52 Italian patients. *Blood Transfus.* 2011 9 (Suppl 3) PO006.
159. Oliovecchio E, Morfini M, Iorio A. EMOCARD diventa EMOWEB: L'evoluzione del registro delle coagulopatie congenite. *Blood Transfus.* 2011 9 (Suppl 6) RE01.
160. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AKC. I Concentrati dei fattori della coagulazione nella prevenzione delle emorragie e delle loro complicanze nei pazienti con emofilia A e B. *Blood Transfus.* 2011 9 (Suppl 6) RE05.
161. Zanon E, Iorio A, Rocino A, Artoni A, Santoro A, Tagliaferri A, Coppola A, Castaman G, Mannucci PM. L'emorragia cerebrale nella popolazione degli emofilici Italiani con o senza inibitore. *Blood Transfus.* 2011 9 (Suppl 6) CO04.
162. Matino D, Iorio A, Gargaro M, Luciani M, Tagariello G, Di Minno G, Coppola A, Di Gennaro L, Puccetti P, Fallarino F. Indoleammina 2,3 diossigenasi e tolleranza al fattore VIII in pazienti affetti da emofilia a grave. *Blood Transfus.* 2011 9 (Suppl 6) CO07.
163. Coppola A, Santagostino E, Rocino A, Scaraggi FA, Tagliaferri A, Biasoli C, Zanon E, Iorio A, Schiavulli M, Schinco P, Santacroce R, Mancuso ME, Morfini M, Margaglione M. Fattori prognostici di successo nell 'Induzione di immunotolleranza' (ITI) negli emofilici A con inibitore high-responding (HR): uno score predittivo dal registro Italiano. *Blood Transfus.* 2011 9 (Suppl 6) CO12.
164. Morfini M, Scaraggi FA, Musso R, Molinari AC, Mannucci PM, Gringeri A, Santagostino E, Rocino A, Coppola A, Zanon E, Gagliano F, Tagliaferri A, Iorio A, Mazzucconi MG, Piseddu G, Schinco P, Castaman G. Consensus conference sulla profilassi peri-operatoria in pazienti emofilici. *Blood Transfus.* 2011 9 (Suppl 6) CO15.
165. Marchesini E, Fierro T, Mosca M, Becattini C, Iorio A, Gresele P. Case Report: Sequestro polmonare in un paziente con emofilia a grave HIV positive. *Blood Transfus.* 2011 9 (Suppl 6) PO81.
166. Marchesini E, Mancini G, Fierro T, Manganelli I, Matino D, Iorio A, Gresele P. Case Report: Infiltrazione di gel piastrinico autologo nel trattamento di un caso di artropatia emofilica del gomito. *Blood Transfus.* 2011 9 (Suppl 6) PO82.
167. U Nowak-Gotti, G Kenet, M Bonduel, A Chan, N Goldenberg, S Holzhauer, A Iorio, J Journeykake, R Junker, C Male, P Masicotte, P Monagle, H Van Ommen, L Raffini, P Simioni, G Young. Impact of persistent antiphospholipid antibodies on symptomatic thromboembolism in children: A systematic review & meta-analysis (observational studies). *Journal of Thrombosis and Haemostasis.* 2011 9(suppl 2) (O-WE-032).
168. A Federici, P Bucciarelli, G Castaman, E Oliovecchio, A Iorio, P Mannucci. Heterogeneity of the clinical, laboratory and molecular markers of VWD Type 3: results from the retrospective/prospective studies on 122/52 Italian patients. *Journal of Thrombosis and Haemostasis.* 2011 9(suppl 2): P-WE-461).

169. A Iorio, F Querol, A Forsyth, F Cassis. HERO, an international initiative exploring unmet psychosocial needs in haemophilia: characteristics of a quantitative survey targeting 1200 subjects in 12 countries. *Journal of Thrombosis and Haemostasis*. 2011;9 (suppl 2) 2011 (P-WE-491).
170. A Iorio, F Cassis, F Querol, A Forsyth. HERO – An International initiative exploring unmet psychosocial needs in haemophilia: results from a qualitative survey targeting 150 subjects in 7 countries. *Journal of Thrombosis and Haemostasis*. 2011;9 (suppl 2) (P-WE-492).
171. A Iorio, A Forsyth, F Cassis, F Querol. Psychological aspects of living with haemophilia: The HERO project and narrative review of the published literature. *Journal of Thrombosis and Haemostasis*. 2011; 9 (suppl 2) (P-WE-493).
172. M Morfini, A Iorio, M Gabriella Mazzucconi, S Cinotti, E Zanon, E Paladino, E Marchesini, C Santoro. Bioequivalence of a B-Domain deleted and plasma derived FVIII concentrates. *Journal of Thrombosis and Haemostasis*. 2011;9 (suppl 2) (P-WE-515).
173. Martino D, Makris M, D'Amico R, Iorio. A Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. *Haemophilia*. (2010) 16 (Suppl 4) 1-158, 06P24.
174. Morfini M, Iorio A, Mazzucconi M, Cinotti S, Zanon E, Paladino E. Bioequivalence of B-domain deleted and plasma derived FVIII concentrates. *Haemophilia*. (2010) 16 (Suppl 4) 1-158, 08P28.
175. Iorio A, Halimeh S, Goldenberg N, Kenet G, Young G, Brandao L. Effect of plasma-derived or recombinant factor VIII on inhibitor development: a systematic review. *Haemophilia* (2010), 16 (Suppl 4) 1-158, 17P40.
176. Marcucci M, Fabbriani G, Brozzetti M, Luciani M, Iorio A. Bone mineral density in hemophilia patients: a meta-analysis. *Haemophilia*. (2010) 16 (Suppl 4) 1-158, 22FP09.
177. Iorio A, Marchesini E, Marcucci M, Stobart K. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B *Haemophilia* (2010) 16 (Suppl 4) 1-158, 29P15.
178. Olioecchio E, Marchesini E, Martino D, Contino L, Alatri A, Carloni M. Transition to a web-based architecture of the Italian hemophilia registry network. *Haemophilia* (2010) 16 (Suppl 4), 1-158, 10F15.
179. Federici AB, Bucciarelli P, Iorio A, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Rodeghiero F, Mannucci PM. Prevalence and determinants of bleeding in severe Von Willebrand Disease Type 3: results of retro/retrospective studies in a cohort of 105/52 Italian patients. *Blood Transfus*. 2010;8 (Suppl 4) OC007.
180. Iorio A, Douketis J, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait C, Tosetto A. D-Dimer to determine risk for disease recurrence after unprovoked venous thromboembolism: Addressing unanswered questions with a large individual patient meta-analysis. *Blood Transfus*. 2010;8 (Suppl 4) OC025.
181. Marcucci M, Tosetto A, Douketis J, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait C, Iorio A. Are men at higher risk for disease recurrence than women? *Blood Transfus*. 2010;8 (Suppl 4) OC033.
182. Morfini M, Iorio A, Mazzucconi MG, Cinotti S, Zanon E, Paladino E, Marchesini E. Bioequivalence of B-Domain Deleted and plasma derived FVIII concentrates. *Blood Transfus*. 2010 8 (Suppl 4) OC046.
183. Iorio A, Halimeh S, Goldenberg N, Kenet G, Young G, Brandao LR, Marchesini E, Marcucci M, Mannucci PM, Nowak-Gottl U. Effect of Plasma-Derived or recombinant factor VIII on inhibitor development. A Systematic Review. *Blood Transfus*. 2010;8 (Suppl 4) OC047.

184. Zanon E, Santagostino E, Rocino A, Mazzucconi MG, Messina M, Tagliaferri A, Giuffrida AC, Coppola A, Santoro R, Iorio A, Valdrè L, Musso R. Intracranial haemorrhage (ICH) in haemophilia A and B: an italian retrospective survey. *Blood Transfus.* 2010;8 (Suppl 4) OC104.
185. Tositto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Clinical prediction of VTE recurrence in patients with previous unprovoked venous thromboembolism results from an individual-level meta-analysis. *Blood Transfus.* 2010;8 (Suppl 4) OC114.
186. Filippucci E, Kearon C, Marcucci M, Pengo V, Siragusa S, Palareti G, Iorio. A venous thromboembolism recurrence after a first episode of provoked venous thrombosis due to a transient risk factor a systematic review of the literature. *Blood Transfus.* 2010;8 (Suppl 4) OC115.
187. Iorio A, Marcucci M, Pasina L, Marengoni A, Salerno F, Corrao S, Nobili A, Mannucci PM on behalf of the REPOSI investigators. Antithrombotic prophylaxis in elderly patients on atrial fibrillation admitted to internal medicine wards in Italy: adherence to guidelines. *Blood Transfus.* 2010;8 (Suppl 4) P021.
188. Marcucci M, Tositto A, Baglin T, Douketis J, Cushman M, Eichinger S, Palareti G, Poli D, Tait C, Iorio A. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient level meta-analysis of 2,554 unselected patients after a first thrombosis. *Blood Transfus.* 2010;8 (Suppl 4) P043.
189. Marcucci M, Douketis J, Tositto A, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait C(9: Iorio A. D-dimer to predict recurrence after a first episode of unprovoked venous thromboembolism: comparison of aggregate and individual patient data meta-analysis. *Blood Transfus.* 2010 8 (Suppl 4) P046.
190. Marchesini E, Marcucci M, Stobart K, Chan A, Iorio A. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with haemophilia A or B. *Blood Transfus.* 2010;8 (Suppl 4) P052.
191. Marcucci M, Marchesini E, Fabbriani GL, Brozzetti B, Luciani M, Iorio A. Bone mineral density in hemophilia patients: a meta-analysis. *Blood Transfus.* 2010 8 (Suppl 4) P057.
192. Martino D, Makris M, D'Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. *Blood Transfus.* 2010;8 (Suppl 4) P061.
193. Olivovichio E, Marchesini E, Rodorigo G, Marietta M, Di Minno G, Perricone C, Macchi S, Castaman G, Morfini M, Iorio A. Transition to a web-based architecture of the italian hemophilia registry network. *Blood Transfus* 2010;8 (Suppl 4) P065.
194. Augusto B Federici, Alfonso Iorio, and Giancarlo Castaman. Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP): In Inherited Von Willebrand Disease (VWD) Types 1 and 2: initial results from the international study group on DDAVP in VWD in a cohort of 229 Patients. *Blood. ASH Annual Meeting Abstracts:* Nov 2010;116: 238.
195. Gili Kenet, Mariana Bonduel, Anthony Chan, Neil Goldenberg, Suzane Holtzhauer, Alfonso Iorio, Janna M Journeycake, Ralf Junker, Christoph Male, Mary Patricia Massicotte, Rolf M Mesters, Paul Monagle, Heleen Van Ommen, Leslie Raffini, Paolo Simioni, Guy Young, and Ulrike Nowak-Gottl. Impact of persistent antiphospholipid antibodies on symptomatic thromboembolism in children: a systematic review & meta-analysis [Observational Studies]. *Blood. ASH Annual Meeting Abstracts:* Nov 2010;116: 3169.
196. Susanne Holtzhauer, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Susan Halimeh, Alfonso Iorio, Gili Kenet, Brigitte Pautard, and Ulrike Nowak-Gottl A. Predictive model for the development of High-Responding inhibitor in children with severe and moderate Hemophilia A- Results of a multicenter cohort study. *Blood. ASH Annual Meeting Abstracts,* Nov 2010;116:710.

197. A Iorio. International clinical trials are the best way to improve global haemophilia care? No. *Haemophilia*. 2009 15: 22 DOI: 101111/j1365-251620091979x.
198. M Marcucci, A Iorio, G Agnelli, A Nobili, F Salerno, S Corrao, PM Mannucci. A nome dei partecipati al progetto Registro Politerapie SIMI Somministrazione di FANS in pazienti in trattamento anticoagulante orale ed eventi emorragici correlati in una coorte di anziani ricoverati in reparti di medicina interna. *Internal and Emergency Medicine*. 2009;4: S11.
199. A Iorio, M Marcucci, G Agnelli, A Nobili, F Salerno, S Corrao, PM Mannucci. A nome dei partecipati al progetto Registro Politerapie SIMI Terapia antitrombotica combinata e correlati eventi emorragici e tromboembolici in una coorte di anziani ricoverati in reparti di Medicina Interna. *Internal and Emergency Medicine*. 2009 4:S14.
200. A Iorio, PM Mannucci, L Pasina, M Marcucci, J Bonazzi, G Agnelli, F Salerno, S Corrao, A Nobili. a nome dei partecipati al progetto Registro Politerapie SIMI La profilassi antitrombotica in pazienti con fibrillazione o flutter atriale (FFA): preesistente ricoverati in reparti di Medicina Interna: adesione alle linee guida. *Internal and Emergency Medicine*. 2009;4: S26.
201. Lisa K Lütkehoff, Manuela Albisetti, Timothy J Bernard, Mariana Bonduel, Leonardo R Brandao, Stephane Chabrier, Anthony Chan, Barbara Fiedler, Heather J Fullerton, Vijeja Ganesan, Neil A Goldenberg, Meredith Golomb, Eric F Grabowski, Christine Heller, Susanne Holzhauer, Alfonso Iorio, Janna Journeycake, Gili Kenet, Fenella J Kirkham, Karin Kurnik, John K Lynch, Christoph Male, Marilyn J Manco-Johnson, Rolf Mesters, Paul Monagle, Heleen C van Ommen, Leslie Raffini, Paolo Simioni, Ronald Stra. Impact of thrombophilia on arterial ischemic stroke or cerebral venous sinus thromboses in children: a systematic review & meta-analysis of observational studies. *Blood*. (ASH Annual Meeting Abstracts) Nov 2009;114: 3993.
202. Alfonso Iorio, Susan Halimeh, Christoph Bidlingmaier, Leonardo R Brandao, Carmen Escuriola-Ettingshausen, Neil A Goldenberg, Alessandro Gringeri, Susanne Holzhauer, Gili Kenet, Ralf Knoefler, Wolfhart Kreuz, Karin Kurnik, Daniela Manner, Emanuela Marchesini, Maura Marcucci, Elena Santagostino, Guy Young, Pier Mannucci, and Ulrike Nowak-Gottl. Rate of inhibitor development in Hemophilia A patients treated with Plasma Derived or Recombinant Factor VIII concentrates. A systematic review of the literature. *Blood*. (ASH Annual Meeting Abstracts) Nov 2009;114: 3154.
203. Augusto B Federici, Paolo Bucciarelli, Alfonso Iorio, Giancarlo Castaman, Maria Gabriella Mazzucconi, Massimo Morfini, Angiola Rocino, and Pier M Mannucci. Prevalence and determinants of bleeding in severe Von Willebrand Disease Type 3: results of centro/prospective studies in a cohort of 105/52 Italian patients. *Blood*. (ASH Annual Meeting Abstracts) Nov 2009 114: 3494.
204. F Ferrante, A Iorio, F Biondo, P Pignoloni and M Mazzucconi. Pharmacokinetics of reformulated B-domain deleted recombinant factor VIII (BDD-rFVIII: Concentrate using chromogenic and one-stage assays with pooled normal plasma (PNP) and refacto laboratory standard (RLS). *Haemophilia*. 2008 14 (Suppl 2), 1-120 (03 PO 08).
205. A Iorio, S Pizzinelli and F Ferrante. Replacement therapy with recombinant FIX – multicentre evaluation of current dosing practice in Italy. *Haemophilia*. 2008, 14 (Suppl 2), 1–120 (03 PO 26).
206. A Iorio, E Olievecchio, E Zanon, M Mazzucconi, A Accorsi and M Luciani. The haemophilia registry of the Italian Association of Haemophilia Centres. *Haemophilia*. 2008;14 (Suppl 2), 1–120 (03 PO 26).
207. Iorio, E Marchesini, F Ferrante, E Olievecchio and L Lotte. Gluud Antiviral therapy for chronic hepatitis C in haemophilia patients with human immunodeficiency virus. *Haemophilia*. (2008), 14 (Suppl 2) 1–120 (07 PO 08).

208. F Ferrante, A Iorio, B Camilloni, M Basileo, G Tagariello and A Iorio. Inhibitor development in mild/moderate haemophilia could influenza vaccination have been the trigger. *Haemophilia*. (2008), 14 (Suppl 2), 1–120 (08 PO 17).
209. G Tagariello, E Santagostino, M Morfini, A Iorio, M Innocenti, M Mancuso, G Pasta, P Radossi, G Rodrigo, C Santoro, R Sartori, A Scaraggi and L Solimeno. Lower than expected frequency of prosthetic surgery in patients with haemophilia B and chronic arthropathy: data from the Italian registry for surgery in haemophilia. *Haemophilia*. (2008), 14 (Suppl 2), 1–120 (12 PO 89).
210. A Iorio, M Basileo, E Marchesini, L Rocchetti, M Marchesi and C Silvani. Critical appraisal of five international guidelines on fresh frozen plasma clinical use. *Haemophilia*. (2008), 14 (Suppl 2), 1-120 (13 PO 25).
211. Iorio A. The Italian registry of hemophilia and allied disorders: a tool to help health care planning for a rare disease. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, November 2008 (1) s3.
212. Tagliaferri A, Franchini M, Rivolta GF, Iorio A, Mannucci PM. AICE final results from the Italian association of hemophilia centers (AICE) survey on the causes of death among Italian hemophiliacs. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16. 2008 *Blood Transfus* 6, Supplement 3, November CO023.
213. Tagariello G, Iorio A, Santagostino E, Morfini M, Innocenti M, Mancuso ME, Pasta PL, Radossi P, Rodorigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP. Hemophilia B patients have a lower risk to undergo orthopaedic surgery than hemophilia-A patients: results from an Italian cohort study and review of the literature. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, CO032.
214. Zanon E, Spiezia L, Santagostino E, Peyvandi F, Coppola A, Tagliaferri A, Rossetti G, Iorio A, Santoro R, Lapecorella M, Mazzucconi G, Dragani A, Giuffrida A, Gamba G, Giancarlo C. Intracranial haemorrhage in haemophilia A and B: an Italian retrospective survey. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, CO120.
215. Basileo M, Camilloni B, Ferrante F, Iorio AM, Tagariello G, Agnelli G, Iorio A. Inhibitor development in mild haemophilia A: could influenza vaccination have been the trigger. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO003.
216. Siboni SM, Zanon E, Mikovic D, Iorio A, Castaman G, Mazzucconi MG, Peyvandi F. Central nervous system (CNS): bleeding in patients with rare bleeding disorders. (RBDS 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO005.
217. Iorio A, Biasoli C, Coppola A, D'Inca M, Federici A, Ferrante F, Girotto M, Landolfi R, Mancuso G, Musso R. 2007 annual update of the haemophilia registry of the Italian association of haemophilia centres. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO008.
218. Santoro C, Iorio A, Ferrante F, Marchesini E, Pignoloni P, Rago A, Biondo F, Agnelli G, Mazzucconi MG. Pharmacokinetics evaluation of the recalibrated refacto laboratory standard in the assessment of post-infusion plasma levels of b-domain deleted recombinant factor VIII concentrate. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO009.
219. Olivoecchio E, Ferrante F, Marchesini E, Carloni MT, Dragani A, Iuliani O, Agnelli G, Iorio A. Web based support for haemophilia management: an inter-regional network in middle Italy. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO010.

220. Guercini F, Ferrante F, Nenci GG, Iorio A. Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. *Haematologica*. (0390-6078) 2008, September, suppl 2, 91, (P041) 56.
221. E Zanon, A Coppola, A Tagliaferri, G Rossetti, M Lapecorella, A Dragani, F Peyvandii, E Santagostino, A Iorio and R Santoro. Haemophilia A and B and other rare bleeding disorders: an Italian retrospective survey on the intracranial haemorrhagic episodes. *Haemophilia*. (2008), 14 (Suppl 2) , 1–120 (05 PO 16).
222. Basileo M, Iorio A, Ferrante F, Marchesini E, Materazzi M, Marchesi M, Esposito A, Pellegrini L, Rocchetti L, Agnelli G, Silvani CM. International guidelines about clinical use of fresh frozen plasma: a critical appraisal. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO011.
223. Basileo M, Iorio A, Marchesini E, Iaboni S, Palazzesi G, Marchesi M, Esposito A, Pellegrini L, Rocchetti L, Agnelli G, Silvani CM. Clinical audit of the use of fresh frozen plasma in Umbria. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO012.
224. Iorio A, Ferrante F, Rocca A, Accorsi A, Barillari G, Biasoli C, Carloni MT, Castaman G, Ciavarella N, Contino L, D'Inca M, Coppola A, Dragani A, Grandini G, Luciani M, Mariani G, Mazzucconi MG, Molinari C, Morfini M, Muleo G, Rocino A, Rodorigo G, Rossetti G, Santagostino E, Schiavulli M, Schinco PC, Scaraggi F, Siboni S, Tagariello G, Tagliaferri AR, Targhetta R, Zanon E. Replacement therapy with recombinant FIX multicentric evaluation of current dosing practice in Italy. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO013.
225. Coppola A, Biasoli C, Iorio A, Castaman G, Messina M, Mansueto F, Feola G, Santoro R, Sartori R, Schinco P, Santagostino E. Managing incomplete or lack of response to the first immune tolerance induction (ITI: course: strategies from the Italian ITI registry (the PROFIT study). 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO064.
226. Iorio A, Marchesini E, Falco A, Caso V, Pastorello M, Tiscione V, Ballarino P, Altomonte F, Baldi G, Agnelli G, Toni D. Randomised, open, prospective, multicenter pilot study to evaluate the efficacy and safety of activated recombinant factor VIIa (NovoSeven: in acute intracerebral haemorrhage in patients treated with oral anticoagulant. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO070.
227. Alfonso Iorio, Esmeralda Filippucci, Maura Marcucci, Clive Kearon, and Gualtiero Palareti. Venous Thromboembolism Recurrence after a first episode of provoked venous thrombosis due to a Transient Risk Factor A Systematic Review of the Literature. *Blood (ASH Annual Meeting Abstracts)* Nov 2008;112: 3029.
228. Iorio A, Marchesini E, Ferrante F, Agnelli G. Antiviral therapy for chronic Hepatitis C in hemophilia patients with human immunodeficiency virus. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008 *Blood Transfus* 6, Supplement 3, PO007.
229. Dragani A, Marchesini E, Carloni M, Olivivecchio E, Ferrante F, Iuliani O, Agnelli G, Iorio A. Haemophilia management through an inter-regional network in middle Italy. *Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis*, Geneva, 2007, July 6–12, M-127.
230. Iorio A [Correspondent Author], Stobart K. Systematic review of randomized controlled trials of prophylactic clotting factor concentrate in hemophilia. *Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis*. Geneva, 2007, July 6–12, P-M-128.

231. Iorio A [Correspondent Author], Gringeri A, Hassan J, Iannaccaro P, Morfini M, Rossetti G, Scaraggi A, Schiavoni M, Schinco P, Tagliaferri A. The Hemophilia registry of the Italian Association of Hemophilia Centres. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6–12, P-M-129.
232. Iorio A, Marchesini E, Agnelli G. Antiviral therapy for chronic Hepatitis C in hemophilia patients with human immunodeficiency virus. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6–12 P-M-147.
233. Iorio A, Marchesini E, Falco A, Caso M, Pastorello M, Tiscione V, Ballarino P, Altomonte F, Baldi G, Agnelli G, Toni D. Randomised, open, prospective, multicenter pilot study to evaluate the efficacy and safety of activated recombinant factor VIIa (NovoSeven) in acute intracerebral haemorrhage in patients treated with oral anticoagulant or antiplatelet agents. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6–12, P-T-162.
234. Santagostino E, Coppola A, Tagliaferri A, Mancuso M, Scaraggi F, Biasoli C, Schinco P, Iorio A, Latella C, Di Minno G. Immune tolerance induction (ITI) in patients with hemophilia a and inhibitors: the Italian retrospective-prospective registry - the profit study. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6-12, P-W-128.
235. Santoro C, Iorio A, Pignoloni P, Rago A, Biondo F, Ferrante F, Agnelli G, Mazzucconi M. Performance of recalibrated ReFacto laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and one-stage assays after infusion of recalibrated ReFacto (B-domain deleted recombinant factor VIII) Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6–12 , P-W-129.
236. A Iorio, J Douketis, M Marcucci, T Baglin, M Cushman, S Eichinger, G Palareti, D Poli, C Tait, and A Tositto. D-dimer to predict thrombosis recurrence after unprovoked venous thromboembolism: effect of patient- and d-dimer-related factors on recurrence prediction. Journal of Thrombosis and Haemostasis. 2007 (9) Suppl 1 OC-TH-002.
237. Tositto, A Iorio, M Marcucci, T Baglin, M Cushman, S Eichinger, G Palareti, D Poli, C Tait, J Douketis Clinical prediction guide to predict thrombosis recurrence after a first unprovoked venous thromboembolism. Journal of Thrombosis and Haemostasis. 2007 (9) Suppl 1 OC-TH-004.
238. Iorio, C Kearon, E Filippucci, M Marcucci, V Pengo, G Agnelli, G Palareti. Venous thromboembolism recurrence after a first episode of provoked venous thrombosis due to a transient risk factor a systematic review of the literature. Journal of Thrombosis and Haemostasis, 2007 (9) Suppl 1 PP-MO-282.
239. Douketis, A Iorio, M Marcucci, T Baglin, M Cushman, S Eichinger, G Palareti, D Poli, C Tait, A Tositto. Does the clinical presentation of venous thromboembolism predict the risk for and type of thrombosis recurrence? Journal of Thrombosis and Haemostasis, 2007 (9) Suppl 1 PP-WE-286.
240. Douketis, A Iorio, M Marcucci, T Baglin, M Cushman, S Eichinger, G Palareti, D Poli, C Tait, A Tositto. Does patient sex and prior hormonal therapy predict risk for thrombosis recurrence after a first venous thromboembolism. Journal of Thrombosis and Haemostasis. 2007 (9) Suppl 1 AS-TH-005.
241. M Marcucci, A Iorio, J Douketis, T Baglin, M Cushman, S Eichinger, G Palareti, D Poli, C Tait, A Tositto. D-dimer to predict thrombosis recurrence: comparison of aggregate data and individual patient data meta-analyses. Journal of Thrombosis and Haemostasis. 2007 (9) Suppl 1 PP-TH-412.
242. M Basileo, E Filippucci, S Iaboni, P Grilli, M Vecchioli, G Agnelli, A Iorio. Computer assisted vka monitoring with point of care device by general practitioners. Journal of Thrombosis and Haemostasis, 2007 (9) Suppl 1 PP-MO-457.

243. Iorio, E Filippucci, M Basileo, S Iaboni, E Paccamiccio, M Vecchioli, G Agnelli. Prospective assessment of clinical endpoints of VKA treatment in a primary care computer assisted management model. *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 PP-MO-458.
244. Zanon, L Spiezia, E Santagostino, A Coppola, A Tagliaferri, G Rossetti, A Iorio, R Santoro, A Dragani, A Giuffrida, R Musso, G Mancuso, G Castaman, G Gamba, G Mazzucconi, M Lapecorella. Intracranial haemorrhage in haemophilia A and B: an Italian retrospective survey. *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 AS-TU-032.
245. A Iorio, M Marcucci, E Marchesini, P Mannucci. Plasma derived (PD) and recombinant (R) Factor VIII (FVIII) concentrates induce a different rate of inhibitor development in Hemophilia A patients. A systematic review of the literature. *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 OC-MO-035.
246. G Tagariello, A Iorio, E Santagostino, M Morfini, R Bisson, M Innocenti, M Mancuso, M Mazzucconi, G Pasta, P Radossi, G Rodorigo, C Santoro, R Sartori, A Scaraggi, L Solimeno, P Mannucci. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the two coagulation disorders. *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 PP-MO-542.
247. M Marcucci, G Fabbriani, M Brozzetti, A Iorio. Bone mineral density in hemophilia patients: a meta-analysis. *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 PP-WE-529.
248. Coppola, M Margaglione, E Santagostino, A Rocino, F Scaraggi, A Tagliaferri, G Castaman, M Messina, M E Mancuso, A Iorio, P Schinco, E Zanon, R Musso, G Mancuso, G Di Minno, P Mannucci. Factor VIII gene (F8: mutations as a predictor of outcome in immune tolerance induction (ITI) in hemophilia A patients with high-responding inhibitors. *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 OC-TU-075.
249. S M Siboni, E Zanon, G Sottolotta, D Mikovic, A Iorio, G Castaman, M Mazzucconi, P M Mannucci, F Peyvandi. Central nervous system (CNS: bleeding in patients with rare bleeding disorders (RBDS). *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 AS-TU-033.
250. Iorio, A Rocca, S Pizzinelli. Multicentric evaluation of current dosing practice of recombinant FIX in Italy. *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 PP-TH-654.
251. M Basileo, M Marchesi, E Marchesini, M Materazzi, A Germani, L Rocchetti, C Silvani, A Iorio. Audit of the clinical use of fresh-frozen plasma in Umbria: study design and results. *Journal of Thrombosis and Haemostasis*. 2007 (9) Suppl 1 PP-WE-688.
252. Camilloni B, Iorio AM, Neri M, Lepri E, Ferrante F, Guercini F, Iaboni S, Paccamiccio E, Iorio A. 6th National Congress of the Italian Society of Virology a joint meeting with the Virus Group of the Society for General Microbiology (UK) Orvieto (TR). 18-20 September 2006, 79 tris 78 2006.
253. Iorio A, Giuliano V, Bassotti G, Castellani D, Filippucci E, Palmerini F, Morelli O, Clerici C, Baldoni M, Gizzi S, Agnelli G, Morelli A. Small intestinal bacterial overgrowth influences warfarin dose requirement in patients on antithrombotic treatment. *Haematologica*. (0390-6078: September, suppl 2, 91, (C036:11 2006).
254. Guercini F, Conti S, Ferrante F, Paccamiccio E, Iaboni S, Vecchioli M, De Punzio I, Basileo M, Camilloni B, Iorio AM, Iorio A. The effect of influenza vaccination in patients on long-term oral anticoagulant therapy. *Haematologica*. (0390-6078: September, suppl 2, 91, (C038) 11 2006.
255. Iorio A, Gringeri A, Iannaccaro P, Morfini M, Rossetti G, Scaraggi A, Schiavoni M, Schinco P, Tagliaferri A. The Hemophilia Registry of the Italian Association of Hemophilia Centres. *Haematologica*. (0390-6078: , September, suppl 2, 91, (C074: 22 2006.

256. Iorio A, Stobart K. Systematic review of randomized controlled trials of prophylactic clotting factor concentrate in hemophilia. *Haematologica* (0390-6078), 2006 September, suppl 2, 91, (C075) 23.
257. Guercini F, Ferrante F, Nenci GG, Iorio A. Safety and efficacy of ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. *Haematologica*. (0390-6078) 2006 September, suppl 2, 91, (P041) 56.
258. Iorio A, Giuliano V, Bassotti G, Castellani D, Filippucci E, Palmerini F, Morelli O, Clerici C, Baldoni M, Gizzi S, Agnelli G, Morelli A. Small intestinal bacterial overgrowth influences warfarin dose requirement in patients on antithrombotic treatment. *Haematologica*. 2006 (0390-6078), September, suppl 2, 91, (C036) 11.
259. Guercini F, Conti S, Ferrante F, Paccamiccio E, Iaboni S, Vecchioli M, De Punzio I, Basileo M, Camilloni B, Iorio AM, Iorio A. The effect of influenza vaccination in patients on long-term oral anticoagulant therapy. *Haematologica*. 2006 (0390-6078), September, suppl 2, 91, (C038) 11.
260. Iorio A, Gringeri A, Iannaccaro P, Morfini M, Rossetti G, Scaraggi A, Schiavoni M, Schinco P, Tagliaferri A. The Hemophilia Registry of the Italian Association of Hemophilia Centres. *Haematologica*. 2006 (0390-6078), September, suppl 2, 91, (C074) 22.
261. Iorio A, Stobart K. Systematic review of randomized controlled trials of prophylactic clotting factor concentrate in hemophilia. *Haematologica*. 2006 (0390-6078) September, suppl 2, 91, (C075) 23.
262. Iorio A, Gringeri A, Iannaccaro P, Morfini M, Scaraggi A, Schiavoni M. The Haemophilia Registry of the Italian association of haemophilia centres: methodology and preliminary analysis *Haemophilia*. 2006 (1351-8216: (suppl 2) 12, 33.
263. Palareti G, Tosetto A, Cosmi B, Legnani C, Brusi C, Pengo V, Ghirarduzzi A, Pattacini A, Testa S, Iorio A, Tripodi A. The D-dimer (DD) test to establish the duration of anticoagulation after a first unprovoked episode of venous thromboembolism (VTE): the prospective randomized 'Prolong' study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA). *Journal of Thrombosis and Haemostasis*. 2005 (1538-7933) August Suppl 1 3 H02.
264. Mantovani L, Monzini M, Mannucci P, Scalone L, Villa M, Gringeri A, for the Conan Study Group. Differences between patients', physicians' and pharmacists' preferences' for treatment products in haemophilia: a discrete choice experiment *Haemophilia*. 2005 (1351-8216) 11 589-597.
265. Belvini D, Salviato R, Radossi P, Pierobon F, Mori P, Castaldo G, Tagariello G, AICE HB study group. Molecular genotyping of the Italian cohort of patients with hemophilia B. *Haematologica*. 2005 (0390-6078) 90 635-642 Iorio A. listed in the Appendix as Chief of the Centro Emofilia di Perugia.
266. V Mackensen S, Gringeri A, Ravera S, the HAEM-A-QoL G. Validation of the Haemophilia-specific Quality of Life Questionnaire for Adult Patients with Haemophilia (Haem-A-QoL). 10th Anniversary Congress of the European Hematology Association (EHA), Stockholm Sweden June 2-5 2005 Iorio A listed as member of the HAEM-A-QoL Group.
267. Stobart K, Iorio A. Systematic Review of Randomized Controlled trials of prophylactic clotting factor concentrate in Hemophilia. *Blood*. 2005 (0006-4971), November 16, issue 11, 106, abstract 3114, Session Type: Poster Session 365-III.
268. Mancuso M, Santagostino E, Rumi M, Linari S, Coppola A, Rocino A, Iorio A, Dragani A, Barillari G, Tagariello G, Nicolin R, Colombo M, Mannucci P. High efficacy of combination therapy with pegylated interferon and ribavirin in hemophiliacs with chronic hepatitis C. *Blood*. 2005 (0006-4971), November 16, issue 11, 106, abstract 3219.

269. Giuliano V, Castellani D, Clerici C, Morelli O, Iorio A, Sabatino G, Baldoni M, Palmerini F, Asciutti S, Morelli A. Oral anticoagulants and small intestinal bacterial overgrowth. *Canadian Journal of Gastroenterology*. 2005 (0835-7900), September, Suppl B, 19.
270. Baldi G, Altomonte F, Altomonte M, Ghirarduzzi A, Brusasco C, Parodi R, Conti S, Iorio A. Determinants of mortality in cerebral hemorrhage patients on antithrombotic treatment: prospective evaluation in the Italian emergency departments of a multicentric cohort of 1071 patients. *Journal of Thrombosis and Haemostasis*. 2005 (1538-7933) August suppl 13 P0257.
271. Iorio A, Guercini F, Ferrante F, Nenci GG. Safety and efficacy of Ximelagatran: meta-analysis of the controlled randomized trials for the prophylaxis or treatment of venous thromboembolism. *Journal of Thrombosis and Haemostasis*. 2005 (1538-7933) August Suppl 13 P1613.
272. Ferrante F, Fattorini L, Bifarini B, Tesoro S, Depunzio I, Peduto V, Iorio A. Coagulation screening for otorhinolaryngoiatric surgery: a pharmacoeconomic appraisal in the setting of the Italian National Health System. *Journal of Thrombosis and Haemostasis*. 2005 (1538-7933) August Suppl 1 3 P0249.
273. Ferrante F, Paccamiccio E, Iaboni S, Iorio A. Validation of laboratory reference standard for clinical use of INR-POC devices: a randomized multicentre exercise. *Journal of Thrombosis and Haemostasis* 2005 (1538-7933) August Suppl 13 P1733.
274. Giuliano V, Iorio A, Castellani D, Gizzi S, Palmerini F, Sabatino G, Morelli O, Clerici C, Filippucci E, Baldoni M, Nenci GG, Morelli A. Host-drug interaction: the influence of small intestinal bacterial overgrowth on oral anticoagulant dose requirement. *Journal of Thrombosis and Haemostasis*. 2005 (1538-7933) August suppl 13 P2219.
275. Mancuso M, Santagostino E, Rumi M, De Filippi F, Linari S, Coppola A, Rocino A, Iorio A, Dragani A, Barillari G, Tagariello G, Nicolin R, Colombo M, Mannucci P. Pegylated interferon and ribavirin anti-hepatitis C therapy in patients with hemophilia is as effective and safe as in non-hemophilic patients. *Journal of Thrombosis and Haemostasis*. 2005 (1538-7933) August Suppl 1 3 P0218.
276. Guercini F, Conti S, Ferrante F, Paccamiccio E, Iaboni S, Vecchioli M, De Punzio I, Basileo M, Camilloni B, Iorio A. Absence of interaction between influenza vaccination and oral anticoagulant therapy: a randomized blinded clinical trial. *Journal of Thrombosis and Haemostasis*. 2005 (1538-7933) August Suppl 1 3 P1027.
277. V Mackensen S, Gringeri A, Skovlund S, Hemo Sat Study Group. Assessment of treatment satisfaction in patients with haemophilia-development and validation of the first disease-specific questionnaire (Hemo-SatA) *Journal of Thrombosis and Haemostasis*. 2005 (1538-7933: August, suppl 1 vol 3 P, Iorio A listed as member of the Hemo-SatA Study Group.
278. Iorio A, Camilloni B, Basileo M, Guercini F, Conti S, Ferrante F, Paccamiccio E, Iaboni S, Vecchioli M, De Punzio I, Iorio A. Influenza vaccination in patients on long-term anticoagulant therapy. 2005 The Second European Influenza Conference Malta 11-14 September.
279. Mancuso M, Santagostino E, Linari S, Coppola A, Rocino A, Iorio A, Dragani A, Barillari G, Tagariello G, Nicolin R, Rumi M, De Filippi F, Colombo M, Mannucci P. Sustained suppression of hepatitis C by pegylated Interferon (PEG-INF) and Ribavirin in hemophilic patients. *Haematologica*. (0390-6078), 2004 September 8 89 30.
280. Iorio A, Ferrante F, Conti S, Nenci GG. LMWH or Ximelagatran versus VKA in the prevention of VTE after major knee surgery: a meta-analysis of randomized controlled trials. *Haematologica*. (0390-6078) 2004 89 37.

281. Castori L, Depunzio I, Servettini I, Ferrante F, Carloni D, Iorio A. Venous thrombotic risk assessment among factor V Leiden carriers undergone a thrombophilic screening by different types of indications. *Haematologica*. (0390-6078), 2004 September, 8, 89, 58.
282. Ghirarduzzi A, Nicolini A, Iotti M, Iorio A, Baldi G. Intracranial bleeding relationship with antithrombotic treatment in 241 cerebral hemorrhages in Reggio Emilia. *Haematologica*. (0390-6078) 2004 September 8 89 61.
283. Ferrante F, Ghirarduzzi A, Silingardi M, Franzoni C, Iorio A 2004 Clinical and laboratory performance evaluation of three point-of-care devices for INR determination (Coagucheck, Protime, Harmony) *Haematologica* (0390-6078), 2004 September, 8, 89, 62.
284. Iorio A, Minciotti A, Ferrante F, Nenci GG. Pharmacoeconomic evaluation of the management of oral anticoagulant treatment with point-of-care devices in the Italian national health care system. *Haematologica* (0390-6078) 2004 89 63.
285. Ferrante F, Bifarini B, Tesoro S, Peduto F, Iorio A. Coagulation screening for otorhinolaryngoiatric surgery: a pharmacoecomomic appraisal in the setting of the Italian national health system *Haematologica*. (0390-6078) 2004 September 8 89 81.
286. Iorio A, Orsini Federici M, Ferrante F, Stabile A, Galli F, Massi Benedetti M. Impairment of fibrinolytic capacity in experimentally induced ketoacidosis in continuous subcutaneous insulin infusion patients *Haematologica*. (0390-6078) 2004 September 8 89 119.
287. Guercini F, Conti S, Iorio A. Low-molecular-weight heparin and cancer survival: pooled analysis of 1726 patients treated for three months. *Haematologica*. (0390-6078) 2004 September 8 89 133.
288. Altomonte F, Altomonte M, Iorio A, Ghirarduzzi A, Ricciardi A, Remollino V, Spinsi L, Saporito A, Caiazza A, Musso G, Cervellin G, Lamberti S, Buzzalino M, De Giorgi F, Del Prato C, Golinelli M, Gai V, Monsù R, Gioffrè M, Giovanari D, Cattaneo S, Frumento F, Caporrella A, Re G, De Iaco F, Bologna G, Nocenti F, Lorenzi C, Zoratti R, Sciolla A, Tiscione V, Pastorello M, Vandelli A, Villa A, Zanna M, De Palma A. Ecaps study: multicentric evaluation of cerebral hemorrhage in anticoagulated/antiaggregated patients in the Italian emergency rooms. *Haematologica*. (0390-6078) 2004 September 8 89 152.
289. Ghirarduzzi A, Iotti M, Cattabiani L, Ieran M, Iorio A, Silingardi M, Iori I. Venous thromboembolic disease: clinical features of 1282 prospective consecutive cases at angiology unit of Reggio Emilia. *Haematologica*. (0390-6078) 2004 September 8 89 161.
290. Paccamiccio E, Ferrante F, Trottini S, Rosafalco M, Duca E, Vecchioli M, Nenci GG, Iorio A. OAT with POC devices and remote computer monitoring in the setting of the Italian NHS: a controlled clinical trial. *Haematologica*. (0390-6078) 2004 89 180-1.
291. Ferrante F, Paccamiccio E, Servettini I, Iorio A. Quality control programs for POC devices to measure INR Results of a pilot exercise. *Haematologica*. (0390-6078) 2004 September 8 89 181.
292. Mackensen S, Gringeri A, Santoni L, Tagliaferri A, Tagariello G, Ciavarella N, Iorio A, Molinari C. Development of disease-specific quality of life questionnaire for adult patients with hemophilia (HAEM-A-QOL). *Haematologica*. (0390-6078) 2004 September 8 89 186.
293. Mackensen S, Gringeri A, Mantovani I, Skovlund S, Santoni L, Tagliaferri A, Tagariello G, Ciavarella N, Iorio A. Development and validation of the first treatment satisfaction scale for adult hemophiliacs (HEMO-SAT). *Haematologica*. (0390-6078) 2004 September 8 89 191.
294. Iorio A, La Torre D, Conti S, Gambelunghe G. Successful treatment of spontaneous intracerebral haemorrhage in a patient with prosthetic mechanical heart valves. *Haemophilia*. (1351-8216), October 2004 Supplement 3 10 9.

295. Iorio A, Chantarangkul V, Ferrante F, Tripodi A. Hemo Web, a web-based tool to handle the external quality control program for the hemophilia center coagulation laboratory. *Haemophilia*. (1351-8216) October 2004 Supplement 3 10 17.
296. Mancuso M, Santagostino E, Linari S, Coppola A, Rocino A, Iorio A, Dragani A, Barillari G, Tagariello G, Nicolini R, Rumi M, De Filippi F, Colombo M, Mannucci P. Sustained suppression of hepatitis C by pegylated interferon (pegINF) and ribavirin in hemophilic patients. *Haemophilia*. (1351-8216) October 2004 Supplement 3 10 48.
297. Von Mackensen S, Gringeri A, Mantovani L, Skovlund S, Santoni L, Tagliaferri A, Tagariello G, Ciavarella N, Iorio A. Development and validation of the first treatment satisfaction scale for adult haemophiliacs (Hemo-SatA). *Haemophilia*. (1351-8216) October 2004 Supplement 3 10 126.
298. Baudo F, Gaidano G, Carloni M, Coppola A, Iorio A, Marietta M, Marongiu F, Mazzucconi M, Miraglia E, Schiavoni M, Schinco P, Fariciotti A. Recombinant activated Factor VII (rFVIIa) for the treatment of bleeding secondary to acquired factor VIII inhibitor. *Journal of Thrombosis and Haemostasis*. (1538-7933) 2004 July, 1 P0596.
299. Massi Benedetti M, Brunetti P, Iorio A, Ferolla P, Stabile A, Akwe J, Canonico V, Celleno R, Timi A. Acute ketoacidosis in continuous subcutaneous insulin infusion treated Type 1 diabetics impairs the fibrinolytic capacity. *Diabetes & Metabolism*. (1262-3636) 2003 29, 4S361 (2738).
300. Ghirarduzzi A, Iorio A, Nicolini A, Silingardi M, Cattabiani L, Belloni L, Iori I. 1286 Prospective consecutive cases of venous thromboembolic diseases at the single venous thromboembolic unit of Reggio Emilia. *Journal of Thrombosis and Haemostasis*. (1538-7933) 2003 July 1, 1286a P1444.
301. Iorio A, Testa S, Parisoli A, Alatri A, Franzoni M, Trottini S, Cinotti R, Rinaldi G, Ghirarduzzi A. Clinical quality assessment program for the oral anticoagulant clinic. Preliminary report of a multicentric Italian exercise. *Journal of Thrombosis and Haemostasis*. (1538-7933), 2003 July 1 P1965.
302. Paccamiccio E, Trottini S, Rosafalco M, Filippucci E, Duca E, Vecchioli M, Nenci GG, Iorio A. Oral anticoagulant therapy with POC device and remote computer monitoring in the setting of the Italian National Health System (INHS) *Journal of Thrombosis and Haemostasis*. (1538-7933) 2003 July 1 P1956.
303. Accardo P, Ghirarduzzi A, Silingardi M, Franzoni M, Iorio A. Clinical and laboratory performance evaluation of three point-of-care devices for INR determination (CoaguCheck, ProTime, Harmony) *Journal of Thrombosis and Haemostasis*. (1538-7933) 2003 July 1 P1966.
304. Iorio A, Guercini F, Conti S, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants *Journal of Thrombosis and Haemostasis*. (1538-7933) 2003 July 1 P1873.
305. Silingardi M, Fornaciari G, Beltrami M, Iorio A, Ghirarduzzi A, D'Inca M, Negri E, Nicolini A, Morini L, Iori I. Hyperhomocysteinemia and other thrombophilic factors in Italian patients with inflammatory bowel disease *Journal of Thrombosis and Haemostasis*. (1538-7933) 2003 July 1 P0463.
306. Iorio A, Ferolla P, Orsini Federici M, Celleno R, Stabile A, Canonico V, Massi Benedetti M. Impairment of fibrinolytic capacity in experimentally induced ketoacidosis in continuous subcutaneous insulin infusion patients. *Journal of Thrombosis and Haemostasis*. (1538-7933) 2003 July 1 P0957.
307. Iorio A, Guercini F, Pini M. Low-molecular-weight-heparin for the long term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparison with oral anticoagulant. *Haematologica*. (0390-6078) 2002 suppl 5 87 31.

308. Ghirarduzzi A, Tortorella G, Iorio A, Casali B, Bellesia E, Silingardi M, Nicolini A, Guiducci U, Iori I. Gemina study: genetic polymorphisms and myocardial infarction among Italian young adults. *Haematologica*. (0390-6078) 2002 suppl 5 87 69.
309. Iorio A, Accardo P, Bellesia E, Tascedda T, Tonelli L, Brini M. Feasibility of the use of filtered plasma in the automated screening test for activated protein C resistance. *Haematologica* (0390-6078) 2002 suppl 5 87 93.
310. Ghirarduzzi A, Silingardi M, Cattabiani L, Nicolini A, Tonelli L, Iorio A. Thrombotic risk and laboratory pattern in 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies. *Haematologica*. (0390-6078) 2002 suppl 5 87 94.
311. Guercini F, Pini M, Iorio A. Low-molecular-weight heparin treatment and cancer: pooled analysis of 908 patients treated for three months. *Haematologica*. (0390-6078) 2002 suppl 5, 87, 127.
312. Nicolini A, Ghirarduzzi A, Silingardi M, Iorio A, Baldi G. Intracranial bleeding in Reggio Emilia epidemiology and relationships with antithrombotic treatment. *Haematologica*. (0390-6078), 2002 suppl 5 87 128.
313. Conti S, Guercini F, Pini M, Iorio A. Low-molecular-weight-heparin treatment and cancer: pooled analysis of 908 patients treated for three months and review of the literature. *Pathophysiology of Haemostasis and Thrombosis*. (1424-8832), 2002 suppl 2, 32, 51.
314. Iorio A, Guercini F, Pini M. Low-molecular-weight-heparin for the long-term treatment of symptomatic venous thromboembolism meta-analysis of the randomized comparisons with oral anticoagulant. *Pathophysiology of Haemostasis and Thrombosis*. (1424-8832) 2002 suppl 2 32 71.
315. Ghirarduzzi A, Tascedda T, Silingardi M, Galimberti D, D'Inca M, Nicolini A, Cattabiani L, Brini M, Iorio A. Thrombotic risk and laboratory pattern in 91 consecutive patients with lupus anticoagulant and/or anticardiolipin antibodies. *Thrombosis and Haemostasis* (0340-6245) 2001 Supplement July P2944.
316. Ghirarduzzi A, Tortorella G, Iorio A, Casali B, Tascedda T, Silingardi M, Guiducci U, Iori I. Studio GEMINA ruolo dei polimorfismi genetici e dell'omocisteinemia nell'infarto del miocardico in giovani-adulti italiani. *Italian Heart Journal*. (1129-471X) 2001 suppl 6 2 67.
317. Tascedda T, Silingardi M, Ghirarduzzi A, Iori I, Brini M, Iorio A. APTT evaluation in the presurgery screening: survey of 5000 patients. *Thrombosis and Haemostasis*. (0340-6245) 2001 Supplement July CD3324.
318. Silingardi M, Ghirarduzzi A, Iori I, Salvarani C, Boiardi L, Bellesia E, Tascedda T, Morini L, Galimberti D, Cantini F, Govoni M, Salvi F, Iorio A. Factor V Leiden and G20210A prothrombin allele are not associated with thrombosis in Behcet's disease. *Thrombosis and Haemostasis*. (0340-6245) 2001 Supplement July P2519.
319. Ghirarduzzi A, Tortorella G, Iorio A, Casali B, Farnetti E, Bellesia E, Tascedda T, Silingardi M, Morini L, Guiducci U, Iori I. Gemina study: genetic polymorphisms and myocardial infarction among Italian young adults. *Thrombosis and Haemostasis* (0340-6245) 2001 Supplement July P1571.
320. Iorio A, Silingardi M, Tascedda T, Ghirarduzzi A, Guidetti D, Iori I, Brini M. Plasma homocysteine measurement: comparison of three different assay methods in plasma from vascular patients. *Haematologica*. (0390-6078) 2000 Suppl 5 85 57 PO-126.
321. Silingardi M, Iorio A, Ghirarduzzi A, D'Inca M, Galimberti D, Tincani E, Iori I. Hyperhomocysteinemia and retinal vein occlusion. *Haematologica*. (0390-6078) 2000 Suppl 5 85 58 PO-127.
322. Agnelli G, Airolidi G, Brambilla G, Buon cristiani P, Severi P, Pasetti S, Giugni E, Iorio A. Risk factors for venous thromboembolism in patients undergoing elective neurosurgery. *Haematologica*. (0390-6078) 2000 Suppl 5 85 88 CO-194.

323. Iorio A, Agnelli G. Low molecular weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. *Haematologica*. (0390-6078) 2000 Suppl 5 85 128 PO-286.
324. Filippucci E, Agnelli G, Leone M, Iorio A, Nenci GG. Inhibition of fluid phase and fibrin bound thrombin: effect of heparin, r-hirudin, PEG-rm-hirudin and a thrombin exosite inhibitor. *Haematologica*. (0390-6078) 2000 Suppl 5 85 139 PO-309.
325. Buratta S, Iorio A, Tascadda T, Andreoli V, Mambrini R, Porcellati S, Mozzi R. Serine base exchange enzyme in commercially available porcine lyophilised platelets: different effect of unfractionated and low molecular weight heparins. *Haematologica*. (0390-6078) 2000 suppl 5 85 120 PO-267.
326. Agnelli G, Prandoni P, Santamaria MG, Bagatella P, Ascani A, Bazzan M, Alatri A, Guazzaloca G, Bertoldi A, Tomasi C, Scannapieco G, Ageno W, Iorio A. Three months compared with one-year of oral anticoagulant treatment after a first idiopathic deep vein thrombosis the warfarin optimal duration Italian trial (WODIT). *Thrombosis and Haemostasis*. (0340-6245) 1999 Suppl 1 81 2164.
327. Iorio A, Agnelli G. Low molecular weight heparin for prevention of venous thromboembolism in elective neurosurgery a metanalysis. *Thrombosis and Haemostasis*. (0340-6245) 1999 Suppl 1 81 2059.
328. Buratta S, Iorio A, Andreoli V, Mambrini R, Porcellati S, Mozzi R. Serine base-exchange enzyme in commercially available porcine lyophilized platelets: different effect of unfractionated and low molecular weight heparin. *Thrombosis and Haemostasis*. (0340-6245) 1999 Suppl 1 81 2137.
329. Schiatti C, Iorio A, Rinaldi G, Silingardi M, Ghirarduzzi A, Guidetti D, Iori I, Brini M. Plasma homocysteine measurement: comparison of three different assay methods in plasma from vascular patients. *Thrombosis and Haemostasis*. (0340-6245), 1999 Suppl 1 81 2440.
330. Silingardi M, Salvarani C, Rinaldi G, Ghirarduzzi A, Boiardi L, Iorio A, D'Inca M, Cantini F, Govoni M, Salvi F. Prothrombin 202120A mutation in Behcet's disease. *Thrombosis and Haemostasis*. (0340-6245) 1999 Suppl 1 81 2112.
331. Ghirarduzzi A, Iorio A, Silingardi M, D'Inca M, Rinaldi G, Iori I. Different management of oral anticoagulant therapy in patients with mechanical prosthetic heart valves: prospective cohort study. *Thrombosis and Haemostasis*. (0340-6245) 1999 Suppl 1 81 2147.
332. Ghirarduzzi A, Iorio A, Silingardi M, D'Inca M, Tincani E, Galimberti D, Rinaldi G, Iori I. Elderly patients treated with oral anticoagulant a prospective cohort study. *Thrombosis and Haemostasis*. (0340-6245) 1999 Suppl 1 81 2148.
333. Berrettini M, Bura A, Lucarelli G, Tagariello G, Castaman G, Scaraggi F, Tagliaferri A, Mazzucconi M, Baudo F, Trapani Lombardo V, Iorio A. The role of thrombophilic states in the bleeding tendency of patients with hemophilia. *Thrombosis and Haemostasis*. (0340-6245) 1999 Suppl 1 81 1544.
334. Agnelli G, Airolidi G, Brambilla G, Buon cristiani P, Severi P, Pasetti S, Giugni E, Iorio A. Risk factors for venous thromboembolism in patients undergoing elective neurosurgery. *Thrombosis and Haemostasis*. (0340-6245) 1999 Suppl 1 81 16.
335. M Silingardi, A Ghirarduzzi, A Iorio, G Rinaldi, CA Zotti, A Fanti. Central retinal vein occlusion in homozygous factor V Leiden. *Thromb Res*. 1998 91(Suppl 1)134.
336. Ghiraduzzi, A Iorio, M Silingardi, G Rinaldi, D Galimberti, I Iori. Different management of oral anticoagulant therapy a prospective cohort study. *Thromb Res*. 1998 91 (Suppl 1) 135A.

337. G Agnelli, A Iorio, F Abbadessa, F Guarraggi, M Casaccia. Plasma heparin level and coronary patency in patients with acute myocardial infarction treated with a double rt-PA bolus and randomised to two different heparin regimens. *Thromb Res.* 1998 91 (Suppl 1) 89A.
- 338.27: G Agnelli, F Piovella, P Buoncristiani, P Severi, M Pini, L Crippa, G Brambilla, M Damiani, G Andrioli, E Giugni, S Pasetti, G Ghetti, C Beltrametti, R Pugliese, A Iorio. Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients a randomised double blind venography study. *Thromb Res.* 1998 91 (Suppl 1) 106A.
339. G Rinaldi, E Bellesia, A Iorio, A Pilia, A Ghirarduzzi, M Silingardi, CA Zotti, A Fanti. Factor V Leiden in young patients with retinal vein occlusion. *Thromb Res.* 1998 91(Suppl 1):132A.
340. M Berrettini, G Tagariello, G Castaman, FA Scaraggi, A Tagliaferri, MG Mazzucconi, F Baudo, V Trapani Lombardo, A Iorio, G Lucarelli, A Sergi. The role of natural anticoagulant systems in the bleeding tendency of patients with hemophilia. *Thromb Res.* 1998 91 (Suppl 1) 107A.
341. D Guidetti, E Bellesia, G Rinaldi, A Iorio, A Pilia, M Brini. Hemocoagulative and molecular biology parameters in 100 cerebrovascular patients. *Thromb Res.* 1998 91 (Suppl 1) 129A.
342. Iorio A, Pilia, G Rinaldi, M Silingardi, A Ghirarduzzi, I Iori, M Brini. Antiphospholipid antibodies: economic evaluation of an automated screening protocol. *Thromb Res.* 1998 91 (Suppl 1) 131A.
343. G Rinaldi, E Bellesia, A Iorio, A Pilia, A Ghirarduzzi. Factor V Leiden and G26210A variation of the prothrombin gene identification by the use of one-step multiplex PCR mediated site-directed mutagenesis. *Thromb Res.* 1998 91 (Suppl 1) 133A.
344. Ascani, A, Iorio, A, Stabile, G, Agnelli. Withdrawal of warfarin therapy after deep vein thrombosis: a randomized study on the effects of a very low fixed dose regimen. *Thromb Haemost.* 1997 78 (Suppl 1) 335A.
- 345.24: G Agnelli, F Piovella, P Buoncristiani, P Severi, M Pini, L Crippa, G Brambilla, M Damiani, G Andrioli, E Giugni, S Pasetti, G Ghetti, C Beltrametti, R Pugliese, A Iorio. Enoxaparin plus compression stockings versus compression stockings alone in the prevention of venous thromboembolism (VTE) in neurosurgery patients a randomised double blind venography study. *Thromb Haemost.* 1997 78 (Suppl 1) 1576A.
346. G Agnelli, A Iorio, F Abbadessa, F Guarraggi, M Casaccia. Plasma heparin level and coronary patency in patients with acute myocardial infarction treated with a double rt-PA bolus and randomised to two different heparin regimens. *Thromb Haemost.* 1997 78 (Suppl 1) 2050A.
347. Iorio A, S. Ricotta, P. Parise, G. Agnelli. Post-discharge clinically overt thromboembolic events in orthopaedic surgery patients with negative venography. *Inter Angio* 1996 15 30.
348. Iorio A, Parise P, Goldhaber SZ, Agnelli G for the BAPE Investigators. Fibrinogenolysis and thrombin activation after accelerated weight adjusted or conventional administration of rt-PA for pulmonary embolism. *Inter Angio.* 1996 15 31.
349. A. Iorio, A. Alatri, V. Ranucci, S. Falconi, V. Pasqualucci, G. Agnelli. Prophylaxis for venous thromboembolism and spinal anaesthesia results of a national survey. *Inter Angio.* 1996 15 32.
350. Agnelli G, Iorio A, Abbadessa F, Guarraggi F, Casaccia M. Plasma heparin level and coronary patency in patients with AMI treated with a double rt-PA bolus and randomised to two different heparin regimens. *Haemostasis.* 1996 26 (Suppl 3) 39A.
351. Iorio A, Nucciarelli F, Leone M, Agnelli G. Effects of dermatan sulfate on activated partial thromboplastin time determined with five different reagents. *Thromb Haemostas.* 1995 (73) 1353.

352. Ricotta S, Iorio A, Parise P, Agnelli G. Post-discharge clinically overt thromboembolic events in orthopaedic surgery patients with negative venography. *Thromb Haemostas*. 1995 73 1095.
353. Agnelli G, Pascucci C, Mezzasoma AM, Iorio A. The displacement of non-specifically bound unfractionated heparin from plasma proteins produces an antithrombotic effect. *Thromb Haemostas*. 1995 73 963.
354. Mozzi R, Andreoli V, Buratta S, Iorio A, Horrocks LA. Regulation of phosphatidylserine synthesis in rat cerebral cortex. *J Neurochem*. 1994 63(1): S23B.
355. S. Buratta, S. Porcellati, A. Iorio and R. Mozzi. Base exchange enzyme activity in porcine liophylized platelets and the effect of heparin on PS synthesis by base exchange. *Italian Biochemical Society Transactions (IBST)* 1994 5 182.
356. Iorio A, Agnelli G, Goldhaber S, Levine M. Effetti sul sistema emostatico di due schemi terapeutici con rt-PA in pazienti con embolia polmonare. *Cardiologia*. 1994 39(2) 51.
357. Parise P, Hauert J, Iorio A, Callegari P, Nenci GG: Fibrinogen degradation products (FgDP) generation is the major determinant of platelet inhibition induced by plasminogen activators (PA). *Thrombosis Research*. 1993 70 (suppl 1) S112.
358. Agnelli G, Renga C, Leone M, Melelli P, Parise P, Iorio A, Nenci GG. Kinetics of plasma thrombin neutralization activity in patients with deep vein thrombosis treated with subcutaneous heparin twice a day. *Thrombosis and Haemostasis*. 1993 69(6) 857.
359. Iorio A, Agnelli G, Renga C, Leone M, Melelli P, Parise P, Nenci GG. Kinetics of plasma thrombin neutralization activity in patients with deep vein thrombosis treated with subcutaneous heparin b. i.d. *Annals of Haematology*. 1993. 66 (suppl 1) A25.
360. G Agnelli, M Leone, P Melelli, C Renga, A. Iorio, GG Nenci. Inhibition of fluid phase and clot-bound thrombin: effects of heparin, hirudin and a thrombin-inhibiting decapeptide (LU 58463). *Thrombosis and Haemostasis* 1993 69(6) 1301.
361. Iorio A, Agnelli G, Leone M, Melelli P, Renga C, Nenci GG. Hirudin and PEG-Hirudin inhibit clot-bound thrombin more efficiently than heparin. *Annals of Haematology*. 1993 66 (suppl 1) A19.
362. Agnelli G, Iorio A, Boschetti E, Nenci GG, Ofosu F, Hirsh J. Low molecular weight heparins show prolonged anti-IIa plasma half-life. *Circulation*. 1993 88,4(2), 1200.
363. Agnelli G, Iorio A, Alatri A, Boschetti E, Mazzolai L, Nenci GG, Ofosu F, Hirsh J. Plasma half-life of the anti-IIa activity of low molecular weight heparins assessed with a sensitive test (PTNA). *Thrombosis and Haemostasis*. 1993 69(6), 768.
364. Iorio A, Agnelli G, Leone M, Boschetti E, Nenci GG, Hirsh J. Enoxaparine shows a prolonged plasma half-life of its anti-IIa activity assessed with PTNA. *Annals of Haematology* 1993 66 (suppl 1) A24.
365. Iorio A, Agnelli G, Alatri A, Boschetti E, Nenci GG, Hirsh J: Prolonged plasma half-life of the anti-IIa activity of Enoxaparine assessed with a sensitive test (PTNA). *Thrombosis Research* 1993 70(suppl 1) S14.
- 366.4: Iorio A, Agnelli G, Nenci GG, Mele A, Bürgi R, Heim J. Thrombolytic and haemorrhagic effects of bolus doses of rt-PA and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA CGP 42935). *Thrombosis Research*. 1993 70(suppl 1) S91.
367. Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Platelet inhibition induced by plasminogen activators: role of fibrinogen degradation products. *Thrombosis and Haemostasis*. 1993 69(6) 1337.

368.Parise P, Hauert J, Iorio A, Callegari P, Nenci GG. Platelet inhibition induced by plasminogen activators role of fibrinogen degradation products. *Annals of Haematology*. 1993 66 (suppl 1) A31.

Peer-reviewed Letter to the Editor and Commentaries:

1. Michael Makris, Alfonso Iorio. Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population? *Research and Practice in Thrombosis and Haemostasis*. Commentary. 2019;3:12-14. Doi: 10.1002/rth2.12172.
2. Coffin D, Herr C, O'Hara, J, Diop S, Hollingsworth R, Srivastava A, Lillicrap D, van den Berg HM, Iorio A, Pierce GF. World bleeding disorders registry: The pilot study. *Haemophilia*. 2018 Feb 1. Doi: 10.1111/hae.13431. PMID: 29388721.

Non-Peer Reviewed Contributions to Books

1. Iorio A, Nenci GG. Manifestazioni Gastroenteriche delle Malattie Internistiche. In Gasbarrini A. *Trattato di Gastroenterologia*. Piccin, 2010, Italia.
2. Iorio, A. The Epidemiology of Inhibitors in Hemophilia. In *Textbook of Hemophilia*, 3rd Edition Christine A. Lee, Erik E. Berntorp, W. Keith Hoots. May 2014, Wiley-Blackwell.
3. Paciaroni M, Iorio A. Subarachnoid hemorrhage. In: Ebell MH, Ferenchick G, Smith M, Barry H, Slawson D, Shaughnessy A, Forsch R, Li S, Wilkes M, Usatine R, eds. *e-Essential Evidence*. 1st ed. Hoboken, NJ: John Wiley and Sons. 01-01-2010 <http://www.essentialevidenceplus.com/content/eee/51>.
4. Makris M, Iorio A. Hemophilia. In: Ebell MH, Ferenchick G, Smith M, Barry H, Slawson D, Shaughnessy A, Forsch R, Li S, Wilkes M, Usatine R, eds. *e-Essential Evidence*. 1st ed. Hoboken, NJ: John Wiley and Sons. 04-02-2010 <http://www.essentialevidenceplus.com/content/eee/264>.
5. Iorio A, Paciaroni M. Intracranial hemorrhage. In: Ebell MH, Ferenchick G, Smith M, Barry H, Slawson D, Shaughnessy A, Forsch R, Li S, Wilkes M, Usatine R, eds. *e-Essential Evidence*. 1st ed. Hoboken, NJ: John Wiley and Sons. 02-11-2009. <http://www.essentialevidenceplus.com/content/eee/38>.
6. A. Iorio and G. Agnelli. Antipyretic analgesics. In: Dukes, Annual 18. Aronson J.K. and van Boxtel C.J. eds., Elsevier Science B.V., Amsterdam 1995.
7. Iorio A. (collaborator) in J. Hirsh, G. Agnelli. *Thromboembolismo venoso - Guida alla diagnosi, profilassi e terapia*. Il Pensiero Scientifico Editore, Roma 1993.
8. Iorio A, Agnelli G. Warfarin. (Update of the Italian Medical Encyclopedia item, volume IV).

Non-Peer Reviewed Journal Articles

1. E Filippucci, A Iorio. I coagulometri portatili. *EsaDia, Rivista di attualità Diagnostiche*. Anno 11, numero 31, pagine 30-37 2008.
2. Conti S, Iorio A. I disordini congeniti ed acquisiti dell'emostasi e della fibrinolisi. *Ann Med. Perugia* 2003 suppl.1, 94, 108-13.
3. Iorio A, Filippucci E. L'organizzazione del centro per il monitoraggio della terapia anticoagulante orale. *Ann Med. Perugia* 2002 suppl. 1, 93: 44-47.

4. Iorio A. Le trombofilie acquisite. *Ann Med. Perugia* 2001 92, suppl. 1: 38-41.
5. M Basileo, A Iorio. Il processo di validazione clinica di un algoritmo computerizzato per il monitoraggio della TAO. *EsaDia, Rivista di attualità Diagnostiche*. Anno 11, numero 38, pagine 4-9 2011.

Other, including Proceedings of Meetings

1. Naccache M, Coffin D, Youttanankorn W, Tootoonchian E, Byams V, Diop S, Hermans C, Noone D, O'Hara J, Pierce GF, Iorio A, Konkle B, Ayoub E. Two-year Update on the WFH World Bleeding Disorders Registry [abstract]. *Res Pract Thromb Haemost*. 2020; 4 (Suppl 1). <https://abstracts.isth.org/abstract/two-year-update-on-the-wfh-world-bleeding-disorders-registry/>. Accessed July 21, 2020.
2. Tootoonchian E, Stonebraker J, Iorio A, Byams V, El Ekiaby M, Makris M, O'Hara J, Chambost H, Weill A, Pierce G, Baumann A, Coffin D. The Annual Global Survey Continues to Close the Gap in Data Collection of Bleeding Disorders [abstract]. *Res Pract Thromb Haemost*. 2020; 4 (Suppl 1). <https://abstracts.isth.org/abstract/the-annual-global-survey-continues-to-close-the-gap-in-data-collection-of-bleeding-disorders/>. Accessed July 21, 2020.
3. Matino D, Iorio A, Keepanasseril A, Germini F, Birkegård AC, Caillaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua C, Sun H, Teitel J, Poon M-. A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting [abstract]. *Res Pract Thromb Haemost*. 2020; 4 (Suppl 1). <https://abstracts.isth.org/abstract/a-canadian-multi-center-retrospective-non-interventional-study-of-clinical-outcomes-from-early-use-of-n9-gp-compared-with-previous-treatment-in-patients-with-hemophilia-b-in-a-real-world-setting/>. Accessed July 21, 2020.
4. de Repentigny K, Hinds M, Grabell J, Keepanasseril A, Iorio A, Rydz N, Jackson S, Robinson S, Sun L, Belletrutti M, James P. The CHiC Study: The Canadian Hemophilia Carriers Study – Preliminary Results [abstract]. *Res Pract Thromb Haemost*. 2020; 4 (Suppl 1). <https://abstracts.isth.org/abstract/the-chic-study-the-canadian-hemophilia-carriers-study-preliminary-results/>. Accessed July 21, 2020.
5. Konkle B, Coffin D, Naccache M, Cary C, George LA, Iorio A, O'Mahony B, Pipe SW, Skinner MW, Watson C, Peyvandi F, Mahlangu JN, Pierce GF. The World Federation of Hemophilia Gene Therapy Registry [abstract]. *Res Pract Thromb Haemost*. 2020; 4 (Suppl 1). <https://abstracts.isth.org/abstract/the-world-federation-of-hemophilia-gene-therapy-registry/>. Accessed July 21, 2020.
6. Germini F, O'Callaghan S, Chai-Adisaksopha C, Curtis R, Frick N, Nichol M, Noone D, O'Mahony B, Page D, Stonebraker J, Skinner M, Iorio A, PROBE investigators . Association Between Aging and Health Status in Persons Leaving with Hemophilia and Controls Without a Bleeding Disorder – Insights from the PROBE Study [abstract]. *Res Pract Thromb Haemost*. 2020; 4 (Suppl 1). <https://abstracts.isth.org/abstract/association-between-aging-and-health-status-in-persons-leaving-with-hemophilia-and-controls-without-a-bleeding-disorder-insights-from-the-probe-study/>. Accessed July 21, 2020.
7. Chai-Adisaksopha C, Curtis R, Frick N, Nichol M, Noone D, Germini F, O'Mahony B, Page D, Stonebraker J, Skinner M, Iorio A, PROBE . Non-Sever Hemophilia Is Not Benign? – Insights from the PROBE Study [abstract]. *Res Pract Thromb Haemost*. 2020; 4 (Suppl 1). <https://abstracts.isth.org/abstract/non-sever-hemophilia-is-not-benign-insights-from-the-probe-study/>. Accessed July 21, 2020.

8. Alfonso Iorio, Suzanne Holzhauser, Christoph Bidlingmaier, Carmen Escuriola-Ettingshausen, Susan Halimeh, Gili Kenet, Brigitte Pautard, Ulrike Nowak-Göttl. Predictive model to assess the risk of inhibitor development in children with severe and moderate hemophilia A - Results of a multicenter cohort study. 4th Annual Congress of the European Association for Haemophilia and Allied Disorders. Geneva 2-4 February 2011.
9. Alfonso Iorio, and Ulrike Nowak-Göttl on behalf of the EAHAD ad hoc working party. Predictors of inhibitor development in Hemophilia A previously untreated patients: the role of factor concentrate type. An individual patient data meta-analysis. 4th Annual Congress of the European Association for Haemophilia and Allied Disorders. Geneva 2-4 February 2011.
10. U Nowak-Göttl, G Kenet, M Bonduel, A Chan, N Goldenberg, S Holzhauser, A Iorio, J Journeykake, R Junker, C Male, P Masicotte, P Monagle, H Van Ommen, L Raffini, P Simioni, G Young. Impact of Persistent Antiphospholipid antibodies on symptomatic thromboembolism in children: A systematic review & meta-analysis (observational studies). XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (O-WE-032).
11. A Federici, P Bucciarelli, G Castaman, E Olievecchio, A Iorio, P Mannucci. Heterogeneity of the clinical, laboratory and molecular markers of VWD Type 3: Results from the retrospective/prospective studies on 122/52 Italian patients. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-461).
12. A Iorio, A Forsyth, F Cassis, F Querol. Psychological Aspects of Living with Haemophilia: The HERO project and narrative review of the published literature. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-493).
13. M Morfini, A Iorio, M Gabriella Mazzucconi, S Cinotti, E Zanon, E Paladino, E Marchesini, C Santoro. Bioequivalence of a B-Domain deleted and plasma derived FVIII concentrates. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-515).
14. Alonso-Coello P, Neumann I, Carrasco-Labra A, Brignardello-Petersen R, Irfan A, Solà I, Dahm P, Glujovsky D, Johnston B, Martinez L, Ramirez-Morera A, Sun X, Vandvik PO, Akl E, Tikkinen KA, Iorio A, Santesso N, Brozek J, Schünemann H, Guyatt. Risk difference estimation and reporting in systematic reviews. Cochrane Colloquium 2011 Madrid, Spain (19-22 October).
15. Tosetto A, Iorio, A, Marcucci M, Baglin T, Cushman M, Sabine E, Palareti G, Poli D, Tait CR, Douketis, JD. Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score. Oral Presentation, Session 322. 53rd ASH Annual Meeting and Exposition. San Diego, California. December 10-13, 2011.
16. Matino D, Iorio A, Gargaro M, Tagariello G, Luciani M, Di Minno G, Coppola A, Di Gennaro L, Puccetti P, Fallarino F. Indoleamine 2,3-Dioxygenase and Peripheral Tolerance to Exogenous Factor XIII: A Multi-Centre Pilot Study. Oral Presentation, Session 322. 53rd ASH Annual Meeting and Exposition. San Diego, California. December 10-13, 2011.
17. A Iorio, S Halimeh, C Bidlingmaier, C Escuriola Ettingshausen, A Gringeri, S Holzhauser, R Knöfler, W Kreuz, K Kurnik, D Manner, E Santagostino, PM Mannucci, U Nowak-Göttl. Effect of plasma-derived or recombinant factor VIII on inhibitor development. A systematic review. III EAHAD meeting, Edimburg February 3-5, 2010.

18. A Iorio, G Fabbriani, M Marcucci, M Brozzetti, M Luciani, P Filippini. Bone mineral density in hemophilia patients. A meta-analysis. III EAHAD meeting, Edinburgh February 3-5, 2010.
19. Iaboni S, Filippucci E, Ferrante F, Grilli P, Vecchioli M, Agnelli G, Iorio A. Anticoagulation management by point of care devices and computer monitoring by general practitioners. XX SISET National Meeting, Florence, September 25-28, 2008 C076.
20. Marchesini E, Ferrante F, Filippucci E, Iaboni S, Agnelli G, Iorio A. Antiviral treatment for chronic hepatitis in patients HIV-infected. XX SISET National Meeting, Florence, September 25-28, 2008 P177.
21. Basileo M, Iorio A, Marchesini E, Iaboni S, Palazzesi GP, Marchesi M, Esposito A, Pellegrini L, Rocchetti L, Agnelli G, Silvani CM. Clinical audit of the use of fresh frozen plasma in umbria: study design and results of the pilot phase. XX SISET National Meeting, Florence, September 25-28, 2008 P182.
22. Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Alatri A, Guazzaloca G, Palareti G for the PROLONG Investigators (on behalf of FCSA, Italian Federation of Anticoagulation Clinics). D-dimer to determine duration of anticoagulation after a first episode of idiopathic venous thromboembolism: extended follow-up of the prolong study. XX SISET National Meeting, Florence, September 25-28, 2008 C066.
23. Ferrante F, Camilloni B, Iorio AM, Tagariello G, Agnelli G, Iorio A. Inhibitor development in mild Haemophilia A: could influenza vaccination have been the trigger? XX SISET National Meeting, Florence, September 25-28, 2008 P196.
24. Ferrante F, Carloni M, Marchesini E, Dragani A, Olivovichio E, Iuliani O, Agnelli G, Iorio A. Management of patients with hemophilia in an inter-regional network in central Italy. XX SISET National Meeting, Florence, September 25-28, 2008 P193.
25. Ghirarduzzi A, Landini F, Pengo V, Corradini S, Iorio A, Prandoni P. New onset of cancer and recurrent venous thromboembolism after discontinuing anticoagulation in patients with venous thromboembolic event. A prospective cohort study in 1,919 patients. XX SISET National Meeting, Florence, September 25-28, 2008 C053.
26. Santoro C, Iorio A, Ferrante F, Marchesini E, Pignoloni P, Rago A, Biondo F, Agnelli G, Mazzucconi M. Pharmacokinetics of the reformulated B-domain deleted recombinant factor VIII concentrate using chromogenic and one-stage clotting assays with pooled normal plasma and refacto laboratory standard. XX SISET National Meeting, Florence, September 25-28, 2008 P190.
27. Filippucci E, Iaboni S, Ferrante F, Paccamiccio E, Vecchioli M, Agnelli G, Iorio A. Prospective evaluation of the clinical quality of oral anticoagulant treatment in a primary care computer assisted management model. XX SISET National Meeting, Florence, September 25-28, 2008 C077.
28. Ferrante F, Iaboni S, Filippucci E, Marchesini E, Vecchioli M, Agnelli G, Iorio A. Quality assurance scheme based on Levey Jennings analysis and Westgard rules application for POC-INR monitoring. XX SISET National Meeting, Florence, September 25-28, 2008 P124.
29. Iorio A, Marchesini E, Falcou A, Caso V, Pastorello M, Tiscione V, Ballarino P, Altomonte F, Baldi G, Agnelli G, Toni D. Randomised, open, prospective, multicenter pilot study to evaluate the efficacy and safety of activated recombinant factor VIIa (NovoSeven) in acute intracerebral haemorrhage in patients treated with oral anticoagulant or antiplatelet agents. XX SISET National Meeting, Florence, September 25-28, 2008 P174.

30. Iorio A, Ferrante F, Pizzinelli S on behalf of the Italian ad hoc study group. Replacement therapy with recombinant fix. Multicentric evaluation of current dosing practice in Italy. XX Siset National Meeting, Florence, September 25-28, 2008 P192.
31. Filippucci E, Vedovati MC, Iorio A, Agnelli G. Safety of R-Hirudin use for heparin-induced thrombocytopenia treatment in a cerebral vein thrombosis patient: a case report. XX Siset National Meeting, Florence, September 25-28, 2008 P153.
32. Basileo M, Iorio A, Ferrante F, Marchesini E, Materazzi M, Marchesi M, Esposito A, Pellegrini L, Rocchetti L, Agnelli G, Silvani CM. The good use of plasma. A critical analysis of five international guidelines. XX Siset National Meeting, Florence, September 25-28, 2008 P178.
33. Iorio A, Barillari G, Gandini G, Molinari C, Rocino A, Santagostino E, Tagariello G, Targhetta R. The haemophilia registry of the Italian association of haemophilia centres. XX Siset National Meeting, Florence, September 25-28, 2008 C102.
34. Coppola A, Daniele F, Rocino A, Targhetta R, Santoro R, Giuffrida A, Zanon E, Iorio A, Mancuso G, Santagostino E for the Italian Association of Haemophilia Centres (AICE) PROFIT Study Group. The Italian registry of immune tolerance induction in haemophilia a with inhibitors: 2-year update (prognostic factors in immune tolerance, the Profit Study). XX Siset National Meeting, Florence, September 25-28, 2008 C100.
35. Massi Benedetti M, Brunetti P, Iorio A, Ferolla P, Stabile A, Akwe J, Celleno R, Canonico V, Timi A. 2003 Alterazione della fibrinolisi durante chetoacidosi diabetica nel corso di sospensione di terapia insulinica infusionale continua sottocutanea (CSII) in diabetici di tipo 1. XIV Congresso Nazionale, Catania (Italia).
36. Ghirarduzzi A, Iorio A, D'Inca M, Silingardi M, Morini L, Salvarani C, Cerioli G, Iori I. Sindrome da anticorpi fosfolipidi. Descrizione di un caso clinico con trombosi atriale dx e revisione della casistica di Reggio Emilia. Atti del 101° Congresso Nazionale della Società Italiana di Medicina Interna, Torino, 18-22 novembre 2000, 431, abs 310.
37. M Silingardi, A Ghirarduzzi, C Salvarani, G Rinaldi, A Iorio, D Galimberti, M Brini, I Iori. Morbo di Behcet: sindrome "catastrofica" vasculitica associata a mutazione 20210A della protrombina. Atti del XCIX Congresso Nazionale della Società Italiana di Medicina Interna. Bari, 10-14 novembre 1998.
38. D Guidetti, E Bellesia, G Rinaldi, A Iorio. Ischemic stroke in young patients: hemocoagulative and molecular biology study. Atti dell'International Workshop "Stroke in the young". Genova, 11-12 dicembre 1998.
39. M Berrettini, A. Iorio et al. The role of natural anticoagulant systems in the bleeding tendency of patients with hemophilia. Hemophilia 1998; vol:pag (Atti del XXIII International Congress of the World Federation of Hemophilia).
40. M Silingardi, M D'Inca, M Ghirarduzzi, A Iorio, G Rinaldi, M Brini, I Iori. Positività per anticorpi antifosfolipidi (aPL) e prevalenza della sindrome da anticorpi antifosfolipidi (APS) primaria in soggetti con piastrinopenia, aborti ripetuti, trombosi venose o arteriose: analisi di 36 casi. Atti del 7° Convegno Nawioanle della FCSA, Bologna, 20-21 febbraio 1997.
41. Ghirarduzzi, M D'Inca, M Silingardi F Mazzali, A Iorio, G Rinaldi, I Iori. Sindrome da anticorpi antifosfolipidi e autoanticorpi anti fattore VIII in corso di leucemia linfatica cronica. Atti del XCVIII Congresso Nazionale della Società italiana di Medicina Interna. Roma, 27-31 ottobre 1997.

42. Alatri, A. Iorio, F Gianese, G Agnelli. Lo "spiazzamento" dell'eparina non frazionata dal legame non specifico con le proteine plasmatiche determina un incremento del suo effetto antitrombotico. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996.
43. Iorio A, Hauert J, Agnelli G, Parise P. Streptochinasi ed rt-P attivano le piastrine con meccanismi diversi: implicazioni sull'incidenza di retrombosi dopo terapia trombolitica nell'infarto del miocardio. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A35.
44. Iorio A, Agnelli G, Alatri A, Melelli P, Boschetti E, Nenci GG. Cinetica dell'attività anti-IIa della nadroparina in volontari sani. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A117.
45. Iorio A, Renga C, Leone M, Melelli P, Parise P and Agnelli G per il gruppo BAPE. Effetti sul sistema emostatico di due schemi terapeutici con rt-PA in pazienti con embolia polmonare. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A316.
46. Renga C, Agnelli G, Iorio A, Nenci GG, Young E, Hirsh J. Legame non specifico alle proteine plasmatiche dell'eparina non frazionata e delle eparine a basso peso molecolare dopo somministrazione in volontari sani. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A118.
47. Agnelli G, Renga C, Iorio A, Melelli P, Leone M, Lormeau JC. Correlazione tra la lunghezza delle catene saccaridiche e l'attività anti-IIa di frazioni epariniche valutata con il plasma thrombin neutralization assay. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A339.
48. Leone M, Melelli P, Renga C, Iorio A, Nenci GG, Agnelli G. Inibizione della trombina libera e legata alla fibrina: confronto tra eparina e LU 58463, un inibitore puro della trombina. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A340.
49. Renga C, Nucciarelli F, Leone M, Iorio A, Agnelli G. Effetti del dermatan solfato sul tempo di tromboplastina parziale attivato determinato con cinque diversi reagenti. Atti del XIII Congresso Società Italiana Studio Emostasi e Trombosi, Lanciano, 26-30 giugno 1994, A342.
50. S Buratta, A Iorio, S Porcellati, V Andreoli, R Mozzi. Effect of heparin on phosphatidylserine synthesis in rat cerebral cortex and porcine platelets. Proceedings of the 35th International Conference on the Biochemistry of Lipids. IV, P24.
51. Ascani, A. Iorio, AM Stabile, G. Agnelli. Sospensione della terapia anticoagulante orale in pazienti con trombosi con trombosi venosa profonda: effetti di una bassa dose fissa di warfarin sui parametri emocoagulativi. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 98.
52. MR Taliani, A. Iorio, F Gianese, GG Nenci, G. Agnelli. Impiego compassionevole del dermatan solfato in pazienti con controindicazioni all'impiego di eparina. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 1996, 98.
53. A Iorio, F Querol, A Forsyth, F Cassis. HERO, An international initiative exploring unmet psychosocial needs in haemophilia: characteristics of a quantitative survey targeting 1200 subjects in 12 countries. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-491).

54. A Iorio, F Cassis, F Querol, A Forsyth. HERO – An International initiative exploring unmet psychosocial needs in haemophilia: results from a qualitative survey targeting 150 subjects in 7 countries. XXIII Congress – The International Society on Thrombosis and Haemostasis. The 57th Annual Meeting of the Scientific and Standardization Committee of the ISTH. Osaka, Japan. July 23-29, 2011. (P-WE-492).
55. Iorio, S Ricotta, P. Parise, G Agnelli. Bassa incidenza del tromboembolismo venoso sintomatico in pazienti sottoposti ad intervento di chirurgia ortopedica con venografia negativa alla dimissione. Atti del XIV Congresso Società Italiana Studio Emostasi e Trombosi, Bergamo, 7-10 luglio 199.
56. Mozzi, V. Andreoli, A. Iorio, F. Pierini. Phosphatidylserine (PS) synthesis by base exchange is inhibited by GTP and activated by heparin in rat brain membranes. Abstract at the 2nd International Union of Biochemistry and Molecular Biology Conference: Biochemistry of Cell.

UNPUBLISHED DOCUMENTS

1. Iorio A, E Olioecchio. Pagine pubbliche del Registro Nazionale delle Coagulopatie Congenite. <http://www.aiceonline.it/PublicPages.htm>.
2. Cartabellotta A, Iorio A. Metodologia di produzione delle LG Siset. <http://www.siset.org/lineeguida/metodologia.pdf>.
3. Iorio A, Bucciarelli P, Coccheri S, De Caterina R, DI Pasquale G, Marino P, Pengo V, Prisco D, Santini M. Profilassi antitrombotica nel paziente con fibrillazione o flutter atriale sottoposto a cardioversione. <http://www.siset.org/lineeguida/LG6.pdf>.
4. M Morfini, G Calizzani, HJ Hassan, A Iorio, C. Molinari, G Muleo, E Santagostino, AR Tagliaferri. Improve AICE. <http://www.improveaice.it>.

PRESENTATIONS AT MEETINGS

Invited Presentations

1. The impact of available PK on management of hemophilia. Annual Saudi Hematology Congress 2021 (virtual) March 4-10, 2021.
2. Key considerations: Advances in gene therapy for hemophilia. ASH 62nd Annual Meeting and Exposition (virtual). December 2-11, 2020.
3. Report on the Annual Global Survey – 20 years on and more informative. 13th Annual Congress of the European Association for Hemophilia and Allied Disorders. The Hague, Netherland, February 5-7, 2020.
4. 19th Australian Conference on haemophilia, VWD & rare bleeding disorders. New Therapies for haemophilia: Can we achieve new goals? Sydney, Australia, 10-12 October 2019.
5. 19th Australian Conference on haemophilia, VWD & rare bleeding disorders. Patient reported outcomes to improve the value of clinical trials in haemophilia (PROBE). Sydney, Australia, 10-12 October 2019.
6. 19th Australian Conference on haemophilia, VWD & rare bleeding disorders. Optimising patient care through PK Analysis (WAPPS). Sydney, Australia, 10-12 October 2019.

7. 10th BIC International Conference. How to optimize the use of extended half-life products (PK Analysis). Genoa, Italy, September 6-8, 2019.
8. ISTH 2019 XXVII Congress. Improving outcomes in hemophilia A. July 9, 2019, Melbourne, Australia.
9. ISTH 2019 XXVII Congress. Exploring Methods to Predict an Individual's Pharmacokinetic Profile when Switching between Factor Concentrates in Hemophilia A. July 8, 2019, Melbourne, Australia.
10. Patient with a hemostatic defect: from symptoms to diagnosis through a rational use of coagulation laboratory tests. 5th McMaster International Review Course in Internal Medicine (MIRCIM) May 9, 2019. Krakow, Poland.
11. Getting personal: incorporating prognostic evidence in clinical decision-making. 5th McMaster International Review Course in Internal Medicine (MIRCIM) May 9, 2019. Krakow, Poland.
12. WAPPS-Hemo PopPK for haemophilia made easy March 14, 2019 – Webinar, Hamilton, Ontario, Canada.
13. Hemophilia pharmacokinetics and its importance on prophylaxis. January 12, 2019. Beijing, China.
14. The application of pharmacokinetics in hemophilia treatment and clinical research. January 13, 2019. Beijing, China.
15. Using pharmacokinetics to individualize hemophilia therapy. American Society of Hematology. December 2-4, 2018. San Diego, California. United States.
16. The application of Pharmacokinetics in hemophilia treatment and clinical research. Beijing, China. January 13, 2019.
17. Hemophilia pharmacokinetics and its importance on prophylaxis. Beijing, China. January 12, 2019.
18. Individualized prophylaxis: The WAPPS-Hemo project. Taiwan Hemophilia Round Table Discussion, November 3-4, 2018, Taipei, Taiwan, Province of China.
19. Current and future considerations for the management of hemophilia. Taiwan Hemophilia Round Table Discussion, November 3-4, 2018, Taipei, Taiwan, Province of China.
20. Considerations for product choice: immunogenicity of clotting factor concentrates. Taiwan Hemophilia Round Table Discussion, November 3-4, 2018, Taipei, Taiwan, Province of China.
21. Individualizing prophylaxis with rIX-FP and rVIII-single chain: the WAPPS-Hemo project. 64th Annual ISTH Meeting, Dublin, Ireland, July 18-21, 2018.
22. From molecule design to monitoring: The science behind extended half-life rFVIII product. Investigating the impact of EHL technologies. 64th Annual ISTH Meeting, Dublin, Ireland, July 18-21, 2018.
23. Empowering people with hemophilia: from HERO insights to action. WFH 2018 World Congress, Glasgow, Scotland, May 20-24, 2018.
24. A patient who bruises easily: how to investigate. MIRCIM – 4th McMaster International Review Course in Internal Medicine, Krakow, Poland. May 9-11, 2018.
25. Assessing Innovation as Part of Stakeholder Communications – Learning from the CorHEM Project. 2018 Global Haemophilia Advocacy Leadership Summit, Budapest, Hungary, January 22, 2018.

26. New Frontiers in Coagulation Medicine: PK/Inhibitors: How to Interpret Hemophilia. Scientific and Academic Coagulation Consortium, Old Windsor, United Kingdom. January 10, 11, 2018.
27. Using Pharmacokinetics to Individualize Hemophilia Therapy. ASH – 59th Annual Meeting & Exposition, Atlanta, Georgia. December 9-12, 2017.
28. Persistent Post-Surgical Pain - A Model for the Study of Chronic Pain. The University Club of McMaster. November 11, 2017.
29. Using Pharmacokinetic Data to Individualize Therapy - Education Program - The Changing Landscape of Hemophilia Therapy. 59th ASH Annual Meeting. Atlanta, Georgia. December 9-12, 2017.
30. What is Achievable Trough with Current Products and at What Cost? ISTH 2017 Congress, Berlin, Germany. July 8-13, 2017.
31. Working Group on Pharmacokinetics and Population Pharmacokinetics. ISTH 2017 Congress, Berlin, Germany. July 8-13, 2017.
32. CBDR Report. Canadian Hemophilia Society – Rendez-Vous 2017, Toronto, Canada. May 25-28, 2017.
33. The NHF-McMaster Guidelines on Models of Care in Hemophilia. Canadian Hemophilia Society – Rendez-Vous 2017, Toronto, Canada. May 25-28, 2017.
34. Using Evidence for Hematology Laboratory Practice. XXXth International Symposium on Technical Innovations in Laboratory Hematology (Webinar). May 4-6, 2017.
35. How important is PK? 10th Annual Congress of EAHAD, Paris, France. February 1-3, 2017.
36. Catastrophic Antiphospholipid Syndrome (CAPS) and Models of Care for Hemophilia Clinical Practice Guidelines: Lessons Learnt. RARE Best Practice Conference 2016. Rome, Italy. November 24, 2016.
37. Connecting Pharmacokinetics and Phenotypes to Tailored Hemophilia Treatment. Bayer Hematology Conference 2016. Madrid, Spain. (Conference Chair). November 3-5, 2016.
38. GRADE for Overall Prognosis. 24th Cochrane Colloquium, Seoul, South Korea. October 23-27, 2016.
39. What is good quality data? World Federation of Hemophilia 2016 World Congress, Orlando, Florida. July 24-28, 2016.
40. Managing inhibitor Risk in Both PUPS and PTPs. World Federation of Hemophilia 2016 World Congress, Orlando, Florida. July 24-28, 2016.
41. Current Adverse Events Reporting in Hemophilia. World Federation of Hemophilia 2016 World Congress, Orlando, Florida. July 24-28, 2016.
42. Evidence-Based Guidance on Comprehensive Care for Hemophilia. World Federation of Hemophilia 2016 World Congress, Orlando, Florida. July 24-28, 2016.
43. Working Group on Pharmacokinetics and Population Pharmacokinetics of Factor Concentrates. The 62nd Annual Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis. Montpellier, France. May 25-28, 2016.

44. Working Group on Reporting Guidelines on Inhibitor Cases in Previously Treated Hemophilia Patients. The 62nd Annual Scientific and Standardization Committee Meeting of the International Society on Thrombosis and Haemostasis. Montpellier, France. May 25-28, 2016.
45. Evidence-Based Practice. 2016 Bi-Regional Annual Conference, Mountain and Western States Regional Hemophilia Treatment Centers. Scottsdale, Arizona. April 24-25, 2016.
46. EB Management of hemophilia: Building the blocks for comparative EBME effectiveness in Canada and beyond: CBDR, CHESS, WAPPS, and Probe. Transfusion Medicine Resident Education Seminar (Webinar). April 19, 2016.
47. Population-based PK in haemophilia A. Frühjahrsforum Hämophilie 2016. Bonn, Germany. April 15-16, 2016.
48. Evidence Based Hemophilia Care - Current Status and Where to Go (keynote speaker). EAHAD 2016. 9th Annual Congress of the European Association for Hemophilia and Allied Disorders. Malmö, Sweden. February 1-5, 2016.
49. Balancing risk factors for inhibitor development in clinical practice: what meta-analysis means (keynote speaker). Hemophilia Symposium. Hamburg, Germany. Nov 13, 2015.
50. Critical Evaluation of New Therapies for hemophilia A: An Evidenced Based Approach for Nurses. CANHC Research and Best Practice Series Hamilton, Ontario, Canada. Nov 6, 2015.
51. How to measure progress in the provision of care for hemophilia. The 9th WFH Global Forum on Research and Treatment Products for Bleeding Disorders. Montreal, Quebec, Canada. Oct 22, 2015.
52. GRADE for prognostic evidence. Special Session #10: GRADE: the past 15 and next...years. Cochrane Colloquium 2015 Vienna, Austria.
53. Risk factors for inhibitor development: any clinical role? (keynote speaker) Hemophilia Federation of Australia, XVII meeting, Gold Coast, Australia. Oct 1, 2015.
54. Building an opportunity for data-driven clinical reflections at HHS: exploring the usage of IV iron supplementation. Sep 4, 2015.
55. The EUHASS/CHESS approach to adverse event surveillance. New methods to predict the immunogenicity of therapeutic coagulation proteins. Public workshop. National Institutes of Health Bethesda, Maryland, United States. Sep 17, 2015.
56. Clinical Practice Guidelines: Care Models for the Management of Hemophilia. National Hemophilia Foundation Annual Meeting. Dallas, Texas, United States. Aug 15, 2015.
57. A Canadian registry for acquired hemophilia: a starter for a critical discussion. AHDCDC Annual Meeting Halifax, Ontario, Canada. Jun 15, 2015.
58. WAPPS project - (Web Accessible Population Pharmacokinetics Service) SSC of the ISTH 2015 Congress Toronto, Ontario, Canada.
59. Inhibitor reporting standardization in previously treated patients. SSC of the ISTH 2015 Congress Toronto, Ontario, Canada.
60. Launch of the Canadian Bleeding Disorder Registry. Canadian Hemophilia Society (CHS). Rendez-vous 2015. Halifax, Ontario, Canada.

61. Study design: A critical aspect of research. XIV International Musculoskeletal Meeting. World Federation of Hemophilia. Belfast, Ireland. May 7, 2015.
62. Using Evidence for Hematology Laboratory Practice (keynote speaker). XXVIIIth International Symposium on Technological Innovations in Laboratory Hematology. Chicago, Ontario, Canada. May 6, 2015.
63. Implementation of a population pharmacokinetic approach to individual PK estimations to tailor treatment in hemophilia patients. Internal seminar given at the FDA (keynote speaker). Washington, District of Columbia, United States. Apr 27, 2015.
64. Iorio, A. HERO - a multi-stakeholder approach to better hemophilia care (keynote speaker). 10th Annual National Hemophilia Congress. Novo Nordisk Satellite Symposium. Izmir, Turkey. Apr 15, 2015.
65. Balancing risk factors for inhibitor development in clinical practice. Hemophilia Research Study Update. Berlin, Germany. Mar 12, 2015.
66. Critical appraisal of inhibitors in PUP data. EHC round table on factor concentrate-related inhibitor risk in hemophilia A. The European Community Parliament. Brussels, Belgium. Mar 2, 2015.
67. Advances in Technology: How can we assess the potential, and then confirm the reality? (Keynote speaker) 8th Annual Congress of European Association of Haemophilia and Allied Disorders. Helsinki, Finland. Feb 11, 2015.
68. Inhibitor developments according to FVIII concentrate in PUPs: how to interpret current evidence? (Keynote speaker) 8th Annual Congress of European Association of Haemophilia and Allied Disorders. Helsinki, Finland. Feb 11, 2015.
69. Population Pharmacokinetics for busy clinicians and active patients: how to get the most out of it? 8th Annual Congress of the European Association of Haemophilia and Allied Disorders. Helsinki, Finland. Feb 11, 2015.
70. DDAVP: Indications and use. CANHC Meeting. Toronto, Ontario, Canada. Jan 11, 2015.
71. WAPPS - Web-based Application for a Population Pharmacokinetic Service (keynote speaker). Convegno Triennale AICE. Florence, Italy. Nov 4, 2014.
72. Comparison studies on safety and efficacy of different generations of recombinant products (keynote speaker). Iranian Ministry of Health. Tehran, Iran, Islamic Republic Of. Oct 23, 2014.
73. Guidelines and Priorities for safe switching between plasma derived and recombinant Factor VIII (keynote speaker). Iranian Ministry of Health. Tehran, Iran, Islamic Republic Of. Oct 23, 2014.
74. Discussion of the impact of new technologies and research on care. Rendez-vous, jointly organized by the Canadian Hemophilia Society and the Association of Hemophilia Directors of Canada. Winnipeg, Manitoba, Canada. Jun 29, 2014.
75. IRS-PTPs: Inhibitor reporting standardization in previously treated patients. International Society on Thrombosis and Haemostasis. Milwaukee, Wisconsin, United States. Jun 23, 2014.
76. Linkage at McMaster Hamilton Health Sciences of ACCESSSS, Clinical Clustering Information, OSCAR and the ad-hoc developed TRUST-XT database. Hamilton Health Sciences, Council of Chiefs Hamilton, Ontario, Canada. Jun 10, 2014.

77. An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness: 10 years of clinical experience. WHF 2014 World Congress. Melbourne, Australia.
78. ADVATE [Antihemophilic Factor [Recombinant], Plasma / Albumin-Free Method] Safety and effectiveness: 10 years of clinical experience. WHF 2014 World Congress. Melbourne, Australia.
79. Real-World Prophylaxis Experience: Perspectives from Clinical Practice. WHF 2014 World Congress. Melbourne, Australia.
80. Assessment of long term safety and efficacy of clotting factor concentrates (keynote speaker). WHF 2014 World Congress. Melbourne, Australia.
81. Non-adherence and its impact on treatment efficacy. WHF 2014 World Congress. Melbourne, Australia.
82. Advate PASS meta-analysis (keynote speaker) XXIV HRSU Washington, District of Columbia, United States. Mar 13, 2014.
83. Does product type influence the development on inhibitor in PTPs and PUPs? Plenary Lecture at the 7th Annual Congress of the European Association for Haemophilia and Allied Disorders (keynote speaker). Brussels, Belgium. Feb 26, 2014.
84. B-domain - is this an issue? (keynote speaker) London 2014 Goring Workshop London, United Kingdom.
85. Iorio, A. Switching products and risk of inhibitors in hemophilia: A real world examination. Hot Topics in Epidemiology of Inhibitor Development in people with hemophilia (Symposium chair and keynote speaker). An ASH Ancillary Meeting. New Orleans, Louisiana, United States. Dec 7, 2013.
86. 10 good reasons to go Bayesian (beginning from rare disorders) (keynote speaker). Hemophilia Clinic Rounds Los Angeles, United States. Nov 20, 2013.
87. Evidence Based Medicine and rare diseases: a few lessons learned from clinical research in hemophilia (keynote speaker). Hematology Grand Rounds. University of Southern California (USC). Los Angeles, United States. Nov 19, 2013.
88. Moving toward evidence based hemophilia care in the surgical and not surgical settings (keynote speaker). Hematology Grand Rounds. University of Southern California (USC). Los Angeles, United States. Nov 21, 2013.
89. Iorio, A. Prevention of recurrent VTE: optimal duration or personalized treatment? (Keynote speaker). The 7th regional meeting of the Lebanese Society of Hematology and Blood Transfusion. Beirut, Lebanon. Oct 3, 2013.
90. Iorio, A. Building evidence based optimal treatment in hemophilia: where are we at? An epidemiologic perspective (keynote speaker). The 7th regional meeting of the Lebanese Society of Hematology and Blood Transfusion. Beirut, Lebanon. Oct 3, 2013.
91. Iorio, A. Improving the efficiency of updating Cochrane Reviews: a joint pilot project of the McMaster PLUS database team and the Musculoskeletal Review Group. 21st Cochrane Colloquium. Quebec City, Quebec, Canada. Sep 18, 2013.
92. Registry based medicine (REM)*: dream or reality? At the meeting: History of Comprehensive Hemophilia Care in Canada. A tribute to the St. Michael's Hospital Program on its 30th Anniversary (keynote speaker). Toronto, Ontario, Canada. Sep 23, 2013.

93. The GRADE approach to evidence appraisal. International Summer School Clinical Practice Guidelines on Rare Diseases. Rome, Italy. Jul 8, 2013.
94. Recommendations using the GRADE approach. International Summer Clinical Practice Guidelines on Rare Diseases. Rome, Italy. Jul 8, 2013.
95. Practical Approaches to Assessing Inhibitor development in clinical trials (keynote speaker). Pfizer Latin American Hemophilia Forum. Cartagena, Colombia. Jun 1, 2013.
96. Clinical cases of inhibitor assessment (keynote speaker). Pfizer Latin American Hemophilia Forum. Cartagena, Colombia. Jun 1, 2013.
97. Iorio, A. The value of meta-analysis in hemostasis thrombosis (keynote speaker). Hospital for Sick Children. Grand Rounds. Toronto, Ontario, Canada. Jun 13, 2013.
98. Iorio, A. Clinical cases in inhibitor assessment. Pfizer Latin America Hemophilia Forum (educational forum). Cartagena, Colombia. Jun 2, 2013.
99. Iorio, A. Practical approaches to assessing inhibitor development in clinical trials. Pfizer Latin America Hemophilia Forum (education forum). Cartagena, Colombia. Jun 2, 2013.
100. Improving Access to Expert Care (Further research on assessment of outcomes) (Chair and keynote speaker). HERO (Haemophilia Experiences, Research and Outcomes) Summit 2013. The Hague, Netherlands.
101. Iorio, A. and Van den Bom, J. Debate: To be resolved: 2nd generation rFL FVIII is more immunogenic than 3rd generation rFL FVIII (keynote speaker) Canadian Hemophilia Physician Update (CHPU). Vancouver, British Columbia, Canada. Jun 15, 2013.
102. Iorio, A. The use of ice in the management of acute joint bleeds. Canadian Hemophilia Society. Rendez-vous 2013. Winnipeg, Manitoba, Canada.
103. Practical approach to the management of inhibitor (keynote speaker). Satellite symposium at the Korean Society on Thrombosis and Hemostasis meeting. Seoul, Korea, Republic Of. May 10, 2013.
104. Practical approach to the management of inhibitor (keynote speaker). Satellite symposium at the Korean Society on Thrombosis and Hemostasis meeting. Daejeon, Korea, Republic Of. May 9, 2013.
105. Masterclass: Case studies in the management of inhibitor development in hemophilia (keynote speaker). AfME/EURIT Summit Istanbul, Turkey. May 12, 2013.
106. Plenary: Practical approaches to assessing inhibitor development - risk factors, clinical trials and management (keynote speaker). AfME/EURIT Summit Istanbul, Turkey. May 12, 2013.
107. The next 10 years of hemophilia care (keynote speaker). Rendez-Vous, jointly organized by the Canadian Hemophilia Society and the Association of Hemophilia Directors of Canada. Winnipeg, Manitoba, Canada. May 24, 2013.
108. Less frequent infusions or higher trough levels? Rendez-vous, jointly organized by the Canadian Hemophilia Society and the Association of Hemophilia Directors of Canada. Winnipeg, Manitoba, Canada. May 25, 2013.
109. The Future of Care. British Columbia Education Day (keynote speaker). Canadian Hemophilia Society. Vancouver, British Columbia, Canada. Apr 27, 2013.

110. Epidemiology lessons learned by study of hemophilia and its treatment (keynote speaker). The Centre for Blood Research Seminar Series. Vancouver, British Columbia, Canada. Apr 26, 2013.
111. Iorio, A. Epidemiology lessons learned by study of hemophilia and its treatment (keynote). The Centre for Blood Research. University of British Columbia. Vancouver, British Columbia, Canada. Apr 26, 2013.
112. Iorio, A. Comparing immunogenicity of factor concentrates through meta-analysis of published studies: strengths and limitations. 10th Annual National Hemophilia Congress. Novo Nordisk Satellite Symposium. Izmir, Turkey. Apr 15, 2013.
113. Iorio, A. Rate of Inhibitor development in patients treated with plasma derived or recombinant factor concentrates (keynote speaker). Pfizer satellite symposium. French Hematology Days. Buenos Aires, Argentina. Apr 14, 2013.
114. Iorio, A. Inhibitors in hemophilia. An evidence based approach (keynote speaker). Pfizer satellite symposium - French hematology days. Buenos Aires, Argentina. Apr 4, 2013.
115. Iorio, A. Insight and hope in hemophilia. HERO: An initiative for a wider understanding of psychosocial issues in hemophilia (keynote speaker). NovoNordisk South America Summit. Buenos Aires, Argentina. Apr 4, 2013.
116. Iorio, A. Rate of inhibitor development in patients treated with plasma derived or recombinant factor concentrates (keynote speaker). NovoNordisk South America Summit. Buenos Aires, Argentina. Apr 4, 2013.
117. Iorio, A. Prophylaxis: The Canadian experience. NovoNordisk South America Summit. Buenos Aires, Argentina. Apr 5, 2013.
118. Iorio, A. Recombinant vs. Plasma derived factors (keynote speaker). Pfizer satellite symposium of the Academia Nacional de Medicina. Buenos Aires, Argentina. Apr 18, 2013.
119. Iorio, A. Acquired Hemophilia: An elusive but important diagnosis for internists (keynote speaker). University of Calgary. Department of Medicine Rounds. Calgary, Alberta, Canada. Apr 18, 2013.
120. Iorio, A. Improving the retrieval and uptake of high quality clinical evidence from the published literature. American Medical Informatics Association Annual Meeting. San Francisco, California, United States. Mar 18, 2013.
121. Effects of switching factor VIII products. Therapy-related risk factors in inhibitor formation. Nijmegen, Netherlands. Mar 7, 2013.
122. Iorio, A. Approaches to assessment of inhibitor development in clinical trials. Global Summit: Managing Haemophilia for Life (keynote speaker). Windsor, United Kingdom. Nov 16, 2012.
123. Iorio, A. & Jimenez-Juste, V. Debate: The majority of inhibitors will resolve with routine low-dose prophylaxis (keynote speaker). Global Summit: Managing Hemophilia for Life. Windsor, United Kingdom. Nov 16, 2012.
124. Iorio, A. Physician's perspective on aging with a bleeding disorder. Hemophilia Ontario CWOR: Aging with a bleeding disorder. Hamilton, Ontario, Canada. Nov 3, 2012.
125. Iorio, A. Factor VII treatment of hemophilia - facting the development and treatment of inhibitors. 3rd Biotest European Haemophilia Forum. Naples, Italy. Oct 15, 2012.

126. Iorio, A. Risk factors for inhibitors: state of the art and epidemiological considerations (keynote speaker). Invited Lecture at the Meet the expert session. Auckland, New Zealand. Sep 27, 2012.
127. Iorio, A. HERO - a multi-stakeholder approach to better hemophilia care (keynote speaker). Novo Nordisk Satellite Symposium. XXX International Congress of the World Federation of Hemophilia. Paris, France. Jul 8, 2012.
128. Iorio, A. Peril and pitfalls in evaluating inhibitor data (keynote speaker). Biogen satellite symposium. XXX International Congress of the World Federation of Hemophilia. Paris, France. Jul 8, 2012.
129. Iorio, A & Aledort, L. Immunogenicity of rBDD FVIII and rFL FVIII: A debate (keynote speaker). Canadian Hemophilia Physician Update. Halifax, Nova Scotia, Canada. Jun 16, 2012.
130. Iorio A. The use of the clinical trial design in Hemophilia: methodological considerations. Hemophilia Centre, University of Perugia, Italy; Health Information Research Unit, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. Invited talk. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 18, page 8 Haemophilia (2012), 18 (Suppl. 1), 1–10. M. Marcucci, G. Kenet, S. Holzhauer, C. Bidlin, G. Maier, C. Escuriola Ettinghausen, A. Iorio, U. Nowak-Gottl. Concentrate type and dose in hemophilia A, Rome, Italy.
131. Update on The Italian Registry of Congenital Coagulopathies, at the XIV Convegno sui problemi clinici e sociali dell'emofilia 4. 6 novembre 2011 Firenze. Italy. 2011.
132. Current Evidence of Immunogenicity of Factor Products at the ASH satellite Symposium New Technologies in the Treatment of Hemophilia: Impact on Clinical Practice December 10, 2011 San Diego, California. California, United States. 2011.
133. Guida alla lettura di un trial clinico and Gli aspetti psico-sociali nell'emofilia at the meeting le coagulopatie congenite: come vivere una vita "normale". Perugia 23-24 Settembre 2011. Perugia, Italy.
134. Iorio, A. Is there still a role for Warfarin in low risk patients with Atrial Fibrillation? At the Preceptorship in cardiology hot issues organized by the Population Health Research Institute. Hamilton, Ontario, Canada. Apr 14, 2011.
135. "Il problema degli inibitori nell'emofilia: i dati nazionali e internazionali", at the Continuing Education Course: Affrontare I problemi psicologici dell'emofiliai", held in Naples on July the 2nd, 2010. Italy. 2010.
136. Chairman of the session on "Pulmonary Embolism" at the 21st International Thrombosis Congress of the Mediterranean League against Thromboembolic diseases, held in Milan on July 6-9, 2010. Italy. 2010.
137. "Evaluation of enhanced on-demand treatment in inhibitor patients", Symposium "Securing and maintain joint health in inhibitor patients" at the Hemophilia World Congress of the World Federation of Hemophilia, held in Buenos Aires, July 9-14 2010. Italy. 2010.
138. Chairman and teacher of the preceptorship course "Optimizing recombinant therapy in Hemophilia B in Japan" at the Hemophilia World Congress of the World Federation of Hemophilia, held in Buenos Aires, July 9-14 2010. Brazil. 2010.
139. How to become a better researcher: Tools to overcome the hurdles. At the NovoNordisk Global Hemophilia Network Meeting "Changing possibilities in Haemophilia" held in London on September 12-14 2010. London, United Kingdom. 2010.

140. Indicazioni CLiniche all'uso del fattore VII. Al Congresso 2010 della Federazione degli Aiuti e Direttori Ospedalieri Internisti, sezione triveneto, Riva del Garda, 7-9 ottobre 2010. Italy. 2010.
141. The Italian Registry of Congenital Coagulopathies, at the XXI Congress of the Italian Society for Thrombosis and Haemostasis, held in Bologna, October 27-30, 2010. Italy. 2010.
142. The Italian Registry of Congenital Coagulopathies, at the First Italian Course for Emerging Physicians in Hemophilia, held in Florance, November 2-5, 2010. Italy. 2010.
143. Chairman of the Educational Advisory Board about Hemophilia Treatment guidelines and opportunities, held in Beirut, Lebanon, on November 4 and 6 2010. 2010.
144. Optimizing therapy in hemophilia B. Interactive workshop at the Pfizer sponsored global summit "Managing Hemophilia for Life", held in Rome on November 26 to 28th, 2010. Italy. 2010.
145. Epidemiology of von Willebrand Disease: data from the AICE registry. Treatment of von Willebrand Disease: from DDAVP to purified factor VIII concentrates. Milan, October 14, 2009. 136: Update on the National Hemophilia Registry, at the AICE meeting, held in Milan on October 15, 2009. Italy.
146. The Sixty plus Prospective Hemophilia Registry and Assessment, at the AICE meeting held in Milan on March 18, 2009. Italy. 2009.
147. Chair of the opening session of the 16th Master Course in Vascular Medicine, University of Perugia, Perugia October 22 to 24, 2009. Italy. 2009.
148. Heparin monitoring: a patient centered view. Innovative solution for health care, held in Vibo Valentia on April 1, 2009. Italy. 2009.
149. International clinical trials are the best way to improve global haemophilia care: No.2nd Congress in Munich. European Association for Haemophilia and Allied Disorders. Thursday 26th February 2009. Germany.
150. NovoSeven® and rare bleeding disorders: laboratory assays, clinical aspects and registries. Factor VII deficiency, at the "NovoSeven Working Day, between experience and innovation, a likely future" held in Rome (Italy) on March 5 to 6, 2009. 2009.
151. Update on the National Hemophilia Registry, at the AICE meeting "Hemophilia treatment and related side effects in the third millennium, held in Milan on March 18, 2009. Italy. 2009.
152. Efficacy and safety results about Moroctocog alpha: studies 310-311. Refacto AF launching symposium, Lisbona, Portugal, April 24th, 2009. Portugal. 2009.
153. Management of bleeding emergencies in the adult patient. XIV National Meeting of the Italian Federation of Internal Medicine Directors, Cenobbio (Como), May 13-16 2009. Italy. 2009.
154. New antiemophilic factors: registrative studies. Symposium: A new generation of anti-hemophilic factors. Rome, June 19th 2009. Italy.
155. A metanalysis of the available cohort studies. At the SIPPET Symposium Boston – July, 14th 2009. Massachusetts, United States. 2009.
156. New Recombinant Derivatives of Factor VIII, Moroctocog alfa (AF-CC): Pharmacokinetics. At the Refacto AF launching symposium, Syros, Greece, September 13th, 2009. Greece. 2009.

157. Interactive review of six case Interactive Sessions: Bridging from Theory to Practice. Bayer-Schering-Plug European Hematology Meeting, Riga, Latvia, September 17-19, 2009. Italy. 2009.
158. Management of the adult hemophilic patient, at the training course "Management of congenital and acquired disorders", held in Florence on January 24 to 26, 2008. Italy. 2008.
159. Management of the hemophilic patient with inhibitor, at the training course "Management of congenital and acquired disorders", held in Florence on January 24 to 26, 2008. Italy. 2008.
160. Management of surgery in the haemophilic patient, at the training course "Management of congenital and acquired disorders", held in Florence on January 24 to 26, 2008. Italy. 2008.
161. Rare haemorrhagic disorders, at the training course "Management of congenital and acquired disorders", held in Florence on January 24 to 26, 2008. Italy. 2008.
162. Acquired hemophilia, at the training course "Management of congenital and acquired disorders", held in Florence on January 24 to 26, 2008. Italy. 2008.
163. Assessment of factor recovery and half-life, at the training course "Management of congenital and acquired disorders", held in Florence on January 24 to 26, 2008. Italy. 2008.
164. Clinical epidemiology about the clinical use of rFVIIa: evidences from registries and survey. XX National Congress of the SISET September 25 to 28, 2008. Italy. 2008.
165. The SISET guidelines, at the Meeting "News about prophylaxis and treatment of venous thromboembolism", held in Cremona on February 15, 2008. Italy. 2008.
166. Open issues in the management of VKA therapy, at the training course on venous thromboembolism organized by the Umbra School of General Medicine held in Bastia Umbra on February 23, 2008. Italy. 2008.
167. Moderazione della sessione la Malattia di Von Willebrand, nell'ambito del convegno "Malattie rare emorragiche e congenite: La profilassi, tenutosi a Verona il 28-29 febbraio 2008. Italy. 2008.
168. "I fattori di rischio nello sviluppo degli inibitori: i vaccini" nell'ambito del workshop "Dall'esperienza clinica alle raccomandazioni internazionali: 20 anni di terapia dell'emofilia A con concentrati ricombinanti", tenutosi a Roma il 14-15 marzo 2008. Italy. 2008.
169. Emorragia Cerebrale, nell'ambito del Corso di Aggiornamento "Il paziente emorragico e l'emorragia critica", tenutosi a Castelfranco Veneto il 3 aprile 2008. Italy. 2008.
170. Moderazione della sessione Bleeding disorders, nell'ambito dell'8th International Winter Meeting on Coagulation: "Basic, Laboratory and Clinical Aspects of Venous and arterial Thromboembolic diseases", tenutosi a Bormio dal 6 al 12 aprile 2008. Italy. 2008.
171. Update sul Registro nazionale dell'emofilia, nell'ambito del Convegno AICE "Il trattamento dell'emofilia e delle sue complicanze nel terzo millennio", tenutosi a Milano il 9 aprile 2008. Italy. 2008.
172. Indicazioni cliniche all'uso del fattore VII attivato, nell'ambito del Convegno "Aggiornamento in Emostasi e Trombosi" tenutosi ad Ancona il 18 aprile 2008. Italy. 2008.
173. Il fattore VII attivato nell'emorragia intracranica spontanea o traumatica del paziente in TAO: quali evidenze? Quali indicazioni?, nell'ambito del Congresso Regionale SIMEU Emilia Romagna "Urgenze trombotiche ed emorragiche in Medicina d'Urgenza, tenutosi a Ravenna il 14 maggio 2008. Italy. 2008.

174. Antivitamin K management: the future?, nell'ambito del 12° European Vascular Course, tenutosi ad Amsterdam dal 15 al 17 maggio 2008. Netherlands. 2008.
175. VKA antagonists treatment: a treatment tool to be better understood. When to use it? at the 25° National Meeting of the SIMG, held in Florence, Novembre 20 to 22, 2008. Italy. 2008.
176. "Bridging therapy" during oral anticoagulant therapy: Cons". XV Course on Vascular Medicine and Stroke, held in Perugia on October 16 to 18, 2008. Italy. 2008.
177. The Italian Registry of Hemophilia and related syndromes: a tool for health care planning of a rare disease at the XIII National Meeting of Clinical and Social Aspects of Hemophilia, held in Milan on October 14 to 16, 2008. Italy. 2008.
178. An emerging pathology: acquired inhibitor of coagulation and their laboratory workup, at the training course "Management of bleeding emergency", held in Rieti on November 18, 2008. Italy. 2008.
179. The Good use of Plasma: Guidelines, at the Symposium: "From Blood collection to pharmacoeconomy: a trip through hemophilia and hemorrhagic emergency" held in Castelfranco Veneto on November 21, 2008. Italy. 2008.
180. Decentralized management of VKA therapy, at the training course on oral anticoagulant therapy, held in Perugia on November 15, 22 and 29, 2008. Italy. 2008.
181. Telemedicine Systems: applications to monitoring of oral anticoagulant therapy and to self-testing, at the SIMeL training course "Quality, efficiency, clinical laboratory automation", held in Francavilla al Mare on May 31, 2007. Italy. 2007.
182. Management of ITI in the hemophilic patient with inhibitor: importance of the anamnestic response and of therapy duration, at the meeting "Scientific update on Coagulopathies, held in Pisa on June 30, 2007. Italy. 2007.
183. Long term treatment of venous thromboembolism, at the XIV post-doctoral course in Vascular Medicine, held in Perugia on September 13 to 15, 2007. Italy. 2007.
184. National Hemophilia Registry - Emocard – State of the Art, at the AIEC Meeting: Organization of Hemophilia Health Care, held in Bari on September 19, 2007. Italy. 2007.
185. Treatment of thromboembolic events in presence of heparin induced thrombocytopenia, at the training course on "Diagnosis, treatment and follow up venous thromboembolism. Results and perspectives of the Prolong studies, held in Bologna on January 15, 2007. Italy. 2007.
186. Clinical indication to factor VIIa use, at the National SISET course, held in Bari on September 20 to 21, 2007. Italy. 2007.
187. Oral anticoagulant therapy management. Role of decentralized systems in peripheral health care units, at the XXXIX National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology, held in Rimini on October 2 to 5, 2007. Italy. 2007.
188. Update of the analysis of the National Haemophilia Registry, at the I 2006 AICE meeting; held on March 30-31 2006, Florence. Italy. 2006.
189. Hormonal cancer therapy and thrombotic risk at the National Meeting Cancer and Thrombosis: up to date of medical knowledge, held on May 13th 2006, Piacenza. Italy. 2006.

190. "The methodology for the SISET guidelines program" at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan. Italy. 2006.
191. "Antithrombotic prophylaxis for patients with atrial fibrillation undergoing electrical cardioversion" at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan. Italy. 2006.
192. "Telemedicine applications for oral anticoagulants management: a health service based model" at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan. Italy. 2006.
193. "Intracerebral haemorrhage treatment in the patient on oral anticoagulants" at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISET) – held on September 14-17 2006, Milan. Italy. 2006.
194. "Iatrogenic causes of an ICH: OAT therapy" at the NovoSeven Working Day – Decennial Rome 27-29 September 2006. Italy. 2006.
195. "The Interregional EmoWeb Database for hemophilia patients: facilities for patients and physicians, at the I Meeting "The union of three regions for scientific research and health care promotion", held on September 30th, 2006, S, Benedetto del Tronto. Italy. 2006.
196. "Intracerebral Haemorrhage treatment" at the Meeting "Critical bleeding and bleeding deficiencies" held on October 13th, 2006 in Florence. Italy. 2006.
197. Oral anticoagulant treatment management: role for the general medical practitioner at the meeting "Prophylaxis and treatment of venous thromboembolism in general medicine" held on October 14, 2006 in Perugia. Italy. 2006.
198. Proposal of Intersociety guidelines about anticoagulant therapy in the Emergency Department, at the V National Meeting of the SIMEU/ACEP, held in Turin, November 9 to 11, 2006. Italy. 2006.
199. Abnormalities of platelet function: which clinical role?, at the training course "Diagnostic and therapeutic pathways for in-hospital bleeding and thrombotic events", held in Palermo, November 27 to 28, 2006. Canada. 2006.
200. Clinical suspicion of Deep Vein Thrombosis and/or Pulmonary Embolism: pre-test clinical probability and choice of diagnostic tests, at the training course "Diagnostic and therapeutic pathways for in-hospital bleeding and thrombotic events", held in Palermo, November 27 to 28, 2006. Italy. 2006.
201. Management of the patient with congenital or acquired disorders of haemostasis, at the training course "Diagnostic and therapeutic pathways for in-hospital bleeding and thrombotic events", held in Palermo, November 27 to 28, 2006. Italy. 2006.
202. Physiopathology of Thrombosis and Haemostasis, at the Meeting "Thrombophilia and thrombosis: risk factors and laboratory workup", held on May 19th, 2005 in Nottola di Montelpuciano by the Italian Society for Laboratory Medicine (SIMEL). Italy. 2005.
203. "Von Willebrand Disease" at the IV Course in Pediatric Haematology and immunohematology, held on January 28-29 2005, Rome. Italy. 2005.
204. "Quality control in the coagulation laboratory: the role for the Italian Association of Hemophilia Centres (AICE), held on March 18-19, 2005, Bari. Italy. 2005.

205. "Sports and bleeding disorders" at the Specialization Course in Sports Medicine, University of Rome, April 18th, 2005, Rome. Italy. 2005.
206. Interim analysis of the Prolong Study" at the Workshop on collaborative italian studies on venous thromboembolism held by the Italian Federation of Anticoagulation Clinics (FCSA), held on May 18th, 2005, Bologna. Italy. 2005.
207. "Does new evidence let us agree new recommendations for the management of venous thromboembolism in the Emergency Department?" at the meeting "Update on the management of deep vein thrombosis and pulmonary embolism. Siset workshop on new pathways on management on venous thromboembolism in the emergency department" May 27-28, 2005 Palermo. Italy. 2005.
208. "Evidence Based Medicine, levels of evidence and recommendations" at the meeting "Update on the management of deep vein thrombosis and pulmonary embolism. Siset workshop on new pathways on management on venous thromboembolism in the emergency department" May 27-28, 2005 Palermo. Italy. 2005.
209. "Emocard, a case report form to improve the quality of hemophilia treatment" at the Launching meeting of the Hemophilia Centre of L'Aquila, held on June 18 L'Aquila. Italy. 2005.
210. China 1, Annual Meeting of the Chinese Society of Haematology, September 11th, 2005, Chengdu, China. China. 2005.
211. "Role of the laboratory in the diagnosis of venous thromboembolism" at the VII Educational Course of the Italian Society of Thrombosis and Haemostasis (Siset) – Approach to the diagnosis of haemorrhagic and thrombotic disorders, September 16-17, 2005, Brescia. Italy. 2005.
212. Antiphospholipid antibodies Syndrome. at the VII Educational Course of the Italian Society of Thrombosis and Haemostasis (Siset) – Approach to the diagnosis of haemorrhagic and thrombotic disorders, September 16-17, 2005, Brescia. Italy. 2005.
213. Oral anticoagulant therapy and telemedicine at the National Training course of the Italian Society for Thrombosis and Haemostasis, held on September 22-24, 2005 Campobasso. Italy. 2005.
214. Hormonal cancer therapy and thrombotic risk at the 1st Italian Meeting about Thrombosis and Haemostasis in the woman and in the child, Held on October 6-8 2005, Padua. Italy. 2005.
215. Annual Training Course of the Italian Association of Dentistry (AIO), "Internal Medicine Course for Dentists", held on October 21st, 2005, Perugia. Italy. 2005.
216. Update of the analysis of the National Haemophilia Registry, at the II 2005 AICE meeting; held on November 17-18 2005, Milano. Italy. 2005.
217. "Toward an interregional network" at the Annual Meeting of the AUAFE (Umbria associations friends of the Hemophilia Foundation), held on November 26th, 2005, Bastia Umbria. Italy. 2005.
218. Update of the analysis of the National Haemophilia Registry, at the I 2005 AICE meeting; held on June 24 2005, Pisa. Italy. 2005.
219. Administrative and gestational issues in the oral anticoagulant management centre. Annual meeting of the Italian Association of Anticoagulation Clinics (FCSA), March 11-12 2004, Milan. Italy. 2004.
220. Hemophilia A: pathogenesis and clinical presentations, at the meeting "Update in congenital coagulopathies: the role for prophylaxis", held on March 27, 2004, Cagliari. Italy. 2004.

221. "Current activities of the Hemophilia Centre in Perugia" at the Annual Meeting of the AUAFE (Umbria associations friends of the Hemophilia Foundation), held on April 17, 2004, Bastia Umbria. Italy. 2004.
222. Telemonitoring of patients on chronic oral anticoagulant therapy, at the Meeting "Internet to extend action in various activity fields" held at the Trade Organization, April 27th, 2004, Milan. Italy. 2004.
223. Update of the analysis of the National Haemophilia Registry, at the I 2004 AICE meeting; held on May 26-28 2004, Parma. Italy. 2004.
224. "Molecular diagnosis" at the Meeting "Clinics and diagnostics of thrombophilic states", held on June 24th, 2004, Amatrice. Italy. 2004.
225. Chairman of the Oral Communication Session "Prevention and Treatment of Venous Thromboembolism" at the XVIII National Meeting of the Italian Society for Thrombosis and Haemostasis, held on September 30 to October 3, 2004, Rome. Italy. 2004.
226. "Approach to the patients on oral anticoagulants who needs to undergo surgery, at the L' approccio terapeutico nel paziente anticoagulato che deve sottoporsi ad interventi chirurgici, at the meeting Oral pathologies in hemophilic and anticoagulant-treated patients" held on October 30th, 2004, Macerata. Italy. 2004.
227. Telemonitoring systems for patients on chronic oral anticoagulant therapy, at the Annual Training course of the Italian Federation of anticoagulation clinics (FCSA), held on November 12-14, 2004, Cagliari. Italy. 2004.
228. Update of the analysis of the National Haemophilia Registry, at the II 2004 AICE meeting; held on November 18-20 2004, Palermo. Italy. 2004.
229. New antithrombotic treatments": at the meeting on "Oral anticoagulant treatment" held on December 11th 2004, Sondrio. Italy. 2004.
230. The management of oral anticoagulant therapy, at the 35° National Meeting of the A.I.Pa.C., held in Pesaro on May 13-16, 2003. 2003.
231. ITT in severe Haemophilia A patient with high level inhibitor. Course "Inhibitor and immunotolerance in haemophilia: State of the Art from the clinical practice to the scientific aspects". Held in Rosia on May 16, 2003. Italy.
232. Automation for the laboratory diagnostics of haemorrhagic diseases. 5° Residenzial Course in Laboratory Medicine "laboratory Diagnosis of Haemorrhagic diseases. Held in Orvieto, on May 26, 2003. Italy.
233. The management of bleeding patients with liver deficiency. Course: Nursing of high risk patients for thromboembolic and haemorrhagic diseases. CEFPAS, Held in Caltanissetta, on October 14 and 15 2003. Italy.
234. The management of gastrointestinal and urinary tract bleeding. Course: Nursing of high risk patients for thromboembolic and haemorrhagic diseases. CEFPAS, Held in Caltanissetta, on October 14 and 15 2003. Italy.
235. Haemophilia: the future has begun", at the 1° National Professional Training Course: "Global Management of the haemophilia patient", held in Perugia on June 20 and 21 2003. Italy. 2003.
236. Randomization, data management and data analysis. Workshop "Venous Thromboembolism recurrences and the Prolong Study, held in Bologna on June 24, 2003. Italy. 2003.

237. Congenital and acquired disorders of haemostasis and fibrinolysis. 10° Course in Vascular Medicine: Cerebrovascular Diseases – Haemorrhagic Coagulopathies, held in Perugia on June 16 to 20, 2003. Italy. 2003.
238. Diagnosis and classification of von Willebrand Disease. First Interregional Meeting on Haemorrhagic Diseases, held in Macerata on May 31 2003. Italy. 2003.
239. Quality control of oral anticoagulant treatment, at the 2003 National Meeting of the FCSA, held in Abano on March 20 and 21 2003. Italy. 2003.
240. Distributed oral anticoagulant treatment at the 2003 National Meeting of the FCSA, held in Abano on March 20 and 21 2003. Italy. 2003.
241. “Use of diagnostic test for DVT”. Course “Venous Thromboembolic Disease” Centro per la formazione permanente e l’aggiornamento del personale del servizio sanitario della regione Sicilia. Caltanissetta, September 30 to October 4, 2002. Italy.
242. Chairman of the session “Thrombophilia I” at the 17th International Congress on Thrombosis of the Mediterranean League against Thromboembolic Diseases. Bologna, October 26-30, 2002. Italy. 2002.
243. “The laboratory diagnosis of platelet function disorders.” ”Ematologia 1999”. Istituto di Ematologia e Oncologia Medica “L. e A. Seragnoli”. Università degli Studi di Bologna. Reggio Emilia, January 16, 1999. Italy.
244. “Anticoagulant therapy after peripheral vascular surgery.” IV Residential Course in “Antithrombotic Prophylaxis and Therapy” Parma, April 10, 1997. 1997.
245. “Anticoagulant therapy after peripheral vascular surgery.” V Residential Course in “Antithrombotic Prophylaxis and Therapy” Parma, October 16, 1997. 1997.
246. “Treatment of thromboembolic disease”. “Venous and arterial Thrombosis: New acquisitions”. Cuneo, November, 1996.
247. “Clinical pharmacology of antithrombotic and thrombolytic agents”, at the 3° meeting of the course ‘Thrombosis in cardiovascular diseases’ organized by the Hearth Foundation ‘Myriam Zito Sacco’ and the Azienda U.S.L. of Rimini held in Rimini on June 24, 1995.
248. Up-to-date course. “Heparin therapy in the ‘90” organized in Milan by the Instrumentation Laboratory on June 16-17 1994, lecture on “New antithrombotic agents”. 1994.
249. Fourth Symposium on Glycosaminoglycans. Non-anticoagulant actions of Glycosaminoglycans - Results and perspectives of the German-Italian collaboration. Como October 6 – 9, 1994.
250. Third Symposium on Glycosaminoglycans, blood cells and endothelium. Results and perspectives of bilateral collaboration on novel approaches to pharmacokinetics and metabolism. Como, May 3-5, 1993.
251. “Laboratory diagnosis and molecular genetics”, at the XL National Congress of the Società dei Neurologi, Neurochirurghi e Neuroradiologi Ospedalieri. Otranto June 3, 2000. Italy.
252. Post-degree Course in Vascular Medicine. “Acquired Thrombophilia”: University of Perugia, Perugia, June 11-15, 2001. Italy.

253. "Information technology in the clinical laboratory" – Lecture at the "Scuola di Specializzazione in Igiene e Medicina Preventiva" of the University of Modena and Reggio Emilia, held in Modena on May 25, 2001. Italy.
254. "Quality, efficacy and appropriateness of health care activities". Lecture in courses organized in Roma by the Moccia Group and sponsored by Merck Sharp & Dohme under the auspices of the Aziende Sanitarie Locali Roma B (Sandro Pertini Hospital), Roma E (S. Spirito Hospital), Roma G (Roccapriore Hospital), 2001. Italy.
255. "Oral anticoagulant therapy management": 9th Post-degree Course in Vascular Medicine. University of Perugia. Perugia, June 10-14, 2002. Italy.
256. "Physiopathology of the hemostatic system" 4th Residential Course in Laboratory Medicine – Thrombophilia – SIMEL Orvieto September 25 and 30 , October 9, 2002, Orvieto. Italy.
257. "Acquired Thrombophilia". Course "Venous Thromboembolic Disease" Centro per la formazione permanente e l'aggiornamento del personale del servizio sanitario della regione Sicilia. Caltanissetta, September 30 to October 4, 2002. Italy.
258. "The laboratory of Hyperhomocyst(e)inemia". Course "Venous Thromboembolic Disease" Centro per la formazione permanente e l'aggiornamento del personale del servizio sanitario della regione Sicilia. Caltanissetta, September 30 to October 4, 2002. Italy.
259. Prevention and treatment of thromboembolic events in the medical patient. ECM Course "Home treatment of the patient at risk for thromboembolic diseases, held in Cortona, on May 24, 2003. Italy.
260. State of the art regarding the National Haemophilia Registry, at the II 2003 AICE meeting; held in Turin on November 21 2003. Italy.
261. China 2, Workshop on new advances in the coagulation laboratory, September 13th, Beijing, China. Italy.
262. Annual Training Course of the Italian Association of Dentistry (AIO), "Internal Medicine Course for Dentists", held on April 3, 2004, Perugia. Italy.
263. "Telemedicine applications for oral anticoagulants management: a health service based model" at the XXXVII National Meeting of the Italian Transfusion Society (SIMTI) – held on October 4-7 2006, Paestum. Italy.
264. "New and old drugs" at the IV° Interregional Meeting "Update in Laboratory Medicine: Deep Venous Thrombosis in Internal Medicine" held on June 8, 2006 in Rieti. Italy.
265. Update of the analysis of the National Haemophilia Registry, at the II 2006 AICE meeting; held on September 13 2006, Florence. Italy.
266. "Prophylactic treatment in haemophilia" at the XIX National Meeting of the Italian Society for Thrombosis and Haemostasis (SISST) – held on September 14-17 2006, Milan. Italy.
267. Iorio, A. Interpreting inhibitor rates in haemophilia A at the international meeting: Managing Haemophilia for Life Summit held on November 18-20, 2011 in Madrid.
268. Iorio, A. Update on The Italian Registry of Congenital Coagulopathies, at the 7th Bari International Conference (BIC)- 21-23 Maggio 2011.

269. Iorio, A. Interventions to reduce inhibitors: Product choice at the Canadian Hemophilia Physician Update, Toronto, June 10-12, 2011. Ontario, Canada.
270. A. Iorio. Profilassi nell'emofilia. La nuova COCHRANE at the XIV Convegno sui problemi clinici e sociali dell'emofilia 4 - 6 novembre 2011 Firenze.
271. Hemophilia outside the realm of the hematologist. Chair's Grand Round, Department of Medicine, McMaster University, Hamilton, February 1st, 2012. Ontario, Canada.
272. Inibitori nei PTP. Hemophilia Care. A lifelong commitment. April 19-20, 2012. Rome, Italy.
273. Medical Update on EAHAD Data. Hemophilia Advisory Board Meeting. Quebec City, QC. April 28, 2012. Ontario, Canada.
274. Iorio A. Health Information Research Unit, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. The use of the clinical trial design in hemophilia: methodological considerations. Plenary Lecture. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 2, page 1.
275. Venous thromboembolism recurrence after a first thrombotic event due to a removable risk factor, at the training course on: follow up after venous thromboembolism and the Dulcis Study, held in Bologna on December 9, 2008.
276. Prophylaxis: Is it a right for all patients? No. During the symposium Hemophilia principles of care. The clinical decision, held in Rome on November 13th, 2009.
277. Iorio, A. Update on the National Hemophilia Registry, at the AICE meeting, held in Milan on March 11, 2010.
278. Iorio, A. Moroctocog alfa: Clinical Evidence and Experience, at the educational program "Treating hemophilia" at the Annual meeting of the ISTH subcommittees, held in Il Cairo on May 21-24, 2010.
279. Managing hemophilia in the elderly: a multimedial approach through the virtual case of Patrizio, held in Padua on April 19-20, May 5-6 and 9-10. Italy.
280. The coagulation laboratory in the monitoring of coagulation active treatments, at the SIMeL training course "Sinergisms between clinics and the laboratory for haemorrhagic and thrombotic disorders", held in Umbertide on January 16, 2008.
281. Haemorrhagic complications caused by overdose of antithrombotic therapy, at the XX National Congress of the SISET, September 25-28, 2008.
282. Quality control in the coagulation laboratory: the AICE experience, at the training course "Management of congenital and acquired disorders", held in Florence on January 24 to 26, 2008. Italy.
283. News about oral anticoagulant management in the new version of the ACCP guidelines. Oral anticoagulant treatment: up to date. Macerata, September 25th, 2009. Italy.
284. Management of bleeding in patients on oral anticoagulant treatment. National Course of the Italian Society of Thrombosis and Haemostasis. Varese, September 25-27 2009.
285. "Open issues in oral anticoagulant therapy", during the training course "Home prophylaxis. Prophylaxis of venous thromboembolism in the medical patient: new evidence" held in Città di Castello on September 29, 2007. Italy.

286. Update on the Italian National Registry of Congenital Coagulopathies, at the AICE meeting in Copanello, April 28 to 29, 2007. Italy.
287. Anticoagulant therapy, at the Brescia Intensive Care Neuroscience meeting, held in Brescia on May 9 to 11, 2007. Italy.
288. Methodology of the Siset Guidelines, at the National Siset course, held in Bari on September 20 to 21, 2007. Italy.
289. Antithrombotic prophylaxis in the patients with atrial fibrillation or atrial flutter undergoing cardioversion, at the National Siset course, held in Bari on September 20 to 21, 2007. Italy.
290. Siset guidelines about antithrombotic treatment for cardioversion, at the X training course “Antithrombotic treatment in cardiology”, held in Florence on May 25 to 17, 2008.
291. Chairman of the round table “Oral contraceptive and hormonal replacement therapy and thrombosis: advice for the woman, at the 2° Italian Congress on Thrombosis and Haemostasis in women and children, held in Padua on May 22 to 24, 2008.
292. Pharmacological prevention of deep vein thrombosis, at the XI educational course of the Siset “The mediterranean sea and prevention in haemostasis and thrombosis, 2° day, held in Lecce on July 11-12, 2008.
293. The Siset guideline methodology: general and special issues, at the XX National Congress of the Siset, held in Bari, September 25-28, 2008.

Contributed Peer Reviewed Presentations

1. Fischer K, Lassila R, Peyvandi F, Gatt A, Hollingsworth R, Lambert T, Kaczmarek R, Bettel A, Samji N, Rivard GE, Carcao M, Iorio A, Makris M on behalf of the EUHASS and CHES participants. Inhibitor development in PUPs with severe haemophilia A was significantly lower in those treated with Pd-FVIII compared to standard SHL-rFVIII. 17th Annual Congress of the European Association for Haemophilia and Allied Disorders. Frankfurt, Germany, February 9, 2024.
2. Matino D, Matta S, Iorio A, Keepanasseril A, Germini F, Caillaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua C, Sun H, Teitel J, Poon M-C. A Canadian, multi-center, retrospective, non-interventional study of clinical outcomes from early use of N9-GP compared with previous treatment in patients with hemophilia B in a real-world setting. ECTH 2021 European Congress on Thrombosis and Haemostasis, Ghent, Belgium, October 13 – 15, 2021.
3. Ganann, R., Gentles, S., Lokker, C., Valaitis, R., Iorio, A., Tahir, I., Okelana, O., Yousif, C., El Shamy, N. Co-design, production, and usability testing of a communication toolbox for delivering evidence-based health information to older adults and their caregivers. North American Primary Care Research Group (NAPCRG) Annual Meeting, Chicago, Illinois, November 9-13, 2018.
4. Gentles, S, Ganann, R, Valaitis, R, Lokker, C, Iorio, A, El Shamy, N, Tahir, I, Okelana, O, Yousif, C. Co-design, production, and usability testing of a communication toolbox for delivering evidence-informed health information to older adults and their caregivers. 25th Cochrane Colloquium, Edinburgh, UK, September 16-18, 2018.
5. Ganann, R, Gentles, S., Valaitis, R., Lokker, C., Iorio, A., Tahir, I., Okelana, O., Yousif, C., El Shamy, N. Co-design, production and usability testing of a communication toolbox for delivering evidence-informed health information to older adults and their caregivers. 2018 Annual Canadian Association for Health Services and Policy Research Conference. Montreal, Quebec, May 29-31, 2018.

6. A. Dougall, S. Chandra Pani, B. Daly, C. Chai-Adisaksopha, R. Curtis, N. Frick, A. Iorio, D. Noone, J. Stonebraker, M.W. Skinner on behalf of the Patient Reported Outcomes, Burdens, and Experiences (PROBE) Investigator Group (2018). The PROBE Study – Global burden of bleeding from the mouth in Haemophilia – a call to action. World Federation of Haemophilia Congress. May 20-24, 2018, Glasgow, Scotland. Oral Presentation: #T-FP-MTD-001 (181).
7. Noone, D, Chai-Adisaksopha, C, Curtis, R, Frick, N, Nichol, M, O’Mahony, B, Page, D, Stonebraker, J, Iorio, A, Skinner, M. Occurrence and Impact of Pain among Patients Living with Hemophilia. 11th Annual Congress of the European Association of Hemophilia and Allied Disorders (EAHAD). Madrid, Spain, February, 2018.
8. Ganann R, Valaitis R, Gentles S, Lokker C, Iorio A, Tahir I, Okelana O. Co-design and production of a communication toolbox for delivering evidence-informed health information to older adults and their caregivers. North American Primary Care Research Group (NAPCRG) Annual Meeting. Montreal, QC. Nov. 17-21, 2017.
9. Augusto Bramante Federici, Giancarlo Castaman, Alfonso Iorio, Emily Oliovecchio, and Prodeswil Investigators. 759 Safety and Effectiveness of Desmopressin for the Management of Delivery and Major Surgery in Patients with Mild-Moderate Von Willebrand Disease: Final Analysis in the Prodeswil Study. 57th ASH Annual Meeting, Orlando, Florida. December 5-8, 2015.
10. Chatree Chai-Adisaksopha, Matthew Cheah, Said Al Kindi, Alfonso Iorio, Mark Crowther, and Lori Ann Linkins. Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer Associated Thrombosis. 57th ASH Annual Meeting, Orlando, Florida. December 5-8, 2015.
11. Chatree Chai-Adisaksopha, Said Al Kindi, Matthew Cheah, Alfonso Iorio, Mark Crowther, and Lori-Ann Linkins. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumors. 57th ASH Annual Meeting, Orlando, Florida. December 5-8, 2015.
12. Chatree Chai-Adisaksopha, Alfonso Iorio, Mark Crowther, Javier de Miguel, Estuardo Salgado, Marija Zdravetska, Manuel Monreal and the RIETE investigators. Switching to warfarin after 6-month completion of anticoagulant treatment of cancer-associated thrombosis. 57th ASH Annual Meeting, Orlando, Florida. December 5-8, 2015.
13. Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, Stefan Lethagen, Nora McCormick, Paul Karner. Factor Consumption and Efficacy: Recombinant Factor IX Fc Fusion Protein Compared with Conventional Recombinant Factor IX. 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Milan, Italy. November 7-11, 2015.
14. Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, Stefan Lethagen, Nora McCormick, Paul Karner. Comparisons of Efficacy and Factor Consumption During Treatment with Recombinant Factor VIII Fc Fusion Protein and Conventional Factor VIII. 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Milan, Italy. November 7-11, 2015.
15. Alfonso Iorio, Sangeeta Krishnan, Karl-Johan Myrén, Stefan Lethagen, Nora McCormick, Paul Karner. Modeling the Impact of Potential Improvements in Real-World Adherence with Extended-Half Life versus Conventional Factor VIII and IX on Bleeding. 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research. Milan, Italy. November 7-11, 2015.
16. Xi M, Navarro-Ruan T, Mammen S, Blanchette V, Hermans C, Morfini M, Collins P, Fischer K, Neufeld EJ, Young G, Kavakli K, Radossi P, Dunn A, Thabane L and Iorio A. for the WAPPS study group. Systematic review of the published evidence on the pharmacokinetic characteristics of factor VIII and IX concentrates. American Society of Hematology Annual Meeting. San Francisco, California. December 6-9, 2014.

17. Augusto Federici, Giancarlo Castaman, Alfonso Iorio, Mariana Bonduel, Elbio D'Amico, Emily Oliovecchio, Christina Santoro, Simona Siboni, Barbara Zieger, Pier Mannucci. Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PA 2.08-1. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
18. Davide Martino, Alfonso Iorio, Marco Gargaro, Elena Santagostino Christina Santoro, Giovanni Di Minno, Massimo Morfini, Paolo Puccetti, Francesca Fallarino. Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. AS 22.3. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
19. Maura Marcucci, Maria Elisa Mancuso, Elena Santagostino, Gili Kenet, Mohssen Elalfy, Susanne Holzhauser, Christoph Bidlingmaier, Carmen Escuriola Ettingshausen, Alfonso Iorio, Ulrike Nowak-Gottl. Effect of type and intensity of FVIII exposure on inhibitors development in hemophilia A: First results of an individual patient data meta-analytic project. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. AS 22.2. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
20. Iorio, A. Inhibitor development in PTP: available registries and harmonization. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. SC01-4.05. June 29, 2013-July 4, 2013. Amsterdam, Netherlands.
21. Alfonso Iorio, Diane Nugent, Ann Marie Stain, Matt Gregory, Louisa Pericleous, David Cooper. Do inhibitors, treatment regimen and bleed frequency impact hemophilia treatment centre and provider utilisation: An analysis of adults with haemophilia in the HERO study. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PB 3.36-6. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
22. Alfonso Iorio, Diane Nugent, Ann Marie Stain, Matt Gregory, Louisa Pericleous, David Cooper. Do inhibitors, treatment regimen and bleed frequency impact hemophilia treatment centre and provider utilisation: An analysis of adults with haemophilia in the HERO study. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PB 3.36-6. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
23. Augusto Federici, Giancarlo Castaman, Alfonso Iorio, Mariana Bonduel, Elbio D'Amico, Emily Oliovecchio, Christina Santoro, Simona Siboni, Barbara Zieger, Pier Mannucci. Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PA 2.08-1. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
24. Davide Martino, Alfonso Iorio, Marco Gargaro, Elena Santagostino Christina Santoro, Giovanni Di Minno, Massimo Morfini, Paolo Puccetti, Francesca Fallarino. Defective indoleamine 2,3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. AS 22.3. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
25. F. Cassis, A. Forsyth, M. Gregory and A. Iorio. Qualitative and quantitative assessment of sexual intimacy in adult patients in the hemophilia experiences results opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-148. Haemophilia 2012, 18 (Suppl. 3), 1–208.

26. Iorio A, Marchesini E, Falco A, Caso V, Pastorello M, Tiscione V, Ballarino P, Altomonte F, Baldi G, Agnelli G, Toni D. Randomised, open, prospective, multicenter pilot study to evaluate the efficacy and safety of activated recombinant factor VIIa (NovoSeven) in acute intracerebral haemorrhage in patients treated with oral anticoagulant. 13^o Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. Blood Transfus 6, Supplement 3, November 2008. PO070. Milan, Italy.
27. Iorio A, Marchesini E, Falco A, Caso M, Pastorello M, Tiscione V, Ballarino P, Altomonte F, Baldi G, Agnelli G, Toni D. 2007 randomised, open, prospective, multicenter pilot study to evaluate the efficacy and safety of activated recombinant factor VIIa (NovoSeven) in acute intracerebral haemorrhage in patients treated with oral anticoagulant or antiplatelet agents. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6–12, P-T-162. Geneva, Italy.
28. Maura Marcucci, Sabine Eichinger, Alfonso Iorio, James Douketis, Alberto Tosetto, Trevor Baglin, Mary Cushman, Gualtiero Palareti, Daniela Poli, Tait Campbell, Paul Kyrle. External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PB 3.70-3. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
29. Maura Marcucci, Sabine Eichinger, Alfonso Iorio, James Douketis, Alberto Tosetto, Trevor Baglin, Mary Cushman, Gualtiero Palareti, Daniela Poli, Tait Campbell, Paul Kyrle. External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database. XXIV Congress of the International Society on Thrombosis and Haemostasis. 59th Annual SSC Meeting. PB 3.70-3. June 29, 2013 – July 4, 2013. Amsterdam, Netherlands.
30. Iorio, A. Practical approaches to assessing inhibitor development – risk factors, clinical trials and management. Plenary Session - Managing Hemophilia for Life: Pfizer AfME / EURIT Hemophilia Forum. 12 May 2013. Istanbul, Turkey.
31. Iorio A. Inhibitor development in previously untreated patients. Experience Symposium. Pfizer Hemophilia Meeting. Korea, Republic Of. May 10, 2013.
32. Iorio, A. Effect of switching FVIII products on inhibitor development in Hemophilia A. Abstract of the 5th Nijmegen Symposium on Factor VIII Inhibitors. March 27, 2013, Nijmegen, The Netherlands. Amsterdam, Netherlands.
33. Athale A, Giguere A, Barbara, AM, Iserman E, Iorio A. Developing a two-sided intervention to facilitate evidence-based practice and shared decision making in haemophilia: Decision Boxes for clinicians and brief Patient Decision Aids for patients. McMaster University's Clinical Epidemiology & Biostatistics (CE&B) Annual Research Day. Sheraton Hotel, Hamilton, March 2013. Poster. Hamilton, Ontario, Canada.
34. Alonso-Coello P, Carrasco-Labra A, Brignardello-Petersen R, Neumann I, Akl E, Sun X, Johnston B, Busse J, Dahm P, Glujovsky D, Iorio A, Irfan A, Martinez L, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Briel M, Granados C, Mustafa R, Guyatt G. Risk difference estimation and reporting in systematic reviews. Abstracts of the 2012 Cochrane Colloquium. Cochrane Database Syst Rev 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200 Auckland, New Zealand.
35. K. Strike, A. Chan, K. Ross, C. Bos, T. Almonte, K. Decker, R. Goldsmith, A. Iorio, I. Walker, K. Webert and L. Waterhouse. Osteochondral Lesions of the Ankle Joint in Patients with Hemophilia A: A Retrospective Case Series. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-212. Haemophilia 2012, 18 (Suppl. 3), 1–208

36. C. Garrido, S. Ramirez, A. Forsyth and A. Iorio. Quality of life (QOL) and well-being of hemophilia patients and parents managing hemophilia: Hero study analysis. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-218. *Haemophilia* 2012, 18 (Suppl. 3), 1–208.
37. D. Nugent, C. Garrido, K. Halter and A. Iorio. Demographic characteristics of parents of children/adolescents with hemophilia responding in the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-MO-200. *Haemophilia* 2012, 18 (Suppl. 3), 1–208.
38. A. Forsyth, M. Gregory and A. Iorio. Demographic characteristics of adult patient respondents in the Hemophilia Experiences Results Opportunities (HERO) study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-MO-199. *Haemophilia* 2012, 18 (Suppl. 3), 1–208.
39. Bos C, Chan A, Webber C, Iorio A, Nagel K, Walker I and Webert K. Low bone mineral density and increased fat mass in boys with severe Hemophilia. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-WE-048. *Haemophilia* 2012, 18 (Suppl. 3), 1–208.
40. Stain A, Sandoval E, Halter K, and Iorio A. Hemophilia knowledge and frequently used and valued information sources: Patient/parent perceptions from the Hero study. Abstracts of the XXX International Congress of the World Federation of Hemophilia, July 8-12, Paris, France PO-TU-088. *Haemophilia* 2012, 18 (Suppl. 3), 1–208.
41. Guyatt G, Spencer F, Iorio A, Vandvik P, You J. Uncertainty in baseline risk can reduce confidence in estimates of effect. Abstracts of the 2012 Cochrane Colloquium. *Cochrane Database Syst Rev* 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200 Auckland, New Zealand.
42. Sun X, Brignardello-Petersen R, Carrasco-Labra A, Neumann I, Alonso-Coello P, Akl E, Johnston B, Briel M, Busse J, Dahm P, Granados C, Glujovsky D, Iorio A, Irfan A, Martinez L, Mustafa R, Ramirez-Morera A, Solà I, Sultan S, Tikkinen K, Vandvik P, Zhang M, Guyatt G. Subgroup analyses in systematic reviews: a survey of Cochrane and non-Cochrane reviews. Abstracts of the 2012 Cochrane Colloquium. *Cochrane Database Syst Rev* 2012 Suppl 1-134. DOI:10.1002/14651858.CD201200 Auckland, New Zealand.
43. Iorio A. IPD meta-analysis to investigate the risk factor for inhibitor development. Perugia Hemophilia Centre, University of Perugia, Italy; Health Information Research Unit, Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. Invited talk. 5th European Association for Hemophilia and Allied Disorders (EAHAD), Rome February 22nd 2012. Abs 2, page 1 *Haemophilia* (2012), 18 (Suppl. 1), 1–10 Rome, Italy.
44. Augusto B. Federici, Alfonso Iorio, and Giancarlo Castaman. Clinical Efficacy and Safety Versus Biological Response of Desmopressin (DDAVP) In Inherited Von Willebrand Disease (VWD) Types 1 and 2: Initial Results From the International Study Group on DDAVP In VWD In a Cohort of 229 Patients. *Blood* (ASH Annual Meeting Abstracts), Nov 2010; 116: 238. Orlando, Florida, United States.
45. Iorio A, Fabbriani G, Marcucci M, Brozzetti M, Luciani M, Filipponi P. Bone mineral density in hemophilia patients. A meta-analysis. III EAHAD meeting, Edinburgh, Scotland. February 3-5, 2010. United Kingdom.

46. Alfonso Iorio, Susan Halimeh, Christoph Bidlingmaier, Leonardo R. Brandao, Carmen Escuriola-Ettingshausen, Neil A Goldenberg, Alessandro Gringeri, Susanne Holzhauer, Gili Kenet, Ralf Knoefler, Wolhart Kreuz, Karin Kurnik, Daniela Manner, Emanuela Marchesini, Maura Marcucci, Elena Santagostino, Guy Young, Pier Mannuccio Mannucci, and Ulrike Nowak-Gottl. Rate of Inhibitor Development in Hemophilia A Patients Treated with Plasma Derived or Recombinant Factor VIII Concentrates. A Systematic Review of the Literature. *Blood* (ASH Annual Meeting Abstracts), Nov 2009; 114: 3154. New Orleans, Louisiana, United States.
47. Lisa K Lütkehoff, Manuela Albisetti, Timothy J. Bernard, Mariana Bonduel, Leonardo R. Brandao, Stephane Chabrier, Anthony Chan, Barbara Fiedler, Heather J. Fullerton, Vijeja Ganesan, Neil A Goldenberg, Meredith Golomb, Eric F. Grabowski, Christine Heller, Susanne Holzhauer, Alfonso Iorio, Janna Journeycake, Gili Kenet, Fenella J Kirkham, Karin Kurnik, John K Lynch, Christoph Male, Marilyn J. Manco-Johnson, Rolf Mesters, Paul Monagle, Heleen C van Ommen, Leslie Raffini, Paolo Simioni, Ronald Strae Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies. *Blood* (ASH Annual Meeting Abstracts), Nov 2009; 114: 3993. New Orleans, Louisiana, United States.
48. Iorio A, Ferrante F, Rocca A, Accorsi A, Barillari G, Biasoli C, Carloni MT, Castaman G, Ciavarella N, Contino L, D'Inca M, Coppola A, Dragani A, Grandini G, Luciani M, Mariani G, Mazzucconi MG, Molinari C, Morfini M, Muleo G, Rocino A, Roderigo G, Rossetti G, Santagostino E, Schiavulli M, Schinco PC, Scaraggi F, Siboni S, Tagariello G, Tagliaferri AR, Targhetta R, Zanon E. Replacement Therapy with Recombinant FIX. Multicentric Evaluation of Current Dosing Practice In Italy. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. *Blood Transfus* 6, Supplement 3, November 2008. PO013. Geneva, Italy.
49. Tagariello G, Iorio A, Santagostino E, Morfini M, Innocenti M, Mancuso M. E, Pasta PL, Radossi P, Roderigo G, Santoro C, Sartori R, Scaraggi A, Solimeno LP. Hemophilia B patients have a lower risk to undergo orthopaedic surgery than hemophilia A patients: Results from an Italian cohort study and review of the literature. 13° Triennial Meeting on Clinical and Social issues in Hemophilia, Milan, November 14-16 2008. *Blood Transfus* 6, Supplement 3, November 2008. CO032 Geneva, Italy.
50. Iaboni S, Filippucci E, Ferrante F, Grilli P, Vecchioli M, Agnelli G, Iorio A. Anticoagulation management by point of care devices and computer monitoring by general practitioners. XX Siset National Meeting, Florence, September 25-28, 2008 C076. Florence, Italy.
51. Marchesini E, Ferrante F, Filippucci E, Iaboni S, Agnelli G, Iorio A. Antiviral treatment for chronic hepatitis in patients HIV-infected. XX Siset National Meeting, Florence, September 25-28, 2008 P177. Italy.
52. Santagostino E, Coppola A, Tagliaferri A, Mancuso M, Scaraggi F, Biasoli C, Schinco P, Iorio A, Latella C, Di Minno G. Immune tolerance induction (ITI) in patients with hemophilia a and inhibitors: the italian retrospective-prospective registry - the Profit Study. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6-12, P-W-128. Geneva, Italy.
53. Santoro C, Iorio A, Pignoloni P, Rago A, Biondo F, Ferrante F, Agnelli G, Mazzucconi M. Of the reformulated B-domain deleted recombinant factor VIII (BDD-RFVIII) concentrate using chromogenic and one-stage assays with pooled normal plasma (PNP) and refacto laboratory standard (RLS). Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6-12, P-W-129. Geneva, Italy.
54. Iorio A, Gringeri A, Hassan J, Iannaccaro P, Morfini M, Rossetti G, Scaraggi A, Schiavoni M, Schinco P, Tagliaferri A. 2007 the hemophilia registry of the italian association of hemophilia centres. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6-12, P-M-129 Geneva, Italy.

55. Iorio A, Marchesini E, Agnelli G. Antiviral therapy for chronic Hepatitis C in hemophilia patients with human immunodeficiency virus. Proceedings of the XXIst Congress of the International Society on Thrombosis and Haemostasis, Geneva, 2007, July 6–12, P-M-147. Geneva, Italy.

Poster Presentations

1. Fischer K, Lassila R, Peyvandi F, Gatt A, Hollingsworth R, Lambert T, Kaczmarek R, Bettle A, Samji N, Rivard GE, Carcao M, Iorio A, Makris M on behalf of the EUHASS and CHES participants. Inhibitor development in PUPs with severe haemophilia A was significantly lower in those treated with Pd-FVIII compared to standard SHL-rFVIII. Feb 9th 2024.
2. Solms A, Shah A, Wiegmann S, Ahsman M, Berntorp E, Tiede A, Iorio A, Mancuso ME, Zhivkov T, Lissitchkov T. Potency-Adjusted Analyses of a Head-to-Head Pharmacokinetic Study of Dmactocog Alfa Pegol (BAY 94-9027) and Efmorotocog Alfa (rFVIII-Fc) in Patients with Severe Hemophilia A. ASH 62nd Annual Meeting and Exposition (virtual). December 2-11, 2020. Poster 878.
3. Lee A, Germini F, Poon M-C, Keepanasseril A, Ibrahim Q, Shang A, Nissen F, Meier O, Sima CS, Matino D, Iorio A. Analysis of Hemophilia A Outcomes and Treatment Patterns Using Real-World Data from the Canadian Hemophilia Bleeding Disorder Registry. ASH 62nd Annual Meeting and Exposition (virtual). December 2-11, 2020. Poster 1793.
4. Germini F, O'Callaghan S, Chai-Adisaksopha C, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Skinner MW, Iorio A. Association between Aging and Health Status in Persons Living with Hemophilia and Controls without a Bleeding Disorder – Insights from the Probe Study. ASH 62nd Annual Meeting and Exposition (virtual). December 2-11, 2020. Poster 2529.
5. Konkle BA, Coffin D, Naccache M, Clark R, George L, Iorio A, Miesbach WA, O'Mahony B, Peyvandi F, Pipe SW, Quartel A, Sawyer EKK, Skinner MW, Tortella BJ, Watson C, Valentin LA, Winburn I, Mahlangu J, Pierce GF. The World Federation of Hemophilia Gene Therapy Registry. ASH 62nd Annual Meeting and Exposition (virtual). December 2-11, 2020. Poster 3453.
- 6.
7. F. Germini, V. Borg Debono, D. Page, M.W. Skinner, V. Zuk, A. Kucher, A. Iorio on behalf of PROBE Investigators. Development and testing of the online PROBE Survey and MyPROBE app and integration with the Canadian Bleeding Disorder Registry. Hemophilia 2020;26:27-181. EAHAD 2020, The Hague, Netherlands. February 5-7, 2020. Poster P097.
8. D. Hadjucek, F. Primacakti, N. Chozie, R. Mir, A. Iorio. Assessing a population pharmacokinetic model of a plasma-derived, Von Willebrand factor-containing FVIII concentrate for bayesian forecasting in low dose scenarios. Hemophilia 2020;26:27-181. Poster P044.
9. J.E. Meglas Vericat, S. Bonanad-Boix, M.F. Martinez-Garcia, R. Berruoco, M.E. Mingot-Castellano, M. Rodriguez, M. Canaro, J. Mateu, I. Larrode, S. Haya, A. Santamaria, M. Mesegue, C. Albo, A. Palomero, N. Vilalta, J.M. Calvo, A.R. Cid, J.L. Poveda, A. Iorio. PK-Guided switch between standard half-life and extended half-life factor VIII products. Hemophilia 2020;26:27-181. Poster P117.
10. David Page, Federico Germini, Victoria Borg Debono, Mark W. Skinner, Alexander Kucher, Michael Sevestre, Alfonso Iorio, and PROBE Investigators. MyPROBE App: Development and Testing with the Canadian Bleeding Disorder Registry. Global Hemophilia Advocacy Leadership Summit. Lisbon, Portugal, January 18-21, 2020. Poster.

11. Juan Eduardo Megias, Santiago Bonanad Boix, Maria Fernanda Martinez Garcia, Ruben Berruero, Maria Eva Mingot-Castellano, Manuel Rodriguez Lopez, Mariana Canaro, Jose Mateo Arranz, Itziar Larrode Lecinena, Saturnino Haya, Amparo Santamaria Ortiz, Carmen Albo, Montserrat Meseguer Medea, Antonio Palomero-Massanet, Noelia Vilalta Seto, Jose Manuel Calvo Villas, Ana R Cid, Gustavo Robayo, Jose Luis Poveda Andres, Guillermo F. Sanz, and Alfonso Iorio. Cross sectional comparative study of PK-guided switch between standard half-life and extended half-life Factor VIII Products. American Society of Hematology. Orlando, Florida, December 7-9, 2019. Poster.
12. Alfonso Iorio, Monika Maas Enriquez, Heinz Delesen, Alexander Solms, Stacy E. Croteau, Erik Berntorp. Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics are similar across different FVIII Products in Patients with Severe Hemophilia A. American Society of Hematology. Orlando, Florida, December 7-9, 2019. Poster.
13. Shen Chu Xie, Anthony K.C. Chan, Raimondo De Cristofaro, Alfonso Iorio, Stefano Lancellotti, Olivia Minelli, Monica Sacco, and Davide Martino. Routine double filtration plasmapheresis affects hemostatic proteins and prolongs clotting tests. American Society of Hematology. Orlando, Florida, December 7-9, 2019. Poster.
14. Vincent P. Diego, Bernadette W. Luu, Afshin Ameri, Meera B. Chitlur, Marcio A. Almeida, Karin Haack, Satish Kumar, Long V. Dinh, Henry Mead, Jerry S. Powell, Miguel A. Escobar, Raja Rajalingam, Sarah Williams-Blangero, Carol K. Kasper, Laura Almasy, Shelley Cole, John Blangero, Tom E. Howard. Disorders of Coagulation or Fibrinolysis. American Society of Hematology. Orlando, Florida, December 7-9, 2019. Poster.
15. M. Skinner, C. Chai-Adisaksopha, B. O'Mahony, D. Noone, R. Curtis, N. Frick, M. Nichol, D. Page, J. Stonebraker, A. Iorio. Patient Reported Outcomes Burdens and Experiences Study Group, International Society of Thrombosis & Haemostasis (ISTH SSC) 2019. Validation of the Patient Reported Outcomes Burdens and Experiences (PROBE) Study Questionnaire. Abstract # OC 32.4. Abstracts, research practice in thrombosis and haemostasis. Doi: 10.1002/rth2.12229. July 6-10, 2019. Melbourne, Australia. Poster.
16. B. Konkle, M. Naccache, J. O'Hara, S. Diop, H. van den Berg, V. Byams, C. Hermans, D. Noone, G. Pierce, D. Coffin, A. Iorio. The WFH World Bleeding Disorders Registry – One Year Later. Abstracts, research practice in thrombosis and haemostasis. Doi: 10.1002/rth2.12229. July 6-10, 2019. Melbourne, Australia. Poster.
17. E. van Balen, B. O'Mahony, M. Cnossen, G. Dolan, V. Blanchette, K. Fischer, D. Gue, J. O'Hara, A. Iorio, S. Jackson, B. Konkle, D. Nugent, D. Coffin, G. Pierce, M. Skinner, C Smit, A. Srivastava, F. Van Eenennaam, J. van derBom, S. Gouw. HaemoValue: Development of a Set of Outcomes for Measuring Value in Persons with Hemophilia. Abstracts, research practice in thrombosis and haemostasis. Doi: 10.1002/rth2.12229. July 6-10, 2019. Melbourne, Australia. Poster.
18. P. Chelle, C. Yeung, S. MacLeod, S. Croteau, J. Lissick, V. Balasa, C. Ashburner, Y.S. Park, S. Bonanad. J.E. Megias Vericat, A. Iorio, A. Edginton. Development and Validation of a Population Pharmacokinetic Model for rAHF-EL-FL-PEG (Adynovate): A report on behalf of the WAPPS-Hemo Investigators and Subgroups. Abstracts, research practice in thrombosis and haemostasis. Doi: 10.1002/rth2.12229. July 6-10, 2019. Melbourne, Australia. Poster.
19. Davide Martino, Giancarlo Castaman, Giovanni Di Minno, Paola Giordano, Maria Elisa Mancuso, Emanuela Marchesini, Flora Peyvandi, Elena Santagostino, Cristina Santoro, Michele Schiavulli, Antonella De Luca, Marco Gargaro, Paolo Puccetti, Francesca Fallarino and Alfonso Iorio. Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Hemophilia A Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. American Society of Hematology. San Diego, California, December 2-4, 2018. Poster.

20. Haowei Linda Sun, Ming Yang, Man-Chiu, Poon, Adrienne Lee, Katherine Sue Robinson, Michelle Sholzberg, John K. Wu, [Alfonso Iorio](#), Victor S. Blanchette, Robert J Klassen, and Shannon Jackson. Observational Study of Real-World Factor Utilization and Health Outcomes in Patients with Hemophilia in Canada. American Society of Hematology. San Diego, California, December 2-4, 2018. Poster.
21. Pierre Chelle, Cindy Yeung, Santiago Bonanad Boix, Juan Cristobal Morales, Margareth C Ozelo, Juan E. Meglas Vericat, Alfonso Iorio, Jeffrey Spears, Roser Mir, and Andrea Edginton. Creating a Population Model for PK-Tailored Dosing Using Real-World Data from the Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) Platform. American Society of Hematology. San Diego, California, December 2-4, 2018. Poster.
22. Mark Skinner, Chatree Chai-Adisaksopha, Randall Curtis, [Alfonso Iorio](#), Michael Nichol, Declan Noone, Brian O'Mahony, David Page, Alexandra Pastarnak, Jeff Stonebraker. Impact of Hemophilia on Employment – Insights from the PROBE Study. 70th Annual NHF Bleeding Disorder Conference, Orlando Florida, October 11-13, 2018. Poster.
23. C. Chai-Adisaksopha, D. Noone, R. Curtis, N. Frick, N. Nichol, B. O'Mahony, D. Page, J. Stonebraker, [A. Iorio](#), M.W. Skinner; PROBE (2018). Exploring Regional Variations in the Cross-cultural, International Implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) Study. Abstract PB189. Res Pract Thromb Haemost, 2:1-368. Doi:10.1002/rth2.12125. International Society on Thrombosis and Haemostasis. July 18-21, 2018. Dublin, Ireland.
24. D. Noone, C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, B. O'Mahony, D. Page, J. Stonebraker, [A. Iorio](#), M.W. Skinner; PROBE (2018). The effect of Inhibitors on Quality of Life and Pain in Adult Patients with Severe Haemophilia in the PROBE Cohort. Abstract PB162. Res Pract Thromb Haemost, 2: 1-368. Doi: 10.1002/rth2.12125. International Society on Thrombosis and Haemostasis. July 18-21, 2018. Dublin, Ireland.
25. A. Pastarnak, R. Curtis, N. Frick, [A. Iorio](#), M. Nichol, D. Noone, B. O'Mahony, D. Page, J. Stonebraker, M.W. Skinner on behalf of the Patient Reported Outcomes, Burdens, and Experiences (PROBE) Investigator Group (2018). The PROBE Data Dashboard – a new tool for real-time data visualization and analysis of patient reported outcomes. World Federation of Haemophilia Congress. May 20-24, 2018, Glasgow, Scotland. Doi:10.1111/hae.13478.
26. Zeller M, Barty R, Wang G, Bourque M, Ramsay N, Liu Y, Iorio A, Heddle N. Antibodies of undetermined significance in solid-phase technology, exploring incidence, associated patient factors and laboratory impact. Canadian Society for Transfusion Medicine, Vancouver, British Columbia, May 12-15, 2016.
27. Barbara AM, Mathew P, Mauser-Bunschoten EP, Rivolta GF, Romanov V, Roussel-Robert V, Tagliaferri A, Windyga J, Iorio A. Investigating determinants of inhibitor development to factor VIII molecules in previously treated hemophilia A patients. Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), Square Brussels Meeting Centre, Brussels, Belgium, February 2014. Poster.
28. Athale A, Giguere A, Barbara, AM, Iserman E, Iorio A. Developing a two-sided intervention to facilitate shared decision making in haemophilia: Decision Boxes for clinicians and brief Patient Decision Aids for patients. American Society of Hematology (ASH) Annual Meeting and Exposition, Ernest N. Morial Convention Center, New Orleans, Louisiana, USA, December 2013. Poster. New Orleans, Louisiana, United States.
29. Athale A, Giguere A, Barbara, AM, Iserman E, Iorio A. Developing a two-sided intervention to facilitate evidence-based practice and shared decision making in haemophilia: Decision Boxes for clinicians and brief Patient Decision Aids for patients. Faculty of Health Sciences Research Plenary. McMaster University, Hamilton, May 2013. Poster. Hamilton, Ontario, Canada.

ADMINISTRATIVE RESPONSIBILITIES

Division/Department

2014 - Present	Director, Health Information Research Unit (HEI), McMaster University
2013 - 2014	Deputy Chief, Health Information Research Unit, Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University
2012 - 2017	Department Education Coordinator, Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University
2015-Present	AFP-HAHSO grant review committee (Scientific officer, current cycle; previous committee member; appointed Chair, next cycle)
2011 - 2016	Member, HRM MSc Admissions Committee, McMaster University

Faculty

2023	Member, Executive Vice Dean and Associate Vice President (Academic), FHS selection committee
2022	Member, Associate Vice President, Global Health, FHS selection committee
2021 – 2024	Non-clinical Chair, FHS Finance Committee, McMaster University

University

2023	Member, Persona Non Grata (PNG) Declarations Policy review committee, McMaster University
2022 July- June 2025	Member, Senate, McMaster University
2022 July-June2025	Vice-Chair, Academic Integrity Committee, McMaster University

Hospital

2014 Nov	Member, Continuing Health Sciences Education Program Advisory Committee
2013 - present	Director, Hamilton Niagara Regional Hemophilia Program
2006 - 2010	Member, Regional Committee for the Appropriateness of the use of plasma and plasma derived products, Umbria Region.
2003 - 2010	Chief of the Program “Health care management network for congenital and acquired bleeding disorders, with particular attention to the haemophilia and oral anticoagulant therapy”, Department of Internal Medicine, Azienda Ospedaliera di Perugia
1999 - 2001	Coordinator of the Departmental Service for Informatics in the Clinical Chemistry Department, Azienda S. Maria Nuova
1998 - 2001	Coordinator of the Data Management Service of the Clinical Chemistry Department, Azienda S. Maria Nuova

1998 - 2001 MRP, coagulation section of Clinical Chemistry, Laboratory of Reggio Emilia

OTHER RESPONSIBILITIES

2016	Chair, Bayer HealthCare European Hematology Conference, “Management of Bleeding Disorders” Madrid October 3-5
2016	Project Lead, Guideline Panel on catastrophic antiphospholipid syndrome, Barcelona, April 26-27
2014 - 2015	Project co-lead, Guideline Panel for Model of care for Hemophilia, NHF-McMaster, May 10 2015
2014	Steering Committee Member, Bayer HealthCare European Hematology Conference, “Management of Bleeding Disorders: Aligning Evidence and Quality” Prague October 9-11
2013	ASH Ancillary Meeting “Hot topics in the epidemiology of inhibitor development in people with haemophilia”, New Orleans, Louisiana
2013	RARE Best Practice Workshop, Freiburg - meeting organization
2013	Chair, HERO (Haemophilia Experiences, Research and Outcomes) Summit, The Hague, Netherlands
2013	Medical and Scientific Symposium Perspectives on personalization of care, Winnipeg, Manitoba - Meeting organization
2005	Chair and organizer, Meeting “Evidence Based Medicine. Report of a controlled clinical trial run in the AUSL 2 of the Umbria Region: Influenza vaccination in patients on oral anticoagulant therapy”, held in Perugia.
2003	Chairman and Trainer and Scientific Secretary of the ECM course for physicians, nurses and laboratory technicians “ The quality systems for the surveillance centre for oral anticoagulant therapy”, held in Reggio Emilia on October 2003.
2002 - 2010	Member, Elected representative as Assistant Professor to the Faculty Council for Teaching, University of Perugia
1999	Chair and organizer, Meeting “Iperomocisteinemia: Aspetti clinici e di laboratorio”, held in Reggio Emilia.
1996	Scientific Secretary, course “Ricerca Clinica. Aspetti metodologici e regolatori “, Smith-Kline Foundation, held in Perugia on October 23 – 25.
1993	Scientific Secretary, course “Metodologia della Ricerca Clinica. Le norme di buona pratica clinica Smith-Kline Foundation, held in Perugia on October 27 – 29.